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Abstract 
Personalised medicine has been area of interest for decades especially in treatment of 
chronic diseases, such as glaucoma. Topical pressure lowering medication is an 
effective mode of treatment. Variation in responsiveness to these medications is well 
recognised. In this thesis, the possible role of genetics in governing the responsiveness 
to topical Timolol XE 0.5% and latanoprost 0.005% was studied. The possible role of 
beta2 adrenoreceptor gene (ADRB2) and prostaglandin FP receptor gene (PTGFR) as 
susceptibility genes for glaucoma was also explored. 
A prospective observational cohort study of 97 and 86 glaucoma patients (POAG and 
NTG) treated with topical timolol monotherapy and topical latanoprost respectively 
was conducted. Intraocular pressure (IOP) was measured at baseline, 1, 3, 6 and 12 
months post-treatment. Venesection was conducted on glaucoma patients and 190 
unrelated age/ethnicity-matched controls. High purity genomic DNA was extracted 
and subjected for multiplex PCR to detect polymorphism at specific codons within 
ADRB2. Direct sequencing was used to screen the PTGFR covering 3000bp upstream 
from 5‟UTR and 1000bp downstream from 3‟UTR.  
Topical timolol and latanoprost provided good pressure lowering effect with mean 
IOP reduction from baseline of 5.4(5.1) mmHg and 7.1(4.2) mmHg respectively. 
Higher baseline IOP was found in patients with -47CC and 79CC of ADRB2. There 
was no significant association between ADRB2 and responsiveness to topical timolol.  
79G and -20T were found to increase the susceptibility to glaucoma 1.9-fold (95%CI 
1.0, 3.6) and 1.7-fold (95% CI 1.1, 2.7) respectively. 
Certain PTGFR polymorphisms appeared to confer protective effects against 
glaucoma.  The minor alleles of rs11162505, rs554185 and rs551253 reduced the 
susceptibility to glaucoma significantly. rs686262GG was associated with 6.3-fold 
(95%CI 1.3, 31.0) risk of poor response to topical latanoprost. 
Therefore, ADRB2 and PTGFR are potential pharmacodynamic genes for the 
responsiveness to topical timolol and latanoprost. ADRB2 and PTGFR may also act as 
susceptibility genes for glaucoma. 
 
 
 
 
 
 
 
4 
 
     TABLE OF CONTENTS 
 PAGE 
TITLE 
 
1 
DECLARATION 
 
2 
ABSTRACT 
 
3 
TABLE OF CONTENTS 
 
4 
LIST OF FIGURES 
 
10 
LIST OF TABLES 
 
12 
ABBREVIATIONS 
 
17 
ACKNOWLEDGEMENT 
 
21 
CHAPTER 1: INTRODUCTION                                                                                                 
 
1.1 The eye 
 
23 
1.2 Glaucoma 
 
24 
1.2.1 Prevalence of glaucoma 
 
27 
1.2.2 Glaucoma in Malaysia 
 
30 
1.3 Genetic basis of primary open-angle glaucoma 
 
38 
1.4 Intraocular pressure 
 
42 
1.4.1 Factors affecting intraocular pressure 
 
44 
1.4.2 Intraocular pressure fluctuation 
 
55 
1.4.3 The important of IOP reduction in glaucoma management 
 
59 
1.4.4 Target IOP 
 
63 
1.5 Topical pressure-lowering drugs 
 
65 
1.6 Topical β-adrenoreceptor antagonists 
 
70 
1.6.1 Topical timolol 
 
73 
1.6.2 Beta 2 adrenoreceptor (ADRB2) 
 
77 
1.6.3 Beta 2 adrenoreceptor gene (ADRB2) 81 
5 
 
1.7 Topical prostaglandin analogue compounds 
 
86 
1.7.1 Topical latanoprost 0.005% 
 
89 
1.7.2 Prostanoid receptors  
 
95 
1.7.3 Prostaglandin F2α receptor (FP) 99 
 
1.7.4 FP receptor gene (PTGFR) 102 
 
1.8 Pharmacogenetics 
 
105 
1.8.1  Pharmacogenetics of topical pressure lowering medications 109 
 
CHAPTER 2: PRESSURE LOWERING EFFECTS OF TOPICAL TIMOLOL AND     
LATANOPROST  
 
2.1 Objectives 
 
113 
2.2 Material and methods 
 
113 
2.2.1 Patients selection 
 
113 
2.2.2 Initiation of treatment 
 
117 
2.2.3 Follow-up visits 
 
118 
2.2.3.1 Visit 1 (1 month post-treatment) 
 
118 
2.2.3.2 Subsequent visits 
 
120 
2.2.4 Statistical analysis 
 
121 
2.3 Results 
 
123 
2.3.1 Topical timolol XE 0.5% monotherapy (Project B) 
 
123 
2.3.1.1 Demographic data 
 
123 
2.3.1.2 Baseline clinical characteristics for glaucoma patients 
 
124 
2.3.1.3 Comparison of demographic and clinical characteristics between Malay and 
Chinese glaucoma patients 
  
125 
2.3.1.4 Factors affecting baseline IOP 
 
126 
2.3.1.5 Mean IOP reduction during 12 months treatment with topical timolol  XE 0.5% 
 
127 
2.3.1.6 Repeated measures analysis of variance (RM ANOVA) of IOP at 1, 3, 6 and 12 
months post-treatment with topical Timolol XE 0.5% monotherapy 
129 
6 
 
 
2.3.1.7 Mean IOP reduction at baseline and 1 month, 3 months, 6 months, and 12 
months post-treatment with between and within subject effects 
 
131 
2.3.1.8 Responsiveness and side effects to topical Timolol XE 0.5% monotherapy 
 
134 
2.3.2 Topical latanoprost 0.005% (Project P) 
 
135 
2.3.2.1 Demographic data of recruited glaucoma patients 
 
135 
2.3.2.2 Distribution of demographic data according to ethnicity and treatment modalities  
 
136 
2.3.2.3 Comparison of baseline clinical characteristics according to type of glaucoma, 
ethnicity and treatment modalities 
 
137 
2.3.2.4 Factors affecting baseline IOP 
 
140 
2.3.2.5 Mean IOP reduction of 12 months treatment with topical latanoprost 0.005% 
 
141 
2.3.2.6 Repeated measure Analysis of variance (RM ANOVA) of IOP at 1, 3, 6 and 12 
months treatment with topical latanoprost 0.005% 
 
142 
2.3.2.7 Mean IOP reduction at baseline and 1 month, 3 months, 6 months and 12 months 
post-treatment with between and within subject effects 
 
144 
2.3.2.8 Responsiveness and side effects of topical latanoprost 0.005% 
 
147 
2.4 Discussion 
 
149 
2.4.1 Pressure lowering effect of topical timolol XE 0.5% 
 
149 
2.4.2 Pressure lowering effect of topical latanoprost 0.005% 
 
150 
CHAPTER 3: THE ROLE OF ADRB2 AND PTGFR GENE IN SUSCEPTIBILITY OF 
GLAUCOMA 
 
3.1 Objectives 
 
154 
3.2 Material and methods 
 
154 
3.2.1 Blood collection for DNA extraction 
 
154 
3.2.2 DNA extraction 
 
155 
3.2.3 ADRB2 screening  
 
156 
3.2.4 PTGFR screening 
 
160 
3.2.4.1 Screening of PTGFR exons 
 
166 
7 
 
3.2.4.2 Screening of PTGFR introns 
 
168 
3.2.4.3 Screening for microsatellite instability (MSI) in Intron 3 of PTGFR   
 
171 
3.2.4.4 Screening for polymorphism in the PTGFR  promoter region 
 
173 
3.2.4.5 Statistical analysis 
 
174 
3.3 Results 
 
177 
3.3.1 ADRB2 (Project B) 
 
177 
3.3.1.1 Demographic data 
 
177 
3.3.1.2 ADRB2 screening  
 
177 
3.3.1.3 Genotype and allele frequency for ADRB2 between glaucoma and control 
subjects 
 
180 
3.3.1.4  Allele frequency of ADRB2  polymorphisms according to sex and ethnicity in 
the Malaysian population 
 
182 
3.3.1.5 The role of ADRB2 polymorphisms in susceptibility of glaucoma in Malays and 
Chinese 
 
183 
3.3.1.6 The role of ADRB2 in susceptibility to POAG and NTG 
 
185 
3.3.1.7 Haplotypes analysis of ADRB2 
 
188 
3.3.2 PTGFR (Project P) 
 
190 
3.3.2.1 Demographic data 
 
190 
3.3.2.2 PTGFR screening in the  Malaysian population 
 
190 
3.3.2.3 Genotype and allele frequency of SNPs found in PTGFR in the Malaysian 
population 
 
213 
3.3.2.4 The effect of population stratification on susceptibility to glaucoma 
 
218 
3.3.2.5 PTGFR on susceptibility to glaucoma in Malays and Chinese 
 
223 
3.3.2.6 PTGFR and susceptibility to glaucoma in the Malaysian population 
 
234 
3.3.2.7 PTGFR and susceptibility to POAG in the Malaysian population 
 
235 
3.3.2.8 PTGFR and susceptibility to NTG in the Malaysian population 
 
242 
3.3.2.9 Haplotypes analysis of polymorphism found in PTGFR  
 
249 
8 
 
3.3.2.10 Microsatellite instability (MSI) of PTGFR in the Malaysian population 
 
251 
3.4Discussion 
 
254 
3.4.1 The role of ADRB2 as glaucoma susceptibility gene in the Malaysian population 
 
254 
3.4.2 PTGFR as glaucoma susceptibility gene in Malaysian population 
 
256 
CHAPTER 4: PHARMACOGENETICS OF TOPICAL TIMOLOL AND LATANOPROST IN 
GLAUCOMA PATIENTS 
 
4.1 Objectives 
 
260 
4.2 Material and methods 
 
260 
4.2.1 Recruitment of subjects 
 
260 
4.2.2 Genetic screening of ADRB2 and PTGFR 
 
261 
4.2.3 Statistical Analysis 
 
266 
4.3 Results 
 
267 
4.3.1 Pressure lowering effect of topical timolol and ADRB2  
 
267 
4.3.1.1 Demographic data 
 
267 
4.3.1.2 Long term pressure lowering effect of topical Timolol XE 0.5% monotherapy 
 
267 
4.3.1.3 Predictors affecting the long term efficacy of monotherapy treatment with topical 
Timolol XE 0.5% 
 
270 
4.3.1.4 ADRB2 and genotype value based on Fisher model 
 
271 
4.3.1.5 ADRB2 and pressure lowering effect of topical Timolol XE 0.5% monotherapy 
 
271 
4.3.1.5 Responsiveness to topical Timolol XE 0.5% monotherapy and ADRB2 
 
274 
4.3.2 Pressure lowering effect of topical latanoprost 0.005% and PTGFR  
 
278 
4.3.2.1 Demographic data 
 
278 
4.3.2.2 Predictors affecting the long term efficacy of topical latanoprost 0.005%  
 
280 
4.3.2.3 SNPs of PTGFR and genotype values based on Fisher model 
 
281 
4.3.2.4 PTGFR and long term pressure lowering effect of topical latanoprost 0.005% 
 
283 
4.3.2.5 PTGFR polymorphism and responsiveness to topical latanoprost 0.005% 
 
288 
9 
 
4.4 Discussion  
 
289 
4.4.1 Pressure lowering effect of timolol and (ADRB2) 
 
289 
4.4.2 Pressure lowering effect and (PTGFR) 
 
291 
CHAPTER 5: DISCUSSION                                                                                                        
 
5.1 Topical timolol and ADRB2 
 
5.1.1 Pressure lowering effect of topical Timolol XE 0.5% 
 
296 
 
296 
5.1.1.1 Mean IOP reduction 296 
  
5.1.1.2 Long term efficacy of topical Timolol XE 0.5% 300 
  
5.1.1.3 Side effects of topical Timolol XE 0.5% 305 
  
5.1.2 ADRB2 and susceptibility to glaucoma  306 
  
5.1.3 ADRB2 and pressure lowering effect of topical Timolol XE 0.5% 314 
  
5.2 Topical latanoprost and PTGFR 
 
5.2.1. Pressure lowering effect of topical latanoprost 0.005% 
318 
 
318 
  
5.2.2 Side effects of topical latanoprost 0.005% 324 
  
5.2.3 PTGFR and susceptibility to glaucoma 
 
327 
5.2.4 PTGFR and pressure lowering effect of topical latanoprost 0.005% 
 
332 
5.3 Limitation and recommendation 
 
336 
5.4 Conclusion: Pharmacogenetics in glaucoma management 337 
REFERENCES 
 
338 
 
APPENDICES 
 
384 
 
      
 
 
 
 
10 
 
LIST OF FIGURES 
  Page 
Figure 1.1 Cut section of the eye illustrating important anatomical structures 
 
24 
Figure 1.2 Map of Malaysia 
 
30 
Figure 1.3 Chemical structure and formula of timolol maleate 
 
73 
Figure 1.4 Molecular and genetic structure of ADRB2 
 
81 
Figure 1.5 Chemical structure of major topical prostaglandin analogue pro-
drugs and their hydrolyzed free acids 
 
87 
Figure 1.6 Molecular structure of the human and bovine FP receptor 
 
99 
Figure 1.7 Chemical structure of PGF2α  
 
102 
Figure 1.8 Human PTGFR based on Ensembl and Havana databases 
 
103 
Figure 2.1 Pattern of pressure lowering effect of topical Timolol XE 0.5% 
monotherapy at baseline, 1 month, 3 months, 6 months and 12 
months post-treatment. 
 
129 
Figure 2.2 Pattern of pressure lowering effect of topical Timolol XE 0.5% 
monotherapy at baseline, 1 month, 3 months, 6 months and 12 
months in POAG and NTG patients 
 
131 
Figure 2.3 Pattern of pressure lowering effect of topical latanoprost 0.005% 
at baseline, 1 month, 3 months, 6 months and 12 months post-
treatment. 
 
143 
Figure 2.4 Pattern of pressure lowering effect of topical latanoprost in POAG 
and NTG patients 
 
145 
Figure 3.1 Gel electrophoresis of multiplex PCR for ADRB2 in control and 
glaucoma patients 
 
178 
Figure 3.2 Schematic diagram of the position of SNPs found in ADRB2 
 
179 
Figure 3.3 Electropherogram of rs3766331 A/G found in the exon 4 of 
PTGFR gene and novel polymorphism rs3766332 A/T found in 
Malaysian population 
 
191 
Figure 3.4 Electropherogram of primer IVS 3-45 of glaucoma patient (P18) 
showing the rs11162504AA and rs11162505AA, and rs554173TC 
and rs554185AG. The position of rs11162504 and rs11162505 is 
just 18bp apart and 7bp apart between rs554173 and rs554185 
 
192 
Figure 3.5 Electropherogram of IVS 3-29 showing the presence of an area of 193 
11 
 
MSI, formed by a CA repeat.  
 
Figure 3.6 Electropherogram of IVS 3-55 of glaucoma patient (P52) showing 
rs501078TT, rs3766335GA and rs7543738CG. 
 
194 
Figure 3.7 Electropherogram of promoter region PRM LR3 primer showing 
rs12093097CT in glaucoma patient (P50) 
 
195 
Figure 3.8 Genotyping result of MSI at IVS 3-29 showing of deletion of 
certain part of MSI 
 
196 
Figure 3.9 Genotyping of IVS 3-56 MSI using capillary electrophoresis 
showing insertion of MSI 
 
197 
Figure 3.10 Distribution of SNPs found in the promoter, Intron 1 and Intron 2 
of PTGFR gene in the Malaysian population 
 
198 
Figure 3.11 Distribution of SNPs found in part of Intron 3 of the PTGFR gene 
in the Malaysian population 
 
199 
Figure 3.12 Distribution of SNPs in the last part of Intron 3 and Exon 4 of 
PTGFR 
 
200 
Figure 3.13 LD plot of PTGFR  
 
248 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
     LIST OF TABLES 
  Page 
Table 1.1 Prevalence of glaucoma in Southeast Asia based on studies 
conducted in Singapore, Southern China and Southern India 
 
37 
Table 1.2 Distribution of Malaysian population according to ethnicity is 
based on the 2000 National Census 
 
38 
Table 1.3 Commercially available topical anti-glaucoma drugs 
 
69 
Table 1.4 Properties of topical β-blockers 
 
72 
Table 1.5 Allele frequencies and phenotypes of ADRB2 polymorphisms 
 
85 
Table 2.1 Grading of conjunctival hyperaemia induced by topical latanoprost 
 
119 
Table 2.2 Demographic data of the recruited glaucoma patients 
 
123 
Table 2.3 Comparison of clinical characteristics between POAG and NTG 
patients 
 
124 
Table 2.4 Distribution of demographic and clinical characteristics of 
glaucoma patients according to ethnicity 
 
125 
Table 2.5 Univariate regression analysis on factors affecting baseline IOP  
 
126 
Table 2.6 Mean IOP reduction and percentage of reduction from baseline at 
1, 3, 6 and 12 months follow-up 
 
127 
Table 2.7 Percentage and reason for „drop-out‟ from study protocol 
 
128 
Table 2.8 Mean IOP difference between follow-up visits 
 
130 
Table 2.9 Mean IOP difference between follow-up visits of POAG and NTG 
patients  
 
132 
Table 2.10 Comparison of mean IOP at follow-up visits between  
hyperlipidemia and non-hyperlipidemia glaucoma patients  
 
133 
Table 2.11 Percentage of  good and poor responder according to different 
definition of responsiveness to topical Timolol XE 0.5% 
134 
 
Table 2.12 
 
Demographic data of recruited glaucoma patients 
 
 
135 
Table 2.13 Comparison of demographic data according to ethnicity and 
treatment modalities 
 
136 
Table 2.14 Comparison of mean age and baseline clinical characteristics 
between POAG and NTG patients 
137 
13 
 
 
Table 2.15 Comparisons of baseline clinical characteristics between Malays 
and Chinese   
 
138 
Table 2.16 Comparison of baseline clinical characteristics between 
monotherapy and adjunctive therapy of topical latanoprost 
 
139 
Table 2.17 Univariate linear regression analysis on factors affecting baseline 
IOP 
 
140 
Table 2.18 Mean IOP and percentage of IOP reduction from baseline  
 
141 
Table 2.19 Comparison of mean IOP and percentage of IOP reduction from 
baseline between monotherapy and adjunctive therapy of topical 
latanoprost 
 
142 
Table 2.20 Comparison of mean IOP difference at follow-up visits 
 
144 
Table 2.21 Mean IOP difference at follow-up visits in POAG and NTG 
patients 
 
146 
Table 2.22 Percentage of good and poor responder according to different 
definition of responsiveness to topical latanoprost 0.005% 
 
147 
Table 2.23 Percentage of ocular side effects according to follow-up visits  
 
148 
Table 3.1 Primers sequence for multiplex PCR  
 
157 
Table 3.2 Primers sequence for exons screening of PTGFR  
 
162 
Table 3.3 Primers sequence for Intron 1 and 2 screening of PTGFR  162 
Table 3.4 Primers sequence for Intron 3 screening of PTGFR  
 
163 
Table 3.5 Primers sequence for MSI screening of IVS 3-29 and IVS 3-53 
 
172 
Table 3.6 Primers sequence for promoter region of PTGFR  174 
Table 3.7 Demographic data of glaucoma and control subjects 174 
Table 3.8 Genotype frequency of ADRB2 polymorphisms between glaucoma 
and control subjects 
 
180 
Table 3.9 Allele frequency of ADRB2 gene polymorphisms between 
glaucoma and control subjects 
 
181 
Table 3.10 Allele frequency of ADRB2 polymorphisms according to  sex and 
ethnicity  
 
182 
Table 3.11 Stratified Mantel-Haenszel meta-analysis on ADRB2 183 
14 
 
polymorphisms and susceptibility to glaucoma 
 
Table 3.12 Univariate logistic regression on predictors for glaucoma 
susceptibility in the Malaysian population 
 
184 
Table 3.13 Stratified Mantel-Haenszel meta-analysis on ADRB2 and 
susceptibility to POAG  
 
185 
Table 3.14 Univariate logistic regression exploring the role of ADRB2 
genotypes and other predictors in influencing risk of POAG 
prevalence relative to unaffected “normal” individuals 
 
186 
Table 3.15 Stratified Mantel-Haenszel meta-analysis on ADRB2 and 
susceptibility to NTG 
 
187 
Table 3.16 Univariate logistic regression exploring the role of ADRB2 
genotypes and other predictors in influencing risk of NTG 
prevalence relative to unaffected “normal” individuals 
 
188 
Table 3.17 Single marker check for ADRB2 polymorphisms based on 
Haploview analysis 
 
189 
Table 3.18 Demographic data of glaucoma and control subjects 190 
 
Table 3.19 Genotyping and allele frequency of SNPs found in PTGFR gene in 
the Malaysian population 
 
213 
Table 3.20 
 
Allele frequency of SNPs found in PTGFR between Malays and 
Chinese 
 
219 
Table 3.21 Linear by linear association between genotype frequency of 
PTGFR and susceptibility to glaucoma in Malays and Chinese 
 
223 
Table 3.22 Stratified Mantel-Haenszel meta-analysis on PTGFR and 
susceptibility to glaucoma in Malays and Chinese 
 
227 
Table 3.23 Univariate logistic regression analysis on predictors for glaucoma 
susceptibility in Malays 
 
232 
Table 3.24 Univariate logistic regression analysis on predictors for glaucoma 
susceptibility in Chinese 
 
233 
Table 3.25 Stepwise logistic regression exploring the PTGFR in influencing 
the risk of prevalence of glaucoma relative to unaffected normal 
individuals 
 
234 
Table 3.26 Stratified Mantel-Haenszel meta-analysis on PTGFR and 
susceptibility to POAG relative to unaffected normal individuals 
in Malays and Chinese  
 
235 
15 
 
Table 3.27 Stepwise logistic regression on PTGFR and predictors for 
susceptibility to POAG in the Malaysian population 
 
240 
Table 3.28 Stratified Mantel-Haenszel meta-analysis on PTGFR and 
susceptibility to NTG relative to unaffected normal individuals in 
Malays and Chinese  
 
241 
Table 3.29 Stepwise logistic regression on PTGFR and susceptibility to NTG 
in the Malaysian population 
 
246 
Table 3.30 Association of haplotypes of PTGFR between glaucoma and 
control subjects 
 
247 
Table 3.31 Association of MSI size found within primer IVS 3-29 between 
glaucoma and control subjects  
 
249 
Table 3.32 Association of MSI size within primer of IVS3-56 between 
glaucoma and control subjects  
 
250 
Table 3.33 Association of the haplotypes pairing of the identified MSI in 
PTGFR between glaucoma patients and controls 
 
251 
Table 4.1 Univariate analysis on the predictors affecting long term efficacy 
to topical Timolol XE 0.5% 
 
262 
Table 4.2 Factors affecting long term efficacy of topical Timolol XE 0.5% 
treatment by stepwise logistic regression model 
 
264 
Table 4.3 
 
Fisher model on genotype value of ADRB2 265 
Table 4.4 Association between ADRB2 and pressure lowering effect of 
topical Timolol XE 0.5% in Malays and Chinese 
 
266 
Table 4.5 Association between ADRB2 and pressure lowering effect of 
topical Timolol XE 0.5% monotherapy in glaucoma patients 
 
267 
Table 4.6 Stratified Mantel-Haenszel meta-analysis on ADRB2 and 
responsiveness to topical Timolol XE 0.5% monotherapy 
 
269 
Table 4.7 Univariate logistic regression on the predictors for responsiveness 
to topical Timolol XE 0.5% monotherapy 
 
270 
Table 4.8 Univariate analysis on the potential clinical predictors that affect 
the ability to complete 12 months treatment of topical latanoprost 
0.005% 
 
272 
Table 4.9 Stepwise logistic regression on factors affecting the ability of 
glaucoma patients to complete study protocol 
 
273 
Table 4.10 Quantitative trait locus on IOP reduction in PTGFR based on 274 
16 
 
Fisher model 
 
Table 4.11 Association between mean IOP at each follow up visit according 
to genotype of selected SNPs of PTGFR in Malays and Chinese 
 
277 
Table 4.12 Association between mean IOP at each follow-up visit and 
genotype frequency of selected SNPs of PTGFR   
 
279 
Table 4.13 Stratified Mantel-Haenszel analysis on PTGFR and responsiveness 
to topical latanoprost 0.005% 
 
282 
Table 4.14 Predictors affecting response to topical latanoprost 0.005% in 
Malay glaucoma patients 
 
286 
Table 4.15 Factor affecting response to topical latanoprost 0.005% in Chinese 
glaucoma patients 
 
287 
Table 4.16 Stepwise logistic regression on factor affecting response to topical 
latanoprost 0.005% in both Malay and Chinese glaucoma patients 
 
288 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
ABBREVIATIONS 
ACG Angle Closure Glaucoma 
 
ADRB1 
 
Beta 1 adrenoreceptor 
ADRB2 
 
Beta 2 adrenoreceptor 
ADRB2 Beta 2 adrenoreceptor gene 
 
AGIS Advanced Glaucoma Intervention Study 
 
ANOVA Analysis of Variance 
 
Apo E Apolipoprotein E 
 
APRRE Acute-Phase Reactant Regulatory Elements 
 
ARMD Age Related Macular Degeneration 
 
ATP 
 
Adenosine Triphosphate 
BAC 
 
Benzylkonium Chloride 
BUP Beta Upstream Peptide 
 
BMI Body Mass Index 
 
cAMP Cyclic Adenosine Monophosphate 
 
CCT Central Corneal Thickness 
 
CH Corneal Hysteresis 
 
CHW Chinese Hamster Fibroblast 
 
CI 
 
Confidence interval 
CIGTS Collaborative Initial Glaucoma Treatment Study 
 
CME 
 
Cystoids Macular Edema 
CNTGS 
 
Collaborative Normal Tension Glaucoma Syndrome 
CRE 
 
Cyclic Adenosine Monophosphate Response Element 
CRTH Chemo-attractant Receptor Homologous Molecules 
 
COX 
 
Cyclooxygenase 
18 
 
CYP  Cytochrome P450 
 
ddH2O Double deionised water  
 
DNA 
 
Deoxyribonucleic Acid 
dNTPs Deoxynucleoside Triphosphate 
 
EDTA 
 
Ethyldiaminetetraacetic acid 
EGPS 
 
European Glaucoma Progression Study 
EM 
 
Extensive metaboliser 
EMGT 
 
Early Manifest Glaucoma Treatment 
EVP 
 
Episcleral Venous Pressure 
GAT 
 
Goldmann Applanation Tonometry 
GDP 
 
Guanosine Diphosphate 
GFS 
 
Gel Forming Solution 
GPCR G Protein-Coupled Receptor 
 
GRKs G Protein-Coupled Receptor Kinases 
 
GTP 
 
Guanosine Triphosphate 
GWAS Genome Wide Association Study 
 
HASM Human Airway Smooth Muscle cells 
 
HFA Humphrey Visual Field Analysis 
 
HLM Human Lung Mast cells 
 
HM Homozygous Mutant 
 
HT Heterozygous 
 
5-HT3 Serotonin 
 
HW 
 
Homozygous Wild 
HWE 
 
Hardy Weinberg Equilibrium 
IOP 
 
Intraocular Pressure 
19 
 
IOPG 
 
Intraocular Pressure Goldmann 
IOPG Goldmann-correlated Intraocular Pressure 
 
JOAG Juvenile Open Angle Glaucoma 
 
5‟-LC 5‟-Leader Cistron 
 
LCI Lower Confidence Interval 
 
LD 
 
Linkage Disequilibrium 
LIID Latanoprost-Induced Iris Darkening 
 
LLA 
 
Linear-by-Linear Association 
LOH Loss Of Heterozygosity 
 
LOXL1 
 
Lysyl Oxidase-Like protein 1 
MAF Minor Allele Frequency 
 
MD Mean Deviation 
 
MgCl2 Magnesium Chloride 
 
MMP Matrix Metalloproteinase 
 
mRNA 
 
Messenger Ribonucleic 
MSI 
 
Microsatellite Instability 
MYOC Myocilin 
 
NAT-1 N-acetyltransferase 1 gene 
 
NAT-2 N-acetyltransferase 2 gene 
 
NTG 
 
Normal Tension Glaucoma 
OAG  Open Angle Glaucoma 
 
OHT Ocular Hypertension 
 
OHTS 
 
Ocular Hypertension Treatment Study 
OPTN Optineurin 
 
OR Odd Ratio 
 
20 
 
PACG 
 
Primary Angle Closure Glaucoma 
PAWS Predictive Analytic Software Programme 
 
PCR Polymerase Chain Reaction 
 
POAG 
 
Primary Open Angle Glaucoma 
PM 
 
Poor Metaboliser 
PSD Pattern Standard Deviation 
 
PTGFR Prostaglandin F2α receptor 
 
PTGFR 
 
Prostaglandin F2α receptor gene 
QOL Quality of Life 
 
QTL Quantitative Trait Locus 
 
RM ANOVA 
 
Regression Measure Analysis Of Variance 
SD Standard Deviation 
 
SE 
 
Standard Error 
SNP 
 
Single nucleotide polymorphism 
TBE Tris-Base, Borate and EDTA 
 
TIGR Trabecular meshwork inducible glucocorticoid responsive  
 
TNF Tumour Necrosis Factor 
 
TPMT Thiopurine Methytransferase 
 
UCI 
 
Upper Confidence Interval 
UTR Untranslated Region 
 
UM Ultra-rapid Metaboliser 
 
VCDR Vertical Cup to Disc Ratio 
 
WDR36 WD40-repeat 36 
 
WHO World Health Organization 
 
XFG Pseudo-exfoliation glaucoma 
 
21 
 
     Acknowledgement 
 
 
First and foremost, I would like to express my sincere gratitude to my 
supervisor, Professor Dr Paul J Foster, who has supported me throughout my 
PhD with his patience and knowledge whilst allowing me the room to work on 
my own. Dr Anand Viswanathan, my co-supervisor who has provided me with 
his guidance and advice. My deepest gratitude to Professor Rusli Ismail, my 
second co-supervisor, who has shared with me his knowledge and expertise in the 
field of pharmacogenetics. 
My genetic laboratory work was conducted in two continents; Asia and Europe, 
which gave me the opportunity not only to learn about molecular genetics but 
also exposed me to various different laboratory techniques and clever innovation. 
I would like to thank Mr Nizam Zahary, who has helped me with the basic 
molecular laboratory work at the initial stage of this research project. He tried 
very hard not to laugh when my eppendorf tubes were overheated or when I ran 
gel electrophoresis without the PCR product!  
I would like to thank Professor Shoami Bhattacharya for allowing me to use his 
laboratory facilities at the Institute of Ophthalmology. His thoughtful advice and 
guidance is of a great value to me. My deepest gratitude goes to Naushin 
Waseem, who is not only a genius in „trouble shooting‟, even through long 
distance communication, but also a great teacher and a big shoulder to cry on. 
To Amna, Sabrina, Anna, Becky, Christina and Bev, thank you for being a good 
listener and for the lively lunch break sessions. To Sancy, thank you for being a 
true friend. Last but not least, I would like to thank Mr Lee Pak Sang, for being 
a great problem solver especially on the technical aspect. 
My laboratory findings will not be meaningful without the statistical analysis 
guidance from Dr Khor Chieun Chen and Ms Karoline Kuchenbacker. To CC 
Khor, thank you for answering all my silly questions and for the step by step 
guide on statistical analysis. This research project was made possible by research 
grant funding from Ministry of Science, Technology and Innovation (MOSTI) 
and Ministry of Higher Education (MOHE), Malaysia.  
To my husband, Zilfalil Alwi, thank you for your understanding and patience. 
To my children, Zahim, Annisa and Aliya, you are my pillar of strength and 
aspiration. To my loving mum and my belated father, who passed away during 
my thesis writing, thank you for instilling the „competitive‟ spirit in me. And to 
my parents in law, thank you for looking after my children whenever I am away. 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
           
     CHAPTER 1 
      Introduction
                                           
 
 
 
23 
 
Chapter 1 
1.1 The eye 
The eye is an important sensory organ that acts as a window in the complex 
physiology of seeing. Light passes through the transparent cornea, the outermost 
avascular structure that refracts light to the lens. The amount of light entering the eye 
is regulated by the iris through its opening, the pupil. The pupil dilates in the dark or 
dim surroundings and constricts in bright surroundings. Light is refracted by the lens 
to the retina. The crystalline lens is a transparent structure behind the pupil, held in 
place by suspensory ligaments and zonules.  
 
The light then reaches the retina. The retina acts in the manner of film in the camera, 
by capturing images, colours, objects and other beautiful sights. The retina contains 
specialized light-sensitive cells known as rods and cones. There are 110 to 125 
million rods, which facilitate vision in dim light. Cones number approximately 6 to 7 
million, are mainly concentrated in the macula, and are responsible for vision in bright 
surroundings and capturing colours. The macula lutea surrounds the depressed, 
yellowish spot known as the fovea. The macula is the most sensitive part of the retina, 
capturing images directly and sending them to the brain through the optic nerve. The 
optic nerve, which contains 1.5 million nerve fibres, acts as an electrical cable sending 
information to the brain. In diseases such as glaucoma, wherein the nerve fibres are 
damaged, the information sent to the brain is affected. The inadequate information 
results in certain patterns of visual field defects that reflect the area of affected nerve 
fibres. Each nerve fibre is responsible for sending information from a specific area of 
the visual field. 
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Figure 1.1: Cut section of the eye illustrating important anatomical structures 
(Adapted from http://www.eyephysiciansoflakewood.com/anatomy-of-the-eye.php) 
 
1.2 Glaucoma 
The word glaucoma originates from the Greek word „glaukos‟, meaning blue, green, 
and cloudy, and was described in the literature as early as 400 BC. It was later 
described as „migraine of the eye‟ and „headache of the pupil‟ in the 13th century. In 
the 18
th
 and 19
th
 centuries, it was thought to be a disease of the vitreous humour, 
arthritis, and iritis, a theory disproven by Helmholtz in 1851. He found that the 
changes in the optic nerve. Based on clinical observation, glaucoma understanding 
evolved. Donder in 1862 observed that glaucoma is a chronic disease with elevated 
pressure but without signs of inflammation causing fixed dilated pupil at the end stage 
(von Graefe, 1862). Later, glaucoma was defined as optic neuropthy resulted from 
numerous risk factors (Drance, 1973). 
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Glaucoma is a complex disease with many underlying mechanisms which has a 
relationship with intraocular pressure (IOP). Elevation of IOP, which exerts 
mechanical pressure, was believed to cause direct damage to the retinal nerve fibre 
layer. Initially, increased IOP was thought of as a causative factor in glaucoma, but 
recently has been regarded as a risk factor, indeed the only modifiable risk factor. The 
new understanding of glaucoma came from observation of those with normal 
pressures who developed glaucomatous cup disc changes with typical patterns of 
visual field defects (Sjögren, 1946; Drance, 1972; Leighton and Philips, 1972).  This 
subtype of glaucoma is then named as normal tension glaucoma (NTG). The changes 
of optic nerve head with normal pressure challenged the pressure-dependent theory, 
which perhaps only applies to cases of elevated IOP. Current theories identify two 
mechanisms responsible for glaucomatous damage to the optic nerve head: pressure-
dependent or pressure-independent.  
 
A pressure-independent mechanism with specific focus on retinal ganglion cell death 
may be a more relevant postulation (Caprioli, 2007). Pressure-independent 
mechanisms encompass various postulations, including impaired microcirculation of 
the optic nerve head, excitotoxicity (Kaushik et al, 2003), abnormal glial-neuronal 
interactions (Tezel and Wax, 2000), neurotrophin starvation (Schuettauf et al, 2002), 
defective endogenous protection (Caprioli et al, 2007), and autoimmunity (Maruyama 
et al, 2000). Glaucoma may result from various predisposing factors and interaction of 
pressure and pressure independent mechanisms. For example genetic predisposing 
factors, initiating factors such as pressure changes, promoting factors such as changes 
in the laminar structure, and sustaining factors such as excitatory mechanisms may be 
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responsible for glaucoma (Caprioli, 2007). Thus, glaucoma is not a single disease with 
one direct cause, as a specific organism causes a specific infectious disease.  
 
Glaucoma represents multiple conditions with a final common pathway leading to 
optic nerve damage and visual field loss. Glaucomatous optic neuropathies can result 
from various causative factors and is commonly classified as open-angle glaucoma 
(OAG) or angle-closure glaucoma (ACG), according to the angle configuration. These 
classifications are further divided according to causative aetiology: primary, or those 
without any explanatory cause and secondary, those associated with systemic and 
other ocular pathologies. Glaucoma is also classified according to age of onset; 
congenital, juvenile and adult onset. 
 
However, glaucoma is not well defined. The variable definitions of glaucoma not only 
create problems in detection and accurate assessments of prevalence, but also cause 
confusion when analyzing the type of glaucoma. The first population-based study to 
identify glaucoma without specific reference to IOP, using visual field, and optic disc 
anatomy to define glaucoma was carried out in south Wales (Hollows and Graham, 
1966). Later, IOP was specifically identified as a modifiable risk factor and not a 
criterion for glaucoma diagnosis (Sommer, 1989). There is no absolute level where 
IOPs above or below are strongly associated with development of or protection 
against glaucoma. In addition, there are factors such as age; diurnal variation, central 
corneal thickness (CCT), and the type of tonometer employed that affect the accuracy 
of IOP measurements. Defining glaucoma solely based on IOP will lead to over- and 
underestimation of incidence and prevalence of glaucoma. However, IOP has 
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remained part of the definition of glaucoma in many population-based studies 
(Dielemans et al, 1994; Klein et al, 1992).  
 
Most studies define glaucoma based on vertical cup-to-disc ratio (VCDR) and visual 
field changes (Klein et al, 1992; Leske 2007; Tielsch et al, 1991; Mitchell et al, 1996). 
Dandona et al (2000) defined their subjects as definite primary open angle glaucoma 
(POAG) on the basis of VCDR and previously obtained visual field data and 
suspected cases included those with suspicious optic disc damage but without 
definitive visual field loss. The Visual Impairment Project (VIP) adopted definite, 
probable and possible diagnoses as defined by a panel of experts (Weih et al, 2001). 
The variable definitions and lack of consensus in various population-based studies 
resulted in certain subjects being diagnosed as having glaucoma in one study and the 
same subject being labelled as suspect, a probable case, or worse, considered a non-
glaucoma subject in another study. Currently, a group of experts in glaucoma research 
defines glaucoma based on structural and functional evidence of glaucomatous optic 
neuropathy, mainly relying on VCDR and visual field changes (Foster et al, 2002).  
 
1.2.1 Prevalence of glaucoma 
Glaucoma was ranked by the World Health Organization (WHO) as the third leading 
cause of vision loss in 1990 and is responsible for 13% of all blindness, affecting 
approximately 5 million people (Thylefors and Négrel, 1994). In the most recent 
WHO report, glaucoma has moved to second place as the leading cause of global 
blindness (Resnikoff S et al, 2004). It is estimated that approximately 1 in 200 of the 
general population over the age of 40 and more than 5% of those older than 75 were 
affected by glaucoma in 1985 (Gibson et al, 1985). By the year 2000, glaucoma was 
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estimated to affect approximately 66.8 million people worldwide, with 6.7 million 
suffering from bilateral blindness (Quigley, 1996). The estimation was based on 111 
published glaucoma prevalence studies in 7 stratified populations with a clear 
definition of glaucoma, random selection of samples, and large sample sizes.  
 
Ten years later, using different criteria, Quigley and Broman (2006) predicted that 
60.5 million people will be affected by glaucoma in 2010 and estimated a further 
increase to 79.6 million in 2020. This prediction was not based entirely on the 
previous 111 publications on glaucoma prevalence used in the 1996 study (Quigley, 
1996) but utilized a new set of criteria emphasizing population-based studies and a 
more definitive definition of glaucoma. It is also estimated that 8.4 million people will 
be bilaterally blind due to primary glaucoma in 2010, with 11.1 million will be 
affected by 2020. Based on a meta-analysis of 8 population-based studies including 
the Baltimore Eye Study, Barbados Eye Study, Beaver Dam Eye Study, Blue 
Mountains Eye Study, Kongwa Eye Project, Proyecto Vision Evaluation Research, 
Rotterdam Study, and the Melbourne Visual Impairment Project, the prevalence of 
glaucoma has been extrapolated to affect 3.36 million Americans by 2020 (Eye 
Disease Prevalence Research Group, 2004). The prevalence of glaucoma is increasing 
but only half of the sufferers are likely to be known to the health system in developed 
countries (Coffey et al, 1993). This number is estimated to be lower in developing 
countries. Furthermore, glaucoma is responsible for irreversible blindness. Unlike 
cataracts, for which timely surgery and intraocular lens implantation can reverse 
vision loss, the burden of glaucoma is more devastating if appropriate measures are 
not taken. With the growing aged population, glaucoma is disease of longevity. 
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OAG is the most common type of glaucoma affecting people in all parts of the world. 
Quigley and Broman (2006) predicted that the mean prevalence of OAG is 1.96% 
among persons over 40 in 2010. The prevalence of OAG based on persons 40 years 
and older is reported to be 1–8% in Africa and higher among those in West Africa (7–
9%), 2–3% in Australia, 1–4% in Asia, and 1–3% in Europe (Leske, 2007; Weih et al, 
2001; Foster et al, 2000).  
 
ACG is more likely to affect people in Asia and the Pacific region, with 80% of them 
in developing countries (Thylefors and Negrel, 1994). Based on the Quigley and 
Broman (2006) estimation, half of the blindness caused by glaucoma was in Asia in 
2000. In 2010, it was predicted that 86.5% of ACG will be in Asia with 46.5% of the 
cases in China. The visual loss in ACG is more profound than in OAG (Foster and 
Johnson, 2001). Although the estimated impact of ACG in 2010 was lower (15.7 
million) compared to OAG (44.7 million), the frequency of ACG-blindness is almost 
equal to that of OAG due to the greater morbidity of ACG (Quigley and Broman, 
2006). Although great emphasis has been given to ACG, OAG is still the most 
common glaucoma in Asia (Quigley and Broman, 2006; Foster and Johnson, 2001). 
The largest absolute number of people affected by both OAG and ACG is in Asia, 
followed by Europe and India. Africa has the highest frequency of glaucoma in the 
adult population. Asia, including East and Southeast Asia, is the most populous 
continent in the world. China is home to 1/5 of the world population, with a recorded 
glaucoma prevalence ranging between 3.0 and 3.8% among those 40 years old and 
older (He et al, 2006; Foster et al, 2000). Thus, it is no surprise that the incidence of 
glaucoma is high in this part of the world.  
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The 1994 World Health Organization (WHO) model estimated that 2.7 million people 
were affected by secondary glaucoma and congenital glaucoma affects 300,000 
children (Thylefors and Negrel, 1994). As most other prevalence models are based on 
populations more than 40 years old, congenital glaucoma is frequently overlooked. 
The WHO model divided the data into congenital, OAG, ACG, and secondary 
glaucoma; IOP was also used as one of the diagnosis criteria. This conflict has 
resulted in different prevalence and estimation outcomes; nonetheless, these studies 
provide us with useful data on the importance of prevention of blindness in glaucoma. 
 
1.2.2 Glaucoma in Malaysia 
 
Figure 1.2: Map of Malaysia  
Malaysia, a Southeast Asian country consists of a peninsula bordering Thailand and 
the northern third of the island of Borneo. The strategic location of peninsular 
Malaysia, surrounded by the Straits of Malacca and the South China Sea, attracted 
Chinese and Indian explorers, Arab traders, Christian missionaries, Portuguese 
crusaders, and traders from other parts of the world. Malaysia was a British colony in 
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the 18
th
 and 19
th
 centuries. During the British era, immigrants from Southern China 
and Southern India were brought in to increase the work force in the rubber and tin 
mining industries. Most immigrants stayed on after Malaysia gained independence in 
1957, enriching the Malaysian population with multi-ethnic Asian cultures and 
beliefs. Based on 2004 statistics, the population is comprised of 50.4% Malays, 23.7% 
Chinese, 11% indigenous people, 7.1% Indians and 7.8% others. The total population 
of Malaysia is 25,715,819 with 31.4% aged 0–14 years, 63.6% aged 15–64, and only 
5% are 65 and older (July 2010 estimation from Department of Statistics, Malaysia). 
Malaysia has a relatively young population and exhibits a broad-based pyramidal 
population distribution. 
 
Since Malaysia gained independence from Great Britain in 1957, the country has 
progressed from exporter of raw materials (especially rubber, tin, and petroleum) to 
manufacturing, service, and tourism. The escalation of economic strength has not only 
improved the quality of life but also the healthcare system, which has increased life 
expectancy. In general, Malaysia has a two-tier health care system comprised of a 
government-run universal health system run by the Ministry of Health and 
supplemented by university hospitals run by the Ministry of Higher Education and a 
private healthcare system. The system is the legacy of British colonization but has 
undergone many transformations to meet the needs of Malaysians (Ismail and 
Rohaizat, 2002).  
 
There are 143 government hospitals and 209 private hospitals with 52,938 beds 
(Planning and Development Division, Ministry of Health, Malaysia, 2009). In 
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addition, there are 802 health clinics, 1927 community clinics, 95 maternal and child 
health clinics, and 193 mobile health clinics run by the Ministry of Health, Malaysia. 
There are 6371 registered private medical clinics and 1435 private dental clinics. The 
infant mortality rate, an important marker of the effectiveness of a health system, is 
ranked 123
rd
 in the world, with 6.3 deaths per 1000 live births (Department of 
Statistics, Malaysia). The life expectancy at birth is 73.3 years and is slightly longer 
for females (76.2 years). The over-50 population has increased drastically from 3.8% 
in 1998 to 4.6% in 2010 (Department of Statistics, Malaysia). Age-related diseases 
including glaucoma and age-related macular degeneration (ARMD) have become 
increasingly important. ARMD was unknown in Malaysia in the late 1970s and on the 
rise lately. 
 
Glaucoma was ranked as the fifth major cause of blindness and visual impairment 
based on the National Eye Survey conducted in 1996 (Zainal M et al, 2002). 
However, the survey was conducted in the respondents‟ homes with the aid of torch 
lights and a direct ophthalmoscope, without appropriate facilities such as slit lamps, 
tonometry, gonioscopic, and visual field assessments required for accurate diagnosis 
of glaucoma. Thus, underestimation of disease prevalence is quite likely. In addition, 
the response rate was low. However, this survey provides an important baseline on 
which to build a strategy for blindness prevention. A cross-sectional study in 3 small 
villages in the Sepang district of Selangor, Malaysia, found that glaucoma was the 
third (4.4%) most common cause of ocular disease among selected individuals aged 
40 years and above (Reddy et al, 2006). However, eye examinations were successfully 
conducted in only 159 participants out of 341 eligible respondents. Seven cases of 
glaucoma were detected, with 5 cases newly diagnosed. In spite of the small number 
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of newly detected cases, 1 had visual impairment and 1 was already blind due to 
glaucoma (Reddy et al, 2006). Based on a retrospective 5-year survey of patients 
attending the ophthalmology clinic at Hospital Kuala Lumpur, the largest hospital in 
Malaysia, POAG was found as the most common type of glaucoma, followed by 
primary angle closure glaucoma (PACG) (Sharif and Selvarajah, 1997). This finding 
did not reflect true prevalence and cannot be extrapolated to the Malaysian population 
at large. Moreover, this data should be analysed with care in light of the lessons 
learned in Singapore. Based on hospital admission, Wong et al (2000) found that 
PACG was the most common type of glaucoma among Chinese in Singapore, but this 
was not reflected in a population-based study (Foster et al, 2000). However, the Sharif 
and Selvarajah (1997) study provides the hospital incidence of a common type of 
glaucoma in Malaysia. Unfortunately, there have been no population-based studies to 
determine the prevalence of glaucoma in Malaysia. The need for a prevalence study is 
timely, as a majority of glaucoma cases present at the advanced stage of disease even 
at their initial presentation to the hospital (Chieng et al, 2005).  
 
Predicting the prevalence of glaucoma is a challenge due to Malaysia‟s ethnic 
diversity. However, the prevalence data from available population-based studies from 
countries with similar ethnicities (table 1.1) may help in predicting the possible 
impact of glaucoma in the Malaysian population. Based on the 2000 Malaysian 
National Census (the next national census is due in 2010), there are 5,419,185 people 
over the age of 40 (Table 1.2) residing in Malaysia. The recently published Singapore-
Malay Eye Study (SiMES) is important in predicting the prevalence of glaucoma in 
Malays especially in the Malay Archipelago. SiMES reported the prevalence of 
glaucoma as 3.4% (Shen et al, 2008). Based on this prevalence, it is estimated that 
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88,306 of the Malay population in Malaysia are affected by glaucoma. However, this 
is likely to be a low estimate as the total number of Malays in Malaysia is much 
higher than in Singapore.  
 
Similar to the Chinese in Singapore, a majority of Chinese in Malaysia originated 
from South China. If the prevalence of 3.5% is used (based on the mean of the 
prevalence from studies conducted in Tanjung Pagar, Singapore, and Guangzhou, 
China), the estimated number of Chinese in Malaysia affected by glaucoma is 64,426. 
The migration of Indians from South India, especially from Chennai and Kerala 
during the British era, led a majority of them to stay on after Malaysia gained 
independence. Based on the prevalence reported in Southern India (Ramakrishnan R 
et al, 2003), the estimated number of Indians affected by glaucoma in Malaysia is 
11,209.  
 
Overall, there is a greater likelihood of underestimation as the vast majority of 
indigenous people (Iban, Kadazan, Senoi, Negrito, etc.) are not included, nor are those 
categorized as „other‟ in Malaysia. The indigenous or Bumiputra population 
contributed 9.2% of the total estimated Malaysian population aged 40 years old and 
older. There are 19 sub-ethnic groups of indigenous people in Peninsular Malaysia, 
mainly Negrito, Senoi, and aboriginal Malays. The aboriginal Malays differ from the 
Deutero-Malays that currently dominate Malaysia in their physical appearance and 
cultural practices. There are more than 30 sub-ethnic groups in Sabah and 50% of 
Sarawak consists of indigenous people. They speak different languages and dialects, 
practice traditional farming, and some still live as nomads in the deep tropical jungles 
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of Malaysia. Although many of them have embraced Islam and Christianity, many 
more still practice animism. There is little knowledge regarding their incidence of 
ocular disease. In spite of the possible under- and overestimation based on available 
predictive data, an alarming 163,941 people over 40 years old are predicted to be 
affected by glaucoma in Malaysia.  
 
Future public health strategy should not only aim to provide better healthcare in urban 
areas, but should also reach out to the indigenous and socioeconomically 
disadvantaged people who live in the remote areas of Malaysia, especially East 
Malaysia, and effectively address their reluctance to accept modern medicine. 
Currently the ophthalmologist-to-population ratio is estimated to be 1:200,000. The 
exact number of ophthalmologists in private practice is not available. The ratio is 
more than adequate based on the WHO minimum recommendation but fails to reach 
the 1:50,000 target of Malaysia‟s Ministry of Health requirements. Furthermore, the 
1:200,000 is not well distributed in Malaysia, especially East Malaysia. The ratio is 
estimated to reach 1:75,000 or even less in urban metropolitan areas such as Kuala 
Lumpur but the gap is greater in rural areas such as Sabah and Sarawak, East 
Malaysia. This disparity will create a huge gap in the quality of health services in 
Malaysia if the issue is not addressed appropriately. 
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Table 1.1: Prevalence of glaucoma in Southeast Asia based on studies conducted 
in Singapore, Southern China and Southern India 
Population    Location Author                Prevalence  
     (95% Confidence Interval) 
Overall^ POAG** PACG** 
Malay          Singapore 
 
 
Chinese      Tg Pagar, 
                   Singapore 
 
Chinese      Guangzhou, 
                   Southern  
                   China 
 
Indian         Chennai,  
                   Southern  
                   India 
 
Indian         Aravind,  
                   Southern  
                   India 
 
Shen et al, 
2008* 
 
Foster et al, 2000* 
 
 
He et al,  2006# 
 
 
 
Vijaya et al, 2005* 
(urban) 
 
 
Ramakrishnan et al, 
2003* 
 
3.4% 
(3.3-3.5) 
 
3.2% 
(2.3-4.1) 
 
3.8% 
(2.8-4.8) 
 
 
 
 
 
 
2.6% 
(2.2-3.0) 
2.5% 
(2.4-2.6) 
 
2.4% 
(1.6-3.2) 
 
2.1% 
(1.4-2.8) 
 
 
3.51% 
(3.04-3.98) 
 
 
1.7% 
(1.3-2.1) 
0.12% 
(0.10-0.14) 
 
1.5% 
(0.8-2.1) 
 
1.5% 
(0.8-2.1) 
 
 
0.88% 
(0.60-1.16) 
 
 
0.5% 
(0.3-0.7) 
 
 
 
* based on population aged ≥ 40 years 
# based on population aged ≥ 50 years 
^age-and –sex standardised prevalence of all type of glaucoma 
**POAG and PACG specific prevalence without considering other type of glaucoma 
(e.g. pseudoexfoliation glaucoma) 
POAG: primary open angle glaucoma, PACG: primary angle closure glaucoma 
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Table 1.2: Distribution of the Malaysian population according to ethnicity is based on the 2000 National Census* 
 
 ETHNICITY 
 
 
Age 
group 
Malay 
 
 
Bumiputra 
(Aboriginal) 
Chinese Indian Other Total 
 Male 
 
Female Total Male Female Total Male Female Total Male Female Total Male Female Total  
40-44 
 
343802 340211 684013 70118 65459 135577 224837 212926 437763 63377 62518 125895 8578 7110 15688 1398936 
45-49 
 
274857 266831 541688 51806 46847 98653 193646 177745 371391 48654 48806 97460 6149 4699 10848 1120040 
50-54 
 
214540 203069 417609 38714 36403 75117 166043 148002 314045 37818 36172 73990 3870 3488 7358 888119 
55-59 
 
142024 137904 279928 31198 27667 58865 114175 102360 216535 19829 20091 39920 2797 2544 5341 600589 
60-64 
 
124156 132252 256408 23064 23425 46489 100201 94085 194286 17058 19872 36930 2458 1849 4307 538420 
65-69 
 
71802 81292 153094 16866 18472 35338 58928 62997 121925 11279 13831 25110 1497 1309 2806 338273 
70-74 
 
60362 67568 127930 12010 11269 23279 40716 46881 87597 7932 7942 15874 1237 1139 2376 257056 
>75 
 
61602 74949 136551 12592 12485 25077 39475 57724 97199 7344 8603 15947 1590 1388 2978 277752 
Total 
 
1293145 1304076 2597221 256368 183413 498395 938021 902720 1840741 213291 217835 431126 28176 23526 51702 5419185 
*This information was provided by the Department of Statistics, Malaysia   
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1.3 Genetic basis of primary open-angle glaucoma 
A definitive genetic basis, or even a specific mode of inheritance, is not well established for 
glaucoma, but genetics remains a potential mechanism for understanding the pathogenesis of 
glaucoma. A genetic basis for this cause of optic neuropathy and blindness was observed as 
early as 1869 (von Graefe, 1869), followed by observations by Duke-Elder (1941) who 
described autosomal dominant inheritance in a family with glaucoma. Since then, more 
observations and studies were conducted in selected families (Posner and Schlossman, 1949; 
Becker et al, 1960). In addition to the autosomal dominant inheritance described in 1941, 
autosomal recessive inheritance has also been described (Probert, 1952). Juvenile-onset open 
angle glaucoma (JOAG) is commonly described as a product of autosomal dominant 
inheritance but the mode of inheritance in POAG (adult-onset) is inconclusive (Nemesure et 
al, 2001). A majority of glaucoma pedigrees do not show a simple Mendelian pattern of 
inheritance. POAG has been described as oligogenic, polygenic, and even multifactorial, and 
is regarded as a complex disease. However, most studies are clinic-based and therefore 
subject to selection bias, ambiguity in assessing family history, and non-standardised 
diagnoses of glaucoma, which perhaps account for the inconclusive mode of inheritance 
(McNaught et al, 2000; Nemesure et al, 2001). Incomplete penetrance of glaucoma further 
complicates the genotype-phenotype association. 
 
Epidemiological studies have determined that a family history of glaucoma increases the risk 
of glaucoma between 13% and 60% (Tielsch et al, 1994; Francois, 1966; Shin et al, 1977). 
The Baltimore Eye Survey, the Barbados Eye Study (BES) and the Vision Impairment 
Project (VIP) found a significant association with first-degree relatives with glaucoma (Leske 
et al, 1995; Weih et al, 2001, Tielsch et al, 1994). The VIP study estimated a 3-fold increased 
risk of glaucoma in those with a family history of the disease (Weih et al, 2001). History of 
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glaucoma among siblings provides a stronger association than does parental history (Leske et 
al, 1995; Wolfs et al, 1998), suggesting the possible interaction of similar genetic inheritance 
and environmental exposure. However, the accuracy of this association has been challenged 
by possible biases while obtaining information regarding family history. Furthermore, 27% of 
previously diagnosed POAG patients were unaware of their positive family history 
(McNaught et al, 2000). The Glaucoma Inheritance Study in Tasmania (GIST), which 
involved more than 1042 glaucoma cases and their unaffected relatives, found that 60% of 
people with glaucoma have a positive family history (Green et al, 2007). A familial 
aggregation study, part of the population-based Rotterdam Eye Study, conducted thorough 
ophthalmological examination in all family members with glaucoma and found that the 
lifetime risk of glaucoma in the relatives of glaucoma patients was 22% or 10-fold greater 
than the risk to those without family members with glaucoma (Wolfs et al, 1998). The family 
members demonstrated higher cup-to-disc ratios and IOP; however, there was no definitive 
mode of inheritance in this complex disease. 
 
A possible candidate gene, Myocilin (MYOC), was identified in a linkage analysis study 
(Stone et al, 1997). MYOC was previously known as the trabecular meshwork inducible 
glucocorticoid responsive (TIGR) gene, located at chromosome 1q23 (GLC1A). Variations in 
the MYOC gene are population specific; founder effects have been reported and not all 
mutations result in abnormal Myocilin protein, which is abundant in ocular tissue (Hewitt et 
al, 2008; Zhou et al, 2008). However, the variations in MYOC were only found in 2% to 4% 
of glaucoma patients and more frequently in juvenile open-angle glaucoma (JOAG) (Fingert 
et al, 1999; Sripriya et al, 2004). To date, more than 70 mutations of the MYOC gene have 
been found to be associated with glaucoma (Hewitt et al, 2008). The GIST found a possible 
association of MYOC with the staging or severity of glaucoma (Craig et al, 2001; Mackey et 
40 
 
al, 2003). The Gln368Stop mutation is associated with mild cases, Thr377Met and 
Gly252Arg are associated with intermediate or moderate cases, and Pro370Leu is more 
common in advanced-stage glaucoma (Craig et al, 2001; Mackey et al, 2003).  
 
The Optineurin (OPTN) gene, located at chromosome 10p15-p14 (GLC1E) was identified in 
a linkage analysis of a large British family with normal tension glaucoma (NTG) (Sarfarazi et 
al, 1998). OPTN mutations are found in only 16.7% of hereditary POAG and are more 
associated with NTG (Rezaie et al, 2002). The Glu50Lys mutation is rare but was found to be 
associated with OAG. Unlike MYOC, minimal variation of OPTN was found to be associated 
with glaucoma (Fuse et al, 2004; Alward et al, 2003; Mukhopadhyay et al, 2005). A 
combination of OPTN variants with certain TNF-α variant have been reported in Japanese 
POAG patients and are associated with a severe phenotype (Funayama et al, 2004).  
 
In 2005, a sequence variant of WD40-repeat 36 (WDR36), located at the GLC1G locus on 
chromosome 5q22, was reported to be responsible for glaucoma (Monemi et al, 2005). The 
frequency of WDR36 variants in glaucoma patients was lower than the frequency of MYOC 
and OPTN gene variants, estimated between 1.6 and 17% (Hauser et al, 2006). Despite the 
lower frequency, variants of WDR36 were associated with a severe glaucoma phenotype, 
suggesting its role in disease susceptibility (Hauser et al, 2006). Apolipoprotein E (Apo E) 
gene was reported as a strong modifier gene for glaucoma. The polymorphism -219T>G in 
the promoter region of the Apo E gene was associated with increased susceptibility to optic 
nerve damage; interaction of -419A>T with -1000C>G increased susceptibility to elevated 
IOP (Copin et al, 2002). Interestingly, Apo E gene variants also interact with MYOC gene 
variants (Copin et al, 2002).  
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Other genes that may be associated with glaucoma include optic atrophy 1 (OPA1), tumour 
protein p53, tumour necrosis factor (TNF), IL-1, noelin 2 (OLM 2), and cytochrome P450 
1B1 (CYP 1B1) (Allingham et al, 2008). Glaucoma is, therefore, a heterogeneous disease 
produced by complex interactions between genetics and the environment. There is also 
evidence of gene-gene interactions in glaucoma. Overexpression of OPTN causes up-
regulation of endogenous MYOC in ocular tissue (Park et al, 2007). Funayama et al (2006) 
found significant association of synonymous single nucleotide polymorphism (SNP) in OLM 
2 (317G>A and 1281C>T) and OPTN 412G>A. Another association was found with OLM 2 
317G>A and 678G>A, and OPTN 603T>A, suggesting a polygenic aetiology. 
 
The advancement of molecular genetics, particularly with the introduction of genome-wide 
association studies (GWAS), will reveal more genes as potential candidates. The 
identification of Lysyl Oxidase-like protein 1 (LOXL1) was a great breakthrough in the 
GWAS quest for glaucoma genes (Thorleifsson et al, 2007). Pseudo-exfoliation glaucoma 
(XFG) is the most common secondary OAG, where fibrillar material is deposited on the 
ocular surfaces, especially on the trabecular meshwork, lens capsule, and papillary margin 
(Ritch, 1994). Deposition of this material at the trabecular meshwork clogs aqueous outflow, 
resulting in IOP elevation; XFG is more resistant than POAG to medical treatment and is 
further complicated by lens-related problems. XFG and pseudoexfoliation syndrome (XFS) is 
most frequent among Caucasians of European descent (Jonasson et al, 2003; Hirvela et al, 
1994). The likelihood of genetic transmission was based on the identification of families with 
XFG or XFS (Allingham et al, 2001).  
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Three LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, are associated with pseudo-
exfoliation glaucoma and pseudo-exfoliation syndrome in many populations (Lemmelä et al, 
2009; Ozaki et al, 2008; Aragon-Martin et al, 2008). The GWAS association of intronic SNP 
rs2165241 was statistically significant but lost its significance after genotyping of non-
synonymous SNPs rs3825942 and rs1048661. Exonic rs3825942 and rs1048661 are in strong 
linkage disequilibrium and the significance of rs2165241 is due to the effective tagging to 
those haplotypes (Thorleifsson et al, 2007). There was no association of LOXL1 with POAG 
and PACG (Chakrabarti et al, 2008; Liu et al, 2008). Thus, the quest for understanding the 
genetics of glaucoma continues. 
 
1.4 Intraocular pressure 
Intraocular pressure (IOP), which is determined by the rate of aqueous humour production, 
drainage resistance, and episcleral venous pressure, represents the ocular pressure. IOP was 
first equated by Goldmann and Schmidt (1957) and later known as IOPG: 
 
The ciliary body and its processes are responsible for aqueous humour production through 
several possible mechanisms including active secretion, passive diffusion, and ultra-filtration. 
The aqueous humour drains through 2 outflow mechanisms: pressure-dependent trabecular 
outflow and pressure-independent uveoscleral outflow. The majority of drainage occurs via 
trabecular outflow and only 20% occurs via uveoscleral outflow, based on perfusion studies 
 IOPG= EVP + Ap/Ad  
 
   
EVP: episcleral venous pressure 
  Ap   : rate of aqueous production 
  Ad   : rate of aqueous drainage 
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with radio-labelled albumin. In the normal eye, the rate of aqueous humour production is 
almost equal to the drainage rate; 2.5 to 2.8 µL/min.  
 
The episcleral veins are connected to the central circulation by a valveless system that creates 
a direct correlation between central venous pressure and IOP. An increase in central venous 
pressure such as occurs in superior vena cava obstruction, Sturge-Weber syndrome, and 
cortico-cavernous fistula causes a direct increase in episcleral venous pressure and 
subsequent increase of IOP (Greenfield, 2000; Jorgensen and Guthoff, 1988). In addition, 
80% of aqueous humour outflow occurs through the Schlemm canal (conventional outflow) 
via a passive mechanism, which is dependent on the gradient of IOP and episcleral venous 
pressure (Mäepea and Bill, 1989). The rate of aqueous humour production has a lesser effect 
on IOP, only exerting its influence at higher IOPs. Episcleral venous pressure plays an 
important role in IOP. IOP is measured by tonometry with the main purpose of obtaining an 
accurate IOP measurement with minimal disturbance to the eye. Manometry is an invasive 
technique causing major disturbance to the eye but provides accurate IOP measurement. Due 
to the invasiveness of the technique, it is more popular as a laboratory technique and is an 
ideal reference pressure for tonometer (Eisenberg et al, 1998). Tonometry is divided into 
force and pressure tonometry; force tonometer includes applanation and indentation 
tonometer. 
 
Adopting the principle that the pressure inside a dry, thin-walled sphere is proportional to the 
force applied to its surface, the Goldmann applanation tonometer (GAT) has been accepted as 
the gold standard in measuring IOP for 5 decades (Goldmann and Schmidt, 1957). 
Applanation force is the force required to cancel the force induced by sclera rigidity and tear 
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film surface tension to produce a circular area of cornea flattening 3.06 mm in diameter. 
Therefore, the applanation force is directly proportional to the IOP in accordance with the 
Imbert-Fick principle (Pressure = force/area) based on an assumed central corneal thickness 
(CCT) of 500 µm. Based on the Imbert-Fick principle, the applanation pressure can be 
manipulated by altering the force or area. The applanation pressure can be measured by 
applying sufficient force to flatten a fixed area (fixed-area tonometer) or measuring the area 
flattened by a fixed force (fixed-force tonometer). Although it is the gold standard, the GAT 
is far from perfect; factors affecting IOP measurements with the GAT are further discussed in 
1.4.1. 
 
1.4.1 Factors affecting intraocular pressure 
In spite of being the gold standard and the most widely accepted tool for IOP measurement, 
GAT is far from perfect. Many factors affect its accuracy but physiological and systemic 
factors also give rise to variations in IOP measurements. These factors are important for 
proper interpretation of IOP. The applanation principle of GAT uses the corneal surface as 
the plane of IOP measurement. Thus, physiological changes or abnormalities of the corneal 
surface affect the IOP measurement. Goldmann and Schmidt (1957) acknowledged the 
possibility of CCT variation affecting the accuracy of GAT. At the time, it was assumed that 
CCT was constant with minimal inter-individual variability. However, thinner CCT requires 
less applanation force, resulting in possible underestimation of IOP, while more applanation 
force is required for thicker corneas. Therefore, CCT is an important factor in providing an 
accurate diagnosis of glaucoma. 
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In 1975, by cannulation of the anterior chamber (manometry) during cataract surgery, Ehlers 
et al found that every 10 µm increase in CCT created a 0.71 mmHg inaccuracy in the IOP 
measurement. The impact of CCT on accuracy of IOP was acknowledged, and ultrasonic 
pachymetry in healthy normal subjects showed that the IOP error was 0.16 to 0.67 mmHg for 
every 10 µm difference in CCT (Shimmyo et al, 2003; Doughty and Zaman, 2000; Saleh et 
al, 2006; Wolfs et al, 1997). CCT exhibits diurnal fluctuations with evidence of thickening 
during sleep and thinning in the afternoon (Fujita, 1980; Feldman et al, 1978). In spite of the 
great interest in the inaccuracy of GAT induced by CCT, there is still no specific acceptable 
nomogram for adjustment of IOP measurements according to CCT. Furthermore, there is no 
difference in IOP measurements by intra-cameral cannulation and applanation tonometry 
with increasing CCT (Feltgen et al, 2001).  
 
Orsenggo and Pye (1999) suggested that, to obtain a true IOP (IOPT) from GAT (IOPG) 
mathematically, corneal biometry including corneal thickness, corneal elasticity or rigidity, 
anterior corneal radius, and area of applanation must be included as factor K. 
 
 
 
 
 
CCT is not the only important corneal biometry affecting the accuracy of IOP measurements. 
Currently, biomechanical properties of the cornea such as corneal hysteresis (CH), central 
                           IOPT =  IOPG  , 
                                        K 
 
                    where K = Bc + Cc + C 
                                               B 
 
Bc : coefficient of IOPG for calibration of cornea 
Cc : coefficient of IOPT for calibration of cornea 
C  : coefficient of IOPT for any cornea 
B  : coefficient of IOPG for any cornea 
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corneal power, axial length, and corneal curvature have also been implicated (Özcura et al, 
2008; Francis et al, 2007; Kohllhass et al, 2006). Although refractive error is a risk factor for 
glaucoma, axial length is poorly correlated with IOP measurement (Özcura et al, 2008; 
Kohllhass et al, 2007). Similar weak correlations are observed with central corneal power and 
corneal curvature (Özcura et al, 2008; Francis et al, 2007). CH has been the main principle of 
ORA; unlike CCT, it is constant with no diurnal influence (Laiquzzaman et al, 2006; Kida et 
al, 2008). CCT and CH have been suggested as pressure-independent risk factors for 
glaucoma (Congdon et al, 2006). 
 
IOP in humans is not consistently calculated by the Goldmann mathematical equation. 
Postural changes, stress, valsalva manoeuvre, exercise, alcohol or caffeine consumption, 
smoking, and marijuana use induce short-term changes that affect IOP (Linder et al, 1988; 
Pasquale and Kang, 2009). IOP in the supine position is 2–4 mmHg higher than IOP 
measured in a seated position and alarming 3-fold increase in complete gravity inversion 
(Galin et al, 1963; Weinreb et al, 1984). IOP increased 2-fold from baseline during a 
headstand posture (Sirsasana) during Yoga exercise (Baskaran et al, 2006). This phenomenon 
is believed to be due to rapidly increased choroidal vessel filling that increases the episcleral 
venous pressure (Linder et al, 1988, Aihara et al, 2003).  
 
IOP is also affected by the valsalva manoeuvre, a physiological phenomenon occurring 
during coughing, lifting, vomiting, straining, and defecation. The sympathetic and 
parasympathetic autonomic nervous systems are stimulated during the straining and release 
phases of the valsalva manoeuvre. During the straining phase, intra-thoracic pressure builds, 
impinging on venous return and causing engorgement of the choroidal vessels. Subsequent 
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sclera rigidity causes an increase in episcleral venous pressure and intraocular pressure. To 
overcome the reduction of venous return, there is concomitant reduction of arterial pressure, 
cardiac output, and blood pressure. Reflex-mediated tachycardia and peripheral 
vasoconstriction then occur to overcome the drop in blood pressure. Reduced arterial pressure 
was believed to reduce choroidal filling (Booth et al, 1991). The physiological changes of 
IOP during the valsalva manoeuvre last for 15 to 30 minutes. Based on experimental valsalva 
manoeuvre, IOP increased during the straining phase (Lanigan et al, 1989). The arterial 
baroreceptor is stimulated during the release phase, increasing the cardiac output that later 
relieves the peripheral constriction, heart rate, and blood pressure, and leads to a drop in IOP. 
Thus straining (holding the breath) during tonometry measurement can produce an effect 
similar to that of the valsalva manoeuvre, and is a source of inaccuracy during IOP 
measurement (Whitacre and Stein, 1993). IOP is affected more by the valsalva manoeuvre 
than by psychological stress (Brody et al, 1998). The measurement of IOP is largely affected 
by an uncooperative patient. 
 
There is conflicting evidence on the effect of exercise on IOP. Within 5 minutes of starting an 
exercise, an initial elevation of IOP is followed by a gradual decrease up to 60 minutes post 
exercise with no change in optic nerve perfusion due to the auto-regulatory mechanisms 
(Qureshi, 1995b; Movaffaghy et al, 1998). However, there is evidence of significant increases 
in pulsatile ocular blood flow (Price et al, 2003). Increased serum osmolarity is believed to be 
responsible for the acute post exercise drop in IOP (Stewart et al, 1970; Martin et al, 1999). 
The reduction in IOP was observed in healthy and glaucoma subjects with a greater drop and 
longer post exercise recovery in glaucoma subjects (Qureshi, 1995a). Acute IOP reduction is 
proportional to the degree and duration of exertion (Qureshi et al, 1996). However, strenuous 
exercises such as weight lifting and bench press exercise may have effects similar to those of 
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the valsalva manoeuvre (Vieira et al, 2008). A consistent IOP reduction was observed in 
sedentary non-glaucoma patients after constant prolonged exercise for 3 months but the effect 
was diminished in athletic patients (Lempert et al, 1967). Unfortunately, the effect is 
inconsistence; other researchers have observed elevated IOP, and others have observed no 
IOP changes (Era et al, 1993).  
 
Nicotine, the primary active substance in cigarettes, is known to have detrimental effects on 
health. Cigarette smoking induces vasoconstriction and increases blood pressure (Tamaki et 
al, 2000). Its effect on IOP is not well established. It is believed that increased blood viscosity 
induced by smoking is responsible for IOP elevation (Yoshida et al, 2003). A significant 
elevation of IOP was observed in 50 healthy normotensive young male subjects after a month 
of smoking 2 cigarettes per day (Timothy and Nneli, 2007). Similarly, an acute increase in 
IOP was observed in both normal and glaucoma subjects 5 minutes after the last puff of a 
cigarette, but the pressure normalized after 15 to 30 minutes in normal subjects (Mehra et al, 
1976). However, other studies have found no significant IOP difference between smokers, 
non-smokers, and ex-smokers (Bahna and Bjerkedahl, 1948; Morgan and Drance, 1975; 
Shephard et al, 1978). Furthermore, there is no evidence of an association between cigarette 
smoking and progression of ocular hypertension to glaucoma (Kang et al, 2003).  
 
Moderate and heavy alcohol consumption may play a protective role in cataract development 
and age-related macular degeneration (Wang et al, 2008). Its impact on IOP and glaucoma is 
not well established. During the acute ingestion of alcohol, there is evidence of IOP 
reduction, which may be due to osmotic effects, suppression of anti-diuretic hormone, and 
inhibition of secretory cells in the ciliary processes (Houle and Grant, 1967; Peczon and 
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Grant, 1965). These mechanisms reduce water movement to the eye and aqueous humour 
production. The ocular hypotensive effect is dose-dependent. Consumption of one alcoholic 
beverage drink (10 grams) yielded no effect; one hour of hypotensive effect was achieved 
with 17 grams and up to 3 hours with 50 grams of alcohol (Obstbaum and Podos, 1973; 
Buckingham and Young, 1986; Houle and Grant, 1967). However, epidemiological studies 
that addressed the effect of alcohol on IOP yielded inconsistent results (Lin et al, 2005; Weih 
et al, 2001; Wu and Leske, 1997). The majority of the studies were based on questionnaires 
and interviews with non-standardized measures of alcohol consumption. Reports described 
elevated IOP with increased consumption, but others reported no effect or a hypotensive 
effect (Yoshida et al, 2003; Leske et al, 1996; Klein et al, 1992). An earlier study suggested 
an inverse relationship between alcohol consumption and elevated IOP (Seddon et al, 1983). 
The association between alcohol and IOP may be modified by sex with higher IOP in men 
than in women of Asian and Afro-Caribbean descent (Lin et al, 2005; Wu and Leske, 1997).  
 
Helper and Frank introduced the potential role played by cannabinoid compounds (found in 
marijuana) in glaucoma management in 1971, based on a study in a small number of subjects. 
A marked 25% reduction of IOP from baseline was observed up to 3–4 hours after smoking 
(Helper et al, 1976). Green (1998) found that the IOP reduction was inconsistent and some 
patients failed to demonstrate any IOP changes. Nevertheless, marijuana and its main 
psychoactive substance, Δ9–tetrahydrocannabinol (THC) is a potential therapeutic drug for 
glaucoma management. The mechanism by which marijuana reduces pressure is poorly 
understood. The promise of its beneficial effects is limited by the risk of potentially 
devastating systemic and ocular side effects. Topical administration of Δ9-THC would be an 
ideal delivery method to minimize potential unwanted side effects, but the lipophilic nature of 
Δ9-THC makes this a challenge.  
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Wearing tight neckties has been found to elevate IOP by 2 mmHg in both normal and 
glaucoma subjects (Teng et al, 2003). There was no significant different between glaucoma 
and normal subjects. The elevation of IOP is postulated to be due to constriction of the 
jugular vein, which elevates episcleral venous pressure (Bigger, 1975). However, no 
persistent elevation of IOP is observed after extended wear of tight neckties and avoidance is 
unnecessary in glaucoma patients (Talty and O‟Brien, 2005). Nevertheless, the accuracy of 
GAT may be affected in subjects wearing a tight necktie. Caffeine consumption (in coffee) 
has also been linked to elevated IOP (Chandrasekaran et al, 2005). Drinking 5 or more cups 
of coffee a day increases the risk of POAG, particularly in those with a positive family 
history of glaucoma (Kang et al, 2008). 
 
Long-term factors that may be associates with IOP changes include age, sex, systemic blood 
pressure, refractive error, iris colour, obesity, and environmental factors such as cold climate. 
The prevalence of glaucoma is age-related. Although IOP is identified as the major 
modifying risk factor for glaucoma, the relationship between IOP and age is inconsistent and 
not linearly correlated. Increasing IOP and increasing age have been positively correlated in 
many longitudinal and large cross-sectional studies in Caucasians (Martin et al, 1985; Klein 
et al, 1992). Age was positively associated with IOP by univariate analysis but not by 
multivariate analysis in a cross-sectional study of Caucasians residing in Australia 
(Rochtchina et al, 2002). Age-related changes in IOP were positively correlated with changes 
in systolic blood pressure and body mass index (BMI) in cross-sectional and longitudinal 
studies (McLeod et al, 1990). Aging causes slight reduction of the outflow capacity at a rate 
of 3.2% per decade after the age of 10 (Brubaker, 1991). At the same time, age-related 
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changes lead to increased intra-orbital fat, which leads to increase episcleral venous pressure. 
In addition, age-related reduction of cells in the trabecular meshwork is believed to cause a 
net effect of IOP elevation with age (Alvarado et al, 1981, Gabelt et al, 2003; Brubaker et al, 
1981).  
 
IOP increases proportionally with age but decreases in Afro-Caribbean over 70 years old, 
partially due to selective mortality (Wu et al, 1997; Wu et al, 2006). An inverse relationship 
between IOP and advanced age was observed in Japanese, which may explain the higher 
prevalence of NTG in this population, well known for longevity (Nomura et al, 1999; Shiose, 
1984; Shiose and Kawase, 1986; Shiose et al, 1991). A similar relationship was observed in 
other East Asian populations (Lin et al, 2005; Xu et al, 2005; Lee et al, 2002). Moreover, 
CCT decreases with age in East Asian populations, which perhaps further strengthens this 
interesting observation (Foster et al, 1998; Foster et al, 2003; Suzuki et al, 2005). The inverse 
relationship of IOP and age is observed in cross-sectional studies but demonstrated an 
exponential relationship in a Japanese longitudinal study (Nomura et al, 1999; Kawase et al, 
2008).  
 
The relationship between age and IOP is dependent on systemic blood pressure and BMI 
(Carel et al, 1984; Klein and Klein, 1981). Hypertension has been associated with IOP 
elevation in many population-based studies (Tielsch et al, 1995; Klein et al, 1992; Wu et al, 
1997; Foster et al, 2003). Increased ciliary pressure induced by changes in hypertension lead 
to increase aqueous humour production, ultimately increasing the IOP (Shiose and Kawase, 
1986; Bulpitt et al, 1975). Increased sympathetic tone and corticosteroid was also postulated 
to be involved, although the mechanism remains unknown (Carel et al, 1984). Both systolic 
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and diastolic blood pressures have been implicated. Positive associations between IOP and 
systolic blood pressure have been observed in many longitudinal and cross-sectional 
population-based studies (Hennis et al, 2003; Dielemans et al, 1995; Klein et al, 2005). The 
Beaver Dam Study reported that for every 10 mmHg increase in systolic blood pressure there 
was a 0.2 mmHg increase in IOP and a 0.4 mmHg increase in IOP for every 10 mmHg 
increase of diastolic pressure (Klein et al, 2005). The Barbados Eye Study reported a more 
marked influence of diastolic blood pressure on IOP (Wu and Leske, 1997). However, there 
was no significant difference between the effects of systolic and diastolic blood pressure. 
From another perspective, reducing blood pressure could have a protective effect in reducing 
IOP and reducing the risk of glaucoma. The Beaver Dam Eye Study found that a decrease in 
either systolic or diastolic blood pressure of 10 mmHg over 5 years is associated with a 
decrease in IOP (Klein et al, 2005).  
 
Body mass index (BMI) has a significant influence on IOP. Obesity leads to increase intra-
orbital fat, elevate episcleral venous pressure, increase blood viscosity and reduce outflow 
capacity (Shiose, 1984; Shiose and Kawase, 1986). IOP is directly correlated with BMI, even 
after controlling for confounding factors such as age, blood pressure, and presence of 
diabetes (Mori et al, 2000; Klein et al, 1992; Wu and Leske, 1997). The Beaver Dam Study 
found a direct exponential relationship between increasing IOP and BMI in Caucasians 
(Klein et al, 1992). Likewise, in cross-sectional studies of East Asian populations, reduced 
incidence of obesity and lower BMI was believed to be responsible for the inverse 
relationship between IOP and age (Nomura et al, 1999; Mori et al, 2000). After an 8 year 
longitudinal study in the same population, a linear relationship between IOP and BMI was 
observed, similar to observation in Caucasians (Nomura et al, 1999; Mori et al, 2000). These 
studies suggest the importance of weight control in preventing elevation of IOP. 
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Those with high BMI are at risk for systemic hypertension, diabetes mellitus, and heart 
diseases. Diabetes mellitus was also associated with changes in IOP in cross-sectional 
population-based and longitudinal studies (Hennis et al, 2003; Mitchell et al, 1997; Wu and 
Leske, 1997; Wu et al, 2006). However, after excluding subjects with cataracts, only a weak 
association was found in the Barbados Eye Study (Hennis et al, 2003). There is also evidence 
that argues against the possible association of diabetes and IOP (Bouzas et al, 1971; Armaly, 
1967). Glycosylated haemoglobin level was exponentially associated with IOP (Klein et al, 
1992). Thicker CCT in diabetes subjects, especially during hyperglycaemic episodes, may 
prompt false detection of high IOP (Bron et al, 1999; Sahin et al, 2009). Diabetes-related 
autonomic dysfunction and the osmotic gradient induced by elevated blood glucose may 
cause a fluid shift into the intraocular space, resulting in IOP elevation (Mapstone and Clark, 
1985, Cristiansson, 1961). A more accepted theory is that fluid shifts from the intraocular 
space into the cells, resulting in the net reduction of IOP (Dielemans et al, 1994). Genetic 
predisposition has also been postulated based on the prevalence of diabetes in glaucoma 
patients with strong family history of glaucoma (Clark and Mapstone, 1986). The relationship 
between IOP and diabetes remains controversial. 
 
Unlike the impact of age on IOP, sex exerts a lesser effect. Some studies have found that IOP 
is higher in women (Normura et al, 1999; Yoshida et al, 2003; Leske et al, 1997), and it has 
been suggested that the higher frequency of hypertension, obesity, and relative longevity in 
women may contribute to this effect (Memarzadeh et al, 2008). Other studies found higher 
IOP in men (Leske et al, 1994; Doshi et al, 2008). Most studies found no association of 
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gender with IOP and postulated selection bias as the probable explanation for any reported 
associations (Weih et al, 2001; Klein et al, 1992). 
 
Refractive error, especially myopia, has been found to influence IOP measurement in case-
control studies (David et al, 1985; Abdalla and Hamdi, 1970; Tomlinson and Philips, 1970). 
The Blue Mountain Eye Study, a population-based cross-sectional study, found a strong 
positive association between myopia and higher IOP (Mitchell et al, 1999). Similar findings 
were documented in Afro-Caribbean and Asian populations (Wu et al, 1999; Nomura et al, 
2004; Xu et al, 2007; Kawase et al, 2008). There is an exponential relationship between 
increasing severity of myopia and progressive elevation of IOP in Caucasians (Wong et al, 
2003). The relationship is believed to be due to the thinner CCT associated with myopia and 
affect IOP measurement. However, Nomura et al (2004) reported a significant exponential 
relationship of myopia severity and IOP even after adjusting for CCT and age. A contrasting 
report described an effect of myopia at a lower IOP with a weakening effect on increasing 
IOP (Grødum et al, 2001). Interestingly, hyperopia has also been associated with significant 
elevation of IOP, but the assertion requires further evaluation (Wong et al, 2003). 
 
Iris colour has also been suggested to affect IOP measurement. Darker iris colour was 
associated with higher IOP in a Caucasian population. The Blue Mountain Eye Study found a 
modest association between iris colour and IOP, supporting the findings of other, smaller 
studies (Mitchell et al, 2003; Hiller et al, 1982; Weih et al, 2001). There was a significantly 
lower IOP in subjects with lighter iris in the Blue Mountain Eye Study (Mitchell et al, 2003). 
However, the reduction in IOP was not statistically significant in green and light brown iris in 
comparison to blue, grey, or green iris in both normal and glaucoma subjects in the 
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Melbourne Visual Impairment Project (Weih et al, 2001). Higher IOP is associated with 
darker iris (Memarzadeh et al, 2008, Semes et al, 2006), although there is no clear 
mechanism or explanation for this relationship.  
 
1.4.2 Intraocular pressure fluctuation 
Similar to blood pressure, IOP is also subject to circadian variation. Fluctuation of aqueous 
humour production is postulated to be responsible for IOP fluctuation, which is highest in the 
early morning, decreases throughout the day, and is lowest during sleep in normal individuals 
(Topper and Brubaker, 1985). Fluorophotometry was used to demonstrate that aqueous 
humour formation occurs through the day (late morning) in normal and glaucoma subjects 
(Friedenwald and Brubaker, 1955; Langley and Macdonald, 1952). Hormonal and 
neurological stimulation has also been implicated (Brubaker, 1991). However, by far the 
strongest evidence points to β-adrenergic stimulation (Larson and Brubaker, 1988). High 
levels of circulating catecholamine drive the production of aqueous humour during the day 
but the lack of this stimulation at night slows production (Armaly, 1963). However, 
sympathetic denervation fails to reduce aqueous humour production, suggesting that 
neurological stimulation may not be as important (Wentworth and Brubaker, 1981). On the 
other hand, there is no evidence of diurnal variations of outflow facility influencing episcleral 
venous pressure (Takeda and Azuma, 1978). Episcleral venous pressure remains constant 
throughout the day (Takeda and Azuma, 1978).  
 
The IOP fluctuation can be divided into diurnal (day time) fluctuation, nocturnal (night time) 
fluctuation, 24 hour fluctuation and long term fluctuation. Similar to glaucoma, the major 
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problem in IOP fluctuation is inconsistency of definition. Some define fluctuation as 
variation in IOP during the diurnal period and the other includes nocturnal fluctuation as 
diurnal fluctuation (Singh and Shrivastava, 2009). For the purpose of discussion, diurnal 
fluctuation is defined as IOP fluctuation in the day time and nocturnal is exclusive for night 
time fluctuation. Long term fluctuation is defined as inter-visit IOP during long period of 
observation. 
 
Based on the circadian curve, IOP fluctuation is further categorized into morning, day, night, 
and flat types (Zeimer, 1996). IOP fluctuation can also be divided into regular and irregular 
groups. Regular fluctuation refers to IOP fluctuation that is generally constant day-to-day and 
irregular refers to those with random pressure peaks (Zeimer, 1996). The commonest 
circadian curve is the morning type, with lowest IOP in the early morning, typically 
following with aqueous humour production (Wilensky, 1991). The range of diurnal 
fluctuation was found to be 2–3 times higher in glaucoma patients than in normal individuals 
(Drance, 1960; Drance, 1963; Hollows and Graham, 1966; Wilensky, 1991). Both normal 
and glaucoma subjects experience a maximal peak before noon (David et al, 1992; Saccà et 
al, 1998). Based on 690 diurnal curves, higher IOP fluctuation was seen in glaucoma and 
ocular hypertension subjects than in normal individuals (David et al, 1992). Higher 
fluctuation was observed in ocular hypertension than in open-angle glaucoma, suggesting that 
the higher the IOP, the greater the range of fluctuation (David et al, 1992).  
 
CCT has been identified as a confounding factor for IOP measurement using GAT. Similar to 
IOP, circadian variation of CCT has been reported in glaucoma patients (Fogagnolo et al, 
2006). Although the 24-hour CCT fluctuations were small, there was a significant difference 
57 
 
between the peak at 4 am and trough at 4 pm (Fogagnolo et al, 2006). It is logical to postulate 
a potential relationship between IOP and CCT fluctuation, although the nature of the 
relationship remains elusive. Fogagnolo et al (2006) found that CCT fluctuation does not 
significantly influence IOP fluctuation in glaucoma patients. Similar findings were observed 
in healthy young volunteers and aging subjects (Kida et al, 2006; Kida et al, 2008). Nocturnal 
peak CCT occurred a few hours earlier than IOP nocturnal peak in young healthy subjects 
(Kida et al, 2006). Based on the available evidence, IOP fluctuation is not affected by CCT 
fluctuation. 
 
Nocturnal IOP is higher than diurnal IOP in habitual positions, with the difference of peak 
and trough as high as 8.2 (SD 1.4) mmHg (Liu et al, 1999). Similarly, nocturnal IOP is 
significantly higher than diurnal IOP but the difference is not as great as in normal subjects 
without ocular diseases. The effect of habitual position on IOP is partly explained by the 
increase in episcleral venous pressure and redistribution of body fluid in the recumbent 
position (Friberg et al, 1987). However, nocturnal fluctuations are also observed in seated 
healthy individuals (Liu et al, 2003). Physiologically lower blood pressure during sleep may 
be detrimental to the optic nerve due to significant reduction of ocular blood perfusion with 
higher IOP (Bagga et al, 2009; Pemp et al, 2008). Based on this postulation, prediction of 
disease progression would require a more accurate 24-hour IOP measurement rather than a 
single measurement during office hours. However, the impact of 24-hour fluctuation on 
glaucoma progression has not been studied prospectively.  
 
The importance of IOP fluctuation measurement is debatable especially without proper 
clinical trials and unavailability of suitable portable devices for accurate measurement. Asrani 
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et al (2000) found a strong correlation between 24-hour IOP fluctuations with visual field 
progression. The accuracy of the home tonometry used in his study and poorly-defined visual 
field progression has been questioned. In contrast, Bengtsson and Heijl (2005) reviewed the 
large data set of the Malmo Ocular Hypertension Treatment Study and found that mean IOP, 
not its fluctuation, was strongly associated with glaucoma progression. IOP fluctuation is 
dependent on IOP level; there was an increase of 0.17 mmHg in IOP fluctuation for each 1 
mmHg increase of mean IOP. In other words, mean IOP is reflective of IOP fluctuation. The 
debate further escalated with the outcome of post hoc analyses of many large prospective, 
multicentre randomized clinical trials.  
 
The earlier post-hoc outcome of the Advanced Glaucoma Intervention Study (AGIS) found 
that long-term fluctuation over a minimum period of 3 years (between visits) is an 
independent risk factor for glaucoma progression (Nouri-Mahdavi et al, 2004). IOP 
fluctuation of ≥ 3 mmHg was significantly associated with visual field progression based on 
AGIS score. In a retrospective review of AGIS, long-term IOP fluctuation was observed at 3 
months post intervention until there was evidence of worsening visual field or completion of 
follow-up, whichever came first (Caprioli and Coleman, 2008). Mean IOP and long-term IOP 
fluctuation were weakly associated. Greater IOP fluctuation was observed in those with low 
mean IOP, suggesting that fluctuation has a more detrimental effect in eyes with low mean 
IOP (Caprioli and Coleman, 2008). 
 
In contrast, Early Manifest Glaucoma Treatment (EMGT) found that higher mean IOP is 
associated with higher IOP fluctuation (Bengtsson et al, 2007). The finding is similar to the 
earlier observation of 690 diurnal curves of glaucoma and normal subjects (David et al, 
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1992). IOP fluctuation is not an independent risk factor for visual field progression. EMGT 
predicted an 11% increased risk of glaucoma progression for every 1 mmHg increase in mean 
IOP (Bengtsson et al, 2007). IOP fluctuation is not an independent risk factor for 
development of glaucoma in untreated ocular hypertensive patients (Medeiros et al, 2008). 
Perhaps the most striking differences between many large randomized clinical trials are due 
to the type of glaucoma and severity of the disease. In advanced glaucoma (AGIS), the 
fluctuation of IOP causes stress and de-stress of the fragile optic nerve fibres, leading to 
further progression (Caprioli and Coleman, 2008). At the earlier stage of glaucoma, such as 
in EMGT and ocular hypertension, the optic nerve is more resistant to stress with a direct 
exponential relationship between IOP fluctuations and mean IOP (Caprioli and Coleman, 
2008). Based on the current available evidence, both mean IOP and IOP fluctuation 
measurements are important in glaucoma management.  
 
1.4.3 The importance of IOP reduction in glaucoma management 
Currently, a diagnosis of glaucoma is independent of the IOP; nevertheless, IOP remains the 
only modifiable risk factor. Most available modes of glaucoma treatment including medical, 
laser, and surgical management, are aimed at IOP modification. There have been many large, 
randomized controlled trials of therapies for various types and severities of glaucoma over 
long periods of prospective observation (Heijl et al, 2002; The AGIS investigators, 2000; 
Musch et al, 2009; Collaborative Normal-Tension Glaucoma Study Group, 1998). Although 
controversial and neglected issues remain unaddressed, these trials have provided insight into 
the natural history of the disease and have revolutionized glaucoma management. Visual field 
progression was used as the endpoint of all these clinical trials, regardless of the type and 
severity of glaucoma. The definition of progression differed in each trial protocol. 
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The risk of glaucomatous optic neuropathy in ocular hypertensive (OHT) patients was 
reduced up to 50% with a 20% reduction of IOP in the Ocular Hypertensive Treatment Study 
(OHTS). OHTS studied the benefit of topical hypotensive treatment in a large, randomized 
controlled trial. Topical hypotensive treatment confers a 10% decreased risk of conversion 
for each mmHg of IOP reduction (Gordon et al, 2002). A meta-analysis of 9 clinical trials 
found a 14% reduction in the relative risk of conversion to glaucoma with each mmHg of IOP 
reduction in OHT patients (Peeters et al, 2010). 
 
The Early Manifest Glaucoma Trial (EMGT), a randomized controlled trial in 255 patients 
with early glaucoma, was conducted to determine the effectiveness of aggressive treatment 
with laser trabeculoplasty and topical betaxolol (Leske et al, 1999). The study also studied the 
effectiveness of the proposed treatment in reducing pressure, identified predictors for 
progression, and described the natural history of newly diagnosed glaucoma. 
Pseudoexfoliative glaucoma and normal tension glaucoma patients were also included. 
Similar to the findings of the OHTS, ocular hypotensive treatment was effective in preventing 
further glaucomatous optic nerve damage with 10% risk reduction for each mmHg of IOP 
reduction from baseline (Heijl et al, 2002). Age and glaucoma severity were also identified as 
predictors for progression. However, increased incidence of cataract was reported following 
the treatment modalities, without a significant increase in cataract surgery. 
 
The European Glaucoma Progression Study (EGPS) recruited OHT patients at lower IOP (22 
to 29 mmHg) and tested the efficacy of topical dorzolamide (The European Glaucoma 
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Progression Study Group, 2002). However, topical dorzolamide exhibited poor effectiveness, 
having little impact on IOP reduction and glaucoma prevention. In fact, the untreated group 
showed a reduction in visual field progression (The European Glaucoma Progression Study 
Group, 2005). Outcomes were affected by a high drop-out rate due to failure to achieve the 
target IOP. 
 
IOP reduction has been proven effective in open-angle glaucoma with higher than normal 
baseline IOP. Does IOP reduction benefit patients with normal tension glaucoma? The 
Collaborative Normal Tension Glaucoma Study (CNTGS) was designed to determine the 
possible benefit of IOP modification with topical treatment, laser therapy, and surgical 
intervention in normal tension glaucoma patients (CNTGS group, 1998a). Target IOP 
reduction was set at 30% from baseline in the treated group. The incidence of cataract was 
significantly higher in the treated group than in the untreated group. The benefit of IOP 
reduction was only significant after the impact of cataract was removed. The effects of 
cataract on visual field progression should be taken into account when assessing field 
changes. However, there were subsets of patients who did not progress or demonstrated slow 
progression even without treatment. Although the treatment group had better survival 
analysis outcomes in terms of progression, there were still cases that progressed in spite of 
achieving target pressure (CNTGS group, 1998b).  
 
The merit of surgical versus medical treatment has been a matter of debate for decades 
(Migdal et al, 1994; Smith, 1972). The Collaborative Initial Glaucoma Treatment Study 
(CIGTS), a longitudinal randomized clinical trial addressed the issue of medical treatment 
versus surgical intervention as the first-line treatment for open-angle glaucoma including 
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pseudoexfoliation and pigmentary glaucoma (Musch et al, 1999). Both modes of treatment 
provide acceptable IOP reduction. However, trabeculectomy provided better and more 
consistent IOP reduction, slowing progression of optic nerve damage (Musch et al, 2009). 
The benefit of trabeculectomy was more pronounced in patients with more advanced visual 
field loss. Diabetes mellitus has a disadvantageous effect on the success of trabeculectomy 
(Musch et al, 2009). As expected, the incidence of cataract was greater in the surgical 
intervention group. 
 
The Advanced Glaucoma Intervention Study (AGIS), a longitudinal randomized control trial, 
was designed to determine the effectiveness of aggressive treatment in advanced glaucoma 
patients (AGIS group, 1994). Caucasian and African Americans were recruited and 
randomized into argon laser trabeculoplasty-trabeculectomy-trabeculectomy (ATT) and 
trabeculectomy-argon laser trabeculoplasty-trabeculectomy (TAT) treatment groups. Argon 
laser trabeculoplasty or trabeculectomy was chosen as first-line management after medical 
treatment failure and subsequent treatment was dependent on reaching the target IOP. Both 
groups demonstrated post intervention IOP reduction and reduced progression of visual field 
defects (AGIS group, 2000). IOP reduction was significantly associated with slowed 
progression of visual field defects even after adjustment for cataract formation and diabetes 
(AGIS group, 2000). 
 
Computer-simulated modelling of the US population demonstrated that glaucoma treatment 
was cost effective if diagnostic assessments are excluded and successful therapy is assumed 
(Rein et al, 2009). Treatment efficacy was based on relative risk of progression and reduction 
of visual field loss based on the model of the EMGT (Leske et al, 1999). The impact of 
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aggressive, more efficacious treatment and surgical intervention was based on the CIGTS 
(Musch et al, 1999). The incremental cost incurred by additional or earlier cataract surgery 
was also included. The model estimated that without treatment, 24.6% would have visual 
field progression of at least -16 dB at the peak of glaucoma impact (75 to 79 years old). On 
the other hand, there was evidence that glaucoma progressed in spite of achieving or 
exceeding the target IOP. Neuro-protective drugs may have better therapeutic potential than 
pressure-lowering drugs. Nevertheless, the importance of pressure-lowering treatment is 
without doubt beneficial, both clinically and economically.  
 
1.4.4 Target IOP 
IOP reduction is important in retarding the progression of glaucomatous damage but the 
question remains: how much IOP reduction is required to stabilize damage and to maintain 
adequate functional vision? The term „target IOP‟ was introduced in 1950 but popularized by 
the committee of the American Academy of Ophthalmology (AAO) Preferred Practice 
Pattern guidelines for POAG in 1989, which was regarded as the „holy grail‟ of glaucoma but 
is now under debate (American Academy of Ophthalmology, 1989; Singh et al, 2000). The 
outcomes of the AGIS and CIGTS supported the setting of a target IOP in prevention of 
glaucoma progression (Palmberg, 2002). The AGIS showed no net visual field progression in 
subjects whose IOP measurements remained below 18 mmHg throughout the study.  
 
Target IOP is defined as the range of IOP sufficient to stop progressive pressure-induced 
optic neuropathy or to cause the rate of ganglion cell loss to be no greater than the age-
dependent rate (Brubaker, 1996). Target IOP is dynamic and cannot be predetermined upon 
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initiation of therapy; it changes according to the disease course and depends on the individual 
response and the resistance of the optic nerve to pressure-related damage (Goldberg, 2003; 
Damji et al, 2003). The initial baseline IOP, amount of baseline damage or disease severity, 
rate of damage, family history, cost of treatment, ocular and systemic side effects, life 
expectancy, and health-related quality of life are taken into account in establishing target IOP 
(Jampel, 1997; Palmberg, 2000). Age and ethnicity are also considered. Even non-pressure 
related risk factors such as diabetes mellitus and migraine have been addressed (Anderson et 
al, 2003).  
 
Establishing the target IOP is a challenge and must be customized to the individual patient. 
An important question is whether a percent reduction or a defined IOP value should be 
chosen as the target IOP (Hitchings and Tan, 2001). The OHTS defined the target IOP as a 
reduction of at least 20% from baseline. The treatment target was set at 30% from baseline in 
the CNTGS (CNTGS group, 1998a). The absolute threshold of ≤ 21 mmHg was defined as 
the target IOP in the Glaucoma Laser Trial and Moorfields Primary Treatment Trial, in which 
individual variation was not addressed (Hitchings and Tan, 2001; Migdal et al, 1994). A 
target IOP range accounts for individual variation and the dynamic nature of IOP and 
provides a working framework for defining therapeutic goals. Jampel (1997) introduced an 
algorithm that accounted for the initial IOP, optic nerve damage severity, and therapeutic 
burden. Optic nerve damage and therapeutic burden are ranked 0 to 3 from the normal disc 
and no effect on QOL to advanced optic disc damage and maximum effect on QOL: Target 
range = [Initial IOP * (1 - Initial IOP/100) – Z + Y] +/- 1 mmHg. Z referred to optic nerve 
damage severity and Y denotes the burden of therapy. The CIGTS used another algorithm: 
target IOP = (1 - [reference or baseline IOP + VF score]/100 X reference IOP (Jampel, 1997). 
Maximum target IOP level or percentage was adopted by many glaucoma guidelines, based 
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on the severity of optic disc damage (Terminology and Guidelines for Glaucoma, 2008; Asia 
Pacific Glaucoma Guideline, 2008).  
 
Lower target IOP is recommended for those with advanced or severe optic disc damage and 
higher baseline IOP. Guideline manuals have been established to provide target IOPs 
according to glaucoma severity (Terminology and Guidelines for Glaucoma, 2003). Further 
reduction of the target IOP is needed in the presence of greater non-pressure risk factors. 
However, target IOP fails to address the issue of IOP fluctuation; instead, it is based on a 
single measurement taken during an office visit. The IOP and its effects on the optic nerve 
fluctuate throughout the day; therefore, selecting one measurement does not represent the 
entire patient scenario (Ziemer et al, 1991, Jampel, 1997). Even worse, in order to establish 
the target IOP, the patient must sustain additional optic nerve damage before that damage can 
be stabilized. 
 
1.5 Topical pressure-lowering drugs 
Glaucoma is an irreversible chronic disease; thus, management is a great challenge. The main 
goal of treatment is to prevent further nerve fibre damage. The present modes of treatment 
include pressure-lowering medications, laser treatment, and surgical interventions, all of 
which aim to reduce IOP. Diversion of aqueous humour outflow through an iatrogenic fistula 
to the sub-conjunctival space is the principle underlying glaucoma surgery. Surgical 
intervention provides sustainable constant IOP reduction but not without intra- and 
postoperative complications (Migdal et al, 1994; Musch et al, 2009). In fact, glaucoma 
surgery hastens cataract formation, which may necessitate further surgical intervention 
(Musch et al, 2009; AGIS group, 2000). Surgical equipment, a proper operating theatre, and 
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an experienced surgeon increase the cost of filtration surgery. The invasiveness of the 
procedure interrupts the natural defence mechanism of the eye, increasing the risk of 
infection. Laser treatment is less invasive and is associated with a lower risk of infection. 
Similar to the filtration surgery, it is a permanent procedure and does not require a high 
technology environment but requires an expensive high-maintenance laser machine. 
However, the pressure-lowering effect is insufficient and temporary (Glaucoma Laser Trial 
Research Group, 1995). Manipulation of aqueous humour production and outflow is the 
mainstay mechanism of topical pressure-lowering medications. Topical medications are 
widely available in industrialised nations, are non-invasive and easily transportable. In 
addition, they are relatively easy to apply without the need for special equipment or a high 
technology environment. Importantly, unlike surgical or laser treatment, it is non-permanent 
and easily discontinued if it is ineffective or produces unwanted side effects.  
 
However, patient compliance is required to ensure maximum effectiveness of medical 
therapy, especially in long-term administration, and is even more challenging in 
asymptomatic disease at the early stage of glaucoma. The term compliance is inappropriate; 
instead, adherence and persistence provide a better description of patients‟ behaviour toward 
medication instillation. Adherence is a measure of the degree to which a patient obeys 
pharmacotherapy instruction over a defined period of time (Schwartz and Quigley, 2008). For 
example, if topical timolol is prescribed twice a day for a month but the patient only instilled 
40 times, his/her adherence is 66%.  
 
Persistence is defined as the time to discontinuation. Accurate assessment of adherence and 
persistence is a challenge, especially when most patients routinely overestimate their 
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adherence (Friedman et al, 2008; Friedman et al, 2007). Poor adherence and persistence are 
associated with drug cost, tolerability, difficulty in instillation, lack of education, 
forgetfulness, denial, schedule and travel issues (Tsai et al, 2003; Friedman et al, 2008). 
„White coat adherence‟ is another issue, in which patients are at their best adherence during 
the 5 days prior to a follow up appointment, followed by a declining pattern until the next 
follow up approaches (Feinstein, 1990). Frequency of dosing and complexity of the regime 
also play important roles; poorer adherence is observed in those receiving adjunctive 
treatment (Nordstrom et al, 2005).  
 
Patients‟ understanding of the importance of taking their medication, their satisfaction with 
the drug, tolerability, and cost are reflected in their persistence. Persistence ranges from 20% 
to 67% (Dasgupta et al, 2002; Spooner, 2002) and differs according to the class of pressure-
lowering drugs. Latanoprost, a prostaglandin analogue, has demonstrated better persistence 
when compared to other drugs (Reardon et al, 2004; Schwartz et al, 2004). Combination 
pressure-lowering therapies have become more popular, such as adding a prostaglandin-β 
blocker, a carbonic anhydrase inhibitor-β blocker, or a pilocarpine-β blocker, with the aim to 
improve adherence and persistence.  
 
In addition to the problems with adherence and persistence, drug-induced subclinical 
conjunctival inflammation and its possible association with the success of trabeculectomy is 
another controversial issue. Long-term and multiple treatments with topical anti-glaucoma 
drugs are believed to induce subclinical inflammation of the conjunctiva that may cause 
excessive scarring of the bleb and eventual trabeculectomy failure (Sherwood et al, 1989; 
Broadway et al, 1994a; Broadway et al, 1994b). The histological evidence is inconsistent. 
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Although there is evidence to suggest that pressure-lowering drugs induce inflammatory 
markers and macrophages, there is also evidence to the contrary (Sherwood et al, 1989; 
Broadway et al, 1994a; Baun et al, 1995; Liza-Sharmini et al, 2007). In addition, it is still not 
clear whether the active ingredient or the preservative exerts a more detrimental effect. 
Benzalkonium chloride, the most common preservative in topical anti-glaucoma medication, 
has been linked to elevation of inflammatory markers in tissue culture and animal models (De 
Saint Jean et al, 1999; Becquet et al, 1998). Preservative-free timolol induces less expression 
of interleukins and inflammatory markers (Baudouin et al, 2004). On the other hand, 
sympathomimetics induce significant conjunctival cell profile changes and are associated 
with poorer trabeculectomy outcome (Broadway et al, 1994a). In fact, discontinuation of 
sympathomimetics and steroid treatment reverses this silent effect of pressure-lowering 
medication (Broadway et al, 1996).  
 
Commercially available topical pressure lowering drugs is illustrated in table 1.3. However, 
only topical β-adrenoreceptor antagonists and prostaglandin analogs are discussed in detail in 
this chapter. 
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Table 1.3: Commercially available topical anti-glaucoma drugs  
Group Mode of action Drugs 
(concentration) 
Dose IOP 
reduction 
Parasympathomimetics 
 
 
 
Sympathomimetics 
 
 
 
 
 
 
 
 
 
 
 
Carbonic anhydrase 
inhibitor 
 
 
 
β-adrenoreceptor 
antagonist 
 
 
 
 
 
 
 
 
 
 
Prostaglandin analogue 
Increased 
aqueous outflow 
 
 
Non-selective 
Decrease aqueous 
production and 
increase outflow 
 
 
Selective 
Decrease aqueous 
production 
 
 
 
Decrease aqueous 
production 
 
 
 
Non-selective 
Decrease aqueous 
production 
 
 
 
 
 
Selective 
Decrease aqueous 
production 
 
Increased 
aqueous outflow 
Pilocarpine 
(0.25-4%) 
 
 
 
Epinephrine 
(0.25-2.0%) 
Dipiverfin 
(0.1%) 
 
 
Apraclonidine 
(0.5-1.0%) 
Brimonidine 
(0.2%) 
 
Dorzolamide 
(2%) 
Brinzolamide 
(1%) 
 
 
Timolol  
(0.1, 0.25, 0.5%) 
Levobunolol 
(0.25, 0.5%) 
Timolol GFS 
(0.25, 0.5%) 
 
 
Betaxolol 
(0.25, 0.5%) 
 
Latanoprost 
(0.005%) 
Travoprost 
(0.004%) 
Unoprostone 
(0.12, 0.15%) 
 
Bimatoprost 
(0.03%) 
TID  
or QID 
 
 
 
TID 
 
BD 
 
 
 
BD or 
TID 
BD 
 
 
BD or 
TID 
 
 
 
 
BD 
 
 
 
Once a 
day 
 
 
BD 
 
 
Once a 
day 
 
 
 
 
 
Once a 
day 
20-25% 
 
 
 
 
 
 
 
 
 
 
20-25% 
 
 
 
 
15-20% 
 
 
 
 
 
20-25% 
 
 
 
 
 
 
 
15-20% 
 
 
25-30% 
 
 
 
 
 
 
25-30% 
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1.6 Topical β-adrenoreceptor antagonists 
The potential benefit of systemic β-adrenoreceptor antagonists in lowering IOP was initially 
evaluated and intravenous propanolol was found to be the most effective (Philips et al, 1967). 
The profound corneal anaesthesia induced by propanolol, however, outweighs its potential 
utility. Intensive ophthalmic research eventually led to the introduction of topical timolol. In 
1978, topical timolol revolutionized glaucoma management and remains until now as the 
first-line treatment for glaucoma.  
 
Topical β-blocker acts predominantly by decreasing aqueous humour production without any 
effect on outflow capacity, despite the presence of beta-2 adrenoreceptor (ADRB2) in the 
trabecular meshwork (Coakes and Brubaker, 1978; Yablonski and Zimmerman, 1978; 
Sonntag et al, 1978). β-Blocker action is predominantly mediated by the abundant ADRB2 in 
the ciliary epithelium and ciliary body. Aqueous humour is produced by ciliary bodies 
through ultra-filtration and active secretion by the ciliary epithelium. The reversible β-blocker 
binding prevents binding of catecholamine that in turn prevents activation of intracellular 
adenylate cyclase and reduces the intracellular concentration of cyclic Adenosine 
Monophosphate (cAMP) at the ciliary body. Through an unknown mechanism, this process 
reduces aqueous humour production (Neufeld, 1979). The basal level of cAMP is maintained, 
as is the response to other transmitters. cAMP is an important second messenger in the 
intracellular cascade. Since the understanding of aqueous humour production is imprecise, 
the mechanism of action of topical β-blocker remains unknown.  
 
β-blocker has a less potent effect on β1-adrenoreceptor in decreasing cAMP synthesis 
(Juzych and Zimmerman, 1997). Serotonin receptor, particularly 5-HT1A, is abundant in the 
iris and ciliary body and has a similar molecular structure as ADRB2. Serotonin receptor, 5-
71 
 
HT1A is negatively coupled to adenyl-cyclase, decreases the intracellular cAMP and causes 
reduction in aqueous production (Osborne and Chidlow, 1996; Tobin and Osborne, 1989). 
Timolol demonstrated high affinity towards 5-HT1A in the ciliary process of rabbits, which 
further supports the effect of timolol as a suppressor of aqueous humour production (Osborne 
and Chidlow, 1996). 
 
Although the classic association of reduced cAMP synthesis and aqueous humour production 
is widely accepted, other evidence disputes this postulation. Schmitt et al (1980) found no 
association between decreased cAMP and the pressure-lowering effect of β-blockers on 
rabbits. Drugs that increase intracellular cAMP such as forskolin and cholera toxin also 
reduce the IOP, which contradicts the previous popular hypothesis (Caprioli et al, 1984). 
Another hypothesis postulated that the reduction of aqueous humour formation is achieved by 
direct inhibition of adrenergic stimulation of the secretory ciliary epithelium by endogenous 
epinephrine (Topper and Brubaker, 1985). Decreased ocular blood flow induced by β-
blockers provides another alternative hypothesis. The effect of β-blockers on the vascular 
smooth muscle of the ciliary body inhibits vasodilatation and induces vasoconstriction of 
ciliary arterioles, which reduces capillary perfusion and stromal ultra-filtration (Vareilles et 
al, 1977). Reduction of aqueous humour production is an indirect consequence of decreases 
ocular blood flow (Watanabe and Chiou, 1983). There is also direct evidence that dopamine 
plays a role in ocular blood circulation. Haloperidol, a dopamine-blocking agent, reduces 
IOP.  
 
For more than 3 decades, the topical β-blockers, particularly timolol, have been proven 
effective ocular hypotensive drugs in many types of glaucoma. Currently, 5 topical β-
blockers are available worldwide: timolol maleate, betaxolol hydrochloride, levobunolol 
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hydrochloride, carteolol hydrochloride, and metipranolol (Table 1.5). In Malaysia, only 
timolol and betaxolol are widely available. Although the aqueous solution of timolol maleate 
is widely used, a gel-forming solution has been introduced and is well accepted. Gel-forming 
solution is prepared from purified Pseudomonas elodea cell wall and forms gel solution upon 
contact with mono-valent and divalent cations in tear film. This novel ophthalmic vehicle 
provides a similar pressure-lowering effect as the aqueous form with once-daily dosing 
(Shedden et al, 2001). It is thought to reduce the incidence of systemic adverse effects but has 
a higher reported incidence of transient blurring of vision (Dickstein et al, 2001; Stewart et al, 
2001).  
Table 1.4: Properties of topical β-blockers 
Property Timolol Betaxolol Levobunolol Carteolol Metipranolol 
Concentrations (%) 
 
Preservatives 
 
 
β-blocker potency* 
 
Serum half life (hrs) 
 
Cardio-selective 
 
Intrinsic 
sympathomimetics 
 
Ocular discomfort 
 
Systemic side effect 
Decreased heart rate 
Respiratory 
impairment 
Hyperlipidemia 
 
Ocular perfusion 
0.25, 0.5 
 
BAC# 
0.01% 
 
4.7 
 
3–5 
 
- 
 
 
- 
 
++ 
 
 
++ 
 
++ 
+ 
 
± 
0.25, 0.5 
 
BAC# 
0.01% 
 
1.0 
 
12–20 
 
++ 
 
 
- 
 
+++ 
 
 
± 
 
± 
? 
 
± 
0.25, 0.5 
 
BAC# 
0.004% 
 
14.6 
 
6 
 
- 
 
 
- 
 
++ 
 
 
++ 
 
++ 
? 
 
? 
1.0 
 
BAC# 
0.005% 
 
10.0 
 
3–7 
 
- 
 
 
++ 
 
± 
 
 
+ 
 
+ 
- 
 
± 
0.3 
 
BAC# 
0.004% 
 
1.8 
 
2 
 
- 
 
 
- 
 
+ 
 
 
++ 
 
++ 
? 
 
? 
*β-blockade potency in comparison to propanolol, #BAC: benzalkonium chloride 
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1.6.1 Topical timolol 
Topical timolol is a lipophilic, non-cardio-selective β antagonist without intrinsic 
sympathomimetics activity. It also lacks the ability to act as partial agonist and lacks 
membrane-stabilizing ability. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-
1, 2, 5-thiadiazol-3-yl) oxy]-2- propanol maleate (1:1) (salt). The asymmetrical carbon atom 
in its structure forms a laevo-isomer (Figure 1.3). The optical rotation of timolol maleate is 
 with a molecular weight of 
432.50. It is an enantiomer; D- and L-enantiomer are stereo-isomers that are non-super-
imposable mirror images of each other.  
 
Timolol maleate is a white crystalline powder soluble in water, methanol, and alcohol, with a 
pKa of approximately 9 in water at 25ºC. It is available as a sterile, isotonic, buffered 
aqueous solution with pH approximately 7.0 (range between 6.5 and 7.5) and osmolarity of 
274–328 mOsm. There are also inactive ingredients such as monobasic and dibasic sodium 
phosphate, sodium hydroxide for pH adjustment, and water for injection. Benzalkonium 
chloride 0.01% is added as a preservative. Timolol maleate as the pure chemical is extremely 
stable to light and temperature, but the formulated topical form is less stable with a shelf life 
of 2 years.  
 
Figure 1.3: Chemical structure and formula of timolol maleate 
(Adapted from Zimmerman and Boger, 1979) 
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The ocular hypotensive effect of timolol is more profound when administered orally but 
significant effect is also achieved topically. Although the ocular hypotensive effect of topical 
timolol is achieved at a concentration as low as 0.008%, the optimal therapeutic dose is 
0.25% and 0.5% twice daily in aqueous solution. The active ingredient in each millilitre of 
0.25% of timolol maleate contains 2.5 mg of timolol (3.4 mg of timolol maleate) and each 
millilitre of 0.5% contains 5 mg of timolol (6.8 mg of timolol maleate). The concentration of 
timolol in the anterior chamber reaches 1–2 µM (8–100 ng/mL) after an hour of topical 
instillation, which is much higher than the minimum amount required to bind ADRB2 in the 
ciliary body (Philips et al, 1985). Thus, the pressure-lowering effect is achieved just 20 to 30 
minutes after instillation with the peak seen 2 hours post instillation (Zimmerman and 
Kaufman, 1977). This is followed by further pressure reduction that is sustained up to 24 
hours. Surprisingly, the half-life of topical timolol is just 1.5 hours (Schmitt et al, 1980). 
 
Reversible binding of timolol to ocular melanin provides a reservoir for slow release of the 
active drug and is responsible for prolonging the pressure-lowering effect of timolol despite 
its short half-life. Animal studies have shown that timolol has a high affinity for and binds 
easily to melanin. Dark-pigmented rabbits demonstrated higher concentration of timolol 
maleate in the iris ciliary body when compared to albino rabbits, reducing the amount of 
active ingredient available for pharmacological action (Menon et al, 1989). Melanin near to 
the site of pharmacological action did not inactivate the active drug. Paradoxically, melanin 
competitively inhibits timolol. The net effect is that highly pigmented eyes require a higher 
concentration than less pigmented eyes, which is reflected in clinical observations in Asians 
and Africans (Ong et al, 2005; Otaleju and Ajayi, 1999; Katz and Berger, 1979).  
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Zimmerman and Kaufman (1977) reported the first 24-hour dose response to topical timolol 
0.25% and 0.5% was similar. Maximum pressure reduction was reported to be nearly 40% in 
glaucoma patients treated with 0.5% topical timolol in short- and long-term dose-response 
studies (Zimmerman and Kaufmann, 1977; Boger et al, 1978; Lin et al, 1979). The pressure-
lowering effect is best in daytime and poor at night, when aqueous humour production is 
reduced to less than half. In its early days, the effectiveness of timolol was compared only to 
topical pilocarpine and epinephrine, and was found to be significantly more effective with the 
added advantage of less frequent dosing (Boger et al, 1978; Zimmerman and Boger, 1979). 
The effectiveness of timolol has earned it status as the „gold standard‟ used as the comparator 
for other new drugs that have flourished the glaucoma pharmaceutical market.  
 
Topical timolol is effective in nearly all types of glaucoma including refractory glaucoma 
such as neovascular, aphakic, and uveitic glaucoma (Weber, 1981, Lin et al, 1979). Perhaps, 
due to its suppressive effect on aqueous humour production, it is also effective in angle-
closure glaucoma (Lass and Pavan-Langston, 1979; Chew et al, 2004). Long-term treatment 
with timolol has been proven effective, but the effect is not sustained in more than half of 
patients after 5 years (Watson et al, 2001). Boger (1979) reported short-term escape and long-
term drift phenomena in certain individuals. Up regulation of ADRB2 receptors in the iris 
and ciliary body is believed to be responsible for blunting the effect of timolol after short-
term treatment (Boger, 1979). A meta-analysis comparing a wide range of topical anti-
glaucoma drugs and prostaglandin analogue found that timolol is as effective as prostaglandin 
analogue in providing good IOP reduction at peak and trough (van de Valk et al, 2005). 
Prostaglandin analogues are slightly but not significantly better than timolol in pressure-
lowering effectiveness.  
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Similar reduction of pressure by timolol was also reported in the contralateral, untreated eye 
(Dunham et al, 1994; Piltz et al, 2000). Absorption of timolol by the nasopharyngeal mucosa 
has raised concerns of potentially life-threatening side effects following topical 
administration (Passo et al, 1984; Diggory and Franks, 1997). The elderly and those with 
cardio-respiratory impairment are at risk, and prescribing timolol in these patients must be 
done with caution (Diggory et al, 1998; Diggory et al, 1994; Leier et al, 1986). Although 
timolol has some effects on hypoglycaemia and hyperlipidemia, the effect is minimal with 
low clinical importance (Coleman et al, 1990; Shorr et al, 1997). Decreased libido, 
depression, and hallucination are among the reported side effects of timolol (Lama, 2002). 
The introduction of gel-forming timolol solution has lessened its systemic effect (Shedden et 
al, 2001).  
 
Timolol gel-forming solution (GFS) increases the viscosity of the drug, promotes ocular 
bioavailability, and facilitates ocular drug penetration. The prolongation of ocular contact 
depends on the gel formulation, which acts as a physical barrier to drainage or as a viscosity 
promoter. The gel in Timolol XE 0.5% promotes viscosity and bleb formation, which creates 
a temporary plug in the inner canthus and impedes timolol drainage through the punctum. 
Once-daily dosing of timolol GFS provides a similar pressure-lowering effect as timolol 
maleate in aqueous form with twice-daily instillation in glaucoma and ocular hypertensive 
patients (Roselund, 1996; Shedden et al, 2001). Plasma concentrations of timolol GFS are 
significantly lower than timolol ophthalmic solution, which perhaps explains the reduced 
systemic side effects associated with the gel solution (Shedden et al, 2001; Dickstein et al, 
2001; Uusitalo et al, 2006). Blurred vision upon instillation of timolol in gel solution and 
ocular discomfort were reported in many patients (Shedden et al, 2001).  
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1.6.2 Beta 2 adrenoreceptor (ADRB2) 
The metabolic and neuro-endocrine effects of adrenaline and nor-adrenaline are mediated by 
a class of membrane-bound proteins designated as the adrenergic receptor. The concept of an 
adrenergic receptor, which was previously regarded as a hypothetical structure, was 
introduced in 1948. Ahlquist (1948) disproved the concept of different epinephrine acting on 
specific receptors. There are actually different receptors that act specifically to produce 
different efferent organ effects. He coined the terms α- and β-receptor mediator to 
differentiate between excitatory and inhibitory functions. However, the action of the 
receptors in his experiment was epinephrine concentration-dependent. 
 
Further observation and experiments (Lands, 1967; Lands, 1952) revealed that the β receptor 
was not a single entity; instead, catecholamine stimulation of the β receptor was dependant on 
the site of the effectors organ. Further research revealed 2 β-receptor subtypes: β1 and β2. β1 
adrenoreceptor (ADRB1) are abundant in the myocardium and adipose tissue and bind nor-
epinephrine and epinephrine with similar affinity. β2 adrenoreceptors (ADRB2) are found in 
the lung, liver, lymphocytes, bronchial smooth muscle, and vascular tissue, and have 10-fold 
greater affinity for epinephrine (Lands, 1967). Initially, the quantification of β adrenoreceptor 
was only possible using autoradiographic ligands in vitro (Spina et al, 1989). ADRB2 was 
found distributed through the airway smooth muscle and in other lung cell types including 
epithelial, endothelial, mast, and type II cells (Johnson, 1992). The invention of positron 
emission tomography has made in vivo quantification of β receptor possible using radio-
ligands (IIC) CGP12177 (Ueki et al, 1993). 
 
Since β-adrenergic agents play a significant role in IOP regulation, the presence of β 
adrenoreceptor in ocular cells is of physiological and clinical importance (Nathanson, 1980). 
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Radio-ligands and hormone-sensitive adenyl cyclase were used to demonstrate that ADRB2 
is the major β-adrenoreceptor subtype (75–90%) in human ciliary processes, similar to its 
distribution in the human lung (Nathanson, 1981). The distribution of ADRB2 is similar in 
the eyes of rabbits and monkeys (Neufeld et al, 1978). Human iris, ciliary body, trabecular 
cells, and trabecular meshwork are also predominantly occupied by ADRB2 (Wax and 
Molinoff, 1987; Wax et al, 1989), further strengthening the possible importance of β 
adrenoreceptor in aqueous humour formation and as a pharmacological target in IOP control.  
 
ADRB2 is a member of the 7-transmembrane receptor super-family; it is composed of a 7-
helix membrane-spanning domain with 3 extracellular and 3 intracellular loops (Figure 1.2). 
The amino terminus is extracellular and the carboxyl terminus is intracellular. The ADRB2 
structure shares significant homology with rhodopsin in terms of the relative orientation of 
the 7 transmembrane helices, but the second extracellular loop has a unique conformation. A 
Cys residue at position 341, immediately after the transmembrane 7 (TMVII) domain, is the 
site of palmitoylation. Palmitoylation is the formation of a reversible covalent attachment of 
fatty acids to cysteine that enhances protein hydrophobicity and functions in sub-cellular 
trafficking (Strosberg, 1993). Palmitoylation enhances the ability of agonist-bound ADRB2 
to mediate adenylyl cyclase stimulation, promoting the insertion of several adjacent residues 
in the membrane (Moffet et al, 1993). Palmitoylation also anchors ADRB2 to the membrane 
and some consider it to be the fourth intra-cytoplasmic loop in the active conformation for G-
protein coupling (Ligget, 1999). ADRB2 contains 2 disulfide bonds essential for ligands 
binding. Cys
106 
and Cys
184
 form one disulfide bond and the other is between Cys
190
 and 
Cys
191
. The most important ligands-binding residue is Asp
113
 in TMIII. Hydrogen bonding 
between Ser
204
 and Ser
207
 in TMV is also essential for ligands binding. Asp
79 
and Asp
130 
in 
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TMII are important for signal transmission, as are Tyr
316
 and Asn
312 
in TMVII (Strosberg, 
1993).  
 
ADRB2 is also known as a G protein-coupled receptor (GPCR), a large family of 
transmembrane receptors that sense diverse extracellular molecular stimuli including odours, 
pheromones, hormones, neurotransmitters, and drugs, translating these signals into a cellular 
response. According to the nomenclature committee of the International Union of 
Pharmacology (NC-IUPHAR), GPCR are categorized into 4 groups; group 1 (also known as 
family A) is comprised of rhodopsin-like receptors; group 2 (family B) includes secretin-like 
receptors; group 3 (family C) includes GABA and metabotropic-glutamate receptors; and the 
last group includes the fizzled family receptors (Foord et al, 2005). ADRB2 is classified into 
group 1 for its structural similarity to rhodopsin; receptor phosphorylation activates the 
cAMP pathway to mediate cellular responses. The Human Genome Project has successfully 
sequenced most of the GPCRs. To date, the cellular or drug interaction functions of most of 
the 726 GPCRs encoded by the human genome have been characterized, but over 100 
GPCRs, especially olfactory receptors, are uncharacterised „orphans‟. Orphan receptors are 
sequenced heptahelical receptors for which neither ligands nor cellular function has been 
identified (Lefkowitz RJ, 2007).  
 
Ligands are signal-triggering molecules, which are specifically bound by target receptor 
proteins to induce a cellular response. Ligands can be an agonist or antagonist drug, which 
exhibits functional selectivity or ligands-induced differential signalling; different ligands can 
induce different receptor conformations (Urban et al, 2007). The strength of ligands depends 
on its affinity (ability of the drug to bind and the strength of ligands-receptor association) and 
efficacy (ability to induce biological response). Partial agonists are less efficacious than are 
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full agonists (Huber et al, 2008). Antagonists have no effect on basal receptor activity, also 
known as „zero efficacy‟, but block access of other ligands. Inverse agonists inhibit basal 
activity. Basal activity refers to the resting state interaction with G-protein.  
 
In the absence of ligands, basal receptor activity is determined by the equilibrium between 
the inactive (R) and active states (R*). The efficacy of ligands is determined by its ability to 
alter this equilibrium. The changes in the ADRB2 receptor are best illustrated by agonist 
binding. An agonist binds to the transmembrane segment and induces conformation changes 
(Hoffmann et al, 2008). Our understanding of these conformation changes and the molecular 
mechanism of cellular response have been facilitated by the formation of engineered 
crystalline structures of human ADRB2 (Rasmussen et al, 2007). Agonist-induced 
conformation changes involve both extracellular and intracellular loops. However, the rate at 
which these conformational changes occur differs between full and partial agonists 
(Ghanouni et al, 2001). The conformation changes induce internalization of the receptor and 
signal transduction via activation of α subunit heterotrimeric G protein (Gs) (Kobilka, 2007) 
that induces coupling with adenylate cyclase and guanosine triphosphate (GTP). Replacement 
of GTP with guanosine diphosphate (GDP) and catalysis by adenylate cyclase changes ATP 
to cAMP. Elevation of intracellular cAMP initiates receptor desensitization, which is 
characterised by phosphorylation, sequestration, and down-regulation of receptor number. 
Desensitization is an auto-regulatory process that prevents overstimulation. Phosphorylation 
of ADRB2 by the cAMP-independent kinase (βARK) or other related G protein-coupled 
receptor kinases (GRKs) results in β-arrestin binding and partial uncoupling of the agonist-
occupied receptor from the Gs protein (Johnson, 1998; Fredholm et al, 2007). Sequestration 
takes place after prolonged agonist exposure (seconds to minutes); internalization of a portion 
of ADRB2 into the sub-cellular compartment makes the receptor unavailable for signal 
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transduction (Liggett, 1999). Longer agonist exposure (hours to days) decreases the total 
complement of ADRB2, which is a process known as receptor down-regulation. 
 
1.6.3 Beta 2 adrenoreceptor gene (ADRB2) 
 
  
Figure 1.4:  Molecular and genetic structure of ADRB2 
(Adapted from Johnson, 1998) 
 
Human ADRB2 is encoded by an intronless gene of 2042 bp, located on the long arm of 
chromosome 5q31-32 (Kobilka et al, 1987). The protein is composed of 413 amino acids with 
a molecular mass of approximately 46,500 Daltons (Da). There are 12 single-nucleotide 
polymorphic sites in the coding region of ADRB2, but only 5 are non-synonymous. There are 
2 non-synonymous SNPs at the N terminus; the 46A/G substitution generates an Arginine to 
Glycine (Arg16Gly) variant; a 79C/G substitution generates a Glutamine to Glutamate 
(Gln27Glu) variant. The remaining SNPs are located in the membrane-spanning domain: 
TM I 
TM II 
TM III 
TM IV 
Carboxyl terminus 
TM V 
TM VI 
Amine terminus 
TM VII 
Arg16Gly 
Gln27Glu 
Val34Met 
Thr164Ile 
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100G/A (Val34Met), 491C/T (Thr164Ile) and 523C/A (Arg175Arg). Amino acid 164 is 
situated in the fourth transmembrane domain adjacent to Ser165, which is postulated to 
interact with β-OH of adrenergic ligands (Johnson, 1998). Based on the functional studies of 
ADRB2 in vitro and in vivo, only 46A/G, 79C/G, and 491C/T are thought to be important. 
Val34Met is rare and the SNP at 523 may be functionally significant based on its recent 
association with bronchodilator responsiveness in asthmatic patients (Silverman et al, 2003). 
 
There are 8 additional SNPs within the 1.5 kb 5′-un-translated region (UTR), which is 
believed to contain the main transcriptional regulatory sequences for ADRB2 ; -20 T/C, -47 
T/C, -367 T/C, -468 C/G, -654 G/A, -1343 A/G, and -1429 T/A (Scott et al, 1999). In 
addition, -47T/C (Arg-19Cys), which is located within a short open reading frame also 
known as the Beta Upstream Peptide (BUP) or the 5′-leader cistron (LC), influences receptor 
expression at the translational level (Scott et al, 1999). The promoter region also contains a 
cAMP response element (CRE), 2 NFL-IL6 sites, 4 AP-2 sites, and a steroid-binding 
hexamer (Parola and Kobilka, 1994).  
 
The impact of ADRB2 polymorphisms on receptor expression, agonist and antagonist binding 
affinity, physical and functional coupling to Gs protein, receptor trafficking, and receptor 
regulation by agonists were studied in vitro and in vivo (Leineweber and Brodde, 2004). 
Polymorphic ADRB2 had no effect on ligands binding or adenylyl cyclase activity in 
specialized COS-7 and Chinese hamster fibroblast (CHW) cells (Green et al, 1993). 
Moreover, Arg16Gly and Gln27Glu do not alter receptor function in human lung mast cells 
(HLM), human airway smooth muscle cells (HASM), and human lymphocytes (Leineweber 
et al, 2004). Ex vivo findings further reaffirmed that 46A/G, 79C/G, and 491C/T do not affect 
ADRB2 activity (Moore et al, 2000; Bruck et al, 2003a). This finding was also reflected on in 
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vivo cardiac and vasodilatory responses; there was no difference in heart rate and contractility 
between wild-type and variant (46A/G and 79C/G) ADRB2 (Bruck et al, 2003b). Based on 
the evidences, ADRB2 polymorphisms may not alter the receptor function. 
 
However, ADRB2 polymorphisms are important in agonist-induced receptor desensitization 
and down-regulation. Studies on transfected CHW cells and HASM with ADRB2 
polymorphisms have shown that 46G (Gly16) enhanced agonist-promoted down-regulation in 
comparison to wild type (Green et al, 1994; Green et al, 1995). In contrast, 79G (Glu27) 
appears to protect against down-regulation. Based on the number of receptors and β2-agonist-
mediated cAMP formation in cultured HASM, 79G (Glu27) down-regulated to a much lesser 
extent than 79C (Gln27) (Green et al, 1994; Moore et al, 2000). The 79G (Glu27) variant 
demonstrated strong resistance towards agonist-promoted down-regulation. In a site-directed 
mutagenesis study, 46G79G (Gly16Glu27) demonstrated a 46G (Gly16)-dominant 
phenotype, but 46A79G (Arg16Glu27) was completely resistant to down-regulation (Green et 
al, 1994, Chong et al, 2000). However, 46A79G (Arg16Glu27) is extremely rare in the 
general population. 
 
491T (Ile164) in CHW cells exhibited extensive signalling defects due to reduce agonist 
affinity (Green et al, 1993). Moreover, reduction of basal and agonist-induced activation of 
adenylyl cyclase and a right-shift of the agonist concentration-effect curve exhibited by 491T 
suggested impairment of receptor-G-protein interaction (Green et al, 1993). Thus, 491T is 
believed to play an important role in adenylyl cyclase coupling and G-protein interaction in 
vivo. There is also evidence to suggest that 491T induces a conformational alteration and 
decreases agonist activation. Agonist-competition binding studies found that 491T does not 
display high-affinity agonist binding in the absence of guanine nucleotides (Green et al, 
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1993). Transgenic mice expressing 491T in cardiomyocytes demonstrated lower basal and 
isoprenaline-stimulated adenylyl cyclase activity in comparison to 491C (Turki et al, 1996). 
Similarly, the 491C/T polymorphism demonstrated reduced receptor signalling in HLM, 
human adipose tissue, and lymphocytes in 3 cystic fibrosis patients (Büscher et al, 2000; Kay 
et al, 2003; Hoffstedt et al, 2001).  
 
ADRB2 expression in COS-7 cells transfected with wild-type ADRB2 and a -47C 
polymorphic variant was determined by radio-ligands binding (McGraw et al, 1998). 
Quantitative ribonuclease protection assays showed that the wild-type and -47C variant 
mRNA levels were the same. The -47C (-19Cys 5′ LC) variant construct yielded a higher 
ADRB2 expression level. In HASM, the -47C yielded approximately 2-fold higher ADRB2 
expression in comparison to -47T (Ligget, 1999). Thus, in vitro, in vivo, and ex vivo studies 
have shown that ADRB2 polymorphisms affect the expression, coupling, and desensitization 
of the ADRB2 receptor.  
 
Some of these SNPs are in linkage disequilibrium (Scott et al, 1999; McGraw et al, 1998; 
Drysdale et al, 2000). Thus, subjects homozygous for 79CC (Glu27) are nearly always 
homozygous for 46GG (Gly16); the 46A79G (Arg16Glu27) haplotypes is extremely rare, 
occurring in less than 1% of the population. There is also tight linkage disequilibrium 
between 46G79G (Gly16Glu27) and -47T (Arg-19). Only 12 haplotypes have been detected 
out of 8192 statistically possible haplotypes of ADRB2 (Drysdale et al, 2000) and a majority 
are uncommon. The 4 major haplotypes are -47T46G79G491T (Arg-19Gly16Glu27Thr164), 
-47C46A79C491T (Cys-19Arg16Gln27Thr164), and -47C46G79C491T (Cys-
19Gly16Gln27Thr164). Linkage disequilibrium is the major confounding factor in the 
inconsistency of the effect of ADRB2 SNPs in vivo and in vitro studies. Tantalizing results 
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from in vitro studies and the strong desensitization effect of ADRB2 in in vivo studies may 
not be easily translated into clinical application. To complicate matters further, the allele 
frequencies of reported ADRB2 SNPs differ between populations (Table 1.5).  
Table 1.5: Allele frequencies and phenotypes of ADRB2 polymorphisms  
Codon Amino 
Acid 
SNP Caucasians African Asian Latino Phenotype 
-20 
 
-47 
 
 
 
46 
 
 
 
79 
 
 
 
491 
 
 
-19 
Arg 
Cys 
 
16 
Arg16 
Gly16 
 
27 
Gln27 
Glu27 
 
164 
Thr164 
Ile164 
 
T/C 
 
C/T 
 
 
 
A/G 
 
 
 
C/G 
 
 
 
C/T 
NA 
 
 
     65.0** 
35.0 
 
 
45.7* 
54.3 
 
 
65.2* 
34.8 
 
 
96.0
@ 
4.0 
NA 
 
 
79.0** 
21.0 
 
 
48.8* 
51.2 
 
 
79.3* 
20.7 
 
 
98.0
@ 
2.0 
NA 
 
 
92.0** 
8.0 
 
 
58.7* 
41.3 
 
 
92.8* 
7.2 
 
 
99.0
@ 
1.0 
 
NA 
 
 
82.4# 
17.6 
 
 
57.9# 
42.1 
 
 
NA 
 
 
 
97.0
@ 
3.0 
Increased expression 
 
Increased expression 
 
 
 
 
Increased 
desensitization 
 
 
Reduced desensitization 
 
 
 
Reduced coupling 
*Xie et al, 1999; #Litonjua et al, 2004; **McGraw et al, 1998; @Small et al, 2003 
NA: not available 
 
 
ADRB2 receptors are expressed and have diverse functions in various tissues; thus, 
polymorphisms of ADRB2 are postulated to play a role in various diseases, particularly 
cardio-respiratory disorders. The ADRB2 gene has been extensively studied in asthma. 
However, the possible role of ADRB2 gene polymorphisms in asthma pathogenesis remains 
inconclusive. A majority of the findings suggested that ADRB2 polymorphisms, alone or as 
haplotypes, may not influence asthma susceptibility, severity, or pathogenesis in various 
populations (Munakata et al, 2006; Weir et al, 1998; Tsai et al, 2006). Perhaps the interplay 
of genetic and environmental risk factors has more influence than genetics alone in a complex 
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disease such as asthma. ADRB2 polymorphisms are likely to influence responsiveness to β-2 
agonist drugs. 
 
Based on the evidence that ADRB2-mediated vasodilation is involved in physiological blood 
pressure regulation, ADRB2 is a candidate gene for hypertension. Vascular response to 
ADRB2 stimulation is impaired in hypertensive patients and in vivo studies have 
demonstrated that ADRB2 affects vasodilation (Brodde, 2007). The findings from association 
studies in various populations remain controversial (Xie et al, 2000; Lee et al, 2004; Brodde, 
2008). However, based on a meta-analysis, ADRB2 polymorphisms are not significantly 
important in the aetiology of hypertension (Hahntow et al, 2006).  
 
Although β1-adrenoreceptor is the predominant adrenergic receptor in the heart, ADRB2-
mediated positive inotropic and chronotropic effect to a certain extent. ADRB2 is anti-
apoptotic in murine and rat cardiomyocytes, suggesting that ADRB2 polymorphisms could 
confer a protective effect in cardiac failure (Bruck et al, 2003). However, the promising role 
of ADRB2 polymorphisms in animal studies has failed to translate effectively into humans 
(Brodde, 2008). The potential role of 46A/G and 79C/G in predicting survival in patients with 
cardiac failure remains unclear.  
 
1.7 Topical prostaglandin analogue compounds 
For 25 years, topical timolol maleate has been widely accepted as the treatment of choice for 
glaucoma. It is undoubtedly efficacious in almost all types of glaucoma. A lack of intolerable 
side effects in comparison to topical non-selective sympathomimetics and mitotic further 
contributed to the popularity of topical timolol. The quest for more potent agents began in the 
early 1980s. During the frenzy of interest in prostaglandin as possible ocular anti-
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inflammatory effects and potential therapeutic role, prostaglandin was infused into 
cannulated experimental animal eyes and was found to cause ocular hypertension with 
breakdown of the blood-aqueous barrier (Bito et al, 1989a). Accidentally, the ocular 
hypotensive effect was achieved with a low concentration of topical prostaglandin with 
breakdown of the blood-aqueous barrier even without cannulation. Naturally occurring 
prostaglandins are relatively polar, hydrophilic molecules that poorly cross biological 
membranes due to their carboxylic acid moiety and several hydroxyl groups. Prostaglandin 
effects differ between species (Bito et al, 1989b). Different prostanoids have different side 
effects on the human eye, consistent with the reported multiplicity and low selectivity of 
naturally occurring prostaglandin for different subtypes of prostanoids (Woodward et al, 
1997).  
 
Figure 1.5: Chemical structure of major topical prostaglandin analogue pro-drugs and 
their hydrolyzed free acids. 
(Adapted from Bean and Camras, 2008) 
Not available 
for patient use 
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There was a major setback in the first experiment with topical prostaglandin in human 
volunteers using a high concentration (200 µg) tromethamine salt form of PGF2α, which 
resulted in severe ocular hyperaemia, ocular pain, and headache (Giuffre, 1985). Lower 
concentrations (up to 100-fold) were found to potentiate better ocular hypotensive effects 
with esterification of the prostaglandin carboxylic acid group, which is the basis of the pro-
drug principle (Kerstetter et al, 1988). Esterification of the carboxylic acid reduces polarity 
and facilitates penetration of the prodrug through biological lipid membranes. The prodrug is 
then converted to free acids to activate the specific FP receptors once it crosses the corneal 
epithelium in the specific direction known as orthrorectified transport or the slow release 
system, which is ideal for chronic therapy in glaucoma and minimizes unwanted ocular and 
systemic side effects (Figure 1.5).  
 
After more than 2 decades in search of a topical prostaglandin with an acceptable therapeutic 
index, Unoprostone (13, 14-dihydro-15-keto metabolite of PGF2α) with the trade name of 
Rescula (Ciba Vision, Duluth GA) was made commercially available in Japan. The drug 
failed to gain popularity worldwide due to lack of efficacy and the requirement for twice-
daily administration. In 1996, latanoprost (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-PGF2α-
isopropyl ester) was marketed as Xalatan (Pfizer Inc, New York) and gained approval 
worldwide. Later, travoprost (Travatan; Alcon) and bimatoprost (Lumigan; Allergan) were 
introduced. Unlike latanoprost and travoprost, bimatoprost has been controversially known as 
prostamide owing to the presence of a C1 ethyl amide group that activates different receptors. 
Topical prostaglandin analogues are believed to achieve pressure-lowering effects by 
increasing uveoscleral outflow without any effect on aqueous humour production (Toris et al, 
1993). However, their effect on the trabecular meshwork remains unclear (Oh et al, 2006; 
Johnson et al, 2010). There was no statistically significant difference in efficacy between the 
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3 commercially available topical prostaglandin analogues but there was a reported borderline 
increased incidence of ocular hyperaemia with bimatoprost (van de Valk et al, 2005; 
Zimmerman et al, 2009). Bimatoprost has the edge in effectiveness but with slightly more 
pronounced side effects (Cracknell and Grierson, 2009). 
 
Topical prostaglandin analogues have changed the paradigm of glaucoma management, most 
notably with the declining rate of glaucoma surgeries in the late 1990s (Bateman et al, 2002). 
Currently, due to their efficacy and better tolerability, topical prostaglandin analogues are 
replacing topical timolol as the first-line drug of choice in glaucoma management 
(Holmstrom et al, 2006). It is amazing that low lipid solubility drugs in low concentrations 
can achieve such an impact in glaucoma management.  
 
1.7.1 Topical latanoprost 0.005% 
Topical prostaglandin analogue PhXA34 (13, 14-dihydro-17-phenyl-18, 19, 20-trinor-PGF2α-
isopropyl ester) known as latanoprost, differs from the naturally occurring PGF2α, where C18 
to C20 have been substituted by a benzene ring, the double bond between C13 and C14 has 
been saturated, and the carboxylic acid moiety on C1 has been esterified with isopropanol 
(Figure 1.7). The molecular weight of latanoprost is 432.6 and the hydrolysed compound 
(free acid) is 390.5 (Stjernschantz and Alm, 1996). The octanol-water partition coefficient is 
4.3 at pH 7.4, with poor solubility in water. It is available as a colourless to slightly yellow oil 
solution in 0.005% concentration (50µg/ mL) preserved with 0.02% benzalkonium chloride. 
It is commercially available in 5 mL plastic bottles (2.5 mL latanoprost solution), which 
requires refrigeration to maintain a temperature of 2 to 8°C for unopened bottles. Once 
opened, bottles can be stored safely at room temperature for a maximum of 6 weeks. 
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Latanoprost can be prescribed as either evening or morning once-daily dosing but evening 
dosing is more efficacious (Alm and Stjernschantz, 1995). 
 
Latanoprost is a selective FP receptor agonist with marginal spillover effect on other 
prostanoid receptors, resulting in fewer unwanted side effects. Naturally occurring PGF2α has 
greater affinity than latanoprost for the FP receptor but also interacts with other prostaglandin 
receptors, which is partly responsible for side effects such as iritis and conjunctival 
hyperaemia (Astin and Stjernschantz, 1997). As a prodrug, it is relatively inactive until the 
hydrolyzation of the isopropyl ester to free acid in the cornea and plasma. Latanoprost in free 
acid form is measurable in the aqueous humour within 4 hours of instillation. Approximately 
1% of topically applied latanoprost is absorbed into the eye, the majority being absorbed into 
the systemic circulation through either conjunctiva vessels and nasal mucosa or 
gastrointestinal tract absorption. The peak concentration is reached about 2 hours after topical 
instillation with the distribution volume of 0.16 ± 0.02 L/kg in humans (Sjöquist and 
Stjernschantz, 2002). The half-life of free acid in human plasma is about 17 minutes. Plasma 
levels of latanoprost acid were below the detection limit in patients treated with latanoprost 
for a year. Latanoprost is metabolized by β-oxidation in the liver; it is not metabolized in the 
cornea and is mainly excreted in the urine (88–98%). 
 
Although the exact mechanism of action of latanoprost is still uncertain, FP receptor plays 
essential role and FP receptor-deficient mice do not exhibit any pressure-lowering effect (Ota 
et al, 2005; Crowston et al, 2004). Aqueous humour production is not significantly affected 
by latanoprost but the most consistent finding is a substantial increase in uveoscleral 
(pressure-insensitive) outflow; a less consistent finding is the role in trabecular (pressure-
sensitive) outflow capacity (Toris et al, 2008; Lim et al, 2008; Johnson et al, 2010). There are 
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3 potential mechanisms by which latanoprost could increase uveoscleral drainage. These 
include: (1) Remodelling of extracellular matrix of the ciliary muscle and sclera causing 
permeability changes, (2) widening of the connective tissue-filled spaces among the ciliary 
muscle bundles, which may be caused by relaxation of the ciliary muscle and (3) changes in 
the shape of ciliary muscle cells as a result of altered actin and vinculin localization (Toris et 
al, 2008; Lindsey et al, 1997). The remodelling of extracellular matrix is believed to be 
responsible for sustaining the long-term pressure-lowering effect (Johnson et al, 2010). 
 
Ciliary muscle relaxation is believed to be responsible for the initial reduction of IOP but the 
effect is not prominent in latanoprost. Remodelling of the extracellular matrix within the 
ciliary muscle and sclera is the most thoroughly understood and most accepted mechanism. 
Latanoprost stimulates induction of Matrix Metalloproteinases (MMPs) 1, 2, and 3 that cause 
dissolution of collagen types I and III within the connective tissue-filled spaces between the 
outer longitudinal muscles (Lütjen-Drecoll and Tamm, 1988). The mRNA of MMP 1, 2, 3, 
11, 12, 14, 15, 16, 17, 19 and 24 were identified in human ciliary body and smooth muscle 
(Oh et al, 2006). Activity of MMP is regulated by family of extracellular inhibitory proteins; 
tissue inhibitors of metalloproteinases (TIMPs). Each TIMP regulates specific MMPs. In 
human ciliary body, only TIMP-1, TIMP-2, TIMP-3 and TIMP-4 are found (Murphy and 
Docherty, 1992). Animal experimental studies showed evidence of changes in ciliary muscle; 
the tissue spaces of the ciliary muscle were enlarged and organized into tube-like spaces 
covered by endothelial-like cells with close basement membrane contact, and contained 
myelinated nerve fibre bundles that resembled a lymphatic system in the choroid (Krebs and 
Krebs, 1988; Richter et al, 2003).  
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Latanoprost induced MMP 3, 9, 17, and TIMP-3, and down-regulated MMP 1, 2, 12, 14, 15, 
16, and TIMP-4 in human ciliary body (Oh et al, 2006). Latanoprost acid induced 
concentration-dependent increases in MMP 1, 3, and 9 gene transcriptions and a 
concentration- and time-dependent increase in TIMP-1 but not TIMP-2 mRNA and protein in 
human ciliary muscle (Anthony et al, 2002). In general, MMP 1, 2, 3 and 9 and TIMP -1 
seem to play important role in remodelling of extracellular matrix.  
 
Cyclooxygenase (COX)-2 is also believed to play a role in the pressure-lowering effect of 
latanoprost (Sales et al, 2008). The mechanism of latanoprost-induced MMP secretion is 
through protein kinase C and extracellular signal-regulated protein kinase 1/2-dependent 
pathways (Chen et al, 2001; Anthony et al, 2002). Mitogen-activated protein kinase and 
tumour necrosis factor α-dependent signalling pathways may also be involved (Yousufzai et 
al, 2000). The vasodilatation effect of latanoprost, although minimal, is also postulated to 
play a role in facilitating uveoscleral outflow. Although increases aqueous outflow through 
non-conventional pathways seems to be responsible for the pressure-lowering effect of 
latanoprost, there are ongoing studies providing evidence of the possible role of trabecular 
meshwork outflow (Oh et al, 2006).  
 
In spite of uncertainty in the mechanism of latanoprost action, latanoprost is a clinically 
proven efficacious topical anti-glaucoma drug. Its effectiveness has been observed in many 
populations. Hedman and Larsson (2002), based on mean diurnal IOP reduction, found that 
latanoprost is more effective than timolol in 8 different populations with greater reduction 
among Mexican and Asian populations. A meta-analysis involving 1256 glaucoma patients 
found that latanoprost is superior to timolol in long-term IOP control (Zhang et al, 2001). 
Latanoprost has the advantage of achieving IOP reduction during both day and night while 
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timolol has a minimal effect on nocturnal IOP (Larsson et al, 2002). In a long-term study, 
latanoprost sustained meaningful IOP reduction (Hedman et al, 2002). Latanoprost is not only 
effective in OAG but also in angle-closure glaucoma (Chew et al, 2004). In spite of its higher 
therapeutic index, there was a reported 18–25% non-responder rate (Scherer, 2002; Cheong et 
al, 2008; Camras and Hedmann, 2003). The definition of a responder varies according the 
predetermined cut-off point. Based on the US latanoprost study group, a greater proportion of 
patients classified as non-responders on any particular visit were responders on all other visits 
if treated with latanoprost rather than timolol (Camras and Hedmann, 2003). Among PG 
analogues, bimatoprost seems to be slightly superior in reducing pressure but not without a 
price (van der Valk et al, 2005). Bimatoprost has a higher incidence of conjunctival 
hyperaemia.  
 
Although PGF2α is responsible for stimulating bronchial hyper-responsiveness, respiratory 
impairment induced by latanoprost has not been reported (Hedner et al, 1997). Short half-life 
and rapid clearance of the active latanoprost acid minimizes unwanted systemic side effects 
(Sjöquist and Stjernschantz, 2002). Furthermore, latanoprost free acids that enter the systemic 
circulation do not permeate tight-junction cell membrane barriers such as the blood-brain 
barrier, minimizing the potential for central nervous system side effects. However, some 
nonspecific systemic side effects such as headache, flulike syndromes, upper respiratory tract 
infections, and musculoskeletal pain have been reported (Alm et al, 1995).  
 
Latanoprost-induced ocular side effects are a major concern. Conjunctival hyperaemia is a 
common side effect with the incidence range between 5 to 15% (Stewart et al, 2003; Walters 
et al, 2004). The incidence is much higher in travoprost and bimatoprost (Honrubia et al, 
2009; Walters et al, 2004). Conjunctival hyperaemia is generally mild and transient, and 
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commonly develops within 1 month of therapy initiation. Vasodilation induced by 
prostaglandin promotes the release of nitric oxide that may be responsible for conjunctival 
hyperaemia (Alm et al, 2008). The saturated double bond in C13 and C14 of latanoprost is 
partly responsible (Resul and Stjernschantz, 1993). Ocular irritation, burning sensation, and 
dry eye are also reported (Stewart et al, 2003). However, the most intriguing side effect is the 
ability of latanoprost to induce pigmentation in the iris, eyelid, and eyelashes. Latanoprost-
induced iris darkening (LIID) was found in higher frequency in heterogeneous hazel irises 
and homogeneous gray and blue irises are less likely to develop LIID in Caucasians (Alm et 
al, 2008). Japanese and South East Asians, in spite of having homogeneous dark brown irises, 
were more likely to develop LIID (Chiba et al, 2004; Chou et al, 2005). During phase III of a 
latanoprost study, latanoprost was postulated to have the ability to promote iris melanocyte 
proliferation (Stjernschantz et al, 2002). However, there was no evidence of increases 
melanogenesis in tissue culture studies (Kashiwagi et al, 2002; Drago et al, 1999). 
Histopathological and morphometric studies found evidence of increased iris melanocyte in 
the stroma and redistribution of the melanocyte to the anterior iris stroma without a net 
increase in number (Cracknell and Grierson, 2009; Cracknell et al, 2003; Albert et al, 2008).  
 
LIID is irreversible and causes cosmetic concerns, especially when it occurs in one eye, but 
has no incapacitating visual side effects. Hyperpigmentation, elongation, and thickening of 
the eyelashes (hypertrichosis) may cause the lashes to touch the spectacles or cause difficulty 
in topical drug instillation but is never a major concern (Johnstone, 1997; Shaikh and Bodla, 
2006). Unlike LIID, hypertrichosis is reversible and disappears several weeks after 
discontinuation of treatment. Peri-ocular hyperpigmentation is also reported and is most 
likely due to accidental spillover during drug administration (Herndon et al, 2003). There 
were also reported cases of hypo-pigmentation (Herndon et al, 2003).  
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Disruption of the blood-aqueous barrier and posterior lens release of inflammatory mediators 
causes cystoids macular oedema (CME) following latanoprost treatment (Miyake et al, 1999). 
Latanoprost-induced CME may cause visual impairment but the incidence is uncommon in 
comparison to the frequency of pigmentation-induced side effects (Warwar et al, 1998). 
Prostaglandin at higher concentrations acts as an inflammatory mediator and anterior uveitis 
was reported following latanoprost treatment (Warwar et al, 1998). Reactivation of herpes 
simplex keratitis has been reported in 3 patients with a history of herpes simplex infection 
(Wand et al, 1999). In patients with a high risk of CME, anterior uveitis, and past history of 
herpes simplex, latanoprost is not recommended for glaucoma treatment. 
 
1.7.2 Prostanoid receptors  
Prostaglandins are lipid-derived autacoids generated by sequential metabolism of arachidonic 
acid by cyclooxygenase (COX) and prostaglandin synthase. Arachidonic acid is released 
from the cell membrane by phospholipase A2 and oxidised by COX to PGG2 followed by 
reduction to unstable endoperoxide PGH2. PGH2 acts as a substrate for prostaglandin synthase 
enzymes, which through enzyme specificity (PGE synthase, PGF synthase, PGD synthase, 
PGI synthase and TX synthase) are responsible for producing 5 principal bioactive 
prostaglandins (prostanoid receptor sub-family); PGE2, PGF2α, PGD2, PGI2 (prostacyclin), 
and TXA2 (thromboxane). The COX enzyme exists as 2 major isozymes. COX-1 is expressed 
constitutively in most cells and is a major source of prostanoid for physiological function, 
while COX-2 expression is inducible in response to inflammatory cytokines, stress, tumour 
promoter, and stimuli such as bacterial lipopolysaccharide (LPS). Prostaglandins are 
ubiquitously produced and act locally in an autocrine or juxtacrine function to produce a 
diverse set of pharmacological effects modulating many physiological systems and 
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influencing a broad array of diseases including cancer, inflammation, cardiovascular disease, 
and hypertension.  
 
The physiological, pharmacological, and pathological effects of prostaglandin are mediated in 
part by G-protein coupled prostanoid receptors. There are 8 well-known prostanoid receptors: 
DP, EP1, EP2, EP3, EP4, FP, IP (prostacyclin), and TP (thromboxane A2). Recently, another 
prostaglandin receptor was discovered; the chemo-attractant receptor homologous molecule 
expressed on Th2 cells (CRTH2) binds to PGD2. Although it is more closely related to 
chemo-attractant receptors, it is identified as the ninth prostaglandin receptor. Individual 
prostanoid receptors share around 20% to 30% sequence identity and encode specific motifs 
common only to members of the subfamily (Hata, 2004). As GPCR is a classical example, 
coupling with the heterotrimeric G protein-mediated signal transduction pathway is required 
and the biological effect depends on ligands affinity, receptor expression profile, differential 
coupling to signal transduction pathways, and cellular expression. The existence of multiple 
receptors coupling to different signal transduction pathways for a given prostaglandin allows 
for synergistic antagonism between prostanoid receptors. Moreover, the structural similarities 
between prostanoid receptors may lead to activation of more than one prostanoid subfamily 
receptor; these characteristics complicate our understanding of the mechanism of action of 
each receptor.  
 
As a member of GPCR, the structure of all prostanoid receptors consists of 7 putative α-
helical membrane-spanning domains with an extracellular amino terminus, an intracellular 
carboxyl terminus, 3 extracellular loops, and 3 intracellular loops. The intracellular loops 
contain potential phosphorylation sites, which mediate receptor desensitization and 
internalization. Potential glycosylation sites are often associated with the amino terminus of 
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G-protein-coupled receptors. In the prostanoid receptor family, 28 amino acid residues are 
conserved in the molecular structure. Eight of these 28 amino acids are shared by other 
GPCR, mainly believed to maintain structure and/or function of receptors in the same group. 
The conserved Asp in the second transmembrane domain in the prostanoid subfamily is 
believed to be responsible in coupling ligands binding to activation of G proteins. Two Cys 
residues in the first and second extracellular loops are also conserved and believed to form a 
disulfide bond critical for stabilization of the receptor and ligands-binding conformations. 
The arginine in the seventh transmembrane domain is conserved in all prostanoid receptors 
and is the proposed carboxyl-binding site. There are also several conserved motifs.  
 
Phylogenetic analysis of prostanoid receptors shows that the receptors segregate into 2 
branches; one branch contains the DP, IP, EP2, and EP4 and the second branch contains the 
EP1, EP3, FP, and TP receptors. Based on their signal transduction and action, the prostanoid 
receptors can be divided into 3 categories; relaxant receptors, contractile receptors, and 
inhibitory receptors. The relaxant receptors include IP, DP, EP2, and EP4, which induce 
smooth muscle relaxation mediated by elevated intracellular cAMP. The contractile receptors 
include TP, FP, and EP1, which induce smooth muscle contraction mediated by calcium 
mobilization. EP3 is the only inhibitory receptor that mediates decreases in cAMP and 
inhibits smooth muscle relaxation. Structure homology between receptors in each category is 
up to 50%.  
 
In spite of molecular structural similarities, the human prostanoid receptors are not encoded 
near each other in the genome. The genes encoding the human EP1, EP3, EP4, FP, IP, and TP 
receptors were mapped to chromosome bands 19p13.1, 1p13.2, 5p13.1, 1p13.1, 19p13.3, and 
19p13.3 (Duncan, 1995). The loci of EP3 and FP receptor genes are in close proximity, 
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suggesting their evolution by gene duplication. Classically, all known members of the 
prostanoid receptor family have a short untranslated exon 1, an exon 2 with a large coding 
region, and exon 3 (Ogawa, 1995). Identification of additional exons encoding carboxyl-
terminal tails in some of the prostanoid receptors and alternative splicing of these exons 
creates various receptor isoforms. Most of these isoforms have almost identical ligand-
binding specificities in each receptor family. However, isoforms of EP3 and TP receptors 
were found to couple with different G proteins and mediated different signalling pathways 
(Namba, 1993; Hirata, 1996). Basal promoter motifs for transcription such as TATA and 
CCAAT boxes have been identified in the 5′ flanking region of EP3 and EP4 but these motifs 
are absent in TP, IP, and FP receptors. Other receptor-specific motifs are important for their 
ligand-binding and signalling pathways. For example, the human TP receptor gene contains 
an SP-1 binding site, AP-2 consensus sequences, a phorbol ester response element (TRE), 
acute-phase reactant regulatory elements (APRRE), a c-myc binding motif, and a 
glucocorticoid response element (Nüsing, 1993).  
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1.7.3 Prostaglandin F2α receptor (FP) 
 
Figure 1.6: Molecular structure of the human and bovine FP receptor.  
(Adapted from Anderson et al, 2001) 
 
PGF2α was first identified in the secretory endometrium during the menstrual cycle (Abel and 
Baird, 1980). The effect of PGF2α on the human reproductive system has been widely studied 
including during parturition, menstruation, and reproductive organ carcinoma (Myatt and 
Lye, 2004). Later, it was found to play a role in renal physiology, cardiac hypertrophy, and 
IOP regulation. FP receptor is expressed in the corpus luteum, renal cells, ocular tissues, and 
Human FP receptor 
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ventricular myocytes. Since the identification of prostaglandin known as „irin‟ in the anterior 
chamber, researchers have been interested in the role of prostaglandin in various ocular 
pathologies (Ambache, 1957).  
 
Immuno-fluorescence labelling revealed abundant FP receptor proteins in human ciliary 
epithelium, the circular portion of the ciliary body, the stromal and smooth muscle of the iris, 
corneal epithelium, conjunctival epithelium, and retinal cell layers except for the Muller cells 
and retinal pigmented epithelium (Schötzer-Schrehardt et al 2002). FP receptor proteins are 
also detected in the trabecular meshwork but in smaller amounts. FP receptor transcripts are 
absent in vessels, corneal stroma, conjunctival stroma, sclera and corneal endothelium but FP 
receptor protein is detected in monkey ocular tissue (Ocklind et al, 1996). In contrast to the 
discrepancy between mRNA expression and FP receptor protein distribution in monkey 
ocular tissue, there is no such discrepancy in humans (Schötzer-Schrehardt et al 2002). FP 
receptors are widely distributed in human ocular tissue, suggesting a functional role for this 
prostanoid receptor type in the eye (Mukhopadhyay et al, 2001). The interest in FP receptor 
increased with the discovery of a topical prostaglandin agonist, a potent pressure-lowering 
drug.  
 
FP receptors in the ocular tissue are structurally similar to those in the corpus luteum. The FP 
receptor protein is 40,060 Da in humans and 40,983 Da in bovines. Bovine and human FP 
receptors share 86% homology. There are 359 amino acids in the open reading frame of 
human FP receptor (Figure 1.4). FP receptor has similar 7 transmembrane loops with an 
extracellular amino terminus and intracellular carboxyl terminus as in other prostanoid and 
GPCR receptors. The proposed specific binding site of FP receptor is at Arg291 and His81. 
Arg291 is believed to form a Schiff base with the carboxyl group (Sakamoto et al, 1995). 
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His81, located at the second transmembrane domain, is in close proximity with Arg291 and is 
believed to act as a hydrogen bond donor. Asn4 and Asn19 are postulated N-glycosylation 
sites (Sakamoto et al, 1994; Abramovitz et al, 1994). Two serine or threonine (Ser-144 and 
Thr-148) in the second intracellular loop and 4 in the carboxyl terminus (Thr-148, Ser-337, 
Ser-341, and Thr-353) have been suggested as potential sites for phosphorylation by protein 
kinase C (PKC). Cysteine residues (Cys-108 and Cys-186) in the first and second 
extracellular loops are likely to form a disulfide bond to stabilize the FP receptor protein 
structure. Three proline residues (Pro-170, Pro-264, and Pro-301) in transmembrane domains 
IV, VI, and VII are likely to form kinks in the α-helices and may be essential in the formation 
of the ligands binding pocket (Figure 1.6). 
 
A common key prostaglandin-binding site was identified at the C1 carboxylic acid and C15 
hydroxyl (Figure 1.6). C1 (first carbon) carboxylic acid of PGF2α appears to form a Schiff 
base with an arginine in the seventh transmembrane domain (Anderson et al, 2001). C15 (15
th
 
carbon) hydroxyl is important in prostaglandin metabolism; enzymatic dehydrogenation of 
C15 by 15-hydroxy-prostaglandin dehydrogenase leads to inactivation of prostaglandin. 
Binding affinity of prostaglandin to FP receptor is reduced when the C15 hydroxyl is changed 
to 15-keto PGF2α or 15-methyl PGF2α. Attaching a phenyl group between C17 and C20, as 
occurs with FP receptor agonists such as latanoprost and fluprostenol, results in longer half 
lives in vivo. C9 and C11 are believed to play a role in the binding specificity of a subfamily 
of prostaglandins. However, alteration of C11 produced little change in binding affinity. 
Changing the hydroxyl group to ketone on C9 confers partial specificity by interacting with 
distinct amino acids of specific prostaglandin receptors (Oien et al, 1975). Alteration of the 
double bond between C5 and C6 dramatically decreased FP receptor binding. Binding of 
PGF2α to the FP receptor leads to numerous intracellular effects: activation of trimeric G 
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proteins Gαq and Gα11, small G-protein Rho, phospholipase C, inositol triphosphate (IP3) 
generation and elevation of intracellular calcium concentration, and activation of 
phospholipase D and mitogen-activated protein kinase (Abramovitz et al, 1994; Pierce et al, 
1999; Gusovsky, 1991; Davis et al, 1987; Chen et al, 1998). Low affinity of cross-reaction 
between several prostanoid receptors and FP receptor has been observed.  
 
 
Figure 1.7: Chemical structure of PGF2α 
(Adapted from Anderson et al, 20001) 
 
1.7.4 FP receptor gene (PTGFR) 
Human FP receptor is encoded by the PGF2α gene known as PTGFR. It is located in the short 
arm of chromosome 1 (13.1) in close proximity to the GIPC2 gene (Betz et al, 1999). PTGFR 
consists of 4 exons and 3 introns spanning 43.3 kb (Vielhauer et al, 2004). The first exon is 
relatively short (165 bp) and comprises most of the 5′-untranslated region (5′-UTR). Intron 1 
is approximately 1.3 kb in size and may contain part of the promoter region. The second exon 
(870 bp) consists of approximately 70 bp of untranslated region, encodes the remaining 5′-
UTR, and the rest of the second exon is translated. The translated region continues up to 
Leu266 near the end of transmembrane VI. However, it is interrupted by the large second 
intron (4.3 kb) and the third intron (38.5 kb). A small third exon is approximately 70 bp in 
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size. The fourth exon is quite large, spanning 3344 bp, but only a small fragment is translated 
and the rest is the 3′-untranslated region (3′-UTR).  
 
 
 
 
 
 
 
 
 
Figure 1.8: Human PTGFR based on Ensembl and Havana databases 
(http://www.ensembl.org/) 
 
The promoter region of human PTGFR, spanning around 4106 bp including 2436 bp 
upstream from the ATG of exon 1, exon 1, intron 1, and part of exon 2, lacks canonical 
TATA- and CAAT-boxes (Zaragoza et al, 2004). However, there are 2 SP-1/GC elements 
located within 100 bp of the transcription start site at positions -114 and -86. It is believed 
that SP-1 functions as a tethering moiety to recruit the general transcription machinery to 
TATA-less promoters. Several GATA and AP-1 sites are found throughout the human FP 
promoter. There is also a STAT site at position -950 and a cAMP response element (CRE) at 
position -2124. There are also possible repressor and enhancer regions, which may be 
important in physiological regulation.  
165bp     
70bp Exon 1 
Exon 2 Exon 3 
Exon 4 870bp 
3344bp 
Untranslated region 
Translated region 
1.3kb 
4.3kb 38.5kb 
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Unlike the EP receptor, there is no reported FP receptor subtype. However, 2 alternative 
spliced isoforms of FP receptors, designated as FPA and FPB, were cloned from human 
corpus luteum, placenta, uterus, heart, and ocular tissue (Pierce et al, 1996; Vielhauer et al, 
2004). The isoforms have almost identical structures except for the carboxyl tail. FPA has 
another 46 amino acids beyond the 9 shared residues, while FPB terminates after only 1 
amino acid (Pierce et al, 1996). The FPB isoform is produced by splicing out a putative 3.2 
kb intron sequence that is retained in the FPA isoform. Although the 2 isoforms have 
indistinguishable radio-ligand binding activity, they differ in functional coupling to 
phosphatidylinositol hydrolysis.  
 
Genetic variation of PTGFR is not as widely studied as it is in ADRB2. Loss of 
heterozygosity (LOH) at chromosome 1p31.1, where PTGFR is located, was associated with 
sporadic breast cancer. PTGFR is therefore implicated as a possible candidate gene for breast 
cancer (Sossey-Alaoui et al, 2001). Dystocia is a condition associated with prolonged or 
dysfunctional labour and cephalopelvic disproportion. There is an association of PTGFR with 
dystocia in animals but not in humans (Algovik et al, 1999). Recently, FP receptor was found 
to be essential in IOP regulation. A study on PTGFR knockout mice found that FP receptor 
signalling is important in IOP reduction by latanoprost treatment (Crowston et al, 2004). 
Based on the response of healthy volunteers to short-term latanoprost treatment, PTGFR gene 
polymorphisms have a possible role in the pressure-lowering effect of latanoprost in humans 
(Sakurai et al, 2007). However, the role of PTGFR in glaucoma has not yet been evaluated. 
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1.8 Pharmacogenetics 
Individual variation in drug response poses a significant clinical problem, ranging from 
failure to respond to a drug to life threatening adverse drug reactions. The causative factors 
are probably genetic, physiological, pathophysiological, and environmental. Genetic factors 
are likely to play an important role in controlling drug absorption, distribution, metabolism, 
and drug-drug interactions. However, the influence of genetic mechanisms is almost certainly 
interrelated with the action of other factors. It is estimated that genetics is responsible for 15–
30% of variation in drug responsiveness (Evan and McLeod, 2003). However, in certain 
drugs, genetic factors could contribute up to 95% of variation. The study of 
pharmacogenetics aims to understand how genetic variations contribute to variations in 
response to medicines. The interest in pharmacogenetics began in the 1950s, strengthened by 
family and twin studies in the 1960s and 70s, extended by biochemical studies in the 1970s, 
and further escalated by molecular studies in the 1980s (Evans and Relling, 2004).  
 
Genetic variations may influence drug action by affecting its pharmacokinetics, which 
includes absorption, distribution, metabolism, and excretion, or its pharmacodynamic 
properties (what the drug does to the body), which involves target receptors, enzyme targets, 
and disease modifiers. Genetic polymorphisms are naturally occurring variations that may not 
cause disease but are responsible in altering the products they encode and have a reported 
frequency of more than 1% of the population (Ford, 1940). The variations in all genes are 
believed to cause different individuals or populations to express different forms of protein 
gene products, including those responsible for metabolizing the drug or the site of drug 
action. Genes encoding drug transporters were also identified as potential factors causing 
alteration in drug response (Evans and McLeod, 2003).  
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The variation of drug response can be divided into Gaussian variation and monogenic (all-or-
none) variation. The initial understanding of pharmacogenetics is based on monogenic 
variation; the impact of a single gene product may lead to all-or-none responsiveness (Kalow, 
1997). Gaussian variation is a mathematically calculated variation in the form of median 
effective or lethal dose of a drug (ED50 or LD50) and determined mainly by environmental 
factors but with hereditary elements (Vesell, 1992; Trevan, 1927). The principle is based on a 
distribution curve of the frequency of response to a standard drug dose in a group of 
individuals. A majority of the known drugs demonstrate a unimodal distribution similar to a 
bell-shaped or Gaussian curve (Turner et al, 2001). Gaussian distribution represents the effect 
of multifactorial determinants by interaction of genetic and environmental factors without 
any single factor having a discernibly large effect on the response. Thus, it is more difficult to 
identify the effects of individual genes. Bimodal distribution is due to separate 
subpopulations with distinctly different drug responses suggesting that a single factor, 
possibly segregation of alleles at a single genetic locus, has a large effect on drug response 
(Murphy, 1964). Responders and non-responders to a certain drug may be represented as a 
bimodal distribution curve (McLaren and Moroi, 2003).  
 
Pharmacogenetics is potentially important in customizing or personalizing medication. 
Tailoring the medication according to the predicted response, minimizing the side effects, and 
maximizing the expected drug response is ideal to promote compliance and persistency of 
medication especially in chronic diseases. „Candidate gene‟ or „candidate pathway‟ 
approaches have been adopted to predict the disposition or response to a given drug. So far, 
polymorphisms are the most studied genetic variations. Polymorphisms can be homozygous 
or heterozygous, depending on how many copies of a variant or wild-type allele are present. 
Based on the balanced polymorphism concept, a double dose of a variant allele (homozygous 
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mutant) may exert a detrimental effect but a single copy may increase fitness (heterozygous 
mutant) (Ford, 1940). The best example is in sickle cell disease; homozygous individuals 
have a poor survival rate and die at a young age due to disease-related complications but 
heterozygous individuals are better able to survive malaria (Kalow, 1997). 
 
The impact of polymorphisms of cytochrome P450 (CYP) enzymes and thiopurine 
methyltransferase (TPMT) are the most established and well studied (Idle and Smith, 1979). 
Cytochrome P450s are a multi-gene family of enzymes found predominantly in the liver, the 
most important site for metabolic elimination of most drugs. Cytochrome P450 CYP2D6 
(known as debrisoquine hydroxylase), CYP2C9, and CYP2C19 are among the most studied 
cytochrome P450s and affect the metabolism of 20–30% of clinically used drugs 
(Kirchheiner et al, 2004; Kirchheiner and Brockmoller, 2005).  
 
Polymorphisms in CYP2D6 result in different metabolic capacities for antidepressants, anti-
hypertensives such as β-blockers, and antipsychotic drugs. Some mutations in CYP2D6 result 
in complete loss of enzyme activity and severely compromises drug metabolism; this is 
known as the „poor metaboliser (PMs)‟ phenotype. Other mutations or duplications of 
CYP2D6 produce increased metabolic capacity; individuals with such variation are known as 
ultra-rapid metabolisers (UMs). Those with wild-type levels of activity are known as 
extensive metabolisers (EMs). PMs require low doses of a drug or higher doses if it is a 
prodrug, while UMs and EMs require higher doses or a more frequent dose administration 
regime. An individual can be a PM of one drug and EM of another. There is evidence of 
racial influence in phenotypic of CYP2D6. It is believed due to the effect of selective 
breeding rather than direct racial influence. CYP2D6 PMs were found in 6–10% of 
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Caucasians, fewer in African populations (5%), and even fewer in Asians (less than 1%) 
(Kalow, 1991; Marez et al, 1997; Masimirembwa et al, 1993).  
 
Another important example is the „isoniazid acetylation polymorphism‟, which was observed 
in tuberculosis patients treated with isoniazid (Bönicke and Reif, 1953). A high incidence of 
peripheral neuropathy was caused by slow clearance of isoniazid compound and patients 
were phenotypic as slow or rapid acetylators (Evans, 1989). Based on family studies, the 
slow acetylator phenotype was found to be inherited as an autosomal recessive trait (Grant, 
1993). Slow acetylators of isoniazid were homozygous for N-acetyltransferase functional 
gene (NAT1 and NAT2). Rapid acetylators were either homozygous or heterozygous for the 
wild type gene (Grant, 1993). Genetic polymorphism of thiopurine methyltransferase 
(TPMT), which is responsible for metabolism of anti-tumour agent 6-mercaptopurine and 6-
thioguanine, is associated with difficulty in achieving an effective dose in childhood 
leukaemia. 
 
However, the concept of single gene effects are now somewhat outdated in the 
pharmacogenetics field. The drug-response phenotype is typically not governed by a single 
gene (monogenic trait) but by multiple genes (polygenic) that has spawned the term 
„pharmacogenomics‟. The effects of most drugs are determined by many proteins and 
composite genetic polymorphisms in multiple genes coupled with non genetics factors are 
postulated to be responsible in drug response. For example; serotonin (5-HT3) antagonist 
tropisetrone, a CYP2D6 substrate if given to patient with high enzyme activity due to gene 
duplication will not achieve effective drug concentrations. Inability to achieve effective drug 
concentration is not entirely due to the CYP2D6 polymorphism but may be due to other 
factors influencing the entire pathway before reaching the target organ or tissue. As 5-HT3 
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antagonist is also a p-glycoprotein (p-gp) substrate, the level of p-gp expression will affect 
ability of HT3 antagonist to transfer from blood to the brain. Once the drug reach the 5-HT3 
receptor, the magnitude of response will depend on the drug concentration, neurotransmitter 
concentration in the synaptic cleft and genetic polymorphisms of the receptor. Moreover, 
serotonin concentration is further influenced by proteins involved in biosynthesis, transport 
and catabolism. Thus, the pharmacogenetics analysis of poor response to 5-HT3 antagonist 
should include all of these candidate genes that involved in the pathway of this drug before 
reaching the target tissue.   
 
1.8.1 Pharmacogenetics of topical pressure lowering medications 
Pharmacogenetics studies have been conducted with various systemic drugs but minimal 
emphasis has been given to topical ophthalmic drugs. The initial observation was on topical 
phenylephrine 4% and homatropine 4%: longer duration was needed to achieve full mydriasis 
in dark-skinned Africans than in Caucasians (Emiru, 1971). Variation of response to topical 
anti-glaucoma drugs has been observed in various populations. Higher concentrations of 
topical timolol are required in African-Americans to achieve the same pressure-lowering 
effect seen in Caucasians at lower concentrations (Katz and Berger, 1979). Iris pigmentation 
was implicated in the difference of response (Otalegu and Ajayi, 1999). Latanoprost has a 
more significant effect in Latinos and Asians than in other populations (Hedmann and 
Larsson, 2002). The influence of ethnicity was also implicated in the variation of response 
(Matthew, 1995). 
 
The term „ethnicity‟ and „race‟ is rather complex, overlapping and often confusing.  Debate 
on the concepts and terminology on ethnicity and race in health research is still on-going 
(Bhopal and Rankin, 1999). The concept of „race‟ as describing genetically different human 
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population is scientifically weak (Bhopal, 1998). It is deemed inappropriate and outdated. 
„Race‟ is believed to provide social origins rather than its biological basis. „Ethnicity‟ is used 
to describe a social grouping of people with similar culture and belief including language, 
religion, diet, marital customs and other factors related ancestry (Senior and Bhopal, 1994; 
Bhopal, 1997). Thus, ethnicity is more suitable to describe the prevalence of disease and 
susceptibility to certain disease in health research (Bhopal and Rankin, 1999). 
 
The main question was „does genetics govern the response to topical pressure lowering 
medication in glaucoma patients?‟  Several pharmacogenetics studies of common topical 
pressure lowering drugs have been conducted in several populations. Genotyping of 210 
glaucoma patients for ADRB1, ADRB2, ADRB3, and CYP2D6 in the Marshfield Clinic 
Personalized Medicine Research Project found that Gln27Glu of ADRB2 was associated with 
meaningful pressure-lowering effectiveness of topical timolol (McCarty et al, 2008). 
CYP2D6 polymorphisms have no influence on the effectiveness of topical β-blocker 
(McCarty et al, 2008). Polymorphisms of PTGFR in the promoter and exon 1 were associated 
with response to latanoprost in normal volunteers (Sakurai et al, 2008). However, the study 
was conducted on normal volunteers and the response to latanoprost may differ in glaucoma 
patients. Furthermore, responsiveness was defined as a predetermined IOP percentage cut-off 
point; the study results, therefore, may not represent the actual clinical scenario and are 
subject to statistical manipulation. In addition, the presence and frequency of genetic 
polymorphisms tend to differ between populations. 
 
Can the ADRB2 and PTGFR polymorphisms reported in the previous studies be replicated in 
Malaysian population?  Does the pressure lowering effect of topical Timolol XE 0.5% and 
latanoprost 0.005% in Malaysian population differ from other reported studies? Another 
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equally important question was whether ADRB2 and PTGFR polymorphisms play a role in 
susceptibility to glaucoma in Malaysian population? A prospective observational cohort with 
12 months follow-up period was conducted. Blood was taken for genetic screening of ADRB2 
and PTGFR. The main objective of this research project was to determine the association of 
ADRB2 and responsiveness of Malaysian glaucoma patients to topical timolol XE 0.5% and 
the association of PTGFR and responsiveness of glaucoma patients to topical latanoprost 
0.005%. In addition, we aimed to determine the possible association of ADRB2 and PTGFR 
in glaucoma susceptibility in Malaysians.  
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Chapter 2 
 
2.1 Objectives 
To determine pressure lowering effect of topical timolol XE 0.5% and topical latanoprost 
0.005% among open angle glaucoma patients in Malaysia 
 
2.2 Material and methods 
2.2.1 Patients selection 
A prospective observational cohort study was conducted involving newly diagnosed primary 
open angle glaucoma (POAG), normal tension glaucoma (NTG) and ocular hypertension 
(OHT) patients seen in the eye clinic of two main hospitals in Kelantan, Malaysia. Hospital 
Universiti Sains Malaysia and Hospital Raja Perempuan Zainab II provide tertiary eye care in 
Kelantan state of Malaysia. Ethical approval was obtained from Research and Ethical 
Committee Universiti Sains Malaysia, ethical committee of Hospital Raja Perempuan Zainab 
II and London School of Hygiene and Tropical Medicine. Written consent was obtained from 
all recruited subjects.  
 
Recruitment of subjects was conducted between May 2007 and August 2008. The selected 
subjects were patients diagnosed with POAG and NTG were prescribed with topical 
antiglaucoma treatment as first line management. Any potential participants with a history of 
intraocular surgery, especially glaucoma filtrating surgery, were excluded. The diagnosis was 
based on visual field assessment, vertical cup to disc ratio, angle structure morphology and 
intraocular pressure measurement. Visual field assessment was based on two consecutive, 
reliable and reproducible tests using a Humphrey Visual Field Analyzer 30-2 programme. 
Visual field test was repeated on a subsequent visit if it was not reliable on the initial visit. 
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Reliability of visual field assessment was based on false negative and false positive of less 
than 33% and less than 50% of fixation loss. Glaucomatous field loss was defined as a 
Glaucoma Hemifield Test graded outside normal limits and a cluster of three contiguous 
depressed points at the 5% level on pattern deviation plot (Foster et al, 2000). Defects 
crossing the horizontal midline and those respecting the vertical midline (i.e. with a 
“neurological” pattern), and those consistent with another ocular (e.g. retinitis pigmentosa or 
extensive laser marks) or systemic disorder that could explain the visual field defect were 
considered non-glaucomatous, and were excluded.  
 
Goldmann two-mirror gonioscopic with contact fluid (Vislube, USA) was conducted to 
assess the angle morphology. Modified Shaffer angle classification was used to describe the 
status of the angle. Exclusion criteria include the presence of any signs that may indicate 
appositional contact between the peripheral iris and posterior trabecular meshwork, abnormal 
vessels, presence of pseudoexfoliation material or pigmentation, abnormal insertion of the iris 
and peripheral anterior synechiae. Slitlamp biomicroscopy examination (Haag-Straig, 
Germany) was then performed to evaluate the status of the anterior segment and to exclude 
signs of secondary glaucoma. For example the presence of pseudoexfoliation material, 
pigment deposition, iris atrophy was among the criteria for exclusion.  
 
Optic nerve head assessment was conducted through dilated pupil with the aid of Volk 90 
dioptre lens (Volk, USA). Vertical cup to disc ratio (VCDR) of more or equal to 0.7 was 
selected as the cut off point for diagnosis of glaucoma. The cut off point of VCDR was 
adopted from other studies based on 97.5
th
 percentile VCDR distribution in various Asian 
populations (Foster et al, 1996; Foster et al, 2000). Other optic nerve head signs related to 
glaucoma including disc haemorrhage, presence of peripapillary atrophy, the characteristic of 
115 
 
the vessel entering the disc, neuroretinal rim status, baring of lamina cribrosa and also other 
retinal changes such as vein occlusion, diabetic retinopathy changes were also sought. Any 
patient with suspicious characteristics of the optic disc that is not clearly associated with 
glaucoma was excluded. Posterior segment photograph (Kowa, Japan) was also obtained for 
baseline documentation.  
 
Goldmann applanation tonometry (GAT) measurement was conducted between 8 am to 12pm 
in clinic setting. Hourly IOP phasing was conducted between 8 am to 5pm for confirmation 
diagnosis of normal tension glaucoma (NTG). IOP was measured in sitting position. Topical 
anaesthesia Benoxinate 0.4% (Novartis, Switzerland) was applied prior to the procedure.  The 
corneal was then stained with fluorescein using fluorescein strip (Chauvin Pharmaceutical, 
England). IOP was taken with gentle or no pressure on the upper eyelid. Baseline IOP was 
defined as IOP taken for the first time by primary investigator (LS) either the highest 
recorded IOP during office  phasing, or prior to commencing of glaucoma medication. 
 
The diagnosis of glaucoma was based on the criteria fulfilling the category 1 described by 
Foster et al (2000). Category 1 is defined as VCDR or asymmetry VCDR ≥0.7 or the 
neuroretinal rim width, or asymmetry ≥0.2, combined with definite evidence of a 
glaucomatous visual field defect. In cases with advanced glaucoma with VCDR ≥0.85 in 
whom reliable visual field testing was not possible, diagnosis was based on structural changes 
only.  NTG was defined as evidence of glaucomatous optic neuropathy with median of 10 
IOP reading (based on hourly phasing) ≤21mmHg and none of the IOP reading exceeded 
24mmHg (Collaborative Normal Tension Glaucoma Study, 1998). In cases when both eyes 
were eligible, only the right eye was selected for analysis. 
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Central corneal thickness (CCT) was also measured in all participants using non contact 
specular microscopy (Specular Microscopy 2000P, Japan). Anterior segment photograph with 
special focus on the conjunctiva, iris and eyelashes was also taken as baseline data before 
instillation of topical latanoprost 0.005%. Systemic co-morbidities such as hypertension, 
diabetes mellitus, hyperlipidemia, cardiovascular disease and cerebrovascular accident were 
also documented based on medical record review. If the recruited patient was treated outside 
the hospital, the local general practitioner who was treating the recruited patient was 
contacted to ascertain the diagnoses of systemic illnesses. Hypertension was defined as 
systolic blood pressure of ≥140mmHg and diastolic blood pressure≥ 90mmHg in subjects 
more than 50 years old (Chobanian et al, 2003). In the presence of type 1 or type 2 diabetes 
mellitus and renal disease, hypertension was defined as blood pressure of 130/80mmHg. 
Diabetes mellitus was defined as fasting blood sugar more or equal to 7.0mmol and 2 hours 
plasma glucose level post oral glucose tolerance test of 11.1mmol (WHO, 1999). 
Hyperlipidemia was defined as elevated fasting serum cholesterol and/or triglyceride level 
with or without the levels of HLDL and LDL. Fasting serum cholesterol of more than 
5.2mmol and triglyceride of more than 2.0mmol was considered elevated, which was 
obtained retrospectively from the initial diagnosis of hyperlipidemia prior to initiation of lipid 
lowering medication. All systemic medications prescribed to the subjects at the time of 
recruitment were also documented. 
 
In view of the recognised variation in genetic polymorphisms attributable to ethnicity, 
eligible subjects were asked to confirm a negative history of any possible interracial marriage 
for at least three generations. A pedigree chart was also drawn to help rule out any possibility 
of family history of glaucoma as well as to rule out the possibility of consanguineous 
marriages. Subjects with a medical contraindication for beta-blocker treatment such as 
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respiratory and cardiac disorders were excluded from the treatment with topical timolol. The 
possible systemic side effects following topical timolol may aggravate an existing systemic 
disorder that may affect compliance or cause discontinuation of the topical timolol. Similarly, 
those who had already experienced allergic reactions to topical timolol or latanoprost were 
also excluded. The recruited subjects and family members were given a full explanation of 
the study purpose and duration, prior to being asked to consent for this research.  
 
2.2.2 Initiation of treatment 
After the confirmation of diagnosis by the primary investigator (LS), the selected patients 
were assigned to either monotherapy with topical timolol XE 0.5% once in the morning 
(Project B) or topical latanoprost 0.005% at night (Project P). Patients who were already on 
topical timolol XE 0.5% monotherapy but failed to achieve target IOP, or if there was 
evidence of progression were also recruited and assigned to Project P for adjunctive treatment 
with topical latanoprost. There was no randomization of treatment as the comparison of the 
effectiveness between the two drugs was not part of the objective of this study.  
 
Detailed explanation of the mode of action of the treatment, possible side effects and adverse 
effects, risks and benefits of the study was given to the subjects and their family members. 
Proper storage of the drug was also explained. The importance of compliance was also 
emphasized. A demonstration of proper drop instillation technique was also given by the 
primary investigator (LS) and a nurse. Double DOT technique was applied in this study, 
which includes punctual occlusion technique (Digital Occlusion Technique) and eyelid 
closure for at least 3 minutes (Do not Open Technique). The subjects who were planned to be 
treated with topical latanoprost as an adjunctive therapy were advised to wait for at least 5 
minutes in between topical instillation. If any of the recruited patients expressed 
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unwillingness or inability to self medication, the family members were asked to appoint at 
least 2 relatives responsible for the instillation of topical drug. Subsequent clinic appointment 
was then given if the appointed member of the family was not present during the briefing. All 
patients were also reminded to bring along all the empty bottles during each visit. 
 
2.2.3 Follow up visits 
2.2.3.1 Visit 1 
All recruited patients were scheduled for visit 1 at 1 month after commencement of treatment. 
The empty bottles were weighted to ensure adherence. Recruited patients were then 
questioned regarding their adherence to treatment and the presence of symptoms suggestive 
of side effects. Subjects were allowed to terminate their participation if they developed 
intolerable ocular or systemic side effects. They were also allowed to terminate their 
participation in this research project at anytime for whatever reason without affecting their 
clinical management. 
 
Anterior segment photographs were taken to document the changes in the eyelashes, injected 
conjunctiva and colour of the iris on subjects in Project P. The assessment of the 
conjunctival, eyelashes and latanoprost induced iris pigmentation was done by two 
optometrists (BH and AS). The assessment was based entirely on printed anterior segment 
photographs and was conducted at different times by the two independent assessors. A third 
assessor (WJ) was also included in cases when there was conflicting assessment outcome.  
 
Slitlamp biomicroscopy (Haag Strait, Germany) examination was conducted to rule out any 
possible inflammation associated with topical latanoprost as well as for detection and grading 
of conjunctival hyperaemia. Serial photographs were taken for most patients. Conjunctival 
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hyperaemia was graded 0 to 4 (Stewart et al, 2003) (Table 2.1). The evaluation was 
conducted in appropriate brightness. An optometrist (WJ) who was masked to the diagnosis 
and treatment protocol was responsible in the grading of the conjunctival hyperaemia. The 
grading was based on the average score of primary investigator (LS) and the optometrist 
(WJ).  
 
Table 2.1: Grading of conjunctival hyperaemia induced by topical latanoprost* 
Grade Classification Clinical Signs 
 
0 None No visible vessel dilation 
 
1 Minimal Barely noticeable regional vessel dilatation 
 
2 Mild Fairly obvious diffuse vessel dilatation giving light pinkish hue 
 
3 Moderate Obvious diffuse vessel dilatation giving moderate pinkish hue 
 
4 Severe Very obvious diffuse vessel dilation giving deep pinkish hue 
 
*Based on the grading by Stewart et al (2003). 
Target IOP was calculated and customised according to individual subjects based on severity 
or staging of glaucoma, type of glaucoma, age, life expectancy and the presence of other risk 
factors.  IOP was measured between 9 am to 12 pm in sitting position by primary investigator 
(LS). However, in cases where the pressure was still elevated and failed to reach target IOP, 
other medication was either added or switched or a decision was made to proceed to filtrating 
surgery. Once there was alteration in management protocol, the patient was automatically 
classified as poor responder and further follow up according to the study protocol was 
discontinued. The subject with good IOP control was prescribed with the respective topical 
antiglaucoma drugs for another 2 months and further appointment was given for Visit 2. 
 
 
120 
 
2.2.3.2 Subsequent visits 
The subsequent visits were scheduled at 3 months (Visit 2), 6 months (Visit 3) and 12 months 
(Visit 4) post commencement of treatment. Similar routine examination and documentation 
of the parameters was conducted during each visit. Humphrey visual field 30-2 test was 
conducted at 6 months and 12 months post commencement of treatment. Whenever the 
subjects failed to achieve target IOP or demonstrated visual field progression, they were 
discontinued from the treatment protocol and scheduled for routine eye clinic glaucoma 
follow up. However, the available clinical data (up to the date of discontinuation) was kept 
for phenotype and genotype association analysis. 
 
At Visit 4, the mean IOP reduction was calculated based on: 
 
 
 
 
For example:  
 
Mean IOP reduction (Subject 1) = Baseline IOP - [IOP at Visit 1+Visit 2+Visit 3+ Visit 4] 
               ----------------------------------------------- 
                                  4 
  
Mean IOP reduction (Subject 2)* = Baseline IOP - [IOP at Visit 1 + Visit 2] 
              ----------------------------- 
          2 
*Subject 2 was discontinued at Visit 2 due to poor IOP control 
 
 
Due to the different in the effectiveness between the topical timolol and latanoprost in 
Malaysian population, two different cut off points were selected. The cut off point of 
percentage of IOP reduction was selected based on the mean percentage of IOP reduction of 
each medication. The patients were then categorised as: 
 
Mean IOP reduction = Baseline IOP - [summation of IOP at subsequent visits] 
       -------------------------------------------- 
      Number of visits 
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2.2.4 Statistical analysis 
All the available data was then analyzed in Statistical Package for Social Science (SPSS) 
Predictive Analytic Software programme for Windows (PASW) version 18.0. Double entry 
was done to avoid any possible error. The acquired data was analyzed using SPSS or PASW 
version 18.0 and Stata SE version 11.0.  
 
Pearson chi-square and student t-test were used to analyse the difference of demographic data 
between racial groups in both projects and treatment modalities in Project P. Independent t-
test was used to determine the difference between the clinical parameters with racial groups 
and treatment modalities. For comparison of clinical parameters of different type of glaucoma 
(POAG and NTG), student t-test was used. The possible confounders for IOP measurement 
was detected using multiple linear regression analysis. Repeated Measure Analysis of 
Variance (RM ANOVA) was used to analyse the pressure lowering effect of topical timolol 
XE 0.5%  and topical latanoprost 0.005% at 1, 3, 6 and 12 months. RM ANOVA within and 
between subject effect was conducted in condition where certain parameters were found to 
affect IOP measurement. Further analysis of between subject effects was done using multiple 
paired t-tests with Bonferroni correction. Multiple paired t-tests with Bonferroni correction 
Project B: 
Good responder: percentage of IOP reduction more or equal to 20% from baseline 
Poor responder: percentage of IOP reduction less than 20% from baseline 
 
Project P: 
Good responder: percentage of IOP reduction more or equal to 25% from baseline 
Poor responder: percentage of IOP reduction less than 25% from baseline 
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was considered significant at 0.005, based on 0.05 divided by the possible number of 
different pairing. Otherwise in all other analysis, level of significant was based on p-value 
less than 0.05. 
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2.3 Results 
2.3.1 Topical timolol XE 0.5% monotherapy (Project B) 
2.3.1.1 Demographic data 
A total of 97 open angle glaucoma patients were recruited with 60 POAG, and 37 NTG. The 
ethnic distribution reflected the distribution of the local population (table 2.2). There was 
almost twice the number of men compared to women recruited in this study. Mean age of 
recruited subjects was 64.1 SD 9.2 years old. Hypertension and hyperlipidemia were the most 
common systemic co-morbidities observed among the glaucoma subjects. Calcium channel 
blocker (34.5%) was the most common first line drug for hypertensive treatment, followed by 
angiotensin converting enzyme inhibitor (23.6%), beta blockers (18.2%) and alpha-agonist 
(18.2%). All hyperlipidemia patients were on Statin drugs. 
Table 2.2: Demographic data of the recruited glaucoma patients 
Characteristic 
 
Number (%) 
N=97 
Ethnicity 
Malay 
Chinese 
 
 
66 (68.0) 
31 (32.0) 
Sex 
Male 
Female 
 
 
62 (63.9) 
35 (36.1) 
Type of glaucoma 
POAG 
NTG 
 
 
60 (61.9) 
37 (37.1) 
 
Systemic co-morbidity 
Hypertension 
Diabetes mellitus 
Hyperlipidemia 
Cardiovascular diseases 
Cerebrovascular accident 
 
55 (56.7) 
38 (39.2) 
43 (44.3) 
11 (11.3) 
3 (  3.1) 
 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension 
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2.3.1.2 Baseline clinical characteristics of glaucoma patients 
Mean baseline IOP in the recruited patients was 22.7 SD 5.7 mmHg, with POAG patients 
demonstrated statistically significantly higher mean IOP. Based on mean deviation of 
Humphrey Visual field, majority of the cases were moderate to advanced glaucoma. The 
severity of glaucoma is based on Hodapp-Parrish and Anderson classification. CCT was 
statistically significant thinner in POAG as compared to NTG.   
Table 2.3: Comparison of clinical characteristics between POAG and NTG patients 
Clinical 
characteristics 
n Mean (SD) p-value* 
 
Baseline 
IOP(mmHg) 
POAG 
NTG 
Total 
 
 
60 
37 
97 
 
26.1 (4.4) 
17.2 (2.4) 
22.7 (5.7) 
 
 
 
<0.001 
MD (dB) 
POAG 
NTG 
Total 
 
 
58 
37 
95 
 
-14.07 (9.42) 
-  7.50 (5.99) 
-11.51 (8.82) 
 
 
<0.001 
PSD (dB) 
POAG 
NTG 
Total 
 
 
58 
37 
95 
 
6.88 (2.95) 
4.70 (2.53) 
6.03 (2.98) 
 
 
<0.001 
VCDR 
POAG 
NTG 
Total 
 
 
60 
37 
97 
 
0.81 (0.07) 
0.78 (0.04) 
0.80 (0.06) 
 
 
0.040 
CCT (µm) 
POAG 
NTG 
Total 
 
 
60 
37 
97 
 
500 (34.2) 
524 (30.3) 
510 (35.1) 
 
 
0.001 
*P<0.05 is considered statistically significant based on student t-test 
IOP: intraocular pressure, POAG: primary open angle glaucoma, NTG: normal tension glaucoma, 
OHT: ocular hypertension, MD: mean deviation, PSD: pattern standard deviation, VCDR: 
vertical cup to disc ratio, CCT: central corneal thickness 
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2.3.1.3: Comparison of demographic and clinical characteristics between Malay and 
Chinese glaucoma patients 
Although Malays presented with more advanced diseases and thinner CCT measurement but 
there was no statistically significant difference in glaucoma parameters between Malay and 
Chinese patients except for pattern standard deviation of visual field. Malays were slightly 
older than Chinese but this was not statistical significant.  
Table 2.4: Distribution of demographic and clinical characteristics of glaucoma patients 
according to ethnicity 
 Malay 
N=66 
Chinese 
N=31 
p-value 
Age (years) 
Mean (SD) 
 
 
64.8 (9.3) 
 
62.8 (8.9) 
 
0.327 
Sex 
Male 
Female 
 
 
43 
23 
 
19 
12 
 
0.717* 
Type of glaucoma 
POAG 
NTG 
 
 
43 
23 
 
 
17 
14 
 
 
0.330* 
Baseline IOP (mmHg) 
Mean (SD) 
 
 
23.1 (5.8) 
 
21.8 (5.5) 
 
0.283 
MD (dB) 
Mean (SD) 
 
 
-12.09 (9.04) 
 
-10.30 (8.37) 
 
0.356 
PSD (dB) 
Mean (SD) 
 
 
6.50 (5.07) 
 
5.07 (2.53) 
 
0.027 
VCDR 
Mean (SD) 
 
 
0.80(0.07) 
 
0.79(0.05) 
 
0.480 
CCT (µm) 
Mean (SD) 
 
 
505 (36) 
 
517 (31) 
 
0.125 
p <0.05 is considered statistically significant based on t-test and Pearson chi-square test* 
IOP: intraocular pressure, POAG: primary open angle glaucoma, NTG: normal tension glaucoma, 
OHT: ocular hypertension, MD: mean deviation, PSD: pattern standard deviation, VCDR: 
vertical cup to disc ratio, CCT: central corneal thickness 
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2.3.1.4 Factors affecting baseline IOP 
Univariate linear regression analysis was conducted to identify the possible variables 
affecting baseline IOP measurement. Age, sex, race, type of glaucoma, central corneal 
thickness and systemic co-morbidities including hyperlipidemia were identified as possible 
variable affecting baseline IOP measurement. Hyperlipidemia was found to have higher 
baseline IOP measurement. NTG was associated with linearly lower IOP compared to POAG.  
 
Table 2.5: Univariate linear regression analysis on factors affecting baseline IOP  
 Coefficient 
value 
 
SE t 95 % CI 
 
p-value# 
Age (years) 
 
0.008 0.044 0.13 -  0.08, 0.10 0.851 
Sex 
 
-0.242 0.847 -0.29 -  1.93, 1.44 
 
0.776 
 
Ethnicity 
 
-0.508 0.830 
 
-0.62 
 
-  2.16, 1.14 
 
0.540 
 
Type of glaucoma 
 
-8.441 0.869 -9.72 -10.17, -6.72 <0.001 
 
CCT 
 
-0.002 0.012 -0.17 -  0.03, 0.02 0.865 
Systemic hypertension 
 
-1.576 
 
1.141 
 
-1.38 
 
-  3.85, 0.69 
 
0.171 
 
Diabetes mellitus 
 
0.008 1.015 
 
0.02 
 
-  2.01, 2.03 
 
0.994 
 
Hyperlipidemia 
 
3.666 1.111 3.30 
 
1.46, 5.87 
 
0.001 
Cardiovascular diseases 
 
-0.184 
 
1.354 -0.01 
 
-  2.88, 2.51 
 
0.892 
 
Cerebrovascular disease 
 
-0.942 2.357 -0.03 -  5.67, 3.74 0.690 
 
# p< 0.05 is considered statistically significant based on simple linear regression analysis 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension, CCT: central corneal thickness 
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2.3.1.5 Mean IOP reduction during 12 months treatment with topical Timolol XE 0.5% 
Overall mean IOP reduction was 5.4 SD 5.1 mmHg, based on the different between the 
baseline IOP and summation of IOP divided by the number of visits. The mean percentage of 
IOP reduction was 22.9 SD 18.1%. At visit 4 (12 months after starting treatment with topical 
timolol) only 50 patients were still on treatment. Topical Timolol XE 0.5% was discontinued 
in two patients due to shortness of breath and chest discomfort.  One patient developed 
progression that required surgical intervention. Additional medication was required in 
majority of the patients due to inability to achieve target pressure (table 2.7). The highest 
number of „drop-out‟ from study protocol was recorded at 6 months post treatment. 
 
Table 2.6: Mean IOP reduction and percentage of reduction from baseline at 1, 3, 6 and 
12 months follow-up 
IOP n Mean (SD) 
mmHg 
Percentage of 
reduction from 
baseline (SD) 
Baseline 
 
97 22.7 (5.7) - 
Visit 1 
(1 month) 
 
97 17.3 (4.7) 22.19 (17.76) 
Visit 2 
(3 months) 
 
85 16.4 (3.8) 24.08 (16.54) 
Visit 3 
(6 months) 
 
63 15.8 (3.5) 23.88 (17.79) 
Visit 4 
(12 months) 
 
50 14.8 (3.5) 27.79 (18.72) 
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Table 2.7:  Percentage and reason of „drop-out‟ from study protocol 
Follow up n# Treatment 
discontinued 
Reasons Additional 
treatment 
required 
Reasons 
Baseline 
N=97 
0  
(0%) 
- - - - 
Visit 1 
(1 month) 
N=97 
0  
(0%) 
- - - - 
Visit 2 
(3 months) 
N=85 
12 
(12.4%) 
2 Side effect 10 Failed to 
reach target 
pressure 
Visit 3 
(6 months) 
N=63 
22 
(25.9%) 
- - 22 Failed to 
reach target 
pressure 
Visit 4 
(12 
months) 
N=50 
7 
(11.1%) 
- - 7 Progression 
(1) 
Failed to 
reach target 
pressure (6) 
# The number and percentage of „drop-out‟ from the last visit. Percentage is calculated from the 
number of „drop-out‟ out of the total number of patients from the last visit e.g. the number of 
„drop-out‟ at 3 months follow up was 12. Total number of patients at last visit was 97. Percentage 
of „drop-out‟=12/97x 100 
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2.3.1.6 Repeated measures Analysis of Variance (RM ANOVA) of IOP at 1, 3, 6 and 12 
months post-treatment with topical Timolol XE 0.5% monotherapy 
There was statistically significant pressure lowering effect of topical Timolol XE 0.5% over 
12 months treatment period based on RM ANOVA (Figure 2.1). Multiple paired t-tests were 
then conducted, significant IOP reduction was observed between baseline and 1 month, 
baseline and 3 months, baseline and 6 months and baseline and 12 months post treatment 
(Table 2.8). However, there was no significant difference of IOP reduction between 
subsequent visits. 
 
Figure 2.1: Pattern of pressure lowering effect of topical Timolol XE 0.5% monotherapy 
at baseline, 1 month, 3 months, 6months and 12 months post-treatment 
*p< 0.05 is considered statistically significant based on RM ANOVA  
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Table 2.8: Mean IOP difference between follow –up visits 
 
Time pairing# 
 
Number of 
observation (n) 
Mean IOP 
difference (SE) 
(mmHg) 
95% CI of mean 
IOP difference 
p-value* 
Visit 1-Visit 2 
 
97 5.4 (0.5) 4.4, 6.5 <0.001 
Visit 1-Visit 3 
 
85 6.1 (0.6) 5.0, 7.2 <0.001 
Visit 1-Visit 4 63 5.9 (0.7) 
 
4.5, 7.3 <0.001 
Visit 1-Visit 5 
 
50 6.8 (0.9) 5.0, 8.6 <0.001 
Visit 2-Visit 3 85 0.4 (0.4) -0.7, 0.7 0.975 
 
Visit 2-Visit 4 60 0.2 (0.4) -0.7, 1.0 0.681 
 
Visit 2-Visit 5 51 0.6 (0.5) -0.3, 1.6 0.197 
 
Visit 3-Visit 4 63 -0.4 (0.3) 
 
-1.1, 0.2 0.200 
Visit 3-Visit 5 
 
50 0.3 (0.5) -0.8, 1.3 0.623 
Visit 4-Visit 5 
 
50 0.6 (0.4) -0.3, 1.4 0.197 
 
# Visit 1 is baseline IOP, Visit 2 is IOP at 1 month, Visit 3 is IOP at 3 months, Visit 4 is IOP at 6 
months and Visit 5 is IOP at 12 months post treatment with topical Timolol XE 0.5% 
monotherapy. SE: standard error 
*p<0.005 is considered statistically significant based on multiple paired t-tests with Bonferroni 
correction 
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2.3.1.7 Mean IOP reduction at baseline and 1 month, 3 months, 6 months and 12 
months post-treatment with between and within subject effects 
Based on the findings of linear regression analysis, type of glaucoma and hyperlipidemia 
status are significantly associated with baseline IOP measurements, RM ANOVA within and 
between subjects was further analyzed. RM ANOVA within and between subjects effect was 
only conducted on 50 subjects that have completed 12 months of IOP measurement. There 
was a statistically significant difference between different type of glaucoma and IOP 
reduction over 12 months (Figure 2.2).  
 
 
Figure 2.2: Pattern of pressure lowering effect of topical Timolol XE 0.5% monotherapy 
at baseline, 1 month, 3 months, 6 months and 12 months in POAG and NTG patients 
*p <0.05 is considered significant based on RM ANOVA  
 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension. 
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Multiple paired t-tests with Bonferroni correction was conducted on POAG and NTG 
patients. There was significant mean IOP difference between baseline and follow up visits 
(visit 2, 3, 4 and 5) in both POAG and NTG patients (Table 2.9).  
Table 2.9: Mean IOP difference between follow up visits of POAG and NTG patients 
 
 
Comparison# 
 
POAG 
N=60 
NTG 
N=37 
Mean IOP 
difference (95% CI ) 
mmHg 
p-value* Mean IOP 
difference (95% CI) 
mmHg 
p-value* 
     
Visit 1-Visit 2 
 
7.0  
(5.4,8.5) 
 
<0.001 2.0 
(2.3, 3.7) 
<0.001 
Visit 1-Visit 3 
 
8.5  
(7.0,10.0) 
 
<0.001 2.8 
(1.8, 3.6) 
<0.001 
Visit 1-Visit 4 9.2 
(7.0, 11.3) 
 
<0.001 
 
2.5 
(1.6, 3.4) 
<0.001 
Visit 1-Visit 5 
 
10.3 
(7.2, 13.5) 
 
<0.001 3.5 
(2.6, 4.4) 
<0.001 
Visit 2-Visit 3 
 
0.1 
(-1.1,1.3) 
 
  0.813 -0.2 
(-0.8, 0.5) 
  0.606 
Visit 2-Visit 4 
 
0.6 
(-0.9, 2.1) 
 
  0.394 -0.3 
(-1.1, 0.6) 
  0.495 
Visit 2-Visit 5 0.7 
(-1.1, 2.5) 
 
  0.416 0.5 
(-0.4, 1.5) 
  0.271 
Visit 3-Visit 4 -0.8 
(-1.7, 0.2) 
 
  0.105 -0.1 
(-1.1, 0.9) 
  0.849 
Visit 3-Visit 5 
 
-0.3 
(-2.2, 1.7) 
 
  0.789 0.7 
(-0.4, 1.8) 
  0.190 
 Visit 4-Visit 5 
 
-0.1 
(-1.7, 1.6) 
 
  0.918 1.2 
(0.4, 2.0) 
  0.006 
*p-value less than 0.005 based on multiple paired t-tests with Bonferroni correction 
# Visit 1 is baseline IOP, Visit 2 is IOP at 1 month, Visit 3 is IOP at 3 months, Visit 4 is IOP at 6 
months and Visit 5 is IOP at 12 months post-treatment with topical timolol XE 0.5% 
monotherapy 
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Hyperlipidemia was found to linearly affect the baseline IOP. Patients with hyperlipidemia 
(treated with “Statin” drugs) demonstrated lower baseline IOP, better and more stable IOP 
reduction. However, there was no statistical significant difference in mean IOP at each follow 
up between patients with hyperlipidemia and non-hyperlipidemia patients except for baseline 
IOP (Table 2.10). None of the patients were diagnosed as hyperlipidemia post topical timolol 
treatment. Mean IOP reduction from baseline of glaucoma patients who received concomitant 
treatment with oral calcium channel blockers and beta blockers were 6.5(3.7) mmHg and 
4.3(3.8) mmHg. There was no significant different of mean IOP reduction between those 
treated with oral beta blockers and non oral beta blockers (p=0.394, student t-test). 
 
Table 2.10: Comparison of mean IOP at follow up visits between hyperlipidemia and 
non-hyperlipidemia glaucoma patients  
 
 
Visits 
Mean IOP (SD) (mmHg)  
p-value* Hyperlipidemia 
N=43 
Non-hyperlipidemia 
N=54 
 
Visit 1 (Baseline) 20.6 (4.5) 24.3 (6.1) 0.001 
 
Visit 2 (1 month) 16.7 (5.0) 17.7 (4.4) 
 
0.282 
Visit 3 (3 months) 15.7 (3.6) 16.9 (3.9) 
 
0.138 
Visit 4 (6 months) 15.3 (3.1) 16.3 (3.7) 0.225 
 
Visit 5 (12 months) 14.0 (3.3) 15.5 (3.7) 0.137 
 
 
*P<0.05 is considered significant based on independent t-test 
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2.3.1.8 Responsiveness and side effects to topical Timolol XE 0.5% monotherapy 
 
A “good responder” was defined by IOP reduction ≥ 20% reduction from baseline at the last 
IOP reading. Based on this definition, slightly more than half of all cases were good 
responders. However, if the criteria of good responder are adjusted at 10%, 15%, 20%, 25%, 
30%, 35%, 40% and 45%, there was different percentage of responder rate according to 
definition provided (table 2.11). Eleven subjects responded very well to timolol with more 
than 45% pressure reduction. On the other hand, 20 subjects responded poorly with pressure 
reduction less than 10% from baseline. 
 
Two subjects (subject 50 and 81) requested to drop out of the study due to chest discomfort 
and shortness of breath. There was no complaint of blurry vision or other ocular related side 
effects. 
 
Table 2.11: Percentage of good and poor responder according to different definition of 
responsiveness to topical Timolol XE 0.5% 
Definition of responder 
 
Good responder 
n (%) 
Poor responder 
n (%) 
≥10% 
 
77 (77.4) 20 (20.6) 
≥15% 
 
71 (73.2) 26 (26.8) 
≥20% 
 
56 (57.7) 41 (42.3) 
≥25% 
 
43 (44.3) 54 (55.7) 
≥30% 
 
31 (32.0) 66 (68.0) 
≥35% 
 
22 (22.7) 75 (77.3) 
≥40% 
 
17 (17.5) 80 (82.5) 
≥45% 
 
11 (11.3) 86 (88.7) 
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2.3.2 Topical latanoprost 0.005% (Project P) 
2.3.2.1 Demographic data of recruited glaucoma patients 
A total of 86 glaucoma patients were recruited with 64 of them diagnosed as POAG and 22 
NTG. Over two thirds of them were Malays (67.4%); the remainder were Chinese. There was 
also preponderance of men (69.8%). The mean age of the recruited patients was 66.9 SD 9.2 
years old. Hypertension remained the most common systemic co-morbidities among the 
recruited patients, followed by hypercholesterolemia and diabetes mellitus. Slightly more 
than half of them received topical latanoprost 0.005% as adjunctive treatment to topical 
timolol XE 0.5%. 
Table 2.12: Demographic data of recruited glaucoma patients 
Characteristic  
N=86 
N (%) 
Sex 
Male 
Female 
 
60 (69.8) 
26 (32.2) 
Ethnicity 
Malays 
Chinese 
 
58 (67.4) 
28 (32.6) 
Type of glaucoma 
POAG 
NTG 
 
64 (74.4) 
22 (25.6) 
Treatment modalities 
Monotherapy 
Adjunctive 
 
39 (45.3) 
47 (54.7) 
Systemic co-morbidities 
Hypertension 
Diabetes Mellitus 
Hypercholesterolemia 
Cardiovascular diseases 
 
 
55 (64.0) 
34 (39.5) 
38 (44.2) 
11 (12.8) 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension 
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2.3.2.2 Distribution of demographic data according to ethnicity and treatment 
modalities 
There was no significant difference between demographic data and ethnicity. Similar 
observation was seen in different treatment modalities but there was significant higher 
number of patients with POAG treated with topical latanoprost as adjunctive therapy (Table 
2.13). 
Table 2.13: Comparison of demographic data according to ethnicity and treatment 
modalities 
Characteristic                    Ethnicity           Treatment modalities 
Malay 
N=58 
Chinese 
N=28 
p-value Monotherapy 
N=39 
Adjunctive 
N=47 
p-value 
 
Mean age 
(SD) 
 
67.7 (9.5) 65.8 (8.4) 0.379# 65.8 (10.6) 68.1 (7.7) 0.252# 
Sex (%) 
Male 
Female 
 
 
44 
14 
 
16 
12 
 
0.077 
 
28 
11 
 
 
32 
15 
 
0.709 
Ethnicity 
Malay 
Chinese 
 
 
--- 
 
--- 
 
--- 
 
29 
10 
 
29 
18 
 
0.212 
Type of 
glaucoma 
POAG 
NTG 
 
 
 
40 
18 
 
 
 
24 
4 
 
 
 
0.095 
 
 
20 
19 
 
 
 
44 
3 
 
 
 
<0.001 
Treatment   
Monotherapy 
Adjunctive 
 
 
29 
29 
 
10 
18 
 
0.212 
 
--- 
 
--- 
 
--- 
P< 0.05 is considered significant based on Pearson chi-square test and # independent t-test 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension 
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2.3.2.3 Comparison of baseline clinical characteristics according to type of glaucoma, 
ethnicity and treatment modalities 
Based on both mean deviation (MD) and pattern standard deviation (PSD) of Humphrey 
Visual Field Analyzer (HFA), majority of recruited glaucoma patients have moderate to 
severe glaucoma. HFA assessment was only conducted on 82 subjects. Four patients were 
unable to perform accurate reliable HFA test and diagnosis was made based on other 
available data (Table 2.14). There was a statistically significant difference between type of 
glaucoma and optic nerve function but not structural parameter (VCDR) (Table 2.14).  
Table 2.14: Comparison of mean age and baseline clinical characteristic between POAG 
and NTG patients 
Clinical 
characteristics 
n Mean (SD) t-statistic(df) p-value* 
 
Age (year) 
POAG 
NTG 
Total 
 
 
64 
22 
86 
 
68.7 (  8.1) 
62.1 (10.5) 
67.1 (  9.2) 
 
3.05 (84) 
 
0.003 
Baseline IOP 
(mmHg) 
POAG 
NTG 
Total 
 
 
64 
22 
86 
 
 
 
23.8 (3.6) 
18.3 (2.8) 
22.4 (4.1) 
 
 
6.61 (84) 
 
 
<0.001 
HFA MD (dB) 
POAG 
NTG 
Total 
 
61 
21 
82 
 
 
-12.36 (8.45) 
-  7.68 (7.46) 
-11.6 (8.42) 
 
2.25 (80) 
 
0.027 
HFA PSD (dB) 
POAG 
NTG 
Total 
 
61 
21 
82 
 
7.01 (3.25) 
5.06 (2.50) 
6.51 (3.18) 
 
 
2.51 (80) 
 
0.014 
VCDR 
POAG 
NTG 
Total 
 
64 
22 
86 
 
0.79 (0.08) 
0.78 (0.08) 
0.79 (0.08) 
 
 
0.38 (84) 
 
0.704 
CCT (µm) 
POAG 
NTG 
 
64 
22 
 
504 (42) 
523 (27) 
 
2.04 (84) 
 
0.045 
138 
 
Total 
 
86 509 (40) 
*p< 0.05 is considered statistically significant based on independent t- test 
IOP: intraocular pressure, POAG: primary open angle glaucoma, NTG: normal tension glaucoma, 
HFA: Humphrey visual field analysis, MD: mean deviation, PSD: pattern standard deviation, 
VCDR: vertical cup to disc ratio, CCT: central corneal thickness 
 
There was statistically significant difference in VCDR between the two major ethnic groups 
in Malaysia (Table 2.15). Malays demonstrated significant more advanced structural damage 
than Chinese. Glaucoma patients who were treated with topical latanoprost as adjunctive 
therapy have significant thinner CCT and more advanced visual field defect based on MD of 
HFA (Table 2.16). 
Table 2.15: Comparison of baseline clinical characteristics between Malays and Chinese 
Clinical 
characteristics 
Ethnics (n) 
N=86 
Mean (SD) 95% CI for 
difference 
 
t-statistic 
(df) 
p-value* 
 
Baseline IOP 
(mmHg) 
 
Malay (62) 
Chinese (28) 
 
 
22.2 (4.4) 
22.9 (3.6) 
 
-2.6, 1.2 
 
-0.73 (84) 
 
0.465 
VCDR Malay (62) 
Chinese (28) 
 
0.80 (0.07) 
0.76 (0.07) 
0.01, 0.07 2.29 (84) 0.025* 
HFA MD 
(dB) 
Malay (54) 
Chinese (28) 
 
-12.21 (8.79) 
-  9.12 (7.37) 
-6.96, 0.77 -1.59 (80) 0.115 
 
HFA PSD (dB) 
 
Malay(54) 
Chinese (28) 
 
 
6.84 (3.27) 
5.87 (2.96) 
 
-0.50, 2.44 
 
1.32 (80) 
 
0.191 
CCT (µm) Malay (62) 
Chinese (28) 
 
508 (41) 
511 (37) 
-20, 16 -0.33 (84) 0.816 
*p<0.05 is considered statistically significant based on independent t-test 
IOP: intraocular pressure, POAG: primary open angle glaucoma, NTG: normal tension glaucoma, 
HFA: Humphrey visual field analysis, MD: mean deviation, PSD: pattern standard deviation, 
VCDR: vertical cup to disc ratio, CCT: central corneal thickness 
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Table 2.16: Comparison of baseline clinical characteristics between monotherapy and 
adjunctive therapy of topical latanoprost  
Clinical 
characteristics 
Treatment 
modalities 
(n) 
N=86 
Mean (SD) 95% CI for 
difference 
 
t-statistic 
(df) 
p-value* 
 
Baseline IOP 
(mmHg) 
 
Monotherapy 
(39) 
Adjunctive 
(47) 
 
 
22.6 (4.1) 
 
23.1 (4.1) 
 
-3.2, 0.3 
 
-1.69 (84) 
 
0.655 
VCDR Monotherapy 
(39) 
Adjunctive 
(47) 
 
0.77 (0.07) 
 
0.80 (0.08) 
-0.07, 0.00 -2.02 (84) 0.152 
HFA MD (dB) Monotherapy 
(38) 
Adjunctive 
(44) 
 
- 8.36 (6.28) 
 
- 13.57 (9.31) 
1.66, 8.77 2.92 (80) <0.001 
 
HFA PSD (dB) 
 
Monotherapy 
(38) 
Adjunctive 
(44) 
 
 
6.28 (3.03) 
 
6.71 (3.33) 
 
-1.83, 0.98 
 
-0.60 (80) 
 
0.822 
CCT (µm) Monotherapy 
(39) 
Adjunctive 
(47) 
 
522 (37) 
 
498 (39) 
7.29, 39.98 2.88 (84) 0.005 
*p< 0.05 is considered statistically significant based on independent t-test 
IOP: intraocular pressure, POAG: primary open angle glaucoma, NTG: normal tension glaucoma, 
HFA: Humphrey visual field analysis, MD: mean deviation, PSD: pattern standard deviation, 
VCDR: vertical cup to disc ratio, CCT: central corneal thickness 
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2.3.2.4 Factors affecting baseline IOP  
Simple linear regression analysis was conducted to assess the possible predictors that may 
affect IOP measurement. Type of glaucoma was identified as significant predictor affecting 
baseline IOP measurement (Table 2.17).  
Table 2.17: Univariate linear regression analysis on factors affecting baseline IOP 
Baseline IOP Coefficient 
 
SE t-stat 95 % confident  
interval 
 
p-
value# 
Age 
 
0.20 0.05 1.83 -  0.01, 0.18 0.071 
Sex 
 
0.03 
 
0.98 0.23 
-- 
-1.72, 2.17 0.821 
Race 
 
0.08 0.96 0.73 -1.20, 2.60 0.465 
Type of glaucoma 
 
-0.64 1.00 -6.09 -8.07, -4.09 <0.001 
 
CCT 
 
-0.09 0.01 -0.96 -  0.03, 0.01 0.339 
Treatment modalities 
 
-0.15 0.91 -1.34 3.04, 0.50 0.185 
Systemic hypertension 
 
-0.02 0.90 -0.17 -1.93, 1.64 0.870 
Diabetes mellitus 
 
-0.08 0.85 -0.76 - 2.33, 1.05 0.452 
Hyperlipidemia 
 
0.16 0.90- 1.50 -0.48, 3.13 0.138 
Cardiovascular 
diseases 
 
-0.03 1.15 
-- 
-0.31 
 
-3.65, 1.94 
 
0.760 
#p-value less than 0.05 is considered statistically significant. POAG: primary open angle 
glaucoma, NTG: normal tension glaucoma, CCT: central corneal thickness 
 
 
 
 
 
 
 
 
141 
 
2.3.2.5 Mean IOP reduction of 12 months treatment with topical latanoprost 0.005% 
In general there was more than a 30% IOP reduction from baseline at most of the follow up 
visits. Overall mean IOP reduction was 6.9 SD 4.0 mmHg, based on the different between the 
baseline IOP and summation of IOP divided by the number of visits. The mean percentage of 
IOP reduction was 26.7%, SD 19.3%. The mean IOP reduction (mean percentage of 
reduction) for patients treated with topical latanoprost 0.005% monotherapy was 7.1 SD 
3.2mmHg (29.2 SD 14.5%) and adjunctive group was 6.8 SD 4.6 mmHg (24.7 SD 22.4%) 
(p=0.724; independent t-test). At the end of 12 months treatment, only 65 patients were still 
on topical latanoprost 0.005% treatment (table 2.18). There was no significant difference of 
mean IOP reduction or mean percentage of IOP reduction from baseline between 
monotherapy and adjunctive therapy (Table 2.19).  
 
Table 2.18: Mean IOP and percentage of IOP reduction from baseline  
Visits n Mean (SD) 
mmHg 
Percentage of 
reduction from 
baseline (SD) 
Baseline 
 
86 22.4 (4.1) - 
Visit 1 
(1 month) 
 
86 15.7 (3.1) 28.86 (13.40) 
Visit 2 
(3 months) 
 
81 15.3 (4.3) 30.86 (19.26) 
Visit 3 
(6 months) 
 
74 15.0 (3.0) 31.93 (13.03) 
Visit 4 
(12 months) 
 
65 14.8 (2.7) 31.39 (15.16) 
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Table 2.19: Comparison of mean IOP and percentage of IOP reduction from baseline 
between monotherapy and adjunctive therapy of topical latanoprost 
 Mean IOP reduction from baseline 
(mmHg) 
 
Mean percentage of IOP reduction from 
baseline 
 
Monotherapy 
n 
Mean (SD) 
Adjunctive 
n 
Mean (SD) 
p-
value* 
Monotherapy 
n 
% (SD) 
Adjunctive 
n 
% (SD) 
p-
value* 
Baseline 
 
39 
--- 
47 
--- 
 39 
--- 
 
47 
--- 
 
1 month 39 
6.9 (5.0) 
47 
6.8 (3.9) 
 
0.891 
39 
28.86 (13.73) 
47 
28.87 (13.27) 
 
 
0.997 
3 months 37 
8.1 (5.2) 
44 
6.6 (6.1) 
 
0.269 
37 
34.37 (13.09) 
44 
27.90 (22.96) 
 
 
0.135 
6 months 35 
7.8 (4.9) 
39 
7.4 (4.2) 
 
0.683 
35 
33.06 (11.42) 
39 
30.92 (14.40) 
 
 
0.484 
12 months 32 
6.8 (3.8) 
33 
6.8 (4.6) 
 
0.919 
32 
32.68 (14.41) 
 
33 
30.15 (15.98) 
 
0.506 
*p < 0.05 is considered significant based on independent t-test  
 
2.3.2.6 Repeated measures Analysis of Variance (RM ANOVA) of IOP at 1, 3, 6 and 12 
months treatment with topical latanoprost 0.005% 
RM ANOVA analyzed only 65 patients who completed 12 months follow up. There was a 
statistical significant IOP reduction over 12 months follow up (Figure 2.3). Further analysis 
was conducted using multiple paired t-tests with Bonferroni correction on the 10 possible 
pairing of the difference between visits (Table 2.20). P-value of 0.005 was deemed 
statistically significant.  Multiple paired t-tests were conducted on the actual number of 
recruited patient according to follow up visit. There was significant pressure lowering effect 
between baseline and 1 month, baseline and 3 months, baseline and 6 months, and baseline 
and 12 months post treatment. However, there was no significant different between the 
subsequent follow up visits pairing. 
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Figure 2.3: Pattern of pressure lowering effect of topical latanoprost 0.005% at baseline, 
1 month, 3 months, 6months and 12 months post-treatment 
*p< 0.05 is considered statistically significant based on RM ANOVA  
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Table 2.20: Comparison of mean IOP difference at follow-up visits 
Time pairing# 
 
Mean IOP 
difference (SD) 
(mmHg) 
95% CI t-statistic(df) p-value* 
Baseline-Visit 1 
 
6.7 (3.7) 6.9, 7.5 17.04 (85) <0.001 
Baseline-Visit 2 
 
7.2 (4.9) 6.1, 8.2 13.19 (80) <0.001 
Baseline-Visit 3 7.4 (3.6) 
 
6.5, 8.2 17.46 (73) <0.001 
Baseline-Visit 4 
 
7.2 (4.0) 6.2, 8.2 14.46 (64) <0.001 
Visit 1-Visit 2 0.3 (3.9) -0.6, 1.1 0.60 (84) 0.554 
 
Visit 1-Visit 3 0.2 (3.4) -0.6, 1.0 0.58 (73) 
 
0.564 
Visit 1-Visit 4 0.4 (3.1) -0.3, 1.2 1.16 (64) 0.249 
 
Visit 2-Visit 3 -0.4 (2.8) 
 
-1.1, 0.2 -1.25 (73) 0.216 
Visit 2-Visit 4 
 
-0.4 (2.8) -1.1, 0.3 -1.23 (64) 0.222 
Visit 3-Visit 4 
 
-0.4 (3.0) -1.1, 0.4 -1.83 (64) 0.305 
*p< 0.005 based on multiple paired t-tests with Bonferroni correction 
# Visit 1 is baseline IOP, Visit 2 is IOP at 1 month, Visit 3 is IOP at 3 months, Visit 4 is IOP at 6 
months and Visit 5 is IOP at 12 months post-treatment with topical latanoprost 0.005% 
 
2.3.2.7 Mean IOP reduction at baseline and 1 month, 3 months, 6 months and 12 
months post-treatment with between and within subject effects 
Type of glaucoma was identified as the significant factor associated with IOP measurement 
based on multivariate analysis. Thus, type of glaucoma was included as between the subject 
factor in RM ANOVA analysis (figure 2.4). Although, treatment modality was not found to 
affect the IOP measurement but it was included out of clinical interest. However, there was 
no significant different in pressure lowering effect of topical latanoprost between 
monotherapy and adjunctive therapy over a year of follow up (p=0.775; RM ANOVA). 
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There was a statistically significant difference between the type of glaucoma and pattern of 
pressure lowering effect of topical latanoprost 0.005% (figure 2.4). The significant reduction 
was seen between baseline IOP and subsequent IOP measurement in both POAG and NTG 
(table 2.21).  
 
 
Figure 2.4: Pattern of pressure lowering effect of topical latanoprost in POAG and NTG 
patients 
P<0.05 is considered statistically significant based on RM ANOVA  
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Table 2.21: Mean IOP difference at follow-up visits in POAG and NTG patients  
 
 
Comparison# 
 
POAG NTG 
Mean IOP 
difference 
(95% CI) 
 
t-stat 
(df) 
p-value* Mean IOP 
difference 
(95% CI) 
t-stat 
(df) 
p-value* 
Visit 1-Visit 2 
 
7.6 (6.7, 8.5) 17.0 
(63) 
<0.001 4.1 (3.0, 5.3) 7.7 
(21) 
<0.001 
Visit 1-Visit 3 
 
7.6 (6.3, 9.0) 11.3 
(60) 
<0.001 5.8 (4.3, 7.2) 8.4 
(19) 
<0.001 
Visit 1-Visit 4 8.0 (7.0, 9.0) 15.9 
(54) 
<0.001 
 
5.4 (4.2, 6.6) 9.7 
(18) 
<0.001 
Visit 1-Visit 5 
 
8.0 (6.7, 9.2) 13.0 
(45) 
<0.001 5.4 (3.8, 6.9) 7.4 
(18) 
<0.001 
Visit 2-Visit 3 
 
-0.1 (-1.2, 1.0)  -0.2 
 (60) 
0.831 1.4 (0.1, 2.7) 2.3 
(19) 
0.036 
Visit 2-Visit 4 
 
0.0 (-1.0, 1.0) 0.0 
(54) 
1.000 0.9 (-0.4, 2.2) 1.4 
(18) 
0.167 
Visit 2-Visit 5 0.3 (-0.6, 1.2) 
 
0.6  
(45) 
0.529 0.8 (-0.8, 2.4) 
 
1.1 
(18) 
0.281 
Visit 3-Visit 4 -0.4 (-1.2, 0.4) 
 
-1.0 
(54) 
0.337 -0.4 (-1.3, 0.5) 
 
-1.0 
(18) 
0.338 
Visit 3-Visit 5 
 
-0.4 (-1.2, 0.4) 
 
-1.1 
(45) 
0.298 -0.5 (-2.0, 1.1) -0.6 
(18) 
0.532 
Visit 4-Visit 5 
 
-0.5 (-1.4, 0.4) -1.2 
(45) 
0.235 -0.1 (-1.6, 1.5) -0.1 
(18) 
0.943 
*p<0.005 based on multiple paired t-tests with Bonferroni correction is considered 
statistically significant 
# Visit 1: baseline IOP, Visit 2: IOP at 1 month, Visit 3: IOP at 3 months, Visit 4: IOP at 6 
months, Visit 5: IOP at 12 months post-treatment with topical latanoprost 0.005% 
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2.3.2.8 Responsiveness and side effects to topical latanoprost 0.005% 
Based on the definition of a good responder (25% of IOP reduction from baseline), 64.0% of 
the subjects were good responders, and 36.0% were poor responders (Table 2.22). 
 
Hypertrichosis was detected at 3 months of treatment (7, 8.6%) and later increased to 85.1% 
at 6 months. At the end of 12 months, all the remaining patients (65, 100%) developed 
hypertrichosis. Conjunctival hyperaemia developed in 3 patients at 1 month post treatment 
with 1 developed grade 1 (mild hyperaemia) and 2 patients developed grade 2 (moderate 
hyperaemia). Latanoprost induced iris pigmentation was detected in 5 patients at 12 months 
(Table 2.23). 
 
Table 2.22: Percentage of good and poor responder according to different definition of 
responsiveness to topical latanoprost 0.005% 
Definition of responds 
 
Good responders 
     n (%) 
Poor responders 
     n (%) 
≥10% 
 
   73 (84.9)     13 (15.1) 
≥15% 
 
   67 (77.9)     19 (22.1) 
≥20% 
 
   62 (72.1)     24 (27.9) 
≥25% 
 
   55 (64.0)     31 (36.0) 
≥30% 
 
   40 (46.5)     46 (53.5) 
≥35% 
 
   31 (36.0)     55 (64.0) 
≥40% 
 
   19 (22.1)     67 (77.9) 
≥45% 
 
   14 (16.3)     72 (83.7) 
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Table 2.23: Percentage of ocular side effects according to follow-up visits 
 Ocular side effects 
 
Visit n Hypertrichosis 
N (%) 
 
Latanoprost induced 
iris pigmentation 
N (%) 
Conjunctival hyperaemia 
N (%) 
1 month 
 
86 0 (0) 0 (0) 3 (3.4) 
3 months 
 
81 7 (8.6) 0 (0) 0 (0) 
6 months 
 
74 63 (85.1) 0 (0) 0 (0) 
12 months 
 
65 65 (100.0) 5 (7.7) 0 (0) 
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2.4 Discussion 
2.4.1 Pressure lowering effect of topical Timolol XE 0.5% 
Topical Timolol XE 0.5% is a gel forming solution of topical timolol, which is believed to 
promote compliance and efficacy with a single dosing and minimizing the unwanted systemic 
side effects. Timolol XE 0.5% has been shown to be as effective as twice dosing of topical 
timolol aqueous solution (Uusitalo et al, 2006). A total of 97 open angle glaucoma (OAG) 
patients were recruited and were followed up for 12months. However, only 50 patients 
(51.5%) completed 12 months monotherapy treatment with topical Timolol XE. Almost half 
of the recruited patients required additional medication in order to achieve target IOP. The 
target IOP was individually set up according to the severity of glaucoma and type of 
glaucoma rather than fixing at certain definitive target.  This study was designed to replicate 
the actual clinical situation rather than the artificial regimental clinical trial. Adherence and 
persistence to the drug was presumed to be presence in all recruited subjects.  
 
A long term follow up study of Caucasian glaucoma patients treated with topical timolol 
aqueous solution found that only 17.7% of total 96 patients were still treated with topical 
timolol monotherapy after 7 years (Watson et al, 2001). At 12 months of follow up, there was 
76 glaucoma patients (82.3%) were still treated with topical timolol. A 12 month prospective 
cohort study was conducted in mainly Caucasians and African Americans (only one Asian 
glaucoma patient) comparing the effectiveness of topical timolol GFS 0.5% and Timolol XE 
0.5%, found that more than half of the patients (69%) achieved target IOP (Schenker and 
Silver, 2000).  
 
Based on the pressure lowering effect in 50 patients, there was significant pressure lowering 
effect at 1 month post treatment from the baseline IOP. However, pressure lowering effect of 
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timolol failed to exert significant effect on subsequent follow-up. Seven years follow up in 
United Kingdom on glaucoma patients treated with 3 different types of topical beta-blockers: 
timolol, betaxolol and carteolol showed a similar pattern. In fact, there was slight increase in 
mean IOP at 3, 6 and 12 months follow up as compared to mean IOP at 1 month in all three 
types of topical beta blockers (Watson et al, 2001). However, this long term study was based 
on topical timolol aqueous solution 0.25% twice daily.  
 
In spite of the differences between Malay and Chinese of the Malaysian populations, both do 
have highly pigmented iris. Perhaps, the high affinity of timolol for reversible binding to 
melanin is responsible in poor responder rate to topical Timolol XE 0.5% in our population. 
Timolol has high affinity for and easily bind to melanocyte (Menon et al, 1989). The 
relationship between timolol and melanin is quite controversial.  
 
Slightly more than half of participants were poor responder to timolol, achieving less than 
25% IOP reduction from baseline at their last visit. However, if the meaningful IOP reduction 
is adjusted to 20%, the number of good responder increased to slightly more than half of the 
total recruited Malaysian subjects.  
 
2.4.2 Pressure lowering effect of topical Latanoprost 0.005% 
Topical Latanoprost 0.005% has been shown to be more effective in Asian population as 
compared to topical timolol (Hedmann and Larsson, 2002). The current study was initially 
started at the early era of increasing popularity of prostaglandin analogs in Malaysia and is 
slowly replacing timolol as the first line antiglaucoma drug. Thus, in the early part of 
recruitment period there were many patients on adjunctive therapy to timolol and in later part 
there were more patients on latanoprost monotherapy. At the end of 12 months follow up, 65 
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subjects were still treated with topical latanoprost. In general, there was significant pressure 
lowering effect of topical latanoprost at every follow up visit from the baseline. However, 
there was no significant additional pressure lowering effect in between subsequent visits. For 
example between 1 month (visit 1) and 3 months (visit 2) post treatment. 
 
Topical latanoprost provides better pressure lowering effect when compared indirectly with 
topical timolol XE monotherapy in project B in this study. The percentage of IOP reduction 
reaches around 32% from baseline IOP. Our finding provides additional evidence of better 
pressure lowering effect of topical latanoprost in Asians population (Hedman and Larsson, 
2002; Aquino and Manalo, 2007). However, variations from the general response were 
observed in certain individual subjects in our study: some failed to achieve any meaningful 
IOP reduction and there were subjects that demonstrated a „see-saw‟ effect on IOP.  This 
inter-individual variation was observed based on individual pattern of 12 months of IOP 
measurement (not included in the result). In spite of the variation in response to latanoprost, 
64.0% of the patients were categorized as good responder (based on ≥25% reduction) and 
72.1% based on ≥20% reduction. A retrospective study on newly diagnosed Malay glaucoma 
patients treated with monotherapy latanoprost demonstrated almost similar percentage of 
good responders compared to Caucasians (≥20% reduction) (Cheong et al, 2008; Scherer, 
2002). 
 
Pressure lowering effect of topical latanoprost as adjunctive therapy has been reported to be 
lower than monotherapy treatment (Rulo et al, 1994). Surprisingly at 1 month post-treatment, 
there was almost similar pressure lowering effect between monotherapy and adjunctive 
therapy even though mean baseline IOP was slightly higher in adjunctive therapy group. 
However, on the subsequent visits, monotherapy treatment demonstrated clinically better 
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pressure lowering effect but without any statistically significant difference in comparison 
between the two treatment modalities. The pressure lowering effect of topical latanoprost is 
equally effective as monotherapy and adjunctive therapy to topical timolol in Malaysian 
population. Although, there was statistically significant difference in term of severity of 
glaucoma (based on HFA) and thinner CCT in adjunctive therapy compared to monotherapy 
subjects. It is of no surprise; lower target pressure is aimed for more advanced disease and 
more than a single topical drug is required to achieve the set target pressure. 
 
There was significant difference in pressure lowering effect of latanoprost according to type 
of glaucoma. Since baseline IOP was found to moderately correlated with the pressure 
lowering effect of latanoprost, there was significant pressure lowering effect seen in POAG 
subjects compared to NTG (Bayer et al, 2005).  In general, topical latanoprost 0.005% 
provides good pressure lowering effect in different type of glaucoma in Malaysian 
population. 
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Chapter 3 
3.1 Objectives 
To determine the role of ADRB2 and PTGFR genes as candidates in aetiology of open angle 
glaucoma.  
 
3.2 Materials and methods 
3.2.1 Blood collection for DNA extraction 
Venesection was conducted on 183 glaucoma patients recruited based on criteria described in 
chapter 2. Blood was drawn from an equal number of age, sex and ethnicity-matched control 
subjects. Five millilitres of venous blood was obtained and kept in an 
ethylenediaminetetraacetic acid (EDTA) collection tube after written, informed consent was 
given by both people with glaucoma and control subjects. 
 
Anterior segment examination, gonioscopy to assess the possibility of angle-closure or 
abnormalities of the angle structure, funduscopy examination to measure the vertical cup to 
disc ratio, visual field assessment and intraocular pressure measurement using Goldmann 
applanation tonometry were conducted in all selected control subjects to rule out possibility 
of glaucoma suspect or undiagnosed glaucoma. Similar examination was conducted in 
glaucoma patient as detailed in chapter 2. Pedigree charts were drawn to rule out any 
possibility of family history of glaucoma as well as to rule out the possibility of 
intermarriages in the family. As genetic polymorphism tends to varies according to 
population the selected control subjects must be of Malay and Chinese linage for 3 
generations.  
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3.2.2 DNA extraction 
DNA extraction was performed using QIAGEN QIAmp DNA Blood Mini Kit (Qiagen Inc., 
USA) according to the manufacturer‟s instructions. DNA extraction was conducted at the 
Human Genome Centre, University Sains Malaysia. Blood in the EDTA collection tubes, 
tubes and columns were arranged according to the sequence of procedure prior to the DNA 
extraction.  Twenty microlitres of proteinase-K was added directly to 200µl of blood to digest 
proteins attached to the DNA.  This was followed by additional 200µl of buffer AL (lysis 
buffer) to induce lysis of red blood cells. The sample was then incubated at 56°C for 10 
minutes to ensure complete lysis of the red blood cells. After incubation, reaction mixture 
was centrifuged to collect the lysate at the bottom of the tube. Then, 200 µl of 96% ethanol 
(BDH Laboratory Supplies, England) was added to the reaction mixture and mixed by pulse-
vortexing for 15 seconds, to ensure the precipitation of DNA. The whole volume of reaction 
mixture was then transferred carefully to QIAmp spin column (with 2 ml collection tube 
provided by manufacturer) and spun at 8000rpm for 1 minute before discarding the collecting 
tube containing filtrate.  
 
The filter column was then transferred to another collecting tube before adding 500µl of 
buffer AW 1 (wash buffer 1) and spun again at 8000rpm for another 1 minute. The spin 
column was then placed into a new collection tube and the previous collection tube was 
discarded. Later 500µl of buffer AW 2 (wash buffer 2) was added and spin at 1400rpm for 3 
minutes. The filtrate was then discarded and centrifuged again at 14000 rpm for 1 minute to 
ensure the removal of all the filtrate. The QIAamp spin column was then placed in a new 1.5 
ml microcentrifuge tube and 200 µl of buffer AE (elution buffer) was added into the spin 
column to elute the DNA. Incubation for 5 minutes with elution buffer helped increase the 
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DNA yield. Buffer AE contained 10 mM Tris-Cl and 0.5 mM EDTA. Finally, the column 
was spin at 8000rpm for 1 minute before discarding the filter column.  
 
The concentration and purity was obtained using spectrophotometer (BioPhotometer, 
Eppendorf, Hamburg, Germany) or nanodrop spectrophotometer (Ultroscope 2000, USA). 
The concentration of DNA and its purity ranged from 30 to 60 ng/µl (260/280 nm) and 1.6 to 
1.9 (A260/A280) respectively. Three microlitres of genomic DNA was also selectively analyzed 
on 1% of agarose gel to ensure it is not degraded. DNA was then kept in -20°C freezer for 
long term storage. 
 
3.2.3 ADRB2 gene screening 
ADRB2 gene screening was done on 100 glaucoma subjects and 100 control subjects. The 
reference sequence used for ADRB2 gene was retrieved from the Gen Bank (accession no. 
M15169). A single tube multiplex PCR protocol was employed in this study. The entire 
procedure was conducted at the Human Genome Centre, Universiti Sains Malaysia. For each 
of the polymorphic loci, two parallel allele-specific reactions were carried out; one with a 
wild-type specific primer and the other with a mutation specific primer. The primers were 
initially designed to detect allelic variants at positions 16 (rs56964295), 27 (rs60374884), 164 
(rs1800888) and at 5‟ Untranslated Region (UTR) for nucleotides at position -20 (rs1081704) 
and -47 (rs1042711) of the β2AR gene. The primers were specifically designed (between 20 
to 30 nucleotides in length) to allow reasonable annealing temperature and with specific 3‟ 
ends to allow differentiation of single nucleotide changes at specific locus. The G and C 
contents in the designed primers were almost similar to ensure similar annealing temperatures 
for multiplex PCR reactions.  
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The primer sequences are given in Table 3.1 and the schematic diagram showing the 
amplification scheme is given in figure 3.1. A duplex PCR was carried out for primer 
Beta16A/G and Beta UTR-20C/T, which has been specifically designed to have almost 
similar annealing temperature while a triplex PCR was carried out for primer Beta27C/G, 
Beta164C/T and Beta UTR-47C/T. The primer Beta2-Fw was used as a common forward 
primer in both duplex and triplex PCR reactions while the Beta 16A/G, Beta UTR-20C/T, 
Beta 27C/G, Beta UTR-47C/T and Beta 164C/T primers were the reverse primers. 
 
Table 3.1: Primers sequence for multiplex PCR 
 
Reproduction with permission from Zilfalil et al (2006) 
  
The PCR protocol was adapted from the protocol by Zilfalil et al (2006) and was optimized 
for the PCR compositions and reaction conditions to produce specific bands for both duplex 
and triplex PCR. For duplex PCR, the final optimized protocol includes a reaction mixture 
comprised of 1X PCR Buffer (Promega, Madison,WI, USA), 1.5 mM MgCl2, 2 U Taq 
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polymerase (Promega, Madison,WI, USA), 0.25 mM dNTPs,  approximately 60 ng genomic 
DNA, 1.25 µM Beta2-Fw and 0.25μM of each primer in 20 μl total reaction volume. 
 
PCR amplification was performed using PTC200 MJ Research (USA) with pre-denaturation 
at 95
0
C for 3 min, followed by 35 cycles of denaturation at 95
0
C for 1 min, annealing at 55
0
C 
for 1 min, extension at 72
0
C for 1 min 30sec and final extension at 72
0
C for 5 min. The 
expected fragment sizes for each allele in the duplex PCR reaction was 179bp for allele 16 
and 114bp for allele -20 (Figure 3.1).  
 
For triplex PCR, the final optimized conditions comprised of 1X PCR Buffer (Promega, 
Madison, WI, USA), 1.5 mM MgCl2, 2 U Taq polymerase (Promega, Madison, WI, USA), 
0.25 mM dNTPs, approximately 60 ng genomic DNA and appropriate primer concentrations 
in a total volume of 25 μl.  
 
PCR amplification was performed using thermal cycler PTC200 MJ Research, (USA) with 
pre-denaturation at 95
0
C for 3 min, followed by 25 cycles of denaturation at 94
0
C for 1 min 
30 s, annealing at 62
0
C for 40 s, extension at 72
0
C for 40 s and final extension for 72
0
C for 7 
min. The expected fragment sizes for each allele in the triplex PCR reaction was 624bp for 
allele 164, 212bp for allele 27 and 86bp for allele -47. Triplex PCR reaction was the most 
challenging part as several of the samples required multiple repeated procedures due to poor 
quality of gel electrophoresis picture.  
 
Two percent agarose gel was prepared using a mixture of 1g agarose powder and 50ml of 
electrophoresis buffer, Tris-Base, Borate and EDTA (TBE). After 3 minutes of heating in the 
microwave, SYBR® Green dye (Qiagen, USA) was added to facilitate visualization of the 
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band. After solidification of the agarose gel, 10µl of PCR product and loading buffer 1X TBE 
was then loaded into the well.   
 
Direct sequencing was done on selected samples to reconfirm the findings. Big Dye 3.1 was 
used according to manufacturer‟s instruction. The purified PCR product was used as template 
for cycle sequencing. Twenty microlitres reaction contained of 7µl of ddH2O, 4µl of 5X 
sequencing buffer, 2µl Big Dye terminator v3.1, 4µl of 5µM of either forward or reverse 
primer and 3µl of 50ng/µl purified PCR product was subjected to cycle sequencing reaction, 
which began with initial denaturation at 96
0
C for 1 min. Then, it was followed by rapid 
thermal ramp (1
0
C/sec) at 96
0
C for 10 sec, 50
0
C for 5 sec and 60
0
C for 4 min and this step 
was repeated for a total of 25 cycles. Samples were held at 4
0
C before proceeding to 
ethanol/EDTA precipitation method for purification of the DNA from aqueous solution. 
 
Ethanol precipitation, also known as EDTA precipitation was conducted to facilitate 
production of consistent signal and to remove the unincorporated dyes. The entire volume of 
cycle sequencing product was then transferred to 1.5ml microcentrifuge tube and 5 µl of 125 
mM EDTA was then added. Extra care was taken to ensure that EDTA reached the bottom of 
the tube. First volume (60µl) of 100% ethanol was then added to the tube, mixed well by 
inverting the tube 4 times and left to incubate at room temperature for 15minutes. Later, the 
reaction mixture was centrifuged at 1300rpm for 15minutes at 4°C (Eppendorf 5415R, Asia 
Pacific; maximum relative centrifuge force 16,110 x g). The supernatant was carefully 
removed from the tube with extra care not to reach the bottom of the tube, avoiding 
accidental removal of DNA.  
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The second volume (70µl) of 100% ethanol was then added and mixed thoroughly. The 
reaction mixture was then centrifuged again at 13000rpm for 15minutes at 4°C and the 
supernatant was carefully removed again. The final step was the addition of 60µl of 70% 
ethanol to the pellet and mixed thoroughly to break the pellet loose and wash it to remove 
some of the remaining salts. The reaction mixture was centrifuged again at 1300rpm for 
15minutes at 4°C and supernatant was removed again. The pellet was then air-dried using 
vacuum regulator (Bio-Rad, CA, USA) for 30 minutes and resuspended in 20µl of Hi-Di 
formamide (Applied Biosystem, Warrington, UK). The pellet was stored at 4°C.  
 
Prior to the sequencing, 10µl of the pellet was then denature for 5 minutes and placed in the 
ice (-70°C) for 3 minutes. The samples were then placed in the ABI Prism 3100 Genetic 
Analyzer sequencer (Applied Biosystem, California, USA).  
 
3.2.4 PTGFR screening 
The examination of PTGFR gene was conducted on 180 samples; 90 glaucoma subjects and 
90 unrelated age, sex and race matched controls. A total of 95 pairs of primers were designed 
to cover the entire PTGFR gene including 3000bp upstream of 5‟UTR and 1000bp 
downstream of 3‟UTR (Table 3.2 - 3.5). The reference sequence was based on Ensembl 
ENSG 00006122420 and NCBI accession number AL136324.6. Sixteen primers were 
designed for all 4 exons including 1000bp 3‟UTR. Four primers were designed for Intron 1, 
12 primers for Intron 2 and 59 primers for Intron 3. Detection of microsatellite instability 
(MSI) or short tandem repeat (STR) was done using special tagged forward primers. 
Promoter region was the most challenging part with more than 10 primers was designed. 
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Critical criteria such as the primer length, melting temperature (Tm), specificity, 
complementary primer sequences, G/C content and 3‟-end sequence was strictly followed 
when designing the primer. The primers were designed between 20 and 28 nucleotides in 
length; there was no increase in specificity with primers longer than 30 nucleotides. The 
melting temperature for the pairs of primers was designed to be from 50
0
C to 60
0
C. The GC 
content of each of the primer was designed to have a 40 to 60% GC content. In addition, 
primers were designed to be exactly complementary to the template DNA and there was no 
complementarity of their 3‟ ends with the other primers to minimise the chances of primer-
dimer formation.  
 
The screening of the PTGFR gene was done in stages at the Human Genome Centre, 
Universiti Sains Malaysia and Department of Genetics, Institute of Ophthalmology, 
University College London. Direct sequencing technique was used in screening exons and 
introns. Genotyping was conducted to detect the presence of MSI or STR. The primers 
sequence used to screen the PTGFR gene are given in table 3.2-3.4. 
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Table 3.2: Primers sequence for exons screening of PTGFR  
Exon Primer Sequence Size 
(bp) 
*Ta (
0
C) 
1 PGFe1-1F 
PGFe1-1R 
5‟cgagagagaagaggaagagg 3‟ 
5‟ctgggtctagataagcgaag 3‟ 
347 50 
2 PGFe2-1F 
PGFe2-1R 
5‟gaaccgcaggcagatatgag 3‟ 
5‟aacgatgccttggacttctg 3‟ 
428 
 
55 
 
 PGFe2-2F 
PGFe2-2R 
5‟agaagtccaaggcatcgttt 3‟ 
5‟aagaagtgggcacagaccag 3‟ 
194 55 
 PGF8246F 
PGF8246R 
5‟ttggtatctgcatggtgt 3‟ 
5‟ttgatgtcttctgtgttgtag 3‟ 
260 55 
 PGFe2-3F 
PGFe2-3R 
5‟acatcaaagactgggaagatag 3‟ 
5‟tccaacaaatacaggagacac 3‟ 
213 50 
3 PGFe4-1F 
PGFe4-1R 
5‟actggaaggccatatgtttgtt 3‟ 
5‟ccttaggaaaatcaagctccaa 3‟ 
171 54 
4 PGFe3-1F 
PGFe3-1R 
5‟tcattgatttctttctgtcagtat 3‟ 
5‟ccacacagatttactgtcctatta 3‟ 
454 50 
 PGFe3-2F 
PGFe3-2R 
5‟ataggacagtaaatctgtgtgg 3‟ 
5‟gcatgtgttaattgaggctac 3‟ 
480 50 
 PGFe3-3F 
PGFe3-3R 
5‟ggctcagtaaaataaagcactc 3‟ 
5‟acctatcattggcatgtagc 3‟ 
453 50 
 PGF899F 
PGF899R 
5‟aagctacatgccaatgataggtg 3‟ 
5‟ttggaaaatttggggagaga 3‟ 
331 55 
 PGFe3-4F 
PGFe3-4R 
5‟caagcacttggggattatta 3‟ 
5‟ccctgaatgagagtttcttct 3‟ 
503 50 
 PGFe3-5F 
PGFe3-5R 
5‟tggagaagaaactctcattcag 3‟ 
5‟acagtaaatcgccaagctac 3‟ 
423 50 
 PGFe4-6F 
PGFe4-6R 
5‟gtgcacatctgacttaagagtt 3‟ 
5‟acacctgtaaaaatcctgac 3‟ 
376 50 
 PGFe4-7F 
PGFe4-7R 
5‟gtaaggcattatccaagcaac 3‟ 
5‟aaactcagagtaggcacaaaac 3‟ 
445 55 
 PGFe4-8F 
PGFe4-8R 
5‟tccctagaggcagaaagttag 3‟ 
5‟gtccaacattatttaccaggtg 3‟ 
362 50 
 PGFe4-9F 
PGFe4-9R 
5‟tagcttcacctgtatacgatca 3‟ 
5‟gaaattcttctcatccagtagc 3‟ 
453 50 
 
Table 3.3: Primers sequence for Intron 1 and 2 screening of PTGFR  
Intron Primers Sequence Size (bp) Ta (
0
C) 
 
1 IVS1-1F 
IVS1-1R 
5‟cgagagagaagaggaagagg 3‟ 
5‟gttagctcgagtacccttcttt 3‟ 
471 50 
 IVS1-2F 
IVS1-2R 
5‟catagagaaagaagggtactcg 3‟ 
5‟ccactcttctctgacctaattc 3‟ 
465 50 
 IVS1-3F 
IVS1-3R 
5‟gaattagctcagagaagagtgg 3‟ 
5‟ttgtcaggcagacataactatc 3‟ 
386 50 
 IVS1-4F 
IVS1-4R 
5‟ggagatagttatgtctgcctga 3‟ 
5‟catctgtaggstaaagggagag 3‟ 
483 50 
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2 IVS2-1F 
IVS2-1R 
5‟cgataatgtgtgtctcctgtat 3‟ 
5‟gagaacccagtagctaatatgc 3‟ 
414 50 
 IVS2-2F 
IVS2-2R 
5‟gaacagattgcagtaagtcttg 3‟ 
5‟ggcatgttgtcacttcttaca 3‟ 
471 50 
 IVS2-3F 
IVS2-3R 
5‟gacaacatgccatgaaagaa 3‟ 
5‟gcctaggaaaactgcattagta 3‟ 
222 50 
 IVS2-4F 
IVS2-4R 
5‟agacaaaggtagtggttgtacc 3‟ 
5‟cagtagcagctatcacaaactt 3‟ 
487 50 
 IVS2-5F 
IVS2-5R 
5‟gtgcagttctaattaacgatcc 3‟ 
5‟agtggctccagtgttgttag 3‟ 
405 50 
 IVS2-6F 
IVS2-6R 
5‟ccagtaagagtctgatctgtga 3‟ 
5‟cctcaaagtagaaacccagtaa 3‟ 
465 50 
 IVS2-7F 
IVS2-7R 
5‟agagacataatccggacaact 3‟ 
5‟ctcaactctccataaaagaagc 3‟ 
498 50 
 IVS2-8F 
IVS2-8R 
5‟gatccaccacaggtattacttt 3‟ 
5‟gctgtcactattacagcacaaac 3‟ 
418 50 
 IVS2-9F 
IVS2-9R 
5‟tagattcccatagttgtgctgt 3‟ 
5‟gacccaaaactactcagaaaag 3‟ 
451 50 
 IVS2-10F 
IVS2-10R 
5‟tttgtgcttgacaggaactact 3‟ 
5‟attctgcatgatcctgtaatgg 3‟ 
470 50 
 IVS2-11F 
IVS2-11R 
5‟cattagggctatctctttgtgt 3‟ 
5‟agagacatcaggagaatgtgtt 3‟ 
469 50 
 IVS2-12F 
IVS2-12R 
5‟aacacattctcctgatgtctct 3‟ 
5‟cttgggtaaactcacctatgta 3‟ 
516 50 
 
Table 3.4: Primers sequence for Intron 3 screening of PTGFR  
Intron Primer Sequence Size (bp) Ta (
0
C) 
 
3 IVS3-1F 
IVS3-1R 
5‟taccttctcttcagggatacag 3‟ 
5‟gtcattagccctttaagacttg 3‟ 
309 50 
 IVS3-2F 
IVS3-2R 
5‟ggagtaacatgacatcatagca 3‟ 
5‟acccactagaatccctcttatt 3‟ 
408 50 
 IVS3-3F 
IVS3-3R 
5‟cttggaatataggtctttcagg 3‟ 
5‟gggatatttgagagaacagaga 3‟ 
477 50 
 IVS3-4F 
IVS3-4R 
5‟tcctctatctgggctatcttta 3‟ 
5‟cttcagaaagtccaagattctc 3‟ 
473 50 
 IVS3-5F 
IVS3-5R 
5‟cttggtggctttactctacatt 3‟ 
5‟gtctgtcggatttttttgag 3‟ 
493 58 
 IVS3-6F 
IVS3-6R 
5‟actatctccctccataaaagt 3‟ 
5‟taaagctaaaactggcaacc 3‟ 
425 50 
 IVS3-7F 
IVS3-7R 
5‟gtactcagagaggacttcatcc 3‟ 
5‟gaagacttgacttgggactatg 3‟ 
336 50 
 IVS3-8F 
IVS3-8R 
5‟ccacttcttagctatgacctta 3‟ 
5‟aggaaacagaggcacagagt 3‟ 
636 58 
 IVS3-9F 
IVS3-9R 
5‟gtatccacttcatagggtggt 3‟ 
5‟cagtttcctgcatatctcttct 3‟ 
420 50 
 IVS3-10F 
IVS3-10R 
5‟ggaagtgtgaaaatgagaagag 3‟ 
5‟gaaggagatagaaagcatgagt 3‟ 
532 50 
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 IVS3-11F 
IVS3-11R 
5‟acagacgtcttctcctttattg 3‟ 
5‟gctatccaaacagttcttgc 3‟ 
358 50 
 IVS3-12F 
IVS3-12R 
5gttagccagttgtcctcaaat 3‟ 
5‟atgcaactaatttgcctcac 3‟ 
321 50 
 IVS3-13F 
IVS3-13R 
5‟cctaacagcaacgtgcgagtgtccc 3‟ 
5‟gaaccaacagagactgactccagg 3‟ 
667 60 
 IVS3-14F 
IVS3-14R 
5‟ctaagaatatagagttctttttggc 3‟ 
5‟ggccatactggaatgaaataccac 3‟ 
648 50 
 IVS3-15F 
IVS3-15R 
5‟ggcacagagtttatagctgttgagtg 3‟ 
5‟cccacactgaaacaaattccaaag 3‟  
695 50 
 IVS3-16F 
IVS3-16R 
5‟ccttcctgtgtagttacttatggg 3‟ 
5‟caatgaccctctgggttaagaagg 3‟ 
758 50 
 IVS3-17F 
IVS3-17R 
5‟gagttgttccaatgggaatttgggcag 3‟ 
5‟cctgtattctggtagctgtttcagttc 3‟ 
489 50 
 IVS3-18F 
IVS3-18R 
5‟actccggaattctgacatta 3‟ 
5‟cagacaaaaaggatatgctagg 3‟ 
331 50 
 IVS3-19F 
IVS3-19R 
5‟gtggtaaaggtgactgaatga 3‟ 
5‟cccttcctctttcttactctct 3‟ 
598 56 
 IVS3-20F 
IVS3-20R 
5‟caggagtggtggcaggag 3‟ 
5‟gactgattaaatggttgtgacg 3‟ 
623 60.2 
 IVS3-21F 
IVS3-21R 
5‟ctcagagggataactcactcat 3‟ 
5‟ccattttacagttccaaagc 3‟ 
611 50 
 IVS3-22F 
IVS3-22R 
5‟cggacaaagaaggacaagctgatgagg 3‟ 
5‟ctacaggcttaacaccatacg 3‟ 
645 59.6 
 IVS3-23F 
IVS3-23R 
5‟ctgtggctcaaagggcctcaggcagat 3‟ 
5‟agagtacactgatgcaaggagt 3‟ 
482 60.2 
 IVS3-24F 
IVS3-24R 
5‟gtaaacccaatgtctgtataccc 3‟ 
5‟cctcctgactgtttcccacacattcc 3‟ 
760 50 
 IVS3-25F 
IVS3-25R 
5‟acgtccttatagctgtggttat 3‟ 
5‟ggtaaaccctctgaacatacat 3‟ 
341 50 
 IVS3-26F 
IVS3-26R 
5‟aatgccctcagtctgataact 3‟ 
5‟ggacatctatctttggctctt 3‟ 
500 50 
 IVS3-27F 
IVS3-27R 
5‟accataccaaggcacttaaa 3‟ 
5‟tagatcacacctttcccttg 3‟ 
647 50 
 IVS3-28F 
IVS3-28R 
5‟gctttcaacctagatgacagat 3‟ 
5‟ctttgctaaaccaacagagaag 3‟ 
268 50 
 IVS3-29F 
IVS3-29R 
5‟gttggtttagcaaaggacat 3‟ 
5‟tctctgctcatgttttacac 3‟ 
528 50 
 IVS3-30F 
IVS3-30R 
5‟atatcacagctcccatcatt 3‟ 
5‟gagataagctttccactctcag 3‟ 
450 50 
 IVS3-31F 
IVS3-31R 
5‟tagcctattgtagtgtgcagaa 3‟ 
5‟gaatcatggccataacagtaac 3‟ 
265 50 
 IVS3-32F 
IVS3-32R 
5‟ccaaccagacactattaccttt 3‟ 
5‟cttctgctcttaggagattgtc 3‟ 
462 50 
 IVS3-33F 
IVS3-33R 
5‟gggatcaatcatggttaaag 3‟ 
5‟atgggaaattaagagagaggag 3‟ 
410 50 
 IVS3-34F 
IVS3-34R 
5‟ctgtctgctcaggtaggatagt 3‟ 
5‟cgtatgtaccagatgaacaaga 3‟ 
350 50 
 IVS3-35F 
IVS3-35R 
5‟gtatgatgctcttgttcatctg 3‟ 
5‟gtgcccactattactactaccg 3‟ 
419 50 
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 IVS3-36F 
IVS3-36R 
5‟gtaagtgtaatggctgttgtagg 3‟ 
5‟ggcagataactttctctagctg 3‟ 
501 50 
 IVS3-37F 
IVS3-37R 
5‟gcttgtccaaccagacttatt 3‟ 
5‟ctaggaatgcttgcatataagg 3‟ 
485 50 
 IVS3-38F 
IVS3-38R 
5‟gcttgttggagattgcttac 3‟ 
5‟ccaacatactgactacctgtga 3‟ 
306 50 
 IVS3-39F 
IVS3-39R 
5‟gtggagtcgctactattgagtat 3‟ 
5‟gtattgccagtgagaaagaaag 3‟ 
492 50 
 IVS3-40F 
IVS3-40R 
5‟ctttctttctcactggcaatac 3‟ 
5‟catttgtccaaagtgtagagc 3‟ 
342 50 
 IVS3-41F 
IVS3-41R 
5‟gtatttgacccaagataaccac 3‟ 
5‟ctcaccataggagtctgttctt 3‟ 
504 50 
 IVS3-42F 
IVS3-42R 
5‟aaaagaacagactcctatggtg 3‟ 
5‟gctaattccagaagactacttcc 3‟ 
551 50 
 IVS3-43F 
IVS3-43R 
5‟caattggaagtagtcttctgga 3‟ 
5‟atactccacagcctctcataaa 3‟ 
315 50 
 IVS3-44F 
IVS3-44R 
5‟tgtgaggtgtaaattgacagag 3‟ 
5‟ccactagagagaaaatttcagc 3‟ 
570 50 
 IVS3-45F 
IVS3-45R 
5‟atacattaccacaagacatggt 3‟ 
5‟aggccatcaatctaacagcctat 3‟ 
324 50 
 IVS3-46F 
IVS3-46R 
5‟caggaactagatgaaagttggt 3‟ 
5‟attctccaggtaacagcctat 3‟ 
549 50 
 IVS3-47F 
IVS3-47R 
5‟ggtaatcatatctggaatgagc 3‟ 
5‟tgcctggacatctaactatgta 3‟ 
436 50 
 IVS3-48F 
IVS3-48R 
5‟cacagaagaccaacacatacat 3‟ 
5‟ggaggtacaatgattcagga 3‟ 
428 50 
 IVS3-49F 
IVS3-49R 
5‟ccttttattcctgaatcattgtacctcc 3‟ 
5‟atgaaactgttccacctcag 3‟ 
708 50 
 IVS3-50F 
IVS3-50R 
5‟actagacataggcagatggaac 3‟ 
5‟gtgtgacaccactcctttaata 3‟ 
579 50 
 IVS3-51F 
IVS3-51R 
5‟gaggtttgagatactgacaggt 3‟ 
5‟atagaccttacatctccccata 3‟ 
370 50 
 IVS3-52F 
IVS3-52R 
5‟cagaccagaagttaaaggtcat 3‟ 
5‟gtgtgacaccactcctttaata 3‟ 
402 50 
 IVS3-53F 
IVS3-53R 
5‟cacacaatcaatacagtttggc 3‟ 
5‟cagctagctccttgatgatgcatctg 3‟ 
628 50 
 IVS3-54F 
IVS3-54R 
5‟catgcctggctagtaaattc 3‟ 
5‟ctaaatgtcagcctttcaca 3‟ 
476 50 
 IVS3-55F 
IVS3-55R 
5‟agtgctgagactttcttctcac 3‟ 
5‟gatgttatcgcatcatctctc 3‟ 
440 50 
 IVS3-56F 
IVS3-56R 
5‟ggtagctcttggaaactgtatg 3‟ 
5‟gccaaactgtattgattgtg 3‟ 
574 50 
 IVS3-57F 
IVS3-57R 
5‟cacacaatcaatacagtttggc 3‟ 
5‟cagctagctccttgatgatgcatctg 3‟ 
628 50 
 IVS3-58F 
IVS3-58R 
5‟gtccaagcttcacttttcag 3‟ 
5‟aactgaccttctcatacttctg 3‟ 
600 50 
 IVS3-59F 
IVS3-59R 
5‟tctcagaagtatgagaaggtca 3‟ 
5‟ccattgtaacctaga aacgaag 3‟ 
317 50 
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3.2.4.1 Screening of PTGFR exons 
Screening of the exons was conducted at the Human Genome Centre, Universiti Sains 
Malaysia. The designed primers were prepared by 1stBASE, Singapore and sent to Human 
Genome Centre in wet format. The primers were then diluted to 100µM by adding purified 
water according to the instruction by the company. Genomic DNA was used as template for 
PCR amplification by using specific oligonucleotide primers in 20µl reaction, which 
contained 1.875 mM MgCl2 (Applied Biosystems, California, USA), 1X GeneAmp PCR 
Buffer II (Applied Biosystems, California, USA), 0.375 mM dNTPs (Applied Biosystems, 
California, USA), 0.2 µM of each forward and reverse specific primers, 4 ng/µl of template 
DNA and 0.05 unit of AmpliTaq Gold DNA Polymerase (Applied Biosystems, California, 
USA). PCR was conducted using Eppendorf Mastercycler Gradient (Eppendorf, Hamburg, 
Germany). Predenaturation process was set at 96°C at 5minutes then followed by 30 cycles of 
denaturation at 95°C for 1 minutes, specific annealing temperature according to primers 
(Table 3.2) for 1 minutes and 90 seconds (1 min 30sec) of primary extension at 72°C. The 
chain reactions ended with final extension at 72°C for 7 minutes. The presence of amplicons 
was detected using 2% agarose gel electrophoresis.  
 
The amplicons were then purified using GENE ALL PCR purification Kit (General 
Biosystem, Seoul, Korea). Five volume of buffer PB (PCR purification buffer) was added to 
a volume of the PCR product (e.g. 75µl of buffer PB was added to 15µl of PCR product) in 
1.5ml tube and thoroughly mixed. The mixture was then pipette into GENE ALL spin column 
and placed in collection tube. DNA was bound selectively to a glassfiber membrane in a 
GENE ALL Spin Column due to the high concentration of salt in the buffer PB. The mixture 
was then centrifuged at 13,000 rpm for 30 seconds to accelerate the process where DNA 
binds to the filter of the column. The flow through was discarded and the spin column was 
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reinserted into the same collection tube to reduce the plastic waste. Later, 700 µl Buffer NW 
(column wash buffer N) was added into the spin column, followed by centrifugation at 
13,000 rpm for 30 seconds. The flow through was then discarded and the spin column was 
reinserted back into the collection tube. The spin column was centrifuged for an additional 2 
minutes to remove residual wash buffer and eliminate the residual ethanol from buffer NW 
that might inhibit subsequent enzymatic reaction. A series of rapid “wash and spin” steps 
removed the contaminating small molecule such as primers, nucleotide and salts while DNA 
remained bound to the glassfiber membrane. After wash and spin process, the spin column 
was then transferred into a new 1.5 ml micro centrifuge tube.  
 
Finally, the purified DNA was eluted by a low salt buffer from a glassfiber membrane by 
adding 50 µl of buffer EB (elution buffer) into the spin column. The elution volume was also 
reduced to 30 µl for certain samples for higher concentration of elute. It is important to 
dispense buffer EB directly onto the centre of spin column membrane to ensure the optimal 
DNA elution. Then, the spin column was allowed to stand for about 1 min and centrifuged at 
13,000 rpm for 1 min. The purified DNA was stored in buffer EB at -20
0
C for long-term 
storage.  
 
The purified PCR product was used as template for cycle sequencing. Twenty microlitres 
reaction contained of 7µl of ddH2O, 4µl of 5X sequencing buffer, 2µl Big Dye terminator 
v3.1, 4µl of 5µM of either forward or reverse primer and 3µl of 50ng/µl purified PCR 
product was subjected to cycle sequencing reaction, which began with initial denaturation at 
96
0
C for 1 min. Then, it was followed by rapid thermal ramp (1
0
C/sec) at 96
0
C for 10 sec, 
50
0
C for 5 sec and 60
0
C for 4 min and this step was repeated for a total of 25 cycles. Samples 
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were held at 4
0
C before proceeding to ethanol/EDTA precipitation method for purification of 
the DNA from aqueous solution. Ethanol precipitation technique was explained in detail in 
3.2.3. The purified product was then placed in the ABI Prism 3100 Genetic Analyzer 
sequencer (Applied Biosystem, California, USA).  
 
3.2.4.2 Screening of PTGFR introns 
Majority of the screening work on PTGFR introns was conducted at the Department of 
Genetics, UCL Institute of Ophthalmology, UK with some additional work conducted in 
Human Genome Centre, Malaysia. The primers designed for introns 1 and 2 were prepared 
by 1stBASE, Singapore. The rest of the primers were prepared by Sigma Aldrich, UK. The 
primers prepared by Sigma Aldrich, UK were in dry format. The primers were centrifuged 
before adding purified water according to instruction, and centrifuged again. The stock 
primers were kept in -20°C.  For PCR amplification 1:20 primer concentration was used. In 
order to facilitate the screening of the large introns, premix extensor hi-fidelity PCR master 
mix (Thermo Scientific, ABgene, United Kingdom) with or without the dye (ReddyMix) was 
used. Ready to use master mix eliminated the need to thaw individual components, indirectly 
reduced the risk of contamination and pipetting errors. The premix contained buffer 2, which 
is recommended for longer than 12kb or problematic amplifications, 500µM of dNTPS, 
2.25mM magnesium chloride and 1.25U ThermoPrime plus Taq DNA polymerase. 
ThermoPrime has the ability to cause 5‟ to 3‟ polymerisation and exonuclease activity but 
lack of 3‟ to 5‟ exonuclease activity. A total reaction volume of 17µl, which contained 12µl 
of premix extensor hi-fidelity PCR, 4µl of 0.2µM forward and 0.2 µM reverse primers and 
1µl of genomic DNA was used for PCR amplicification. PCR amplification was done using 
Techne TC-500 thermal cycler (Techne, Burlington, USA) with predenaturation at 95°C for 5 
minutes, followed by 30 cycles of denaturation at 95°C for 30seconds, specific annealing 
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temperatures according to primers (table 3.3 and 3.4) and primary extension at 72°C at 1 
minute, and final extension at 72°C for 7 minutes. The presence of amplicons was determined 
by 2% gel electrophoresis. 
 
The amplicons were then purified using ExoSAP-IT (USB, Affymetrix, USA), which 
contains two hydrolytic enzymes; Exonuclease I and Shrimp Alkaline Phosphatase in a 
special formulated buffer. Exonuclease I removed residual single-stranded primers and any 
extraneous single-stranded DNA produced during PCR process, while Shrimp Alkaline 
Phosphatase removed the remaining dNTPs from the PCR product. One microliter of 
ExoSAP-IT reagent was added into 13.5µl of purified water and later added directly into 1µl 
of PCR product. The reaction mixture of 15µl in volume was incubated at 37°C for 15 
minutes and inactivated by heating at 80°C at 15 minutes in thermal cycler. The purified PCR 
product was then ready for cycle sequencing. 
 
The purified PCR product was used as template in cycle sequencing step. The forward and 
reverse primers were diluted into 10ng/µl from 100ng/µl in concentration by adding 9µl of 
purified water into 1µl of 100ng/µl primer dilution. One microliter of diluted 10ng/µl forward 
or reverse primer was then added into the whole volume of purified PCR product together 
with 0.5µl of Big Dye terminator v3.1 and 3.5µl of 5X sequencing buffer. Twenty microlitres 
of the reaction mixture was then subjected for 30 cycles of cycle sequencing reaction, which 
began with denaturation at 96°C for 30 seconds, annealing at 50°C for 30 seconds and 
primary extension at 60°C for 4 minutes.  
 
The cycle sequencing product was then subjected for multiwell unit purification procedure 
using gel filtration with Sephadex G-50 superfine beads (SigmaAldrich, Sweden). The 
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Sephadex plate was prepared prior to the procedure. A multiscreen 96 wells HV plate with 
durapore PVDF MSHVN 4550 (Millipore, USA), multiscreen column black loader plate 
MACL 09645 (Millipore, USA), sliding scraper and distilled water were used in this cleaning 
up procedure. The dry Sephadex beads were poured into the multiscreen column black loader 
plate and spreaded evenly using the sliding scraper. The sliding scraper was then slided on 
top of the column loader plate and tapped hard to ensure that the beads filled up each well 
evenly. The excess of resin was then removed. The multiscreen 96 wells HV plate with 
durapore MSHVN 4550 was then placed on top of the column black loader plate and inverted 
upside down. Adequate tapped was given to all side of the plate to ensure that all the beads 
have fallen into the wells of multiscreen plate. Once all the wells have already filled up with 
Sephadex beads and 350µl of distilled water was then pipette using multichannel pipetor into 
each well to expand the resin and referred as Sephadex plate. The Sephadex plate was then 
allowed to set for 30 minutes (can be left in the room temperature up to 3 hours) and ready to 
be used for sequencing reaction clean up. The plate can be wrapped with damp tissue and 
cling film to be used later. It is best to store in 4°C fridge for long term usage. 
 
The 96 wells collection plate was placed under the Durapore membrane of the pre-prepared 
Sephadex plate. For the plate that has been kept in the 4°C, 100µl of distilled water was 
added to each well. Each wells of the collection plate must be placed directly below the well 
of the pre-prepared Sephadex plate containing expanded resin. Both plates were then 
centrifuged at 910gm for 3 minutes. The excess liquid from the collecting plate was then 
discarded, the empty collecting plate was again placed under the Sephadex plate and 100µl of 
distilled water was then added into each well of the Sephadex plate. Both plates were than 
centrifuged again at 910gm for 5 minutes. The excess liquid in collecting plate must be of 
similar volume in all 96 wells before discarding them again. Finally, 10µl of sequencing 
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reaction volume was placed using multichannel pipetor at the centre of each well in the 
Sephadex plate and 12µl of distilled water was then added. A new 96 wells of PCR 
microplate with elevated skirt (Axygen, USA) was then placed under the Sephadex plate. A 
cellophane tap was placed to temporarily bind and aligned both plates and to ensure that each 
well was properly placed. Both plates were centrifuged again at 910gm for 5 minutes; the 
purified sequencing product collected in the PCR microplate was then ready to be loaded into 
the sequencer. ABI Prism 3730xl sequencer Genetic Analyzer (Applied Biosystem, 
California, USA) was used for sequencing. 
 
3.2.4.3 Screening for microsatellite instability (MSI) in Intron 3 of PTGFR 
Two areas of MSI or short tandem repeats (STRs) were identified within primer sequence of 
IVS 3-29 and IVS 3-53 while screening for polymorphisms in introns 3. MSI is a repeat in 
the number of due to defects in DNA repair. „CA‟ repeats are the commonest MSI, which 
was found in IVS 3-29 and „TA‟ repeats were found within the IVS3-53 sequence. Two 
forward primers were designed and chemically labelled with fluorescent dyes (6 FAM™) to 
amplify this region (Table 3.5).  The reverse primers were not labelled. Generally, the G and 
C content of the primers were designed between 50 to 55%, closely matched to melting 
temperature and not exceeding 18 bases. However, in both of the primers in our MSI, the G 
and C contents were less than 50%. Thus, the designed primers were extended to ensure the 
melting temperature was less than 45°C and minimized the chances of secondary 
hybridization. The G or C bases were designed not to exceed more than 2 in the last 5 bases 
at the 3‟ end of the primer to avoid mispriming. The primers used for amplification are given 
in Table 3.5. All primers were prepared by SigmaAldrich, UK.  
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Table 3.5: Primers sequence for MSI screening of IVS 3-29 and IVS 3-53 
Primer 
 
Sequence Size (bp) Ta°C 
IVS 3-29 MSI 5‟ (6FAM)ccactgcagcatttgtcattacag 3‟ 
5‟ ctaacatgcaatacatgctctg 3‟ 
120 57 
IVS 3-53 MSI 5‟ (6FAM) ctgaggctccagaactggaagtttatgcc 3‟ 
5‟ gggtaacagagttgagactctgtctc 3‟ 
289 60 
 
The primers were used at 100ng/ l.  Earlier attempt to use qPCR master mix (Finnzymes, 
Finland) for amplification of the genomic DNA failed, instead Reddy extensor hi-fidelity 
PCR master mix (ThermoScientific, Abgene, UK) was used and proven successful. The total 
reaction volume of 17µl that consisted of 12µl of premix extensor hi-fidelity PCR master 
mix, 2µl of 0.2µM FAM labelled forward primer, 2µl of 0.2µM reverse primer and 1µl of 
genomic DNA was used for PCR amplification. The amplification was done using the Techne 
TC-500 thermal cycler (Techne, Burlington, USA) with predenaturation at 96°C for 15 
minutes, followed by 30 cycles of denaturation at 96°C for 30seconds, annealing 
temperatures according to primers (table 3.5) for 30seconds and primary extension at 72°C at 
30seconds, and final extension at 72°C for 5 minutes. 
 
Passive reference dye Genesan™ROX™ 500(Applied Biosystem, USA) was used to label 
the reaction for quantitative analysis of MSI. The reference dye ROX™ 500 was diluted with 
high deionised Hi-Di™ formamide 1 in 50; 1000µl of HiDi formamide was added in every 
20µl of ROX™. The diluted reference dye was then added to the PCR product and subjected 
to heat denaturation at 95°C for 3 minutes before placing it on the ice for another 2 minutes. 
 
The reaction mixture was then loaded in the sequencer machine ABI 3730 for genotyping 
procedure. Analysis of quantification of MSI was done using Genemapper® 4.0 software. 
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Genemapper®4.0 is designed to identify peaks in predefined „bins‟ and ranges, where each 
bins represent a possible allele within a marker. 
 
3.2.4.4 Screening for polymorphisms in the PTGFR promoter region 
The promoter region of PTGFR gene was the most challenging part in screening of the entire 
PTGFR gene. After several fruitless attempts of DNA amplification, the amplification of the 
genomic DNA was eventually successful using KOD hot start DNA polymerase (Novagen®, 
Darmstadt, Germany). KOD hot start DNA polymerase is a premixed complex of high 
fidelity KOD DNA polymerase and two monoclonal antibodies that inhibit the DNA 
polymerase and 3‟-5‟ exonuclease activities at ambient temperature. KOD DNA polymerase 
contains enzyme produced by Thermoccus kodakaraensis that has the elongation capability 
of 106 to 138 bases per second and ability to extend more than 300 nucleotide bases in one 
catalytic reaction by one DNA polymerase molecule. It is ideal for amplification of difficult 
region and GC-rich target region. 
 
Primers were specifically designed to exceed 21 bases of 3‟ end complementary to the target 
sequence due to the strong activity 3‟5‟ exonuclease activity in KOD hot start DNA 
polymerase after thermoactivation. The G/C content of the designed primers was between 40 
to 60% to ensure better amplification result. Primers PRMLF3 and PRMR2 covered 3219 
base pairs upstream from exon 1 of PTGFR gene.   
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Table 3.6: Primers sequence for promoter region screening of PTGFR  
Primer Sequence 
 
Size (bp) Ta°C Notes 
PRMLF3 
PRMR2 
5‟ccctctctcatcactcgtattccacatag 3‟ 
5‟cagcctctggagggatggtaccttg 3‟ 
3219 60 PCR amplification 
PRMF4 5‟cacataggtagtggcaacattttac 3‟   Sequencing 
PRMLF1 5‟ctggaccccattccttataccttatac 3‟   Sequencing 
PRMSEQF1 5‟catagaaccaacccaaatgcccatc 3‟   Sequencing 
PRMLR4 5‟gcatagtttgaagtcaggtagcatgatg 3‟   Sequencing 
PRMLR3 5‟gctgaggatgatagcatccagg 3‟   Sequencing 
  
The final optimised concentration contained 0.1mM of dNTPs, 1mM of magnesium sulphate, 
0.12ml of 10X PCR buffer, 4U of KOD hot start DNA polymerase, 1.5µl of 0.15µM forward 
and reverse primers respectively and 100ng of genomic DNA in 25µl of total volume 
reaction. The PCR amplification was conducted with predenaturation at 95°C for 2 minutes, 
followed by 35 cycles of denaturation at 95°C for 15 seconds, annealing at 60°C for 
30seconds and primary extension at 72°C for 65seconds. Lastly, final extension at 72°C for 3 
minutes 20seconds.The duration of primary extension was based on 20seconds for every 
1000bases and final extension of 1 minute for every 1000bases. The amplicons were detected 
in 1% agarose gel. The PCR products were then sequenced as described in section 3.2.4.2. 
 
3.2.4.5 Statistical analysis 
The genotype findings for both genes were documented in SPSS PAWS 18.0. Analysis was 
conducted using SPSS PAWS 18.0 and STATA version 11.0. Allele frequency was 
calculated based on Hardy Weinberg equilibrium (HWE). HWE is the situation where, in 
large randomly mating population with a closed gene pool, the allele frequencies remain 
constant from generation to generation. Allele frequency is defined as the proportion of a 
particular type of allele to the total of all alleles at this genetic locus in a population. For 
example, the allele frequency of A in a population of AA (homozygous dominant), Aa 
(heterozygous) and aa (homozygous recessive), frequency of allele A is calculated as the 
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summation of frequency of homozygous AA times two and frequecncy of Aa, and divided by 
total allele (A and a) in the population. The inclusion of two subpopulation; Malays and 
Chinese in this present study may give rise population stratification. Genomic control 
analysis was used to detect the possibility of spurious associations or type-1 and type-2 errors 
due to confounding variables such as sex and race with polymorphisms and disease (Devlin 
and Roeder, 1999). Genomic control analysis is based on Bayesian outlier test as means of 
determining which markers exhibit significant linkage disequilibrium with the disorder 
without the need for Bonferroni correction for multiple tests (Devlin and Roeder, 1999). This 
analysis is recommended for analysing the possibility of a dense set of SNPs in susceptibility 
to complex disease such as glaucoma. The inflation factor λ was determined by selecting 
unrelated SNPs. The selected SNPs must not have vast different mutation rates, not strongly 
influenced by sub-population specific selection and vary greatly across loci (Chakraborty and 
Jin, 1992). 
 
Trend test was adopted to look into the trend of susceptibility of certain SNPs to glaucoma. 
Stratified meta-analysis was conducted to determine the possible association of allele 
frequency of each of the polymorphism found in ADRB2 and PTGFR between glaucoma and 
control subjects. The analysis was conducted separately between Malays and Chinese. 
Breslow-Day test for heterogeneity was used to identify the heterogeneity between the two 
ethnic groups (Ioannidis et al, 2001). Stratified Cochran Mantel-Haenszel analysis was then 
conducted to determine the possible increase or decrease susceptibility to glaucoma 
(Cochran, 1954; Armitage, 1955). Univariate logistic regression was conducted to determine 
the relationship of predictor variable including age, sex, race and polymorphisms found in 
each gene to the criterion variables; glaucoma versus control.  The „goodness of fit‟ of the 
final regression model was checked using the Hosmer- Lemeshow test.  Stepwise logistic 
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regression was then conducted to identify the SNPs that may confer protective or 
predisposition effect on susceptibility to glaucoma in Malaysian population. The final model 
was obtained using the likelihood ratio based on maximum likelihood estimate.  
 
Haploview programme (http://www.broad.mit.edu/mpg/haploview/) was used to determine 
the presence of haplotypes association between the identified polymorphisms as well as the 
HWE. The eligibility of SNPs to be considered for haplotypes analysis was based on HW p-
value >0.05, minimum minor allele frequency (MAF) of 0.1, maximum number of Mendel 
error of 1 and minimum included genotype of 75%. Quantification of MSI was further 
analysed using FAMHAP programme (http://www.meb.uni-bonn.de/famhap/) for single 
marker and possible haplotypes pairing. Global p-value was used in this programme, which 
combined multiple markers, sexes, 1000 mutations stimulation (Monte Carlo mutation) and 
Bonferroni correction of 2 (Becker et al, 2005). 
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3.3 Results 
3.3.1: ADRB2 (Project B)  
3.3.1.1 Demographic data 
A total of 97 glaucoma (60 Primary Open Angle Glaucoma and 37 Normal Tension 
Glaucoma patients) and 100 controls were recruited. There was no significant difference in 
age, sex and race characteristics between glaucoma patients and controls. The breakdown of 
the samples is given in table 3.7. 
 
Table 3.7 Demographic data of glaucoma patients and controls 
 Glaucoma 
N=97 
Control 
N=100 
p-value 
Age  
Mean (SD) 
Range 
 
 
64.1 (9.2) 
 
62.2 (9.2) 
 
0.134* 
Sex 
Male 
Female 
 
 
62 
35 
 
66 
34 
 
0.759# 
Race 
Malay 
Chinese 
 
 
66 
31 
 
57 
43 
 
0.110# 
p <0.05 is considered statistically significant based on *student t-test and #Pearson chi-square 
test. 
 
3.3.1.2 ADRB2 screening 
ADRB2 gene screening was successfully conducted in all samples. Figure 3.1 illustrated the 
gel electrophoresis picture of both duplex and triplex PCR outcome for a single glaucoma 
(B20) and control (C33) sample. The position of selected polymorphism is illustrated in 
Figure 3.2. 
178 
 
                      
                                      
 
 
Figure 3.1: Gel electrophoresis of multiplex PCR for ADRB2 in control and glaucoma 
patient 
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-20CC 
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Lane and size of PCR product 
 
Lane 1: Duplex PCR- 46A (179bp), -20C (114bp) 
Lane 2: Duplex PCR- 46G (179bp), -20T (114bp) 
Lane 3: Triplex PCR- 491C (624bp), 79C (212bp) 
Lane 4: Triplex PCR- -47T (86bp) 
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500bp 
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624bp 
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Figure 3.2: Schematic diagram of the position of SNPs found in ADRB2 
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BUP: beta upstream peptide 
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3.3.1.3 Genotype and allele frequency for ADRB2 between glaucoma and control 
subjects 
There was no significant difference of ADRB2 between glaucoma and control subjects (table 
3.8). There was no polymorphism present at in codon 491C/T in our population (all 491C). 
There was also no significant difference of allele frequency of polymorphisms in ADRB2 
between glaucoma and control subjects (table 3.9). 
 
Table 3.8 Genotype frequency of ADRB2 gene polymorphisms between glaucoma and 
control subjects 
Codon SNP Glaucoma 
N=97 
Control 
N=100 
LLA, p-
value 
 
46 rs1042713 
AA 
AG 
GG 
 
 
0.39 
0.57 
0.04 
 
0.28 
0.71 
0.01 
 
1.20, 
0.273 
79 rs1042714 
CC 
CG 
GG 
 
 
0.84 
0.13 
0.03 
 
0.71 
0.26 
0.03 
 
2.99, 
0.084 
491 rs1800888 
CC 
CT 
TT 
 
 
1.00 
 
1.00 
 
- 
-20 rs1801704 
TT 
TC 
CC 
 
 
0.11 
0.34 
0.55 
 
0.09  
0.21 
0.70 
 
3.39, 
0.066 
-47  rs1042711 
TT 
TC 
CC 
 
 
0.01 
0.10 
0.89 
 
0.03 
0.14 
0.83 
 
1.61, 
0.204 
p<0.05 is considered statistically significant difference based on linear-by-linear association 
(df=1). LLA: linear-by-linear association 
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Table 3.9: Allele frequency of ADRB2 polymorphisms between glaucoma and control 
subjects 
Codon SNPs Glaucoma 
N=97 
Control 
N=100 
χ2, p-
value 
 
46 rs1042713 
A 
G 
 
 
0.675 
0.325 
 
0.635 
0.365 
 
0.36, 
0.550 
79 rs1042714 
C 
G 
 
 
0.902 
0.098 
 
0.840 
0.160 
 
1.59, 
0.207 
491 rs1800888 
C 
T 
 
 
1.00 
 
1.00 
 
--- 
-20 rs1801704 
T 
C 
 
 
0.284 
0.716 
 
0.195 
0.805 
 
1.75, 
0.185 
-47 rs1042711 
T 
C 
 
0.062 
0.938 
 
 
0.100 
0.900 
 
1.09, 
0.297 
p <0.05 is considered statistically significant different based on Pearson chi-square test. 
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3.3.1.4 Allele frequency of ADRB2polymorphisms according to sex and ethnicity in the 
Malaysian population 
There was no significant effect of sex and ethnicity on allele frequency of ADRB2 
polymorphism at codon 46, 79, 491, -47 and -20 (table 3.10). However, genomic control 
analysis was not conducted due to small number of SNPs screened in this study.  
 
Table 3.10: Allele frequency of ADRB2 polymorphisms according to sex and ethnicity 
 
 
Codon 
 
 
SNP 
Sex 
 
Ethnicity 
 
Male 
N=128 
Female 
N=69 
χ2, p-
value 
Malay 
N=123 
Chinese 
N=74 
χ2, p-
value 
46 rs1042713 
A 
G 
 
0.648 
0.352 
 
0.667 
0.354 
 
0.13, 
0.717 
 
0.646 
0.354 
 
0.669 
0.331 
 
0.21, 
0.648 
79 rs1042714 
C 
G 
 
 
0.875 
0.125 
 
0.862 
0.138 
 
0.12, 
0.721 
 
0.841 
0.159 
 
0.919 
0.081 
 
3.03, 
0.082 
491 rs1800888 
C 
T 
 
1.000 
 
1.000 
 
1.000 
 
1.000 
 
1.000 
 
1.000 
-20 rs1801704 
T 
C 
 
 
0.246 
0.754 
 
0.225 
0.775 
 
0.23, 
0.634 
 
0.776 
0.224 
 
 
0.736 
0.264 
 
 
0.81, 
0.368 
-47 rs1042711 
T 
C 
 
 
0.086 
0.914 
 
 
0.072 
0.928 
 
 
0.22, 
0.640 
 
0.098 
0.902 
 
0.054 
0.946 
 
2.34, 
0.126 
P < 0.05 is considered statistically significant based on Pearson chi square test 
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3.3.1.5 The role of ADRB2 polymorphisms in susceptibility of glaucoma in Malays and 
Chinese 
Due to the possibility of population stratification, stratified Cochran Mantel-Haenszel meta-
analysis was conducted according race; Malays and Chinese. -47T/C and 491C/T were 
excluded from the univariate logistic regression. The major allele of 79C/G (p=0.037) and -
20T/C is associated with increased susceptibility to glaucoma (p=0.030) (table 3.11). The 
major allele of -20T/C and 79C/G increased the risk of glaucoma 1.7-fold and 1.9-fold 
respective as compared to controls. Further analysis using univariate logistic regression (age 
and sex was added), there was no significant association of ADRB2 and glaucoma (table 
3.12).  
Table 3.11: Stratified Mantel-Haenszel meta-analysis on ADRB2 polymorphisms and 
susceptibility to glaucoma 
  
 
 
SNPs 
Malays Chinese Stratified Meta-analysis 
 
Allele frequency Allele frequency OR 
(95%CI) 
SE P-meta P-het 
Glaucoma 
N=68 
Control 
N=57 
Glaucoma 
N=32 
Control 
N=43 
    
46 A/G 
A 
G 
 
 
0.654 
0.346 
 
0.632 
0.368 
 
0.710 
0.290 
 
0.640 
0.360 
 
1.21 
(0.79, 
1.84) 
 
0.21 
 
0.369 
 
0.654 
79C/G 
C 
G 
 
 
0.879 
0.121 
 
0.798 
0.202 
 
0.952 
0.048 
 
0.895 
0.105 
 
1.93 
(1.04, 
3.57) 
 
0.31 
 
0.037 
 
0.769 
491C/T 
C 
T 
 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
-- 
 
-- 
 
-- 
 
-- 
-20T/C 
T 
C 
 
 
0.265 
0.735 
 
 
0.175 
0.825 
 
 
0.323 
0.677 
 
 
0.221 
0.779 
 
 
1.69 
(1.05, 
2.71) 
 
0.24 
 
0.030 
 
0.984 
-47T/C 
T 
C 
 
 
0.076 
0.924 
 
0.123 
0.877 
 
0.032 
0.968 
 
0.070 
0.930 
 
0.55 
(0.26, 
1.17) 
 
0.39 
 
0.119 
 
0.769 
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OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
 
Table 3.12: Univariate logistic regression on predictors for glaucoma susceptibility in 
the Malaysian population 
 
Predictors OR SE 95% CI for OR p-value 
 
46A/G 
AA 
AG 
GG 
 
-- 
0.52 
1.44
 
 
-- 
0.34 
1.20 
 
-- 
0.27, 1.03 
0.14, 15.26 
 
-- 
0.059 
0.761 
 
79C/G 
CC 
CG 
GG 
 
 
-- 
0.43 
1.41 
 
-- 
0.53 
1.22 
 
-- 
0.15, 1.20 
0.13, 15.32 
 
-- 
0.107 
0.779 
-20T/C 
TT 
TC 
CC 
 
 
-- 
1.02 
0.39 
 
 
-- 
0.57 
0.55 
 
 
-- 
0.34, 3.10 
0.13, 1.15 
 
 
-- 
0.973 
0.088 
Sex 
Male 
Female 
 
0.93 
-- 
 
 
0.32 
-- 
 
0.50, 1.73 
-- 
 
0.811 
-- 
Age 
 
1.02 0.02 0.99, 1.05 0.243 
OR: odd ratio, CI: confidence interval 
The goodness of fit of this model was checked using the Hosmer-Lemeshow test; p=0.994. 
This result gives no evidence of lack of fit of the model. 
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3.3.1.6 The role of ADRB2 in susceptibility to POAG and NTG 
 
There was no evidence of heterogeneity based on Mantel-Haenszel analysis between Malays 
and Chinese (table 3.13). The minor allele of 79C/G (79G) reduced the risk of POAG 0.3 fold 
(95% CI 0.1, 0.7) compared to normal healthy volunteers (table 3.13). -20T increased the risk 
for NTG (OR 2.0[95%CI 1.1, 3.7]) (table 3.15). Age and sex were also included as the 
predictors for susceptibility to different type of glaucoma. 
 
Table 3.13: Stratified Mantel-Haenszel meta-analysis on ADRB2 and susceptibility to 
POAG 
 Malays Chinese Stratified Meta-analysis 
 
SNPs Allele frequency Allele frequency OR 
(95%CI) 
SE p-
meta 
p-het 
 POAG 
N=43 
Control 
N=57 
POAG 
N=17 
Control 
N=43 
    
46A/G 
A 
G 
 
 
0.686 
0.314 
 
0.632 
0.368 
 
0.706 
0.294 
 
0.640 
0.360 
 
0.77 
(0.47, 
1.25) 
 
0.25 
 
0.293 
 
0.911 
79C/G 
C 
G 
 
 
0.930 
0.070 
 
0.798 
0.202 
 
0.971 
0.029 
 
0.895 
0.105 
 
0.29 
(0.12, 
0.69) 
 
0.44 
 
0.005 
 
0.908 
491C/T 
C 
T 
 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
-- 
 
-- 
 
-- 
 
-- 
-20T/C 
T 
C 
 
 
0.256 
0.744 
 
 
0.175 
0.825 
 
 
0.265 
0.735 
 
 
0.221 
0.779 
 
 
1.48 
(0.86, 
2.56) 
 
0.28 
 
0.157 
 
0.679 
-47T/C 
T 
C 
 
 
0.047 
0.953 
 
0.123 
0.877 
 
0.000 
1.000 
 
0.070 
0.930 
 
3.72 
(1.21, 
11.48) 
 
0.58 
 
0.022 
 
0.348 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
 
 
186 
 
Table 3.14: Univariate logistic regression exploring the role of ADRB2 genotypes and 
other predictors in influencing risk of POAG prevalence relative to unaffected 
“normal” individuals 
Genotype OR SE 95% CI for OR 
LCI, UCI 
p-value 
79C/G 
CC 
CG 
GG 
 
 
-- 
0.24 
1.11 
 
-- 
0.70 
1.44 
 
-- 
0.06, 0.96 
0.07, 18.43 
 
 
-- 
0.044 
0.945 
-47T/C 
TT 
TC 
CC 
 
 
-- 
1.256e9 
9.626e8 
 
-- 
21918.72 
21918.72 
 
-- 
0.00 
0.00 
 
-- 
0.999 
0.999 
Sex 
Male 
Female 
 
1.01 
-- 
 
 
0.36 
-- 
 
0.50, 2.03 
-- 
 
0.987 
-- 
Age 
 
1.02 0.02 0.99, 1.06 0.208 
OR: odds ratio, CI: confidence interval, LCI: lower confidence interval, UCI: upper 
confidence interval.  
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.531. 
This result gives no evidence of lack of fit of the model. 
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Table 3.15: Stratified Mantel-Haenszel meta-analysis on ADRB2 and susceptibility to 
NTG 
          Malays       Chinese Stratified Meta-analysis 
 
SNPs   Allele frequency   Allele frequency OR 
(95%CI) 
SE p-
meta 
p-het 
 NTG 
N=23  
Control 
N=57 
NTG 
N=14 
Control 
N=43 
    
46A/G 
A 
G 
 
 
0.609 
0.391 
 
0.632  
0.368 
 
0.714 
0.286 
 
0.640 
0.360 
 
0.94 
(0.54, 
1.64) 
 
0.29 
 
0.814 
 
0.459 
79C/G 
C 
G 
 
 
0.783 
0.217 
 
0.798 
0.202 
 
0.929 
0.071 
 
0.895 
0.105 
 
0.97 
(0.47, 
2.03) 
 
0.38 
 
0.944 
 
0.575 
491C/T 
C 
T 
 
 
1.000 
    0 
 
1.000 
    0 
 
1.000 
    0 
 
1.000 
    0 
 
-- 
 
-- 
 
-- 
 
-- 
-20T/C 
T 
C 
 
 
0.283 
0.717 
 
 
0.175 
0.825 
 
 
0.393 
0.607 
 
 
0.221 
0.779 
 
 
2.03 
(1.11, 
3.70) 
 
0.31 
 
0.022 
 
0.736 
-47T/C 
T 
C 
 
 
0.130 
0.870 
 
0.123 
0.877 
 
0.071 
0.929 
 
0.070 
0.930 
 
0.94 
(0.40, 
2.26) 
 
0.45 
 
0.898 
 
0.965 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
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Table 3.16: Univariate logistic regression exploring the role of ADRB2 genotypes and 
other predictors in influencing risk of NTG prevalence relative to unaffected “normal” 
individuals 
 
 OR SE 95% CI for OR 
LCI, UCI 
p-value 
 
79C/G 
CC 
CG 
GG 
 
 
-- 
0.76 
0.90 
 
 
-- 
0.48 
0.99 
 
 
-- 
0.30, 1.96 
0.13, 6.27 
 
 
-- 
0.565 
0.914 
 
-20T/C 
TT 
TC 
CC 
 
 
-- 
2.70 
1.93 
 
 
-- 
0.45 
0.65 
 
 
-- 
1.12, 6.50 
0.69, 8.80 
 
 
-- 
0.027 
0.165 
 
Sex 
Male 
Female 
 
 
0.72 
-- 
 
0.41 
-- 
 
0.32, 1.60 
-- 
 
0.418 
-- 
Age 
 
1.02 0.02 0.97, 1.06 0.479 
OR: odd ratio, CI: confidence interval, LCI: lower confidence interval, UCI: upper 
confidence interval.  
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.500. 
This result gives no evidence of lack of fit of the model. 
 
3.3.1.7 Haplotypes analysis of ADRB2 
The possible haplotypes of ADRB2 gene was further analysed using haplotypes software; 
Haploview. 46A/G and -47T/C was excluded from the analysis due to statistically significant 
Hardy Weinberg equilibrium (HWE) for combination of Malay and Chinese (table 3.19). 
491C/T was also excluded due to minor allele frequency.  Haplotypes analysis was only 
assessed on 79C/G and -20T/C. There was 84% of association between 79C/G and -20T/C. 
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Table 3.17: Single marker check for ADRB2 polymorphisms based on Haploview 
analysis 
Codon Allele Observed Predicted HW 
p-value 
Minor allele 
Frequency 
 
Malays 
(N=123) 
-47 
-20 
46 
79 
491 
 
 
T/C 
T/C 
A/G 
C/G 
C 
 
 
 
0.146 
0.285 
0.642 
0.236 
0 
 
 
0.176 
0.347 
0.457 
0.267 
0 
 
 
 
0.080 
0.171 
6.791E-6 
0.312 
1.000 
 
 
 
0.098 
0.226 
0.354 
0.159 
0 
 
Chinese 
(N=74) 
-47 
-20 
46 
79 
491 
 
 
 
T/C 
T/C 
A/G 
C/G 
C 
 
 
 
0.081 
0.257 
0.635 
0.135 
0 
 
 
0.102 
0.388 
0.443 
0.149 
0 
 
 
0.009 
0.362 
2.0E-4 
0.768 
1.000 
 
 
0.054 
0.264 
0.331 
0.081 
0 
Both 
(N=197) 
-47 
-20 
46 
79 
491 
 
 
 
T/C 
T/C 
A/G 
C/G 
C 
 
 
0.122 
0.274 
0.640 
0.198 
0 
 
 
0.149 
0.363 
0.452 
0.225 
0 
 
 
0.001 
0.053 
1.531E-9 
0.163 
1.000 
 
 
0.081 
0.239 
0.345 
0.129 
0 
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3.3.2: PTGFR (Project P) 
3.3.2.1 Demographic data  
A total of 86 glaucoma (64 POAG and 22 NTG) and 90 unrelated control subjects were 
included in this study. There was no significant different between the glaucoma and control 
subjects in mean age at recruitment, sex and ethnicity (table 3.18). 
Table 3.18: Demographic data of glaucoma and control subjects 
 Glaucoma 
N=86 
Control 
N=90 
p-value 
Age 
Mean (SD) 
 
 
67.1 (9.2) 
 
64.5 (11.1) 
 
0.100* 
Sex 
Male 
Female 
 
 
60 
26 
 
62 
28 
 
0.899# 
Race 
Malay 
Chinese 
 
 
58 
28 
 
62 
28 
 
0.837# 
P<0.05 is considered significant based on *student t-test and # Pearson chi-square test 
 
3.3.2.2 PTGFR screening in the Malaysian population 
A total 63 SNPs were identified in the PTGFR gene including one novel polymorphism 
rs3766332 at the flanking region of exon 4 (figure 3.3). Only one SNP was found within the 
exon 4, rs3766331 (figure 3.3). The rest were intronic SNPs with a large number being 
detected at Intron 3 (47 SNPs). The example of the outcome of PTGFR gene screening of 
Introns 3 is illustrated in figure 3.4 and 3.6. The accidental finding of „CA‟ repeats, one of the 
areas of microsatellite instability (MSI), was noted on the electropherogram of IVS 3-29 
(figure 3.5) and further quantification was done using special tagged primer. The finding was 
illustrated in figure 3.8 and 3.9. A schematic diagram showing all the SNPs investigated is 
shown in figure 3.10 to 3.12. 
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Figure 3.3: Electropherogram of rs3766331 A/G found in the exon 4 of PTGFR gene and 
novel polymorphism rs3766332 A/T (rs3766332AT) found in Malaysian population 
rs3766331 
rs3766332 
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Figure 3.4: Electropherogram of primer IVS 3-45 of glaucoma patient (P18) showing 
rs11162504AA and rs11162505AA, and rs554173TC and rs554185AG. The position of 
rs11162504 and rs11162505 is just 18bp apart and 7bp apart between rs554173 and 
rs554185 
 
 
rs554173 
rs554185 
rs11162504 
rs11162505 
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Figure 3.5: Electropherogram of IVS 3-29 showing the presence of an area of MSI, 
formed by a CA repeat 
3.5A: overlapping spike at the beginning of CA repeat 
3.5B: a segment of readable CA repeats followed by unreadable sequence towards the end  
 
A 
B 
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Figure 3.6: Electropherogram of IVS 3-55 of glaucoma patient (P52) showing 
rs501078TT, rs3766335GA and rs7543738CG. 
 
 
 
 
rs501078 
rs3766335 
rs7543738 
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Figure 3.7: Electropherogram of promoter region PRM LR3 primer showing 
rs12093097CT in glaucoma patient (P50) 
 
 
rs12093097 
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Figure 3.8: Genotyping result of MSI at IVS 3-29 showing of deletion of certain part of 
MSI 
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Figure 3.9: Genotyping of IVS 3-56 MSI using capillary electrophoresis showing 
insertion of MSI 
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Figure 3.10: Distribution of SNPs found in the promoter, Intron 1 and Intron 2 of PTGFR in the Malaysian population 
 
EXON 1 EXON 2    EXON 3 
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Figure 3.11: Distribution of SNPs found in part of Intron 3 of PTGFR in the Malaysian population 
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                 Novel SNP 
 
Figure 3.12: Distribution of SNPs in the last part of Intron 3 and Exon 4 of PTGFR  
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3.3.2.3: Genotype and allele frequency of SNPs found in PTGFR gene in the Malaysian 
population 
There was significant difference in genotype and allele frequency of rs11162505 and 
rs554185 between glaucoma cases and control subjects (table 3.19). The homozygous wild 
state in all significant SNPs increased the apparent susceptibility to glaucoma (table 3.19).  
Table 3.19: Genotyping and allele frequency of SNPs found in PTGFR gene in the 
Malaysian population 
SNPs                     Genotype frequency 
 
                       Allele frequency 
 Glaucoma 
N=86 
Control 
N=90 
LLA, 
p-
value* 
 Glaucoma 
N=86 
Control 
N=90 
χ2 
, p-
value# 
         
         
rs3766331 AA 
AG 
GG 
 
60 (69.8) 
23 (26.7) 
 3  ( 3.5) 
59 (65.6) 
25 (27.8) 
6 (6.7) 
0.15, 
0.696 
A 
G 
0.833 
0.167 
0.794 
0.206 
0.52, 
0.471 
rs3766355 CC 
CA 
AA 
 
25 (29.1) 
42 (48.8) 
19 (22.1) 
 
28 (31.1) 
45 (50.0) 
17 (18.9) 
 
0.24, 
0.622 
C 
A 
0.535 
0.465 
0.561 
0.439 
0.08, 
0.776 
rs3766353 GG 
GT 
TT 
 
51 (59.3) 
26 (30.2) 
 9  (10.5) 
 
45 ( 50.0) 
37 (41.1) 
8 (8.9) 
0.59 
0.441 
G 
T 
0.744 
0.256 
0.706 
0.294 
0.23, 
0.635 
rs35978825 CC 
CT 
TT 
 
71 (82.6) 
14 (16.3) 
1 (1.1) 
72 (80.0) 
17 (18.9) 
1 (1.1) 
0.15, 
0.698 
C 
T 
0.907 
0.093 
0.894 
0.106 
0.22, 
0.637 
rs1830673 AA 
AG 
GG 
 
14 (16.3) 
43 (50.0) 
29 (36.4) 
 
14 (15.6) 
41 (45.6) 
35(38.9) 
 
0.32, 
0.574 
A 
G 
0.413 
0.587 
0.383 
0.617 
0.19, 
0.664 
rs3766351 TT 
TC 
CC 
 
70 (81.4) 
 9 (10.5) 
   7 (8.1) 
 
74 (82.2) 
9 (10.0) 
7 (7.8) 
 
0.02, 
0.895 
T 
C 
0.866 
0.134 
0.872 
0.128 
0.00, 
1.000 
rs1555541 TT 
TC 
CC 
 
15 (17.4) 
25 (29.1) 
 46 (53.5) 
 
14 (15.6) 
33 (36.7) 
43(47.8) 
 
0.12, 
0.734 
T 
C 
0.320 
0.680 
0.339 
0.661 
0.09, 
0.764 
rs10489785 AA 73 (84.9) 74 (82.2) 0.28, A 0.913 0.894 0.22, 
214 
 
AT 
TT 
11 (12.8) 
  2  (2.23) 
13 (14.4) 
3 (3.3) 
 
0.599 T 0.087 0.106 0.637 
rs12094298 CC 
CA 
AA 
78 (90.7) 
6 (7.0) 
2 (2.3) 
 
 
79 (87.8) 
9 (10.0) 
2 (2.2) 
0.22, 
0.641 
C 
A 
0.942 
0.058 
0.928 
0.072 
0.08, 
0.774 
rs34077564 AA 
AG 
GG 
 
73 (84.9) 
9 (10.5)                  
4 (4.7) 
 
75 (83.3) 
9 (10.0) 
6 (6.7) 
 
 
0.06, 
0.803 
A 
G 
0.872 
0.128 
0.883 
0.117 
0.05, 
0.831 
rs35123627 CC 
CT 
TT 
 
73 (84.9) 
11 (12.8) 
2 (2.3) 
 
76 (84.4) 
11 (12.2) 
3 (3.3) 
 
0.05, 
0.833 
C 
T 
0.913 
0.087 
0.906 
0.094 
0.00, 
1.000 
rs2146489 AA 
AG 
GG 
 
10 (11.6) 
45 (52.3) 
31 (36.1) 
 
19 (21.1) 
44 (48.9) 
27 (30.0) 
 
2.26, 
0.133 
A 
G 
0.378 
0.622 
0.456 
0.544 
1.31, 
0.252 
rs2057424 AA 
AG 
GG 
48 (55.8) 
21 (24.4) 
17 (19.8) 
 
43 (47.8) 
23 (25.6) 
24 (26.7) 
 
1.46, 
0.227 
A 
G 
0.680 
0.320 
0.606 
0.394 
1.07, 
0.301 
rs15101588 GG 
GA 
AA 
 
23 (26.7) 
44 (51.2) 
19 (22.1) 
 
24 (26.7) 
42 (46.7) 
24 (26.7) 
 
0.19, 
0.667 
G 
A 
0.523 
0.477 
0.500 
0.500 
0.18, 
0.671 
rs34528585 TT 
TA 
AA 
 
72 (83.7) 
12 (14.0) 
2 (2.3) 
77 (85.6) 
11 (12.2) 
2 (2.2) 
 
0.09, 
0.769 
T 
A 
0.907 
0.093 
0.917 
0.083 
0.06, 
0.800 
rs12044011 TT 
TA 
AA 
 
23 (26.7) 
45 (52.3) 
18 (21.0) 
 
29 (32.2) 
40 (44.4) 
21 (23.3) 
 
0.08, 
0.776 
T 
A 
 
0.529 
0.471 
0.544 
0.456 
0.02, 
0.887 
rs1322930 GG 
GA 
AA 
 
81 (94.2) 
4 (4.7) 
1 (1.1) 
82 (91.1) 
7 (7.8) 
1 (1.1) 
0.40, 
0.529 
G 
A 
0.965 
0.036 
0.95 
0.05 
0.52, 
0.470 
rs34852041 CC 
CT 
TT 
 
74 (86.0) 
11 (13.8) 
1 (1.2) 
72 (80.0) 
16 (17.8) 
2 (2.2) 
 
1.18, 
0.276 
C 
T 
0.924 
0.076 
0.889 
0.111 
0.52, 
0.469 
rs33994937 TT 
TC 
CC 
74 (86.0) 
11 (13.8) 
1 (1.2) 
72 (80.0) 
16 (17.8) 
2 (2.2) 
 
1.18, 
0.276 
T 
C 
0.924 
0.076 
0.889 
0.111 
0.52, 
0.469 
rs6424776 TT 24 (27.9) 23 (25.6) 0.78, T 0.547 0.500 0.50, 
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TC 
CC 
46 (53.5) 
16 (18.6) 
 
44 (48.9) 
23 (25.6) 
 
0.378 C 0.453 0.500 0.479 
rs72673925 TT 
TG 
GG 
71 (82.6) 
13 (15.1) 
2 (2.3) 
75 (83.3) 
14 (15.6) 
1 (1.1) 
 
0.09, 
0.761 
T 
G 
0.901 
0.099 
0.911 
0.089 
0.22, 
0.637 
rs28832602 CC 
CT 
TT 
69 (80.3) 
15 (17.4) 
2 (2.3) 
75 (83.3) 
13 (14.4) 
2 (2.2) 
 
0.22, 
0.642 
C 
T 
0.890 
0.110 
0.906 
0.094 
0.22, 
0.637 
rs34572897 AA 
AG 
GG 
 
72 (83.7) 
12 (14.0) 
2 (2.3) 
75 (83.3) 
14 (15.6) 
1 (1.1) 
0.02, 
0.898 
A 
G 
0.907 
0.093 
0.911 
0.089 
0.06, 
0.809 
rs1590314 TT 
TC 
CC 
 
12 (14.0) 
42 (48.8) 
32 (37.2) 
 
12 (13.3) 
46 (51.1) 
32 (35.6) 
 
0.01, 
0.919 
T 
C 
0.384 
0.616 
0.389 
0.611 
0.02, 
0.884 
rs12058120 CC 
CG 
GG 
 
71 (82.6) 
 8 (9.3) 
7 (8.1) 
71 (78.9) 
17 (18.9) 
2 (2.2) 
0.08, 
0.781 
C 
G 
0.872 
0.128 
0.883 
0.117 
0.05, 
0.831 
rs12725125 GG 
GA 
AA 
 
71 (82.6) 
8 (9.3) 
7 (8.1) 
73 (81.1) 
15 (16.7) 
2 (2.2) 
 
0.31, 
0.577 
G 
A 
0.872 
0.128 
 
0.894 
0.106 
0.19, 
0.663 
rs4261075 AA 
AG 
GG 
 
16 (18.6) 
40 (46.5) 
30 (34.9) 
 
13 (14.4) 
43 (47.8 
34 (37.8) 
 
0.45, 
0.505 
A 
G 
0.419 
0.581 
0.383 
0.617 
0.33, 
0.564 
rs34012602 GG 
GT 
TT 
 
73 (84.9) 
11 (12.8) 
2 (2.3) 
 
75 (83.3) 
15 (16.7) 
0 (0) 
 
0.02, 
0.899 
G 
T 
0.911 
0.089 
0.917 
0.083 
0.22, 
0.637 
rs67351117 CC 
CT 
TT 
 
73 (84.9) 
10 (11.6) 
3 (3.5) 
75 (83.3) 
14 (15.6) 
1 (1.1) 
0.02, 
0.901 
C 
T 
0.907 
0.093 
0.911 
0.089 
 
0.00, 
1.000 
rs672561 TT 
TC 
CC 
 
74 (86.0) 
10 (11.6) 
2 (2.3) 
 
73 (81.1) 
15 (16.7) 
2 (2.2) 
0.52, 
0.472 
T 
C 
0.919 
0.081 
0.911 
0.089 
0.00, 
1.000 
rs12401416 GG 
GA 
AA 
24 (27.9) 
43 (50.0) 
19 (22.1) 
 
24 (26.7) 
45 (50.0) 
21 (32.2) 
 
0.05, 
0.816 
G 
A 
0.529 
0.471 
0.517 
0.483 
0.02, 
0.887 
rs6424778 CC 
CT 
TT 
77 (89.5) 
9 (10.5) 
0 (0) 
84 (93.3) 
6 (6.7) 
0 (0) 
0.81, 
0.368 
C 
T 
0.948 
0.052 
0.967 
0.033 
0.52, 
0.470 
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rs577333 TT 
TC 
CC 
9 (10.5) 
42 (48.0) 
35 (40.7) 
 
7 (7.8) 
44 (48.9) 
39 (43.3) 
 
0.31, 
0.579 
T 
C 
0.349 
0.651 
0.322 
0.678 
0.20, 
0.653 
rs520171 AA 
AC 
CC 
43 (50.0) 
40 (46.5) 
3 (3.5) 
47 (52.2) 
32 (35.6) 
11 (12.2) 
 
0.46, 
0.498 
A 
C 
0.733 
0.267 
0.700 
0.300 
0.22, 
0.638 
rs551253 GG 
GC 
CC 
 
57 (66.3) 
25 (29.1) 
4 (4.7) 
55 ( 61.1) 
17 (18.9) 
18 (20.0) 
 
3.68, 
0.055 
G 
C 
0.808 
0.192 
0.706 
0.294 
2.74, 
0.098 
rs552328 AA 
AG 
GG 
 
33 (38.4) 
40 (46.5) 
13 (15.1) 
 
31 (34.5) 
37 (41.1) 
22 (24.4) 
 
1.44, 
0.231 
A 
G 
0.616 
0.384 
0.550 
0.450 
1.01, 
0.315 
rs11162504 AA 
AG 
GG 
 
57 (66.3) 
25 (29.1) 
4 (4.7) 
56 (62.2) 
28 (31.1) 
6 (6.7) 
0.45, 
0.501 
A 
G 
0.808 
0.192 
0.778 
0.222 
0.28, 
0.599 
rs11162505 AA 
AG 
GG 
 
76 (87.4) 
 9 (10.5) 
1 (1.1) 
59 (65.5) 
25 (27.8) 
6 (6.7) 
12.62, 
<0.00
1* 
A 
G 
0.936 
0.064 
0.794 
0.206 
9.64, 
0.002 
rs554173 TT 
TC 
CC 
 
58 (67.4) 
24 (27.9) 
4 (4.7) 
54 (60.0) 
31 (34.4) 
5 (5.6) 
0.88, 
0.347 
T 
C 
0.814 
0.186 
0.772 
0.228 
0.71, 
0.401 
rs554185 AA 
AG 
GG 
 
37 (43.0) 
40 (46.5) 
 9 (10.5) 
31 (34.4) 
39 (43.3) 
20 (22.2) 
 
3.60, 
0.058* 
A 
G 
0.663 
0.337 
0.561 
0.439 
4.42, 
0.035 
rs556817 AA 
AG 
GG 
 
67 (77.9) 
15 (17.4) 
4 (4.7) 
 
57 (63.3) 
28 (31.1) 
5 (  5.5) 
3.19, 
0.074 
A 
G 
0.866 
0.134 
0.789 
0.211 
2.27, 
0.132 
rs473027 AA 
AG 
GG 
 
28 (32.6) 
43 (50.0) 
15 (17.4) 
 
29 (32.2) 
36 (40.0) 
25 (27.8) 
 
0.92, 
0.338 
A 
G 
0.576 
0.424 
0.522 
0.478 
0.73, 
0.394 
rs668005 CC 
CT 
TT 
 
36 (41.9) 
36 (41.9) 
14 (16.2) 
 
30 (33.3) 
36 (40.0) 
24 (26.7) 
 
2.77, 
0.096 
C 
T 
0.628 
0.372 
0.533 
0.467 
2.05, 
0.152 
rs2146490 GG 
GA 
AA 
 
74 (86.0) 
10 (11.7) 
2 (2.3) 
76 (84.4) 
12 (13.3) 
2 (2.2) 
 
0.05, 
0.819 
G 
A 
0.919 
0.081 
0.856 
0.144 
1.84, 
0.175 
rs530871 GG 33 (38.4) 31 (34.4) 1.34, G 0.605 0.539 1.00, 
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GA 
AA 
 
38 (44.2) 
15 (17.4) 
 
35 (38.8) 
24 (26.7) 
 
0.247 A 0.395 0.461 0.317 
rs538275 GG 
GA 
AA 
 
32 (37.2) 
39 (45.3) 
15 (17.4) 
 
31 (34.4) 
35 (38.7) 
24 (26.7) 
 
1.12, 
0.290 
G 
A 
0.599 
0.401 
0.539 
0.461 
0.73, 
0.391 
rs589958 GG 
GA 
AA 
32 (37.2) 
39 (45.3) 
15 (17.4) 
 
30 (33.3) 
35 (38.7) 
25 (27.8) 
 
1.57, 
0.211 
G 
A 
0.599 
0.401 
0.528 
0.472 
1.00, 
0.318 
rs3766338 TT 
TC 
CC 
 
50 (58.1) 
30 (34.9) 
6 (7.0) 
52 (57.8) 
28 (31.1) 
10 (11.1) 
 
0.02, 
0.651 
T 
C 
0.756 
0.244 
0.733 
0.267 
0.24, 
0.626 
rs590309 TT 
TC 
CC 
 
32 (37.2) 
38 (44.2) 
16 (18.6) 
 
29 (32.2) 
36 (40.0) 
25 (27.8) 
 
1.55, 
0.214 
T 
C 
0.593 
0.407 
0.522 
0.478 
0.99, 
0.319 
rs622346 GG 
GC 
CC 
 
43 (50.0) 
36 (41.9) 
7 (8.1) 
43 (47.8) 
36 (40.0) 
11 (12.2) 
 
0.39, 
1.530 
G 
C 
0.709 
0.291 
0.678 
0.322 
0.21, 
0.645 
rs13374108 TT 
TA 
AA 
 
70 (81.4) 
15 (17.4) 
1 (1.2) 
67 (74.4) 
22 (24.4) 
1 (1.1) 
1.03, 
0.309 
T 
A 
0.901 
0.099 
0.867 
0.133 
0.44, 
0.506 
rs34012237 TT 
TC 
CC 
 
75 (87.2) 
 9 (10.5) 
2 (2.3) 
76 (84.4) 
12 (13.3) 
2 (2.2) 
0.17, 
0.681 
T 
C 
0.924 
0.076 
0.911 
0.089 
0.06, 
0.800 
rs33966768 TT 
TC 
CC 
 
74 (86.0) 
10 (11.6) 
2 (2.4) 
76 (84.4) 
12 (13.3) 
2 (2.2) 
0.05, 
0.819 
T 
C 
0.919 
0.081 
0.911 
0.089 
0.06, 
0.800 
rs501078 CC 
CT 
TT 
 
14 (16.3) 
39 (45.3) 
33 (38.4) 
 
12 (13.3) 
35 (38.9) 
43 (47.8) 
 
1.34, 
0.248 
C 
T 
0.390 
0.610 
0.328 
0.672 
1.07, 
0.301 
rs3766335 GG 
GA 
AA 
 
76 (88.4) 
 8 (9.3) 
2 (2.3) 
75 (83.3) 
13 (14.4) 
2 (2.2) 
0.58, 
0.446 
G 
A 
0.930 
0.070 
0.906 
0.094 
0.27, 
0.602 
rs7543738 CC 
CG 
GG 
 
78 (90.7) 
7 (8.1) 
1 (1.2) 
 
84 (93.3) 
5 (5.6) 
1 (1.1) 
0.30, 
0.584 
C 
G 
0.948 
0.052 
0.961 
0.039 
0.12, 
0.733 
rs686262 AA 
AG 
GG 
20 (23.3) 
37 (43.0) 
29 (33.7) 
14 (15.6) 
36 (40.0) 
40 (44.4) 
2.72, 
0.099 
A 
G 
0.448 
0.552 
0.356 
0.644 
1.68, 
0.195 
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rs4650581 TT 
TA 
AA 
 
73 (84.9) 
11 (12.8) 
2 (2.3) 
75 (83.3) 
11 (12.2) 
4 (4.4) 
0.26, 
0.608 
T 
A 
0.913 
0.087 
0.894 
0.106 
0.22, 
0.637 
rs3766332 AA 
AT 
TT 
47 (54.7) 
35 (38.9) 
4 (4.4) 
 
55 (61.1) 
28 (31.1) 
7 (7.8) 
0.13, 
0.719 
 
A 
T 
0.750 
0.250 
0.767 
0.233 
0.11, 
0.741 
rs3753380 TT 
TC 
CC 
9 (10.5) 
40 (46.5) 
37 (43.0) 
 
7 (7.8) 
40 (44.4) 
43 (47.8) 
 
0.59, 
0.444 
T 
C 
0.337 
0.663 
0.300 
0.700 
0.01, 
0.923 
rs12093097 CC 
CT 
TT 
52 (60.5) 
29 (33.7) 
5 (5.8) 
 
65 (72.2) 
22 (24.4) 
3 (3.3) 
 
2.71, 
0.100 
C 
T 
0.773 
0.227 
0.844 
0.156 
1.56, 
0.212 
rs1073610 GG 
GA 
AA 
53 (61.6) 
24 (27.9) 
9 (10.5) 
 
66 (73.3) 
18 (20.0) 
6 (6.7) 
2.55, 
0.110 
G 
A 
0.756 
0.244 
0.833 
0.167 
1.50, 
0.220 
rs1073611 AA 
AG 
GG 
54 (62.8) 
23 (26.7) 
9 (10.5) 
66 (73.3) 
18 (20.0) 
6 (6.7) 
 
2.19, 
0.139 
A 
G 
0.762 
0.238 
0.833 
0.167 
1.20, 
0.273 
LLA; linear by linear association *p<0.05 based on LLA, #p<0.05 based on Pearson chi-
square test 
 
 
3.3.2.4: The effect of population stratification on PTGFR in the Malaysian population  
To identify the effect of population stratification in this study, linear by linear association 
analysis was conducted on the genotype frequency of SNPs between Malays and Chinese 
recruited in this study. There was significant difference in genotype frequency between 
Malays and Chinese in 25SNPs identified in this study (table 3.20). 
However, after examining 16 unlinked SNPs in the vicinity of the gene, we observed no 
inflation of their test statistics (λ gc = 0.92), thus suggesting that the significant P-values 
observed within the gene are unlikely to be due to gross population stratification. Future, 
more detailed genotyping will be needed to exclude the possibility of cryptic population 
stratification. 
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Table 3.20: Allele frequency of SNPs found in PTGFR between Malays and Chinese 
SNPs Allele Malay 
N=120 
Chinese 
N=56 
χ2 p-value 
rs3766331 A 0.817 0.866 1.59 0.207 
 G 0.183 0.134   
      
rs3766353 G 0.758 0.652 2.91 0.088^ 
 T 0.242 0.348   
      
rs3766355 C 0.567 0.509 0.72 0.395 
 A 0.433 0.491   
      
rs35978825 C 0.888 0.929 0.98 0.323 
 T 0.112 0.071   
      
rs1830673 A 0.421 0.348 1.03 0.309 
 G 0.579 0.652   
      
rs3766351 T 0.842 0.929 3.98 0.046* 
 C 0.158 0.071   
      
rs1555541 T 0.321 0.348 0.20 0.653 
 C 0.679 0.652   
      
rs10489785 A 0.879 0.955 4.35 0.037* 
 T 0.121 0.045   
      
rs12094298 C 0.917 0.973 0.41 0.121 
 A 0.083 0.027   
      
rs34077564 A 0.854 0.929 3.27 0.071^ 
 G 0.146 0.071   
      
rs35123627 C 0.904 0.920 0.24 0.621 
 T 0.096 0.080   
      
rs2146489 A 0.454 0.339 2.53 0.112 
 G 0.546 0.661   
      
rs2057424 A 0.638 0.652 0.02 0.883 
 G 0.362 0.348   
      
rs15101588 G 0.521 0.491 0.18 0.617 
 A 0.479 0.509   
      
rs34528585 T 0.904 0.929 0.58 0.447 
 A 0.096 0.071   
      
rs12044011 T 0.550 0.509 0.32 0.571 
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 A 0.450 0.491   
      
rs1322930 G 0.954 0.964 0.12 0.733 
 A 0.045 0.036   
      
rs34852041 C 0.875 0.973 5.84 0.016* 
 T 0.125 0.027   
      
rs33994937 T 0.879 0.964 4.35 0.037* 
 C 0.121 0.036   
      
rs6424776 T 0.525 0.518 0.02 0.887 
 C 0.475 0.482   
      
rs72673925 T 0.888 0.946 2.45 0.118 
 G 0.112 0.054   
      
rs28832602 C 0.875 0.946 3.15 0.076^ 
 T 0.125 0.054   
      
rs34572897 A 0.888 0.955 3.53 0.060* 
 G 0.112 0.045   
      
rs1590314 T 0.380 0.402 0.08 0.772 
 C 0.620 0.598   
      
rs12058120 C 0.854 0.929 3.27 0.071^ 
 G 0.146 0.071   
      
rs12725125 G 0.863 0.929 2.61 0.106 
 A 0.137 0.071   
      
rs4261075 A 0.392 0.420 0.19 0.666 
 G 0.608 0.580   
      
rs34012602 G 0.892 0.964 3.53 0.060^ 
 T 0.108 0.036   
      
rs67351117 C 0.892 0.946 2.45 0.118 
 T 0.108 0.054   
      
rs672561 T 0.879 0.964 4.35 0.037* 
 C 0.121 0.036   
      
rs12401416 G 0.533 0.500 0.18 0.671 
 A 0.467 0.500   
      
rs6424778 C 0.963 0.946 0.42 0.516 
 T 0.037 0.054   
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rs577333 T 0.338 0.330 0.02 0.881 
 C 0.662 0.670   
      
rs520171 A 0.683 0.786 3.11 0.078^ 
 C 0.317 0.214   
      
rs551253 G 0.746 0.777 0.25 0.617 
 C 0.254 0.223   
      
rs552328 A 0.608 0.527 1.31 0.253 
 G 0.392 0.473   
      
rs11162504 A 0.792 0.795 0.03 0.361 
 G 0.208 0.205   
      
rs11162505 A 0.867 0.857 0.04 0.836 
 G 0.133 0.143   
      
rs554173 T 0.817 0.741 1.86 0.172 
 C 0.183 0.259   
      
rs554185 A 0.633 0.563 1.02 0.313 
 G 0.367 0.437   
      
rs556817 A 0.838 0.804 0.54 0.462 
 G 0.162 0.196   
      
rs473027 A 0.583 0.473 2.47 0.119 
 G 0.417 0.527   
      
rs668005 C 0.625 0.482 4.56 0.033* 
 T 0.375 0.518   
      
rs2146490 G 0.900 0.946 1.80 0.179 
 A 0.100 0.064   
      
rs530871 G 0.613 0.482 3.41 0.065^ 
 A 0.387 0.518   
      
rs538275 G 0.625 0.446 6.52 0.011* 
 A 0.375 0.554   
      
rs589958 G 0.613 0.455 4.52 0.033* 
 A 0.387 0.545   
      
rs3766338 T 0.808 0.607 8.68 0.003# 
 C 0.192 0.393   
      
rs590309 T 0.613 0.438 5.79 0.016* 
 C 0.387 0.562   
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rs622346 G 0.717 0.643 1.47 0.225 
 C 0.293 0.357   
      
rs13374108 T 0.900 0.848 1.29 0.257 
 A 0.100 0.152   
      
rs34012237 T 0.896 0.964 2.77 0.096^ 
 C 0.104 0.036   
      
rs33966768 T 0.892 0.964 2.77 0.096^ 
 C 0.108 0.036   
      
rs501078 C 0.371 0.330 0.35 0.553 
 T 0.629 0.670   
      
rs3766335 G 0.892 0.973 4.92 0.027* 
 A 0.108 0.027   
      
rs7543738 C 0.946 0.973 0.52 0.470 
 G 0.054 0.027   
      
rs686262 A 0.421 0.357 0.76 0.384 
 G 0.579 0.643   
      
rs4650581 T 0.883 0.946 2.45 0.118 
 A 0.117 0.054   
      
rs3766332 A 0.771 0.732 0.43 0.514 
 T 0.229 0.268   
      
rs3753380 T 0.341 0.268 1.16 0.282 
 C 0.659 0.732   
      
rs12093097 C 0.804 0.821 0.13 0.778 
 T 0.196 0.179   
      
rs1073610 G 0.788 0.813 0.13 0.724 
 A 0.112 0.187   
      
rs1073611 G 0.792 0.813 0.13 0.724 
 A 0.108 0.187   
      
p<0.1, *p<0.05, #p<0.01 based on Pearson chi-square test 
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3.3.2.5: The role of PTGFR on susceptibility to glaucoma in Malays and Chinese 
Gender and racial group were identified as factors that may influence the genotype frequency 
of SNPs in PTGFR. Based on linear by linear association and Mantel-Haenszel test, 
rs11162505, rs554185, rs551253, rs556817 and rs668005 were identified to significantly 
associate with glaucoma susceptibility in Malays (table 3.21 and 3.22). There was significant 
difference in genotype of rs11162505 between glaucoma and controls of Malay ethnicity 
(p=1.72E-4). 
 
Table 3.21: Linear by linear association analysis between genotype frequency of PTGFR 
and susceptibility to glaucoma in Malays and Chinese 
SNPs Malays 
 
Chinese 
Glaucoma 
N=58 
Control 
N=62 
LLA, p-
value 
Glaucoma 
N=28 
Control 
N=28 
LLA, p-value 
      
rs3766331 AA 38(65.5) 39(62.9) 0.00, 0.952 22(78.6) 20(71.4) 0.08, 0.783 
 AG 18(31.0) 17(27.4)    5(17.9)   8(28.6)  
 GG 2(3.5) 6(9.7)     1(3.6)   0  
rs3766353 GG 38(67.7) 33(53.2) 1.35, 0.246 13(46.4) 12(42.9) 0.04, 0.851 
 GT 16(25.8) 24(38.7)    10(35.7)   13(46.4)  
 TT 4(6.5) 5(8.1)  5(17.9) 3(10.7)  
rs3766355 CC 18(31.0) 19(30.6) 0.01, 0.943   7(25.0)   9(32.1) 0.79, 0.373 
 CA 30(51.7) 32(53.2)   12(42.9)   13(46.4)  
 AA 10(17.2) 11(16.1)  9(32.1) 6(21.4)  
rs35978825 CC 46(79.3) 49(7.9) 0.00, 0.984 25(89.3) 23(82.1) 0.57, 0.449 
 CT 11(19.0) 12(19.4)    3(10.7)   3(10.7)  
 TT 1(1.7) 1(1.6)    0   0  
rs1830673 AA 10(17.2) 10(16.1) 1.91, 0.167   4(14.3)   4(14.3) 0.88, 0.348 
 AG 34(58.6) 27(43.5)  9(32.1) 14(50.0)  
 GG 14(24.1) 25(40.3)    15(53.6) 10(35.7)  
rs3766351 TT 45(77.6) 48(77.4) 0.01, 0.916 25(89.3) 26(92.9) 0.31, 0.580 
 TC 8(13.8) 8(12.9)    1(3.6)   1(3.6)  
 CC 5 (8.6) 6(9.7)    2(7.1)   1(3.6)  
rs1555541 TT 10(17.2) 7(11.3) 0.04, 0.842   5(17.9)   7(25.0) 0.69, 0.408 
 TC 18(31.0) 25(40.3)  7(25.0) 8(28.6)  
 CC 30(51.7) 30(48.4)    16(57.1)   13(46.4)  
rs10489785 AA 48(82.8) 48(77.4) 0.51, 0.477 25(89.3) 26(92.9) 0.22, 0.642 
 AT 8(13.8) 11(17.7)    3(10.7)   2(7.1)  
 TT 2(3.4) 3(4.8)    0   0  
rs12094298 CC 51 (89.7) 52(83.9) 0.45, 0.504 26(92.9) 27(96.4) 0.35, 0.556 
 CA 4 (6.9) 8(12.9)    2(7.1)   1(3.6)  
 AA 2 (3.4) 2(3.2)    0   0  
rs34077564 AA 48 (82.8) 49(79.0) 0.00, 0.981 25(89.3) 26(92.9) 0.31, 0.580 
 AG 3 (5.2) 8(12.9)    1(3.6)   1(3.6)  
 GG 7 (12.1) 5(8.1)    2(7.1)   1(3.6)  
rs35123627 CC 49(84.5) 52(83.9) 0.00, 0.964 24(85.7) 24(85.7) 0.10, 0.748 
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 CT 7(12.1) 8(12.9)     4(14.3)   3(10.7)  
 CC 2(3.4) 2(3.2)    0   1(3.6)  
rs2146489 AA 8(13.8) 16(25.8) 0.49, 0.483   2(7.1)   3(10.7) 2.83, 0.093^ 
 AG 34(58.6) 27(43.5)  11(39.3)   17(60.7)  
 GG 16(27.6) 19(30.6)  15(53.6) 8(28.6)  
rs2057424 AA 33(56.9) 26(41.9) 4.28, 0.038 15(53.6) 17(60.7) 0.59, 0.444 
 AG 17(29.3) 18(29.0)    4(14.3)   5(17.9)  
 GG 8(13.8) 18(29.0)    9(32.1)   6(21.4)  
rs1510158840 GG 16(27.6) 16(25.8) 0.17, 0.681   7(25.0)   8(28.6) 0.03, 0.859 
 GA 30(51.7) 31(50.0)    14(50.0)   11(39.3)  
 AA 12(20.7) 15(24.2)  7(25.0) 9(32.1)  
rs34528585 TT 48(82.8) 52(83.9) 0.00, 0.963 24(85.7) 25(89.3) 0.44, 0.505 
 TA 9(15.5) 8(12.9)    3(10.7)    3(10.7)  
 AA 1(1.7) 2(3.2)    1(3.6)   0  
rs12044011 TT 15(25.9) 20(32.3) 0.05, 0.832   8(28.6)   9(32.1) 0.03, 0.863 
 TA 33(8.9) 29(46.8)    12(42.9)   11(39.3)  
 AA 10(17.2) 13(21.0)  8(28.6) 8(28.6)  
rs1322930 GG 55(94.8) 55(88.7) 1.78, 0.182 26(92.9) 27(96.4) 0.69, 0.407 
 GA 3(5.2) 6(9.7)    1(3.6)    1(3.6)  
 AA 0 1(1.6)    1(3.6)   0  
rs34852041 CC 47(81.0) 46(74.2) 0.87, 0.351 27(96.4) 26(92.9) 0.35, 0.556 
 CT 10(17.2) 14(22.6)    1(3.6)   2(7.1)  
 TT 1(1.7) 2(3.2)     0    0  
rs33994937 TT 48(82.8) 46(74.2) 1.29, 0.256 26(92.9) 26(92.9) 0.00, 1.000 
 TC 9(16.5) 14(22.6)    2(7.1)   2(7.1)  
 CC 1(1.7) 2(3.2)    0   0  
rs6424776 TT 16(27.6) 15(24.2) 1.20, 0.274   8(28.6)   8(28.6) 0.00, 1.000 
 TC 33(56.9) 31(50.0)    13(46.4)   13(46.4)  
 CC 9(15.5) 16(25.8)  7(25.0) 7(25.0)  
rs72673925 TT 47(81.0) 49(79.0) 0.00, 0.985 24(85.7) 26(92.9) 0.73, 0.392 
 TG 9(15.5) 12(19.4)    4(1.3)   2(7.1)  
 GG 2(3.4) 1(1.6)    0   0  
rs28832602 CC 45(77.6) 49(79.0) 0.03, 0.857 24(85.7) 26 (92.9)   0.73, 0.392 
 CT 11(19.0) 11(17.7)    4(14.3)   2(7.1)  
 TT 2(3.4) 2(3.2)    0   0  
rs34572897 AA 47(81.0) 49(79.0) 0.00, 0.985 25(89.3) 26(92.9) 0.22, 0.642 
 AG 9(15.5) 12(19.4)    3(10.7)   2(7.1)  
 GG 2(3.4) 1(1.6)    0   0  
rs1590314 TT 7(12.1) 7(11.3) 0.08, 0.774   5(17.90   5(17.9) 0.31, 0.580 
 TC 31(53.4) 32(51.6)  11(39.3)   14(50.0)  
 CC 20(34.5) 23(51.1)  12(42.9) 9(32.1)  
rs12058120 CC 47(81.0) 46(74.2) 0.00, 0.979 24(85.7) 25(89.3) 0.44, 0.505 
 CG 5(8.6) 14(22.6)    3(10.7)   3(10.7)  
 GG 6(10.3) 2(3.2)    1(3.6)   3(10.7)  
rs12725125 GG 47(81.0) 48(77.4) 0.11, 0.741 24(85.7) 25(89.3) 0.44,0.505 
 GA 5(8.6) 12(19.4)    3910.7)   3(10.7)  
 AA 6(10.3) 2(3.2)    1(3.6)   0  
rs4261075 AA 10(17.2) 7(11.3) 0.93, 0.335   6(21.4)   6(21.4) 0.03, 0.860 
 AG 29(50.0) 31(50.0)  11(39.3) 12(42.9)  
 GG 19(32.8) 24(38.7)  11(39.3) 10(35.7)  
rs34012602 GG 46(79.3) 50(80.6) 0.34, 0.563 27(96.4) 25(89.3) 1.06, 0.304 
 GT 10(17.2) 12(19.4)    1(3.6)   3(10.7)  
 TT 2(3.4) 0    2(7.1)   0  
rs67351117 CC 48(82.8) 49(79.0) 0.05, 0.826 25(89.3) 26(92.9) 0.53, 0.465 
 CT 8(13.8) 12(19.4)     2(7.1)   2(7.1)  
 TT 2(3.4) 1(1.6)    1(3.6)   0  
rs672561 TT 48(82.8) 47(75.8) 0.54, 0.463 26(92.9) 26(92.9) 0.00, 1.000 
 TC 8(13.8) 13(21.0)    2(7.1)   2(7.1)  
 CC 2(3.4) 2(3.2)    0   0  
rs12401416 GG 16(27.6) 16(25.8) 0.09, 0.762   8(28.6)   8(28.6) 0.00, 1.000 
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 GA 31(53.4) 30(53.2)    12(42.9)   12(42.9)  
 AA 11(19.0) 13(21.0)  8(28.6) 8(28.6)  
rs6424778 CC 54(93.1) 57(91.9) 0.06, 0.809 23(82.1) 27(96.4) 2.93, 0.087^ 
 CT 4(6.9) 5(8.1)    5(17.9)   1(3.6)  
 TT 0 0    0   0  
rs577333 TT 5(8.6) 4(6.5) 2.11, 0.147   4(14.3)   3(10.7) 0.93, 0.336 
 TC 34(58.6) 29(46.8)  8(28.6) 15(53.6)  
 CC 19(32.8) 29(46.8)    16(57.1) 10(35.7)  
rs520171 AA 26(44.8) 29(46.8) 0.24, 0.625 17(60.7) 18(64.3) 0.20, 0.655 
 AC 29(50.0) 25(40.3)   11(39.3)   7(25.0)  
 CC 3(5.2) 8(12.9)  0   3(10.7)  
rs551253 GG 39(67.2) 35(56.5) 4.76, 0.029 18(64.3) 20(71.4) 0.04, 0.851 
 GC 17(29.3) 14(22.6)    8(28.6)   3(10.7)  
 CC 2(3.4) 13(21.0)    2(7.1)   5(17.9)  
rs552328 AA 26(44.8) 23(37.1) 2.48, 0.116   7(25.0)   8(28.6) 0.04, 0.848 
 AG 25(43.1) 23(37.1)    15(53.6)   14(50.0)  
 GG 7(12.1) 16(25.8)  6(21.4) 6(21.4)  
rs11162504 AA 40(69.0) 37(59.7) 0.92, 0.337 17(60.7) 19(67.9) 0.05, 0.823 
 AG 15(25.9) 21(33.9)    10(35.7)   7(25.0)  
 GG 3(5.2) 4(6.5)  1(3.6) 2(7.1)  
rs11162505 AA 54(93.1) 38(61.3) 16.59,1.72E-
4 
22(78.6) 21(75.0) 0.23, 0.635 
 AG 4(6.9) 20(32.3)    5(17.9)   5(17.9)  
 GG 0(0) 4(6.5)    1(3.6)   2(7.1)  
rs554173 TT 42(72.4) 39(62.9) 0.54, 0.463 16(57.1) 15(53.6) 0.400, 0.526 
 TC 13(22.4) 21(33.9)    11(39.3)   10(35.7)  
 CC 3(5.2) 2(3.2)  1(3.6) 3(10.7)  
rs554185 AA 29(50.0) 23(37.1) 4.56, 0.033   8(28.6)   8(28.6) 0.04, 0.840 
 AG 24(41.4) 24(38.7)    16(57.1)   15(53.6)  
 GG 5(8.6) 15(24.2)  4(14.3) 5(17.9)  
rs556817 AA 47(81.0) 39(62.9) 2.57, 0.109 20(71.4) 18(64.3) 0.74, 0.391 
 AG 8(13.8) 21(33.9)    7(25.0)   7(25.0)  
 GG 3(5.2) 2(3.2)    1(3.6)   3(10.7)  
rs473027 AA 22(37.9) 22(35.5) 1.75, 0.186   6(21.4)   7(25.0) 0.03, 0.854 
 AG 29(50.0) 23(37.1)    14(50.0)   13(46.4)  
 GG 7(12.1) 17(27.4)  8(28.6) 8(28.6)  
rs668005 CC 30(51.7) 23(37.1) 4.19, 0.041   6(21.4)   7(25.0) 0.00, 1.000 
 CT 21(36.2) 23(37.1)    15(53.6)   13(46.4)  
 TT 7(12.1) 16(25.8)  7(25.0) 8(28.6)  
rs2146490 GG 50(86.2) 50(80.6) 0.37, 0.541 24(85.7) 26(92.9) 0.73, 0.392 
 GA 6(10.3) 10(16.1)    4(14.3)   2(7.1)  
 AA 2(3.4) 2(3.2)    0   0  
rs530871 GG 27(46.6) 24(38.7) 2.78, 0.095   6(21.4)   7(25.0) 0.00, 1.000 
 GA 24(41.4) 21(33.9)    14(50.0)   14(50.0)  
 AA 7(12.1) 17(27.4)  8(28.6) 7(25.0)  
rs538275 GG 26(44.8) 25(40.3) 1.86, 0.172   6(21.4)   6(21.4) 0.00, 1.000 
 GA 26(44.8) 22(33.5)    13(46.4)   13(46.4)  
 AA 6(10.4) 15(24.2)  9(32.1) 9(32.1)  
rs589958 GG 26(44.8) 24(38.7) 2.10, 0.147   6(21.4)   6(21.4) 0.03, 0.853 
 GA 25(43.1) 22(35.5)    14(50.0)   13(46.4)  
 AA 7(12.1) 16(25.8)  8(28.6) 9(32.1)  
rs3766338 TT 42(72.4) 38(61.3) 1.76, 0.184   8(28.6) 14(50.0) 0.53, 0.465 
 TC 14(24.1) 20(32.3)    16(57.1)   8(28.6)  
 CC 2(3.4) 4(6.5)  4(14.3)   6(21.4)  
rs590309 TT 27(46.6) 23(37.1) 3.75, 0.053^   5(17.9)   6(21.4) 0.31, 0.575 
 TC 25(43.1) 22(35.5)  13(46.4)   14(50.0)  
 CC 6(10.3) 17(27.4)  10(35.7) 8(28.6)  
rs622346 GG 33(56.9) 31(50.0) 0.61, 0.435 10(35.7) 12(42.9) 0.00, 1.000 
 GC 20(34.5) 24(38.7)  16(57.1)   12(42.9)  
 CC 5(8.6) 7(11.3)  23(7.1) 4(14.3)  
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rs13374108 TT 50(86.2) 47(75.8) 2.43, 0.119 20(71.4) 20(71.4) 0.07, 0.790 
 TA 8(13.8) 14(22.6)    7(25.0)    8(28.6)  
 AA 0 1(1.6)    1(3.6)    0  
rs34012237 TT 49(84.5) 40(80.6) 0.168,0.682 26(92.9) 26(92.9) 0.00, 1.000 
 TC 7(12.1) 10(16.1)    2(7.1)   2(7.1)  
 CC 2(3.4) 2(3.2)    0   0  
rs33966768 TT 48(82.8) 50(80.6) 0.05, 0.832 26(92.9) 26(92.9) 0.00, 1.000 
 TC 8(13.8) 10(16.1)    2(7.1)   2(7.1)  
 CC 2(3.4) 2(3.2)     0   0  
rs501078 CC 11(19.0) 8(12.9) 1.03, 0.309    3(10.7)   4(14.3) 0.33, 0.564 
 CT 25(43.1) 26(41.9)  14(50.0) 9(32.1)  
 TT 22(37.9) 28(45.2)  11(39.3) 15(53.6)  
rs3766335 GG 49(84.5) 49(79.0) 0.34, 0.558 27(96.4) 26(92.9) 0.35, 0.556 
 GA 7(12.1) 11(17.7)    1(3.6)   2(7.1)  
 AA 2(3.4) 2(3.2)    0   0  
rs7543738 CC 51(87.9) 58(93.5) 0.75, 0.386 27(96.4) 26(92.9) 0.35, 0.556 
 CG 6(10.3) 3(4.8)    1(3.6)   2(7.1)  
 GG 1(1.7) 1(1.6)    0   0  
rs686262 AA 15(25.9) 10(16.1) 1.62, 0.204   5(17.9)   4(14.3) 1.20, 0.273 
 AG 24(41.4) 27(43.5)  13(46.4) 9(32.1)  
 GG 19(32.8) 25(40.3)  10(35.7) 15(53.6)  
rs4650581 TT 48(82.8) 50(80.6) 0.28, 0.597 25(89.3) 25(89.3) 0.00, 1.000 
 TA 8(13.8) 8(12.9)    3(10.7)   3(10.7)  
 AA 2(3.4) 4(6.2)    0   0  
rs3766332 AA 35(60.3) 38(61.3) 0.579, 0.447 12(42.9) 17(60.7) 03.15, 0.076 
 AT 22(37.9) 17(27.4)    13(46.4)   11(39.3)  
 TT 1(1.7) 7(11.3)  3(10.7) 0  
rs3753380 TT 6(10.3) 5(8.1) 2.38, 0.123   3(10.7)   2(7.1) 0.66, 0.418 
 TC 33(56.9) 27(43.5)  7(25.0) 13(46.4)  
 CC 21(39.9) 30(48.4)    18(64.3) 13(46.4)  
rs12093097 CC 32(55.2) 47(75.8) 3.86, 0.049 20(71.4) 18(64.3) 0.001, 1.000 
 CT 23(39.7) 12(19.4)    6(21.4)    10(35.7)  
 TT 3(5.2) 3(4.8)    2(7.1) 0  
rs1073610 GG 32(55.2) 48(77.4) 4.18, 0.041 21(75.0) 18(64.3) 0.05, 0.829 
 GA 20(34.5) 9(14.5)    4(14.3)   9(32.1)  
 AA 6(10.3) 5(8.1)    3(10.7)   1(3.6)  
rs1073611 GG 33(56.9) 48(77.4) 3.62, 0.057^ 21(75.0) 18(64.3) 0.05, 0.827 
 GA 19(32.8) 9(14.5)    4(14.3)   9(32.1)  
 AA 6(10.3) 5(8.1)    3(10.7)   1(3.6)  
P<0.05 based on linear-by-linear association analysis (LLA), df=1 
 
There was statistically significant difference of allele frequency of rs11162505 and 
rs2057424 between the Malays and Chinese based on Breslow-Day test for homogeneity 
(table 3.22), suggesting significant population stratification. The minor allele for rs11162505 
(OR 0.3 [95% CI 0.1, 0.5]), rs554185 (OR 0.7 [95% CI 0.4, 1.0) and rs551253 (OR 0.6 [95% 
CI 0.4, 0.9]) is associated with decrease susceptibility to glaucoma in Malays (table 3.22). 
 
227 
 
Table 3.22: Stratified Mantel-Haenszel meta-analysis on PTGFR and susceptibility to 
glaucoma in Malays and Chinese 
            Malays           Chinese              Stratified meta-analysis 
 
SNPs Allele frequency Allele frequency OR SE P-meta P-Het 
 Glaucoma 
N=58 
Control 
N=62 
Glaucoma 
N=28 
Control 
N=28 
    
rs3766331 
A 
G 
 
0.810 
0.190 
 
0.766 
0.234 
 
0.875 
0.125 
 
0.857 
0.143 
 
0.79 
(0.46, 
1.35) 
 
0.28 
 
0.388 
 
0.862 
rs3766353 
G 
T 
 
0.793 
0.207 
 
 
0.726 
0.274 
 
0.643 
0.357 
 
0.661 
0.339 
 
0.82 
(0.51, 
1.31) 
 
0.24 
 
0.397 
 
0.369 
rs3766355 
C 
A 
 
0.569 
0.431 
 
0.565 
0.435 
 
0.464 
0.536 
 
0.554 
0.446 
 
 
1.11 
(0.73, 
1.69) 
 
0.21 
 
0.632 
 
0.414 
rs35978825 
C 
T 
 
0.888 
0.112 
 
0.887 
0.113 
 
0.946 
0.054 
 
0.875 
0.054 
 
0.98 
(0.48, 
2.01) 
 
0.37 
 
0.953 
 
0.940 
rs1830673 
A 
G 
 
0.466 
0.534 
 
0.379 
0.621 
 
0.304 
0.696 
 
0.393 
0.607 
 
0.88 
(0.58, 
1.35) 
 
0.22 
 
0.559 
 
0.115 
rs3766351 
T 
C 
 
0.845 
0.155 
 
0.839 
0.161 
 
0.911 
0.089 
 
0.946 
0.054 
 
1.07 
(0.57, 
1.99) 
 
0.32 
 
0.840 
 
0.473 
rs1555541 
T 
C 
 
0.328 
0.672 
 
0.315 
0.685 
 
0.304 
0.696 
 
0.393 
0.607 
 
1.09 
(0.70, 
1.70) 
 
0.23 
 
0.697 
 
0.348 
rs10489785 
A 
T 
 
0.897 
0.103 
 
0.863 
0.137 
 
 
0.946 
0.054 
 
0.964 
0.036 
 
0.82 
(0.40, 
1.67) 
 
0.37 
 
0.582 
 
0.458 
rs12094298 
C 
A 
 
0.931 
0.069 
 
0.903 
0.097 
 
0.964 
0.036 
 
 
0.982 
0.018 
 
0.80 
(0.34, 
1.89) 
 
0.44 
 
0.613 
 
0.402 
rs34077564 
A 
G 
 
0.853 
0.147 
 
0.855 
0.145 
 
0.911 
0.089 
 
0.946 
0.054 
 
1.12 
(0.59, 
2.14) 
 
0.33 
 
0.728 
 
0.520 
rs35123627 
C 
T 
 
0.905 
0.095 
 
0.903 
0.097 
 
0.929 
0.071 
 
0.911 
0.089 
 
0.92 
(0.44, 
1.90) 
 
0.37 
 
0.819 
 
0.790 
rs2146489         
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A 
G 
0.431 
0.569 
0.476 
0.524 
0.268 
0.732 
0.411 
0.589 
1.37 
(0.90, 
2.10) 
0.22 0.147 0.335 
rs2057424 
A 
G 
 
0.716 
0.284 
 
0.565 
0.435 
 
0.607 
0.393 
 
0.696 
0.304 
 
0.73 
(0.47, 
1.12) 
 
0.22 
 
0.148 
 
0.028 
rs15101588 
G 
A 
 
0.534 
0.466 
 
0.508 
0.492 
 
0.500 
0.500 
 
0.482 
0.518 
 
0.91 
(0.60, 
1.38) 
 
0.21 
 
0.657 
 
0.940 
rs34528585 
T 
A 
 
0.905 
0.095 
 
0.903 
0.097 
 
0.911 
0.089 
 
0.946 
0.054 
 
1.13 
(0.54, 
2.37) 
 
0.38 
 
0.739 
 
0.511 
rs12044011 
T 
A 
 
0.543 
0.457 
 
0.556 
0.444 
 
0.500 
0.500 
 
0.518 
0.482 
 
1.06 
(0.70, 
1.62) 
 
0.21 
 
0.781 
 
0.970 
rs1322930 
G 
A 
 
0.974 
0.026 
 
0.935 
0.065 
 
0.946 
0.054 
 
0.982 
0.018 
 
0.69 
(0.24, 
1.98) 
 
0.54 
 
0.489 
 
0.101 
rs34852041 
C 
T 
 
0.897 
0.103 
 
0.855 
0.145 
 
0.982 
0.018 
 
0.964 
0.036 
 
0.62 
(0.30, 
1.30) 
 
0.38 
 
0.269 
 
0.802 
rs33994937 
T 
C 
 
0.905 
0.095 
 
0.855 
0.145 
 
0.964 
0.036 
 
0.964 
0.036 
 
0.66 
(0.32, 
1.38) 
 
0.38 
 
0.268 
 
0.658 
rs6424776 
T 
C 
 
0.560 
0.440 
 
0.492 
0.508 
 
0.518 
0.482 
 
0.518 
0.482 
 
0.83 
(0.55, 
1.26) 
 
0.21 
 
0.382 
 
0.549 
rs72673925 
T 
G 
 
0.888 
0.112 
 
0.887 
0.113 
 
0.929 
0.071 
 
0.964 
0.036 
 
1.14 
(0.55, 
2.34) 
 
0.37 
 
0.727 
 
0.444 
rs28832602 
C 
T 
 
0.871 
0.129 
 
0.879 
0.121 
 
0.929 
0.071 
 
0.964 
0.036 
 
1.21 
(0.60, 
2.42) 
 
0.36 
 
0.596 
 
0.496 
rs34572897 
A 
G 
 
0.888 
0.112 
 
0.887 
0.113 
 
0.946 
0.054 
 
0.964 
0.036 
 
1.07 
(0.51, 
1.92) 
 
0.37 
 
0.867 
 
0.670 
rs1590314 
T 
C 
 
0.388 
0.612 
 
0.371 
0.629 
 
0.375 
0.625 
 
0.429 
0.571 
 
1.02 
(0.67, 
1.57) 
 
0.22 
 
0.916 
 
0.529 
rs12058120 
C 
G 
 
0.853 
0.147 
 
0.855 
0.145 
 
0.911 
0.089 
 
0.946 
0.054 
 
1.12 
(0.59, 
2.14) 
 
0.33 
 
0.723 
 
0.520 
229 
 
rs12725125 
G 
A 
 
0.888 
0.112 
 
0.871 
0.129 
 
0.911 
0.089 
 
0.946 
0.054 
 
1.00 
(0.50, 
1.98) 
 
0.33 
 
0.987 
 
0.405 
rs4261075 
A 
G 
 
0.422 
0.578 
 
0.363 
0.637 
 
0.411 
0.589 
 
0.429 
0.571 
 
0.87 
(0.57, 
1.33) 
 
0.22 
 
0.505 
 
0.487 
rs34012602 
G 
T 
 
0.879 
0.121 
 
0.903 
0.097 
 
0.982 
0.089 
 
0.946 
0.054 
 
1.07 
(0.50, 
2.26) 
 
0.36 
 
0.408 
 
0.793 
rs67351117 
C 
T 
 
0.897 
0.103 
 
0.887 
0.113 
 
0.929 
0.071 
 
0.964 
0.036 
 
1.06 
(0.51, 
2.20) 
 
0.37 
 
0.872 
 
0.392 
rs672561 
T 
C 
 
0.897 
0.103 
 
0.863 
0.137 
 
0.964 
0.036 
 
0.964 
0.036 
 
0.76 
(0.37, 
1.57) 
 
0.37 
 
0.457 
 
0.770 
rs12401416 
G 
A 
 
0.543 
0.457 
 
0.500 
0.452 
 
0.500 
0.500 
 
0.500 
0.500 
 
0.95 
(0.63, 
1.44) 
 
0.21 
 
0.809 
 
0.868 
rs6424778 
C 
T 
 
0.966 
0.034 
 
0.960 
0.040 
 
0.911 
0.089 
 
0.982 
0.018 
 
1.59 
(0.56, 
4.57) 
 
0.54 
 
0.387 
 
0.137 
rs577333 
T 
C 
 
0.379 
0.621 
 
0.298 
0.702 
 
0.286 
0.714 
 
0.375 
0.625 
 
0.89 
(0.57, 
1.38) 
 
0.23 
 
0.597 
 
0.115 
rs520171 
A 
C 
 
0.698 
0.302 
 
0.669 
0.331 
 
0.804 
0.196 
 
0.768 
0.232 
 
0.86 
(0.54, 
1.37) 
 
0.24 
 
0.516 
 
0.884 
rs551253 
G 
C 
 
0.819 
0.181 
 
0.677 
0.323 
 
0.786 
0.214 
 
0.768 
0.232 
 
0.57 
(0.35, 
0.94) 
 
0.25 
 
0.027 
 
0.225 
rs552328 
A 
G 
 
0.664 
0.336 
 
0.556 
0.444 
 
0.518 
0.482 
 
0.536 
0.464 
 
0.76 
(0.49, 
1.16) 
 
0.22 
 
0.199 
 
0.257 
rs11162504 
A 
G 
 
0.819 
0.181 
 
0.766 
0.234 
 
0.786 
0.214 
 
0.804 
0.196 
 
0.83 
(0.50, 
1.39) 
 
0.26 
 
0.484 
 
0.446 
rs11162505 
A 
G 
 
0.966 
0.057 
 
0.774 
0.226 
 
0.875 
0.125 
 
0.839 
0.161 
 
0.27 
(0.13, 
0.54) 
 
0.36 
 
<0.001 
 
0.015 
rs554173 
T 
C 
 
0.836 
0.164 
 
0.798 
0.202 
 
0.768 
0.232 
 
0.714 
0.286 
 
0.77 
(0.46, 
 
0.27 
 
0.321 
 
0.962 
230 
 
1.29) 
rs554185 
A 
G 
 
0.706 
0.293 
 
0.565 
0.435 
 
0.571 
0.429 
 
0.554 
0.446 
 
0.65 
(0.42, 
1.00) 
 
0.22 
 
0.049 
 
0.241 
rs556817 
A 
G 
 
0.879 
0.121 
 
0.798 
0.202 
 
0.839 
0.161 
 
0.768 
0.232 
 
0.57 
(0.33, 
1.01) 
 
0.29 
 
0.055^ 
 
0.800 
rs473027 
A 
G 
 
0.629 
0.371 
 
0.540 
0.460 
 
0.464 
0.536 
 
0.482 
0.518 
 
0.80 
(0.52, 
1.22) 
 
0.22 
 
0.299 
 
0.341 
rs668005 
C 
T 
 
0.698 
0.302 
 
0.556 
0.444 
 
0.482 
0.518 
 
0.482 
0.518 
 
0.67 
(0.43, 
1.03) 
 
0.22 
 
0.065^ 
 
0.188 
rs2146490 
G 
A 
 
0.914 
0.086 
 
0.887 
0.113 
 
0.929 
0.071 
 
0.964 
0.036 
 
0.92 
(0.43, 
1.94) 
 
0.38 
 
0.818 
 
0.288 
rs530871 
G 
A 
 
0.672 
0.328 
 
0.556 
0.444 
 
0.464 
0.536 
 
0.500 
0.500 
 
0.76 
(0.49, 
1.16) 
 
0.22 
 
0.198 
 
0.170 
rs538275 
G 
A 
 
0.672 
0.328 
 
0.581 
0.419 
 
0.446 
0.554 
 
0.446 
0.554 
 
0.77 
(0.50, 
1.18) 
 
0.22 
 
0.230 
 
0.398 
rs589958 
G 
A 
 
0.664 
0.336 
 
0.565 
0.435 
 
0.464 
0.536 
 
0.446 
0.554 
 
0.74 
(0.48, 
1.13) 
 
0.22 
 
0.162 
 
0.452 
rs3766338 
T 
C 
 
0.845 
0.155 
 
0.774 
0.226 
 
0.571 
0.429 
 
0.643 
0.357 
 
0.87 
(0.53, 
1.42) 
 
0.25 
 
0.577 
 
0.136 
rs590309 
T 
C 
 
0.681 
0.319 
 
0.548 
0.452 
 
0.411 
0.589 
 
0.464 
0.536 
 
0.74 
(0.48, 
1.13) 
 
0.22 
 
0.162 
 
0.093^ 
rs622346 
G 
C 
 
0.741 
0.259 
 
0.694 
0.306 
 
0.643 
0.357 
 
0.643 
0.357 
 
0.86 
(0.54, 
1.35) 
 
0.23 
 
0.506 
 
0.628 
rs13374108 
T 
A 
 
0.931 
0.069 
 
0.871 
0.129 
 
0.839 
0.161 
 
0.857 
0.143 
 
0.71 
(0.36, 
1.37) 
 
0.34 
 
0.304 
 
0.229 
rs34012237 
T 
C 
 
0.905 
0.095 
 
0.726 
0.113 
 
0.964 
0.036 
 
0.964 
0.036 
 
1.28 
(0.59, 
2.76) 
 
0.39 
 
0.394 
 
0.719 
rs33966768 
T 
 
0.897 
 
0.887 
 
0.964 
 
0.964 
 
0.92 
 
0.39 
 
0.827 
 
0.929 
231 
 
C 0.103 0.113 0.036 0.036 (0.43, 
1.96) 
rs501078 
C 
T 
 
0.405 
0.595 
 
0.339 
0.661 
 
0.357 
0.643 
 
0.304 
0.696 
 
0.76 
(0.49, 
1.18) 
 
0.22 
 
0.223 
 
0.930 
rs3766335 
G 
A 
 
0.905 
0.095 
 
0.879 
0.121 
 
0.982 
0.018 
 
0.964 
0.036 
 
0.73 
(0.33, 
1.58) 
 
0.40 
 
0.420 
 
0.736 
rs7543738 
C 
G 
 
0.931 
0.069 
 
0.960 
0.040 
 
0.982 
0.018 
 
0.964 
0.036 
 
1.38 
(0.50, 
3.78) 
 
0.52 
 
0.535 
 
0.335 
rs686262 
A 
G 
 
0.466 
0.534 
 
0.379 
0.621 
 
0.411 
0.589 
 
0.304 
0.696 
 
0.68 
(0.44, 
1.04) 
 
0.22 
 
0.075^ 
 
0.811 
rs4650581 
T 
A 
 
0.897 
0.103 
 
0.871 
0.129 
 
0.946 
0.054 
 
0.946 
0.054 
 
0.82 
(0.40, 
1.67) 
 
0.37 
 
0.578 
 
0.788 
rs3766332 
A 
T 
 
0.793 
0.207 
 
0.750 
0.250 
 
0.661 
0.339 
 
0.804 
0.196 
 
1.09 
(0.67, 
1.78) 
 
0.25 
 
 
0.725 
 
 
0.064^ 
 
rs3753380 
T 
C 
 
0.388 
0.612 
 
0.298 
0.702 
 
0.232 
0.768 
 
0.304 
0.696 
 
0.84 
(0.54, 
1.31) 
 
0.23 
 
0.441 
 
0.132 
rs12093097 
C 
T 
 
0.750 
0.250 
 
0.855 
0.145 
 
0.821 
0.179 
 
0.821 
0.179 
 
1.59 
(0.93, 
2.72) 
 
0.27 
 
0.090^ 
 
0.255 
rs1073610 
G 
A 
 
0.724 
0.276 
 
0.847 
0.153 
 
0.821 
0.179 
 
0.804 
0.196 
 
1.61 
(0.96, 
2.72) 
 
0.27 
 
0.073^ 
 
0.137 
rs1073611 
G 
A 
 
0.733 
0.267 
 
0.847 
0.153 
 
0.821 
0.179 
 
0.804 
0.196 
 
1.56 
(0.93, 
2.64) 
 
0.27 
 
0.095^ 
 
0.159 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
 
Univariate logistic regression was then conducted on the selected SNPs, sex, and age at 
presentation on Malays and Chinese separately (table 3.23 and table 3.24). rs551253GC (OR 
7.1 [95% CI 1.0, 50.0]) and rs554185AG (OR 17.8 [95% CI 1.5, 213.7]) are found to increase 
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the susceptibility to glaucoma in Malays (table 3.23). Whereas, rs551253GC, rs554185AG 
and rs3766338TC showed association with glaucoma in Chinese (table 3.24). Chinese men 
were less susceptible to glaucoma compared to Chinese women (table 3.24). 
 
Table 3.23: Univariate logistic regression analysis on predictors for glaucoma 
susceptibility in Malays 
Predictors OR SE p-value 95% CI for OR 
(LCI, UCI) 
rs2146489 
AA 
AG 
GG 
 
-- 
4.19 
2.54 
 
-- 
0.75 
0.75 
 
-- 
0.057 
0.212 
 
-- 
0.96, 18.32 
0.59, 11.00 
rs551253 
GG 
GC 
CC 
 
-- 
7.08 
7.60 
 
-- 
0.99 
1.59 
 
-- 
0.050 
0.203 
 
-- 
1.00, 50.02 
0.33, 172.39 
rs11162505 
AA 
AG 
GG 
 
-- 
0.01 
0.00 
 
-- 
1.62 
760.92 
 
-- 
0.002 
0.999 
 
-- 
0.00, 0.13 
0.00 
rs554185 
AA 
AG 
GG 
 
-- 
17.77 
157.27 
 
-- 
1.27 
2.58 
 
-- 
0.023 
0.050 
 
-- 
1.47, 213.73 
1.01, 24519.85 
rs556817 
AA 
AG 
GG 
 
-- 
0.05 
0.07 
 
-- 
1.02 
2.27 
 
-- 
0.003 
0.238 
 
-- 
0.01, 0.36 
0.00, 5.91 
rs668005 
CC 
CT 
TT 
 
-- 
0.27 
0.15 
 
-- 
1.03 
1.65 
 
-- 
0.198 
0.244 
 
-- 
0.04, 2.00 
0.01, 3.70 
rs686262 
AA 
AG 
GG 
 
-- 
0.76 
1.56 
 
-- 
0.64 
0.80 
 
-- 
0.663 
0.577 
 
-- 
0.22, 2.65 
0.33, 7.50 
rs12093097 
CC 
CT 
TT 
 
-- 
0.65 
1.19 
 
-- 
1.04 
1.10 
 
-- 
0.684 
0.877 
 
-- 
0.09, 5.05 
0.14, 10.20 
Sex 
Male 
Female 
 
2.32 
-- 
 
0.54 
-- 
 
0.119 
-- 
 
0.81, 6.70 
-- 
Age at presentation 
 
1.01 0.03 0.642 0.96, 1.06 
233 
 
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.673. 
This result gives no evidence of lack of fit of the model. 
 
 
Table 3.24: Univariate logistic regression analysis on predictors for glaucoma 
susceptibility in Chinese 
 
Predictors OR SE p-value 95% CI for OR 
(LCI, UCI) 
rs551253 
GG 
GC 
CC 
 
-- 
15.32 
2.48 
 
-- 
1.31 
2.46 
 
-- 
0.037 
0.712 
 
-- 
1.18, 199.29 
0.02, 305.25 
rs3766338 
TT 
TC 
CC 
 
-- 
36.43 
14.92 
 
-- 
1.67 
1.60 
 
-- 
0.031 
0.092^ 
 
-- 
1.39, 954.22 
0.65, 345.37 
rs11162505 
AA 
AG 
GG 
 
-- 
0.29 
6.18 
 
-- 
1.59 
2.80 
 
-- 
0.435 
0.516 
 
-- 
0.01, 6.51 
0.03, 1505.84 
rs554185 
AA 
AG 
GG 
 
-- 
0.03 
0.09 
 
-- 
1.72 
1.77 
 
-- 
0.041 
0.168 
 
-- 
0.00, 0.87 
0.00, 2.79 
Sex 
Male 
Female 
 
0.01 
-- 
 
1.73 
-- 
 
0.009 
-- 
 
0.00, 0.32 
-- 
Age at presentation 
 
1.00 0.04 0.913 0.94, 1.08 
OR: odd ratio, LCI: low confidence interval, UCI: upper confidence interval 
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.953. 
This result gives no evidence of lack of fit of the model. 
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3.3.2.6 PTGFR and susceptibility to glaucoma in the Malaysian population 
Predictors that were found to be statistically significant in univariate logistic regression in 
Malays and Chinese were included in stepwise logistic regression. rs11162505, rs556817, 
rs551253, rs554185, rs3766338 and sex were included. Backward stepwise logistic 
regression was used as the final model.  
rs11162505AG and rs556817AG conferred strong protective against glaucoma with 
reduction of risk of 0.2 fold (95%CI 0.0, 0.6) and 0.1 fold (95%CI 0.0, 0.5) respectively 
(table 3.25). rs551253GC increases the susceptibility to glaucoma 3.3fold (95% CI 1.2, 9.4). 
Similarly, rs3766338TC increases the susceptibility to develop glaucoma in both Malay and 
Chinese up to 4.2fold (95% CI 1.2, 14.0).  
 
Table 3.25: Stepwise logistic regression exploring the PTGFR in influencing the risk of 
glaucoma relative to unaffected normal individuals 
Predictors ORc ORr SE p-value 95% CI 
(UCI, LCI 
rs551253 
HW-GG 
HT-GC 
HM-CC 
 
-- 
2.57 
1.30 
 
-- 
3.33 
1.40 
 
-- 
0.53 
0.97 
 
-- 
0.023 
0.731 
 
-- 
1.18, 9.40 
0.21, 9.32 
rs11162505 
HW-AA 
HT-AG 
HM-GG 
 
-- 
0.09 
0.02 
 
-- 
0.16 
0.10 
 
-- 
0.68 
1.44 
 
-- 
0.007 
0.114 
 
-- 
0.04, 0.61 
0.01, 1.73 
rs556817 
HW-AA 
HT-AG 
HM-GG 
 
-- 
0.08 
0.22 
 
-- 
0.13 
1.11 
 
-- 
0.66 
0.98 
 
-- 
0.002 
0.916 
 
-- 
0.04, 0.46 
0.16, 7.52 
rs3766338 
HW-TT 
HT-TC 
HM-CC 
 
-- 
3.40 
0.43 
 
-- 
4.15 
0.59 
 
-- 
0.62 
0.81 
 
-- 
0.022 
0.507 
 
-- 
1.23, 13.95 
0.12, 2.85 
 ORc: crude odd ratio, ORr: logistic odd ratio, CI: confident interval, OR: odd ratio 
The goodness of fit of the model was checked using the Hosmer-Lemeshow test (p= 0.092). 
This result gives no evidence of lack of fit of the model. 
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3.3.2.7 PTGFR and susceptibility to POAG in the Malaysian population 
Patients diagnosed as POAG, NTG and OHT were included in this study. Due to small 
number of patients with OHT, patients with OHT were excluded from the analysis. There 
were 2 SNPs that demonstrated significant difference in 2 subpopulation; Malays and 
Chinese (rs11162505 and rs2057424). Minor allele frequency of rs12094298, rs551253, 
rs11162505, rs12093097, rs686262 and rs1073610 were found to demonstrate statistically 
significant association with POAG (table 3.26). However, Breslow-Day test for heterogeneity 
was statistically significant in rs11162505 suggesting the possible effect of population 
stratification.  
Table 3.26: Stratified Mantel-Haenszel meta-analysis on PTGFR and susceptibility to 
POAG relative to unaffected normal individuals in Malays and Chinese  
            Malays 
 
          Chinese              Stratified meta-analysis 
 
SNPs Allele frequency Allele frequency OR SE P-meta P-Het 
 Glaucoma 
N=40 
Control 
N=62 
Glaucoma 
N=24 
Control 
N=28 
    
rs3766331 
A 
G 
 
0.800 
0.200 
 
0.766 
0.234 
 
0.875 
0.125 
 
0.857 
0.143 
 
0.83 
(0.46, 
1.49) 
 
0.30 
 
0.532 
 
0.946 
rs3766353 
G 
T 
 
0.763 
0.238 
 
 
0.726 
0.274 
 
0.625 
0.375 
 
 
0.661 
0.339 
 
0.95 
(0.57, 
1.56) 
 
0.26 
 
0.825 
 
0.508 
rs3766355 
C 
A 
 
0.550 
0.450 
 
0.565 
0.435 
 
0.458 
0.542  
 
 
0.554 
0.446 
 
 
1.19 
(0.75, 
1.87) 
 
0.23 
 
0.461 
 
0.509 
rs35978825 
C 
T 
 
0.900 
0.100 
 
0.887 
0.113 
 
0.979 
0.021 
 
0.875 
0.054 
 
0.59 
(0.26, 
1.33) 
 
0.41 
 
0.202 
 
0.111 
rs1830673 
A 
G 
 
0.425 
0.575 
 
0.379 
0.621 
 
0.313 
0.438 
 
0.393 
0.607 
 
0.96 
(0.60, 
1.53) 
 
0.24 
 
0.863 
 
0.372 
rs3766351 
T 
C 
 
0.863 
0.138 
 
0.839 
0.161 
 
0.958 
0.042 
 
0.946 
0.054 
 
0.82 
(0.40, 
1.70) 
 
0.37 
 
0.592 
 
0.940 
rs1555541         
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T 
C 
0.338 
0.663 
0.315 
0.685 
0.292 
0.708 
0.393 
0.607 
1.10 
(0.68, 
1.77) 
0.25 0.713 0.283 
 
rs10489785 
A 
T 
 
0.938 
0.063 
 
0.863 
0.137 
 
 
0.979 
0.021 
 
0.964 
0.036 
 
0.44 
(0.17, 
1.14) 
 
0.49 
 
0.091 
 
0.815 
rs12094298 
C 
A 
 
0.988 
0.013 
 
0.903 
0.097 
 
0.979 
0.021 
 
 
0.982 
0.018 
 
0.21 
(0.05, 
0.96) 
 
0.77 
 
0.044 
 
0.145 
rs34077564 
A 
G 
 
0.863 
0.138 
 
0.855 
0.145 
 
0.979 
0.021 
 
0.946 
0.054 
 
0.84 
(0.39, 
1.78) 
 
0.39 
 
0.643 
 
0.451 
rs35123627 
C 
T 
 
0.938 
0.063 
 
0.903 
0.097 
 
0.958 
0.042 
 
0.911 
0.089 
 
0.56 
(0.23, 
1.40) 
 
0.47 
 
0.216 
 
0.740 
rs2146489 
A 
G 
 
0.425 
0.575 
 
0.476 
0.524 
 
0.271 
0.729 
 
0.411 
0.589 
 
1.41 
(0.88, 
2.24) 
 
0.24 
 
0.151 
 
0.408 
rs2057424 
A 
G 
 
0.725 
0.275 
 
0.565 
0.435 
 
0.625 
0.375 
 
0.696 
0.304 
 
0.71 
(0.44, 
1.14) 
 
0.24 
 
0.153 
 
0.046 
rs15101588 
G 
A 
 
0.488 
0.513 
 
0.508 
0.492 
 
0.458 
0.542 
 
0.482 
0.518 
 
1.09 
(0.69, 
1.72) 
 
0.23 
 
0.708 
 
0.978 
rs34528585 
T 
A 
 
0.913 
0.088 
 
0.903 
0.097 
 
0.938 
0.063 
 
0.946 
0.054 
 
0.96 
(0.42, 
2.22) 
 
0.43 
 
0.925 
 
0.779 
rs12044011 
T 
A 
 
0.538 
0.463 
 
0.556 
0.444 
 
0.458 
0.542 
 
0.518 
0.482 
 
1.14 
(0.72, 
1.80) 
 
0.23 
 
0.567 
 
0.740 
rs1322930 
G 
A 
 
0.975 
0.025 
 
0.935 
0.065 
 
0.938 
0.063 
 
0.982 
0.018 
 
1.13 
(0.41, 
3.15) 
 
0.52 
 
0.814 
 
0.219 
rs34852041 
C 
T 
 
0.913 
0.088 
 
0.855 
0.145 
 
1.000 
0.000 
 
0.964 
0.036 
 
0.49 
(0.20, 
1.22) 
 
0.46 
 
0.126 
 
0.329 
rs33994937 
T 
C 
 
0.925 
0.075 
 
0.855 
0.145 
 
0.979 
0.021 
 
0.964 
0.036 
 
0.49 
(0.20, 
1.20) 
 
0.46 
 
0.120 
 
0.890 
rs6424776 
T 
C 
 
0.513 
0.975 
 
0.492 
0.508 
 
0.479 
0.521 
 
0.518 
0.482 
 
1.00 
(0.64, 
1.56) 
 
0.23 
 
1.000 
 
0.141 
237 
 
rs72673925 
T 
G 
 
0.900 
0.100 
 
0.887 
0.113 
 
0.958 
0.042 
 
0.964 
0.036 
 
0.92 
(0.40, 
2.11) 
 
0.43 
 
0.842 
 
0.792 
rs28832602 
C 
T 
 
0.900 
0.100 
 
0.879 
0.121 
 
0.958 
0.042 
 
0.964 
0.036 
 
0.86 
(0.38, 
1.96) 
 
0.42 
 
0.720 
 
0.738 
rs34572897 
A 
G 
 
0.900 
0.100 
 
0.887 
0.113 
 
0.979 
0.021 
 
0.964 
0.036 
 
0.83 
(0.35, 
1.95) 
 
0.44 
 
0.664 
 
0.751 
rs1590314 
T 
C 
 
0.363 
0.638 
 
0.371 
0.629 
 
0.354 
0.646 
 
0.429 
0.571 
 
1.14 
(0.71, 
1.83) 
 
0.24 
 
0.577 
 
0.582 
rs12058120 
C 
G 
 
0.888 
0.113 
 
0.855 
0.145 
 
0.938 
0.062 
 
0.946 
0.054 
 
0.82 
(0.39, 
1.75) 
 
0.39 
 
0.608 
 
0.629 
rs12725125 
G 
A 
 
0.888 
0.113 
 
0.871 
0.129 
 
0.938 
0.062 
 
0.946 
0.054 
 
0.92 
(0.43, 
1.97) 
 
0.39 
 
0.824 
 
0.736 
rs4261075 
A 
G 
 
0.413 
0.588 
 
0.363 
0.637 
 
0.396 
0.604 
 
0.429 
0.571 
 
0.92 
(0.58, 
1.46) 
 
0.24 
 
0.711 
 
0.488 
rs34012602 
G 
T 
 
0.913 
0.088 
 
0.903 
0.097 
 
1.000 
0.00 
 
0.946 
0.054 
 
0.68 
(0.27, 
1.71) 
 
0.47 
 
0.410 
 
0.145 
rs67351117 
C 
T 
 
0.913 
0.088 
 
0.887 
0.113 
 
0.958 
0.042 
 
0.964 
0.036 
 
0.82 
(0.35, 
1.92) 
 
0.44 
 
0.643 
 
0.694 
rs672561 
T 
C 
 
0.925 
0.075 
 
0.863 
0.137 
 
1.000 
0.000 
 
0.964 
0.036 
 
0.44 
(0.17, 
1.16) 
 
0.49 
 
0.096 
 
0.353 
rs12401416 
G 
A 
 
0.513 
0.488 
 
0.500 
0.452 
 
0.458 
0.542 
 
0.500 
0.500 
 
1.10 
(0.69, 
1.73) 
 
0.23 
 
0.693 
 
0.814 
rs6424778 
C 
T 
 
0.963 
0.038 
 
0.960 
0.040 
 
0.896 
0.104 
 
0.982 
0.018 
 
1.91 
(0.64, 
5.71) 
 
0.56 
 
0.247 
 
0.130 
rs577333 
T 
C 
 
0.363 
0.638 
 
0.298 
0.702 
 
0.271 
0.729 
 
0.375 
0.625 
 
0.98 
(0.60, 
1.58) 
 
0.25 
 
0.917 
 
0.140 
rs520171 
A 
C 
 
0.700 
0.300 
 
0.669 
0.331 
 
0.813 
0.188 
 
0.768 
0.232 
 
0.84 
(0.50, 
 
0.26 
 
0.493 
 
0.824 
238 
 
1.40) 
rs551253 
G 
C 
 
0.863 
0.138 
 
0.677 
0.323 
 
0.813 
0.188 
 
0.768 
0.232 
 
0.45 
(0.25, 
0.80) 
 
0.29 
 
0.006 
 
0.178 
rs552328 
A 
G 
 
0.638 
0.363 
 
0.556 
0.444 
 
0.542 
0.458 
 
0.536 
0.464 
 
0.80 
(0.50, 
1.27) 
 
0.24 
 
0.337 
 
0.524 
rs11162504 
A 
G 
 
0.850 
0.150 
 
0.766 
0.234 
 
0.813 
0.188 
 
0.804 
0.196 
 
0.69 
(0.38, 
1.24) 
 
0.30 
 
0.211 
 
0.433 
rs11162505 
A 
G 
 
1.000 
0.000 
 
0.774 
0.226 
 
0.896 
0.104 
 
0.839 
0.161 
 
0.15 
(0.06, 
0.41) 
 
0.50 
 
<0.001 
 
0.002 
rs554173 
T 
C 
 
0.813 
0.188 
 
0.798 
0.202 
 
0.771 
0.229 
 
0.714 
0.286 
 
0.84 
(0.48, 
1.47) 
 
0.28 
 
0.546 
 
0.722 
rs554185 
A 
G 
 
0.688 
0.313 
 
0.565 
0.435 
 
0.583 
0.417 
 
0.554 
0.446 
 
0.68 
(0.43, 
1.09) 
 
0.24 
 
0.111 
 
0.414 
rs556817 
A 
G 
 
0.838 
0.163 
 
0.798 
0.202 
 
0.833 
0.167 
 
0.768 
0.232 
 
0.73 
(0.40, 
1.31) 
 
0.30 
 
0.292 
 
0.811 
rs473027 
A 
G 
 
0.613 
0.388 
 
0.540 
0.460 
 
0.500 
0.500 
 
0.482 
0.518 
 
0.81 
(0.51, 
1.27) 
 
0.23 
 
0.355 
 
0.646 
rs668005 
C 
T 
 
0.700 
0.300 
 
0.556 
0.444 
 
0.500 
0.500 
 
0.482 
0.518 
 
0.66 
(0.41, 
1.05) 
 
0.24 
 
0.080 
 
0.269 
rs2146490 
G 
A 
 
0.930 
0.063 
 
0.887 
0.113 
 
0.958 
0.042 
 
0.964 
0.036 
 
0.62 
(0.25, 
1.56) 
 
0.47 
 
0.310 
 
0.479 
rs530871 
G 
A 
 
0.675 
0.325 
 
0.556 
0.444 
 
0.479 
0.521 
 
0.500 
0.500 
 
0.75 
(0.47, 
1.19) 
 
0.24 
 
0.220 
 
0.234 
rs538275 
G 
A 
 
0.663 
0.338 
 
0.581 
0.419 
 
0.458 
0.542 
 
0.446 
0.554 
 
0.79 
(0.49, 
1.25) 
 
0.24 
 
0.312 
 
0.543 
rs589958 
G 
A 
 
0.650 
0.350 
 
0.565 
0.435 
 
0.479 
0.521 
 
0.446 
0.554 
 
0.76 
(0.48, 
1.20) 
 
0.24 
 
0.240 
 
0.644 
rs3766338 
T 
 
0.825 
 
0.774 
 
0.542 
 
0.643 
 
1.01 
 
0.27 
 
0.969 
 
0.172 
239 
 
C 0.175 0.226 0.458 0.357 (0.60, 
1.70) 
rs590309 
T 
C 
 
0.675 
0.325 
 
0.548 
0.452 
 
0.417 
0.583 
 
0.464 
0.536 
 
0.76 
(0.48, 
1.21) 
 
0.24 
 
0.248 
 
0.141 
rs622346 
G 
C 
 
0.738 
0.263 
 
0.694 
0.306 
 
0.646 
0.354 
 
0.643 
0.357 
 
0.87 
(0.53, 
1.43) 
 
0.25 
 
0.579 
 
0.696 
rs13374108 
T 
A 
 
0.925 
0.075 
 
0.871 
0.129 
 
0.854 
0.146 
 
0.857 
0.143 
 
0.72 
(0.35, 
1.47) 
 
0.37 
 
0.363 
 
0.403 
rs34012237 
T 
C 
 
0.925 
0.075 
 
0.726 
0.113 
 
0.854 
0.146 
 
0.964 
0.036 
 
0.53 
(0.21, 
1.34) 
 
0.47 
 
0.178 
 
0.942 
rs33966768 
T 
C 
 
0.925 
0.075 
 
0.887 
0.113 
 
0.854 
0.146 
 
0.964 
0.036 
 
0.63 
(0.25, 
1.58) 
 
0.47 
 
0.324 
 
0.939 
rs501078 
C 
T 
 
0.425 
0.575 
 
0.339 
0.661 
 
0.375 
0.625 
 
0.304 
0.696 
 
0.70 
(0.44, 
1.13) 
 
0.24 
 
0.145 
 
0.926 
rs3766335 
G 
A 
 
0.925 
0.075 
 
0.879 
0.121 
 
0.854 
0.146 
 
0.964 
0.036 
 
0.59 
(0.23, 
1.47) 
 
0.47 
 
0.256 
 
0.985 
rs7543738 
C 
G 
 
0.950 
0.050 
 
0.960 
0.040 
 
0.854 
0.146 
 
0.964 
0.036 
 
1.03 
(0.32, 
3.32) 
 
0.60 
 
0.959 
 
0.579 
rs686262 
A 
G 
 
0.500 
0.500 
 
0.379 
0.621 
 
0.417 
0.583 
 
0.304 
0.696 
 
0.61 
(0.38, 
0.97) 
 
0.24 
 
0.038 
 
1.000 
rs4650581 
T 
A 
 
0.913 
0.088 
 
0.871 
0.129 
 
0.958 
0.042 
 
0.946 
0.054 
 
0.67 
(0.29, 
1.54) 
 
0.43 
 
0.346 
 
0.870 
rs3766332 
A 
T 
 
0.763 
0.238 
 
0.750 
0.250 
 
0.688 
0.313 
 
0.804 
0.196 
 
0.84 
(0.50, 
1.39) 
 
0.26 
 
 
0.488 
 
 
0.592 
 
rs3753380 
T 
C 
 
0.375 
0.625 
 
0.298 
0.702 
 
0.208 
0.792 
 
0.304 
0.696 
 
0.92 
(0.57, 
1.51) 
 
0.25 
 
0.751 
 
0.121 
rs12093097 
C 
T 
 
0.725 
0.275 
 
0.855 
0.145 
 
0.792 
0.208 
 
0.821 
0.179 
 
1.97 
(1.12, 
3.44) 
 
0.29 
 
0.018 
 
0.227 
rs1073610         
240 
 
G 
A 
0.700 
0.300 
0.847 
0.153 
0.792 
0.208 
0.804 
0.196 
2.09 
(1.21, 
3.61) 
0.28 0.008 0.556 
rs1073611 
G 
A 
 
0.713 
0.288 
 
0.847 
0.153 
 
0.792 
0.208 
 
0.821 
0.179 
 
1.73 
(0.99, 
3.02) 
 
0.28 
 
0.052 
 
0.225 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
 
Age at presentation, sex, rs12094298, rs551253, rs11162505, rs12093097, rs686262 and 
rs1073610 were included in stepwise logistic regression analysis. Age remains a significant 
predictor for susceptibility to POAG on stepwise logistic regression analysis (table 3.27). The 
presence of the minor allele rs11162505G in the heterozygous state (rs11162505AG) reduces 
the susceptibility to POAG 0.2 fold (95% CI 0.0, 0.6) in the Malaysian population (table 
3.27). 
 
Table 3.27: Stepwise logistic regression analysis on PTGFR and predictors for 
susceptibility to POAG in the Malaysian population 
Predictors ORc ORr SE p-value 95%CI for OR 
(LCI, UCI) 
rs11162505 
AA 
AG 
GG 
 
-- 
0.17 
0.00 
 
-- 
0.15 
0.00 
 
-- 
0.73 
15884.90 
 
-- 
0.010 
0.999 
 
-- 
0.04, 0.63 
0.00,--- 
rs551253 
GG 
GC 
CC 
 
-- 
3.22 
0.72 
 
-- 
2.78 
0.60 
 
-- 
0.53 
1.29 
 
-- 
0.051 
0.690 
 
-- 
0.10,7.79 
0.05, 7.53 
Age 
(at presentation) 
1.06 1.04 0.02 0.022 1.01, 1.08 
ORc: crude odd ratio, ORr: logistic odd ratio, CI: confidence interval, OR: odd ratio, LCI: 
lower confidence interval, UCI: upper confidence interval 
The goodness of fit of the model was checked using the Hosmer-Lemeshow test (p= 0.261). 
This result gives no evidence of lack of fit of the model. 
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3.3.2.8 PTGFR and susceptibility to NTG in the Malaysian population 
 
Breslow-Day test on heterogeneity between the sub-populations was found to be significant 
in several SNPs found in PTGFR (table 3.28). The minor allele of four SNPs (rs7543738G, 
rs556817G, rs577333C and rs6424776C) was found to be significantly associated with NTG 
based on stratified meta-analysis between the two sub-populations (table 3.28).  
 
Table 3.28: Stratified Mantel-Haenszel meta-analysis on PTGFR and susceptibility to 
NTG relative to unaffected normal individuals in Malays and Chinese  
            Malays 
 
          Chinese              Stratified meta-analysis 
 
SNPs Allele frequency Allele frequency OR SE P-meta P-Het 
 Glaucoma 
N=18 
Control 
N=62 
Glaucoma 
N=4 
Control 
N=28 
    
rs3766331 
A 
G 
 
0.833 
0.167 
 
0.766 
0.234 
 
0.875 
0.125 
 
0.857 
0.143 
 
0.97 
(0.34, 
2.78) 
 
0.54 
 
0.956 
 
0.900 
rs3766353 
G 
T 
 
0.861 
0.139 
 
 
0.726 
0.274 
 
0.750 
0.250 
 
0.661 
0.339 
 
0.62 
(0.25, 
1.50) 
 
0.45 
 
0.287 
 
0.945 
rs3766355 
C 
A 
 
0.611 
0.389 
 
0.565 
0.435 
 
0.500 
0.500 
 
0.554 
0.446 
 
 
0.90 
(0.46, 
1.76) 
 
0.34 
 
0.752 
 
0.631 
rs35978825 
C 
T 
 
0.861 
0.139 
 
0.887 
0.113 
 
0.750 
0.250 
 
0.875 
0.054 
 
1.68 
(0.66, 
4.32) 
 
0.48 
 
0.279 
 
0.190 
rs1830673 
A 
G 
 
0.556 
0.444 
 
0.379 
0.621 
 
0.500 
0.500 
 
0.393 
0.607 
 
0.52 
(0.27, 
1.01) 
 
0.34 
 
0.053^ 
 
0.740 
rs3766351 
T 
C 
 
0.806 
0.194 
 
0.839 
0.161 
 
0.625 
0.375 
 
0.946 
0.054 
 
1.82 
(0.80, 
4.12) 
 
0.42 
 
0.150 
 
0.031 
rs1555541 
T 
C 
 
0.306 
0.694 
 
0.315 
0.685 
 
0.375 
0.625 
 
0.393 
0.607 
 
1.05 
(052, 
2.14) 
 
0.36 
 
0.892 
 
0.970 
rs10489785 
A 
T 
 
0.806 
0.194 
 
0.863 
0.137 
 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.95 
(0.82, 
4.64) 
 
0.44 
 
0.132 
 
0.113 
rs12094298         
242 
 
C 
A 
0.806 
0.194 
0.903 
0.097 
0.875 
0.125 
 
0.982 
0.018 
2.52 
(0.97, 
6.56) 
0.49 0.058^ 0.403 
rs34077564 
A 
G 
 
0.833 
0.167 
 
0.855 
0.145 
 
0.625 
0.375 
 
0.946 
0.054 
 
1.79 
(0.77, 
4.17) 
 
0.43 
 
0.178 
 
0.028 
rs35123627 
C 
T 
 
0.833 
0.167 
 
0.903 
0.097 
 
0.875 
0.125 
 
0.911 
0.089 
 
1.79 
(0.69, 
4.66) 
 
0.47 
 
0.236 
 
0.847 
rs2146489 
A 
G 
 
0.044 
0.694 
 
0.476 
0.524 
 
0.500 
0.500 
 
0.411 
0.589 
 
1.63 
(0.82, 
3.25) 
 
0.35 
 
0.163 
 
0.199 
rs2057424 
A 
G 
 
0.694 
0.306 
 
0.565 
0.435 
 
0.500 
0.500 
 
0.696 
0.304 
 
0.76 
(0.38, 
1.52) 
 
0.35 
 
0.441 
 
0.098 
rs1510158840 
G 
A 
 
0.778 
0.361 
 
0.508 
0.492 
 
0.750 
0.250 
 
0.482 
0.518 
 
0.52 
(0.26, 
1.04) 
 
0.35 
 
0.064^ 
 
0.500 
rs34528585 
T 
A 
 
0.889 
0.111 
 
0.903 
0.097 
 
0.750 
0.250 
 
0.946 
0.054 
 
1.66 
(0.61, 
4.52) 
 
0.51 
 
0.320 
 
0.151 
rs12044011 
T 
A 
 
0.556 
0.444 
 
0.556 
0.444 
 
0.750 
0.250 
 
0.518 
0.482 
 
0.77 
(0.39, 
1.50) 
 
0.34 
 
0.444 
 
0.114 
rs1322930 
G 
A 
 
0.972 
0.028 
 
0.935 
0.064 
 
1.000 
0.000 
 
0.982 
0.018 
 
0.39 
(0.05, 
3.18) 
 
1.08 
 
0.377 
 
0.806 
rs34852041 
C 
T 
 
0.861 
0.139 
 
0.855 
0.145 
 
0.875 
0.125 
 
0.964 
0.036 
 
1.12 
(0.42, 
2.98) 
 
0.50 
 
0.818 
 
0.291 
rs33994937 
T 
C 
 
0.861 
0.139 
 
0.855 
0.145 
 
0.875 
0.125 
 
0.964 
0.036 
 
1.12 
(0.42, 
2.98) 
 
0.50 
 
0.818 
 
0.291 
rs6424776 
T 
C 
 
0.667 
0.333 
 
0.492 
0.508 
 
0.750 
0.250 
 
0.518 
0.482 
 
0.46 
(0.23, 
0.93) 
 
0.36 
 
0.030 
 
0.749 
rs72673925 
T 
G 
 
0.861 
0.139 
 
0.887 
0.113 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.77 
(0.69, 
4.55) 
 
0.48 
 
0.238 
 
0.085 
rs28832602 
C 
T 
 
0.806 
0.194 
 
0.879 
0.121 
 
0.750 
0.250 
 
0.964 
0.036 
 
2.22 
(0.92, 
5.36) 
 
0.45 
 
0.076^ 
 
0.150 
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rs34572897 
A 
G 
 
0.861 
0.139 
 
0.887 
0.113 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.77 
(0.69, 
4.55) 
 
0.48 
 
0.238 
 
0.085 
rs1590314 
T 
C 
 
0.444 
0.556 
 
0.371 
0.629 
 
0.500 
0.500 
 
0.429 
0.571 
 
0.74 
(0.38, 
1.45) 
 
0.34 
 
0.378 
 
0.984 
rs12058120 
C 
G 
 
0.778 
0.222 
 
0.855 
0.145 
 
0.750 
0.250 
 
0.946 
0.054 
 
2.03 
(0.88, 
4.69) 
 
0.43 
 
0.098 
 
0.246 
rs12725125 
G 
A 
 
0.778 
0.222 
 
0.871 
0.129 
 
0.750 
0.250 
 
0.946 
0.054 
 
2.29 
(0.98, 
5.36) 
 
0.43 
 
0.056^ 
 
0.306 
rs4261075 
A 
G 
 
0.444 
0.556 
 
0.363 
0.637 
 
0.500 
0.500 
 
0.429 
0.571 
 
0.72 
(0.37, 
1.41) 
 
0.34 
 
0.337 
 
0.951 
rs34012602 
G 
T 
 
0.806 
0.194 
 
0.903 
0.097 
 
0.875 
0.125 
 
0.946 
0.054 
 
2.29 
(0.90, 
5.85) 
 
0.48 
 
0.084 
 
0.932 
rs67351117 
C 
T 
 
0.861 
0.139 
 
0.887 
0.113 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.77 
(0.69, 
4.55) 
 
0.48 
 
0.238 
 
0.850 
rs672561 
T 
C 
 
0.833 
0.167 
 
0.863 
0.137 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.69 
(0.69, 
4.12) 
 
0.46 
 
0.250 
 
0.078 
rs12401416 
G 
A 
 
0.611 
0.389 
 
0.500 
0.452 
 
0.750 
0.250 
 
0.500 
0.500 
 
0.61 
(0.31, 
1.22) 
 
0.35 
 
0.163 
 
0.423 
rs6424778 
C 
T 
 
0.972 
0.028 
 
0.960 
0.040 
 
1.000 
0.000 
 
0.982 
0.018 
 
0.61 
(0.07, 
5.30) 
 
1.10 
 
0.654 
 
0.754 
rs577333 
T 
C 
 
0.417 
0.583 
 
0.298 
0.702 
 
0.375 
0.625 
 
0.375 
0.625 
 
0.66 
(0.34, 
1.31) 
 
0.35 
 
0.238 
 
0.551 
rs520171 
A 
C 
 
0.694 
0.306 
 
0.669 
0.331 
 
0.750 
0.250 
 
0.768 
0.232 
 
0.93 
(0.45, 
1.91) 
 
0.37 
 
0.833 
 
0.825 
 
rs551253 
G 
C 
 
0.722 
0.278 
 
0.677 
0.323 
 
0.625 
0.375 
 
0.768 
0.232 
 
0.97 
(0.47, 
1.99) 
 
0.37 
 
0.927 
 
0.311 
rs552328 
A 
G 
 
0.722 
0.278 
 
0.556 
0.444 
 
0.375 
0.625 
 
0.536 
0.464 
 
0.66 
(0.33, 
 
0.35 
 
0.231 
 
0.107 
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1.31) 
rs11162504 
A 
G 
 
0.750 
0.250 
 
0.766 
0.234 
 
0.625 
0.375 
 
0.804 
0.196 
 
1.30 
(0.61, 
2.75) 
 
0.38 
 
0.500 
 
0.372 
rs11162505 
A 
G 
 
0.889 
0.111 
 
0.774 
0.226 
 
0.750 
0.250 
 
0.839 
0.161 
 
0.60 
(0.25, 
1.52) 
 
0.47 
 
0.280 
 
0.170 
rs554173 
T 
C 
 
0.889 
0.111 
 
0.798 
0.202 
 
0.750 
0.250 
 
0.714 
0.286 
 
0.57 
(0.23, 
1.46) 
 
0.48 
 
0.244 
 
0.615 
rs554185 
A 
G 
 
0.750 
0.250 
 
0.565 
0.435 
 
0.500 
0.500 
 
0.554 
0.446 
 
0.55 
(0.27, 
1.12) 
 
0.36 
 
0.101 
 
0.217 
rs556817 
A 
G 
 
0.972 
0.028 
 
0.798 
0.202 
 
0.875 
0.125 
 
0.768 
0.232 
 
0.19 
(0.04, 
0.80) 
 
0.74 
 
0.024 
 
0.323 
rs473027 
A 
G 
 
0.667 
0.333 
 
0.540 
0.460 
 
0.250 
0.750 
 
0.482 
0.518 
 
0.80 
(0.41, 
1.57) 
 
0.35 
 
0.516 
 
0.087 
rs668005 
C 
T 
 
0.694 
0.306 
 
0.556 
0.444 
 
0.375 
0.625 
 
0.482 
0.518 
 
0.69 
(0.35, 
1.37) 
 
0.35 
 
0.288 
 
0.231 
rs2146490 
G 
A 
 
0.861 
0.139 
 
0.887 
0.113 
 
0.750 
0.250 
 
0.964 
0.036 
 
1.77 
(0.69, 
4.55) 
 
0.48 
 
0.238 
 
0.085 
rs530871 
G 
A 
 
0.667 
0.333 
 
0.556 
0.444 
 
0.375 
0.625 
 
0.500 
0.500 
 
0.77 
(0.39, 
1.52) 
 
0.35 
 
0.451 
 
0.257 
rs538275 
G 
A 
 
0.694 
0.306 
 
0.581 
0.419 
 
0.375 
0.625 
 
0.446 
0.554 
 
0.72 
(0.36, 
1.44) 
 
0.35 
 
0.354 
 
0.363 
rs589958 
G 
A 
 
0.694 
0.306 
 
0.565 
0.435 
 
0.375 
0.625 
 
0.446 
0.054 
 
0.68 
(0.34, 
1.37) 
 
0.35 
 
0.282 
 
0.323 
rs3766338 
T 
C 
 
0.889 
0.111 
 
0.774 
0.226 
 
0.750 
0.250 
 
0.643 
0.357 
 
0.47 
(0.19, 
1.20) 
 
0.48 
 
0.114 
 
0.745 
rs590309 
T 
C 
 
0.694 
0.306 
 
0.548 
0.452 
 
0.375 
0.625 
 
0.464 
0.536 
 
0.66 
(0.33, 
1.31) 
 
0.35 
 
0.237 
 
0.250 
rs622346 
G 
 
0.750 
 
0.694 
 
0.625 
 
0.643 
 
0.82 
 
0.38 
 
0.594 
 
0.687 
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C 0.250 0.306 0.375 0.357 (0.39, 
1.71) 
rs13374108 
T 
A 
 
0.944 
0.056 
 
0.871 
0.129 
 
0.750 
0.250 
 
0.857 
0.143 
 
0.69 
(0.23, 
2.08) 
 
0.57 
 
0.507 
 
0.155 
rs34012237 
T 
C 
 
0.861 
0.139 
 
0.726 
0.113 
 
0.875 
0.125 
 
0.964 
0.036 
 
1.22 
(0.70, 
3.34) 
 
0.51 
 
0.695 
 
0.328 
rs33966768 
T 
C 
 
0.833 
0.167 
 
0.887 
0.113 
 
0.875 
0.125 
 
0.964 
0.036 
 
1.75 
(0.67, 
4.57) 
 
0.49 
 
0.255 
 
0.510 
rs501078 
C 
T 
 
0.444 
0.639 
 
0.339 
0.661 
 
0.250 
0.750 
 
0.304 
0.696 
 
0.97 
(0.48, 
1.96) 
 
0.36 
 
0.928 
 
0.700 
rs3766335 
G 
A 
 
0.861 
0.139 
 
0.879 
0.121 
 
1.000 
0.000 
 
0.964 
0.036 
 
1.08 
(0.37, 
3.16) 
 
0.54 
 
0.889 
 
0.560 
rs7543738 
C 
G 
 
0.833 
0.167 
 
0.960 
0.040 
 
1.000 
0.000 
 
0.964 
0.036 
 
3.76 
(1.17, 
12.09) 
 
0.60 
 
0.026 
 
0.270 
rs686262 
A 
G 
 
0.389 
0.611 
 
0.379 
0.621 
 
0.375 
0.625 
 
0.304 
0.696 
 
0.91 
(0.46, 
1.80) 
 
0.35 
 
0.786 
 
0.751 
rs4650581 
T 
A 
 
0.861 
0.139 
 
0.871 
0.129 
 
0.875 
0.125 
 
0.946 
0.054 
 
1.23 
(0.46, 
3.28) 
 
0.50 
 
0.685 
 
0.523 
rs3766332 
A 
T 
 
0.861 
0.139 
 
0.750 
0.250 
 
0.000 
1.000 
 
0.804 
0.196 
 
1.19 
(0.56, 
2.54) 
 
0.39 
 
 
0.651 
 
 
0.001 
 
rs3753380 
T 
C 
 
0.417 
0.583 
 
0.298 
0.702 
 
0.375 
0.625 
 
0.304 
0.696 
 
0.62 
(0.31, 
1.23) 
 
0.35 
 
0.171 
 
0.821 
rs12093097 
C 
T 
 
0.806 
0.194 
 
0.855 
0.145 
 
1.000 
0.000 
 
0.821 
0.179 
 
1.03 
(0.41, 
2.56) 
 
0.47 
 
0.953 
 
0.140 
rs1073610 
G 
A 
 
0.778 
0.222 
 
0.847 
0.153 
 
1.000 
0.000 
 
0.804 
0.196 
 
1.12 
(0.47, 
2.67) 
 
0.44 
 
0.803 
 
0.104 
rs1073611 
G 
A 
 
0.778 
0.222 
 
0.847 
0.153 
 
1.000 
0.000 
 
0.804 
0.196 
 
1.12 
(0.47, 
2.67) 
 
0.44 
 
0.803 
 
0.104 
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OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
 
Age at presentation, sex, rs6424776, rs12725125, rs556817 and rs7543738 were included in 
the stepwise logistic regression analysis. The final model of stepwise logistic regression, 
demonstrated that the minor allele rs556817G in the heterozygous state (rs556817AG) 
increases the risk of NTG 5.4 fold (95%CI 1.1, 26.1), whereas the homozygousity for the 
most common allele at rs12725125 (rs12725125AA) reduces the risk of NTG (OR 0.1 
[95%CI 0.0, 0.8]) in the Malaysian population (table 3.29). 
 
Table 3.29: Stepwise logistic regression on PTGFR and susceptibility to NTG in the 
Malaysian population 
Predictors ORc ORr SE p-value 95%CI for OR 
(LCI, UCI) 
rs556817 
AA 
AG 
GG 
 
-- 
4.44 
3.06E8 
 
-- 
5.43 
0.00 
 
-- 
0.80 
856.88 
 
-- 
0.035 
0.999 
 
 
-- 
1.13, 26.11 
0.00,-- 
rs12725125 
GG 
GA 
AA 
 
-- 
2.77 
0.13 
 
-- 
2.22 
0.12 
 
-- 
0.82 
0.96 
 
-- 
0.327 
0.028 
 
-- 
0.45, 10.99 
0.02, 0.80 
 
ORc: crude odd ratio, ORr: logistic odd ratio, CI: confidence interval, OR: odd ratio, LCI: 
lower confidence interval, UCI: upper confidence interval 
The goodness of fit of the model was checked using the Hosmer-Lemeshow test (p= 0.989). 
This result gives no evidence of lack of fit of the model. 
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3.3.2.9: Haplotypes analysis on PTGFR  
The possible linkage disequilibrium of polymorphisms found in PTGFR gene was analysed 
using available software Haploview (http://www.broad.mit.edu/mpg/haploview/). Based on 
single marker check, rs3766351, rs34077564, rs2057424, rs12058120, rs12725125, rs551253 
and rs1073611 were found to violate HWE and were excluded from further analysis. There 
was significant difference in haplotypes frequency of rs11162504G and rs556817G between 
glaucoma and control subjects. There were six possible haplotypes blocks (Figure 3.13). 
Haplotypes of GG and GA of rs11162505 and rs554185 in block 3 demonstrated statistically 
significant association with glaucoma (table 3.30). Haplotypes of rs556817C, rs473027G and 
rs668005G also shown significant association with glaucoma (p=0.026).  
 
Table 3.30: Association of haplotypes of PTGFR between glaucoma and control subjects 
Block Haplotypes Frequency  Allele frequency 
 
χ² p-value 
Glaucoma Control 
1 CT 0.898 0.907 0.889 0.31 0.576 
 TC 
 
0.097 0.081 0.111 0.89 0.346 
2 AA 0.790 0.808 0.772 0.69 0.406 
 GG 0.136 0.070 0.200 12.65 4.0E-4 
 GA 
 
0.071 0.122 0.022 13.22 3.0E-4 
3 TAA 0.610 0.661 0.561 3.73 0.054 
 TGA 0.180 0.147 0.211 2.46 0.116 
 CGG 0.167 0.122 0.211 4.97 0.026 
 CGA 
 
0.033 0.051 0.016 3.21 0.073 
4 GG 0.562 0.599 0.528 1.80 0.179 
 AA 0.423 0.384 0.461 2.16 0.142 
 
5 TT 0.553 0.592 0.516 2.06 0.151 
 CC 0.243 0.225 0.260 0.57 0.450 
 TC 
 
0.197 0.176 0.218 0.98 0.322 
6 GTTTCG 0.345 0.380 0.312 1.79 0.181 
 GTTTTG 0.243 0.254 0.232 0.22 0.639 
 CTTTTG 0.202 0.189 0.214 0.33 0.567 
 GATTTG 0.101 0.069 0.132 3.86 0.050 
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 CTCCTA 0.082 0.076 0.089 0.21 0.650 
 CTTTCG 0.011 0.008 0.014 0.25 0.620 
Block 1: rs6424776 and rs72673925 
Block 2: rs11162505 and rs554185 
Block 3: rs556817, rs473027 and rs668005 
Block 4: rs3766338 and rs590309 
Block 5: rs622346 and rs13374108 
Block 6: rs34012237, rs33966768, rs501078, rs3766335, rs7543738 and rs686262 
 
 
Figure 3.13: LD plot of PTGFR   
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 3.3.2.10: Microsatellite instability (MSI) of PTGFR in the Malaysian population 
There were 2 (areas of) MSI found in Intron 3; „CA‟ deletion was found within primer IVS 3-
29 and „TA‟ insertion within primer IVS 3-56. There were multiple combinations of 
quantitative analysis of MSI based on FAMHAP programme (http://www.meb.uni-
bonn.de/famhap/) in PTGFR gene. Based on global p-value of FAMHAP programme, both 
MSIs showed no statistically significant difference between glaucoma patients and normal 
individuals (table 3.31 and 3.32).  
Table 3.31: Association of MSI size found within primer IVS 3-29 between glaucoma 
and control subjects  
MSI 
size 
        Frequency OR 95% CI OR 
LCI, UCI 
p-value* 
Glaucoma 
N=86 
Control 
N=90 
      
96 0.167 0.156 1.09 0.62, 1.91 0.603 
111 0.067 0.078 0.85 0.38, 1.89 
92 0.256 0.328 0.70 0.45, 1.11 
109 0.122 0.089 1.43 0.72, 2.82 
105 0.083 0.100 0.82 0.40, 1.68 
107 0.050 0.078 0.62 0.26, 1.48  
113 0.133 0.089 1.58 0.81, 3.08 
90 0.011 0.006   
94 0.011 0.011 1.00 0.14, 7.18 
80 0.006 0.000   
89 0.006 0.000   
95 0.011 0.000   
98 0.011 0.011 1.00 0.14, 7.18 
93 0.044 0.022 2.05 0.61, 6.92 
102 0.006 0.000   
103 0.006 0.017 0.33 0.03, 3.20 
97 0.000 0.011 0.00 -9.00, -9.00 
115 0.000 0.011 0.00  
100 0.000 0.006   
*p-value is based on global p-value for single marker using FAMHAP software 
OR: odd ratio, LCI: lower confident interval, UCI: upper confident interval 
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Table 3.32: Association of MSI size within primer of IVS3-56 between glaucoma and 
control subjects  
MSI 
size 
      Frequency OR 95% CI of OR 
LCI, UCI 
p-value* 
Glaucoma 
N=86 
Control 
N=90 
294 0.206 0.283 0.65 0.40, 1.06 0.077 
318 0.050 0.028 1.84 0.61,5.61  
299 0.061 0.072 0.84 0.36, 1.92  
316 0.033 0.028 1.21 0.36, 4.03  
298 0.133 0.100 1.38 0.72, 2.65  
314 0.044 0.106 0.39 0.17, 0.93  
296 0.156 0.072 2.37 1.18, 4.73  
311 0.028 0.022 1.26 0.33, 4.76  
292 0.017 0.000    
307 0.011 0.000    
315 0.011 0.011 1.00 0.14, 7.18  
301 0.050 0.078 0.62 0.26, 1.48  
286 0.039 0.011 3.60 0.74, 17.58  
290 0.006 0.000    
312 0.050 0.028 1.84 0.61, 5.61  
310 0.028 0.017 1.69 0.40, 7.16  
287 0.011 0.017 0.66 0.11, 4.02  
317 0.011 0.000    
320 0.006 0.017 0.33 0.03, 3.20  
303 0.033 0.011 3.07 0.61, 15.41  
319 0.006 0.011 0.50 0.04, 5.53  
313 0.006 0.000    
308 0.006 0.050 0.11 0.07, 0.85  
306 0.000 0.017 0.00 -9.00, -9.00  
309 0.000 0.011 0.00 -9.00, -9.00  
300 0.000 0.011 0.00 -9.00, -9.00  
*p-value is based on global p-value for single marker using FAMHAP software 
OR: odd ratio, LCI: lower confident interval, UCI: upper confident interval 
 
 
There were 130 haplotypes pairings identified between MSI found in introns 3 PTGFR gene, 
but only certain pairing was illustrated in table 3.33. The selected haplotypes were those with 
frequency found in both glaucoma and control subjects.  
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Table 3.33: Association of the haplotypes pairing of the identified MSI in PTGFR 
between glaucoma patients and controls 
Haplotypes          Frequency 
 
OR 
 
 
95% CI of OR 
LCI, UCI 
 
p-value* 
Glaucoma 
N=86 
Control 
N=90 
105 294 0.006 0.026 0.21 0.02, 1.81 0.103 
105 312 0.022 0.011 2.02  0.37, 11.19  
107 294 0.006 0.021 0.27 0.03, 2.45  
107 314 0.011 0.038 0.28 0.06, 1.38  
109 294 0.028 0.030 0.92 0.27, 3.16  
111 294 0.025 0.028 0.89 0.25, 3.21  
111 299 0.006 0.012 0.47 0.04, 5.09  
111 301 0.006 0.011 0.50 0.04, 5.53  
113 294 0.039 0.022 1.83 0.52, 6.42  
113 298 0.034 0.034 0.99 0.32, 3.09  
113 299 0.010 0.018 0.54 0.09, 3.36  
92 287 0.002 0.011 0.21 0.01, 5.84  
92 294 0.025 0.046 0.52 0.16, 1.69  
92 296 0.040 0.017 2.46 0.63, 9.61  
92 298 0.052 0.036 1.45 0.52, 4.04  
92 299 0.023 0.030 0.76 0.21, 2.77  
92 301 0.017 0.046 0.35 0.09, 1.35  
92 311 0.006 0.011 0.50 0.04, 5.53  
92 314 0.007 0.044 0.16 0.03, 1.02  
92 316 0.006 0.011 0.50 0.04, 5.53  
92 318 0.028 0.018 1.53 0.37, 6.23  
96 294 0.061 0.072 0.85 0.37, 1.94  
96 296 0.052 0.014 3.88  0.95, 15.38  
96 312 0.011 0.011 1.00 0.14, 7.18  
98 294 0.006 0.011 0.50 0.04, 5.53  
*p-value is based on global p-value for haplotypes markers using FAMHAP software 
OR: odd ratio, LCI: lower confident interval, UCI: upper confident interval 
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3.4 Discussion 
3.4.1 The role of ADRB2 as glaucoma susceptibility gene in the Malaysian population 
ADRB2 has been intensively studied in various diseases in many populations (Weir et al, 
1998; Xie et al, 2000; Hahntow et al, 2006). Most studies emphasized Arg16Gly and 
Gln27Glu polymorphisms, which were believed to be important in determining risk of 
asthma and hypertension (Brodde, 2008; Xie et al, 2000; Scott et al, 1999). However, after 
more than 2 decades the functional role of 46A/G and 79C/G are still uncertain due to 
inconsistent findings (Kotanko et al, 1997; Lee et al, 2004; Kato et al, 2001). Recently, the 
SNPs found within 1.5kb 5 untranslated region (UTR) upstream from the ATG start codon or 
the promoter region; -20 T/C, -47 T/C, -367 T/C, -468 C/G, -654 G/A, -1343 A/G and -1429 
T/A has created new interest, especially as these SNPs are believed to play an important role 
in transcriptional regulatory activity of ADRB2 (Scott et al, 1999). 
 
Great emphasis was given to codon 16 and 27 of ADRB2, which was reflected in various 
studies involving many diseases (Brodde, 2008; Xie et al, 2000; Scott et al, 1999). Previous 
studies have suggested that mutations/polymorphisms within ADRB2 were not associated 
with an increased risk of glaucoma in Turkish, Caucasians and African Americans 
populations (Güngör K et al, 2003; McLaren N et al, 2006). There was no significant 
association between 46A/G and 79C/G with susceptibility to glaucoma in Japanese but there 
was significant difference in other phenotypes: age at diagnosis and IOP at diagnosis (Inagaki 
et al, 2007).  Japanese POAG patients with 46AG and 46GG of ADRB2 were found to 
diagnose with glaucoma at younger age compared to 46AA (Inagaki et al, 2007). While those 
with 79CG and 79GG was found to have significantly higher IOP at presentation compared to 
Gln/Gln (homozygous wild).  
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In this study, five codons that were believed to be functionally important were selected 
46A/G, 79C/G, 491C/G, -20T/C and -47T/C. The minor allele of 79C/G (79G) and -20T/C (-
20C) was found to associate with the susceptibility to glaucoma. Genomic control analysis 
was not conducted due to the small number of markers included in this current study. In 
addition, the minor allele of 79C/G (79G) was found to confer protective effect against 
POAG (OR 0.3[95%CI 0.1, 0.7]) and -20C increases the susceptibility to NTG up to 2.0 folds 
(95%CI 1.1, 3.7). Thus, 79C/G and -20T/C of ADRB2 may play a role in the susceptibility to 
glaucoma in the Malaysian population. 
 
3.4.2 PTGFR as glaucoma susceptibility gene in Malaysian population 
The role of PTGFR as a risk modifying gene for glaucoma has not been studied before. A 
study on knock-out mice found that PTGFR was crucial in functionality of latanoprost 
(Crowston et al, 2004).  In addition, PTGFR was found to play an important role in 
pharmacogenetics of topical latanoprost has been observed in normal volunteers in Japan 
(Sakurai et al, 2008). SNPs at the promoter rs3753380 and at introns 1 rs3766355 of PTGFR 
were significantly associated with short term response to topical latanoprost in normal 
healthy volunteers (Sakurai et al, 2008). In our preliminary screening of the exons of PTGFR 
in a small sample of Malaysia population, we have identified 2 SNPs including 1 novel SNP 
in Malaysian population (Hoh et al, 2007). Novel SNP was identified at -97 upstream of exon 
3 (IVS-97A>T) (Hoh et al, 2007). The possibility of functional importance of this novel SNP 
was not explored in this early report (Hoh et al, 2007).  
 
The majority of the SNPs identified are intronic (non-coding) polymorphisms. In general, 
PTGFR confers protective against glaucoma in the Malaysian population.  Minor allele of 
rs11162505 and rs554185 reduce the susceptibility of glaucoma. These two intronic SNPs are 
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in linkage disequilibrium. There was significant association of GG (p=4.0 x 10
-4
) and GA 
(p=3.0 x 10
-4
) haplotypes of rs11162505 and rs554185 respectively with susceptibility to 
glaucoma. There was also significant heterogeneity between Malay and Chinese in allele 
frequency of rs11162505.  
 
Based on these findings, PTGFR appear not only to influence the response to topical 
prostaglandin analogues as previously reported, but a potential candidate gene for 
development of glaucomatous optic neuropathy (both POAG and NTG) in Malaysian people. 
This finding was based on a mixed cohort of Malay and Chinese people, and as such, 
population stratification is a concern. Genomic control analysis had shown no inflation 
suggesting lack of the possibility of gross population stratification. However, there were 
several SNPs found to associate with glaucoma in Malays but not among our Chinese people 
and vice versa.   
 
Microsatellite instability (MSI) was also identified in PTGFR in Malaysian population. There 
was „CA‟ deletion and „TA‟ insertion identified within Intron 3. However, based on the 
global p-value adopted in FAMHAP software, there was no significant association between 
the identified MSI and the susceptibility to develop glaucoma. The importance of MSI in 
glaucoma susceptibility remains to be explored. MSI was proven important in susceptibility 
of hereditary non-polyposis colorectal cancer, responsible in causing frameshift mutation that 
alter tumour suppressor gene (Peltomaki et al, 1993). 
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      CHAPTER 4 
 
___________________________________________________________________________ 
 
Pharmacogenetics of topical timolol 
and latanoprost in glaucoma patients 
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Chapter 4 
4.1 Objective 
To determine the association of ADRB2 and PTGFR gene polymorphisms with the 
responsiveness to topical timolol XE 0.5% and topical latanoprost 0.005% respectively 
 
4.2 Material and method 
4.2.1 Recruitment of subjects 
A total of 183 glaucoma patients were recruited; 97 of them were newly diagnosed glaucoma 
(58 primary open angle glaucoma and 37 normal tension glaucoma) and treated with 
monotherapy of topical Timolol 0.5% XE. Another 86 patients were treated with topical 
latanoprost 0.005% either as monotherapy (41 patients) or adjunctive therapy to topical 
timolol (49 patients).  The detail of selection criteria is available in chapter 2. Systemic co-
morbidity such as hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease and 
cerebrovascular accident were also documented based on medical record review. The detail 
of definition of systemic co-morbidity is available in chapter 2. 
 
After confirmation of the diagnosis as described in chapter 2, intraocular pressure (IOP) was 
taken using Goldmann applanation tonometry (GAT) between 8am to 12pm during the first 
visit before the commencement of medication, and was termed as baseline IOP. Topical 
Timolol 0.5% XE and latanoprost 0.005% was then prescribed to the subjects accordingly 
after demonstration of proper instillation. The importance of adherence and persistence was 
also explained to the recruited patients and their family members. Target pressure was set up 
for each individual patient. Target pressure was determined based on type and severity of 
glaucoma. IOP was measured after a month of medication. A subsequent visit was then 
scheduled at 3 months, 6 months and 12 months post commencement of treatment. IOP 
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measurement was taken and documentation of side effects was conducted during each visit. 
Humphrey visual field 30-2 test was conducted at 6 months and 12 months post 
commencement of treatment. Whenever the patients failed to achieve target IOP or 
demonstrated visual field progression, they were discontinued from the treatment protocol 
and scheduled for routine glaucoma clinic follow up. However, the available clinical data (up 
to the date of discontinuation) was included for phenotype and genotype association analysis. 
The detail of treatment schedule is available in chapter 2.  
 
At the end of the follow up period, the subjects were categorised as either responders or non 
responders based on the percentage different between IOP at the final follow up and baseline 
IOP. The cut off point for classification as responders was based on the mean IOP of 
respective topical antiglaucoma drugs. All responders (good responder) to topical Timolol 
XE 0.5% was defined as more or equal to 20% reduction from the baseline IOP. All 
responders (good responder) to topical latanoprost 0.005% were identified as having at least a 
25% reduction from the baseline IOP. Both cut off points were based on the mean percentage 
IOP reduction of Timolol XE 0.5% (22.9 SD 18.1%) and latanoprost 0.005% (26.7 SD 
19.3%) respectively. 
 
4.2.2 Genetics screening of ADRB2 and PTGFR 
Venesection was performed and 3ml of venous blood was obtained for genetic screening of 
ADRB2 and PTGFR. DNA extraction was done using commercially available QIAGEN 
QIAmp DNA Blood Mini Kit (Qiagen Inc., USA). The detail procedure for genomic DNA 
extraction was explained in chapter 3.  
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Genomic DNA was then used for further screening for ADRB2 and PTGFR. A single tube 
multiplex PCR was conducted to screen 5 codons of ADRB2 gene; allelic variants at positions 
16, 27, 164 and at 5‟ Untranslated Region (UTR) for nucleotides at positions -20 and -47 on 
the ADRB2 gene. For each of the polymorphic loci, two parallel allele-specific reactions were 
carried out; one with a wild-type specific primer and the other with a mutation specific 
primer. ADRB2 screening was conducted on 97 glaucoma subjects and 100 age and race 
matched unrelated control.  
 
A duplex PCR was carried out for primer Beta16A/G and Beta UTR-20C/T and triplex PCR 
was carried out for primer Beta27C/G, Beta164C/T and Beta UTR-47C/T. The primer Beta2-
Fw was used as a common forward primer in both duplex and triplex PCR reactions while the 
Beta 16A/G, Beta UTR-20C/T, Beta 27C/G, Beta UTR-47C/T and Beta 164C/T primers were 
the reverse primers. For detail explanations of the procedures and thermocycler settings 
referred to chapter 3. The presence of amplicons was determined by 2% agarose gel 
electrophoresis. Direct sequencing was then conducted for selected sample to confirm the 
findings. 
 
Screening of PTGFR gene was conducted on 176 samples; 86 glaucoma subjects and 90 
unrelated controls, matched for age and ethnicity. The screening of PTGFR was more 
complicated due to its size and the presence of microsatellite instability (MSI) or short 
tandem repeats (STR). In total  95 primers were designed to cover the entire PTGFR 
including 3000bp‟s upstream of 5‟UTR and 1000bp‟s downstream of 3‟UTR. Detection of 
MSI was done using special tagged forward primers. The detail of primer design is available 
in chapter 3.  
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The amplification of genomic DNA using specific primers was described in chapter 3. PCR 
product was then purified using two hydrolytic enzymes; Exonuclease I and Shrimp Alkaline 
Phosphatase (ExoSAP-IT) (USB, Affymetrix, USA) or using GENE ALL PCR purification 
Kit (General Biosystem, Seoul, Korea). The purified PCR products were then used as 
template for cycle sequencing as described in chapter 3. The cycle sequencing products were 
later purified using ethanol/alcohol precipitation technique or using gel filtration with 
Sephadex G-50 superfine beads (SigmaAldrich, Sweden) as explained in chapter 3. The 
purified product was loaded into ABI Prism 3730xl Genetic Analyzer (Applied Biosystem, 
California, USA) or ABI Prism 3100 Genetic Analyzer sequencer (Applied Biosystem, 
California, USA).  
 
Two MSIs or STRs were identified within primer sequence of IVS 3-29 and IVS 3-53 while 
screening for polymorphisms in introns 3. The quantification of MSI was done using 
capillary electrophoresis using forward primers that were designed and chemically labelled 
with fluorescent dyes (6 FAM™). The reverse primers were not labelled. The primer 
sequence was illustrated in table 3.5 of chapter 3. PCR amplification was conducted using 
premix extensor hi-fidelity PCR master mix (Thermo Scientific, ABgene, United Kingdom).  
The details of the volumes of the reagents needed were explained in detail in chapter 3.  
Passive reference dye Genesan™ROX™ 500(Applied Biosystem, USA) was used during 
labelling reaction on fluorescent dye for quantitative analysis of MSI. The reaction mixture 
then was uploaded in the sequencer machine ABI 3730xl for genotyping procedure. Analysis 
of quantification of MSI was done using Genemapper® 4.0 software. The detail explanation 
of MSI screening is available in chapter 3.  
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4.2.3 Statistical analysis 
The descriptive analysis has been outlined in chapters 2 and 3. In this chapter, the analysis 
mainly aimed to explore the associations between ADRB2 and PTGFR genetic structure and 
pressure lowering effects of topical timolol and latanoprost respectively. Wright-Fisher 
module (Fisher RA, 1930; Wright S, 1931) was used to determine the contribution of a single 
biallelic quantitative trait locus (QTL) of the gene towards the mean and variance in the 
population, as well as the covariance between relatives. Genotype value in this study was 
analysed based on the mean IOP reduction for each SNP. Additive genotype value is often 
chosen for complex disease such as glaucoma. Due to limited number of SNPs that expressed 
additive genotype effect, SNPs with significant dominant value were also selected.  
 
One way ANOVA test was conducted to determine the effect of SNPs  at 5 codons of ADRB2 
and selected  SNPs of PTGFR on mean IOP reduction at each follow-up visits. Association 
between responsiveness to topical Timolol XE 0.5% and topical latanoprost 0.005% to 
ADRB2 and PTGFR respectively was assessed by stratified Cochran Mantel-Haenszel meta-
analysis. Univariate logistic regression was then conducted on Malays and Chinese glaucoma 
patients. The effect of ADRB2 and PTGFR on the responsiveness to topical Timolol XE 0.5% 
and topical latanoprost 0.005% respectively was then determined by stepwise logistic 
regression. The final model was based backward model on combination of Malay and 
Chinese glaucoma patients. Age at initial presentation, sex, type of glaucoma, baseline IOP, 
central cornea thickness and mean deviation of Humphrey visual field analysis were also 
included in the final model of stepwise logistic regression.   
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4.3 Results 
4.3.1 Pressure lowering effect of topical timolol and ADRB2 
4.3.1.1 Demographic data 
A total of 97 glaucoma subjects were recruited for monotherapy treatment with topical 
timolol XE 0.5% (60 POAG and 37 NTG); 66 of them were Malays and 31 of them were 
Chinese. Almost two thirds of them were male (63%). Average “mean defect” on visual field 
analysis was -11.51dB (SD 8.82) and mean vertical cup: disc ratio (VCDR) of the optic disc 
was 0.80 (SD 0.60). Detailed demographic data is available in chapter 2.  
 
4.3.1.2 Long term pressure lowering effect of topical Timolol XE 0.5% monotherapy 
The mean IOP reduction of topical timolol 0.5% monotherapy was 5.4 (SD 5.1) mmHg, 
based on the difference between baseline IOP and mean IOP during follow-up. The mean 
percentage IOP reduction was 22.9% (SD 18.1). Table 2.6 in chapter 2 illustrated the details 
of IOP reduction from baseline, 1 month, 3 months, 6 months and 12 months post treatment 
with topical timolol. 
 
After 12 months of follow up, only 50 patients were still on topical timolol XE 0.5% 
monotherapy. More than 2/3 of POAG patients failed to achieve target pressure within 12 
months follow up (Table 4.1). In addition, glaucoma patients with more advanced glaucoma 
based on mean VCDR, MD and PSD and thinner CCT were associated with failure to achieve 
target pressure within 12 months follow up (Table 4.1).  
 
 
 
262 
 
Table 4.1: Univariate analysis on the predictors affecting the long term efficacy of 
topical Timolol XE 0.5% 
Characteristics Completed 12 
months treatment 
N=50 
Incomplete 12 
months treatment** 
N=47 
p-value 
Age 
Mean (SD) 
Range 
 
 
64.9 (8.7) 
41-81 
 
63.4 (9.6) 
42-82 
 
0.430* 
Sex (n (%)) 
Male 
Female 
 
32 (64.0) 
18 (36.0) 
 
 
30 (63.8) 
17 (36.2) 
 
0.00, 
0.986# 
Race (n (%)) 
Malay 
Chinese 
 
30 (60.0) 
20 (40.0) 
 
 
36 (76.6) 
11 (23.4) 
 
3.07, 
0.080# 
Hypertension^ (n (%)) 
Yes 
No 
 
 
28 (56.0) 
22 (44.0) 
 
27 (57.4) 
20 (42.6) 
 
0.02, 
0.886# 
Diabetes mellitus^ (n (%)) 
Yes 
No 
 
 
19 (38.0) 
31 (62.0) 
 
19 (40.4) 
28 (59.6) 
 
0.06, 
0.807# 
Hyperlipidemia^ (n (%)) 
Yes 
No 
 
 
25 (50.0) 
25 (50.0) 
 
18 (38.3) 
29 (61.7) 
 
1.34, 
0.246# 
Cardiovascular disorder^ (n 
(%)) 
Yes 
No 
 
 
7 (14.0) 
43 (86.0) 
 
4 (  8.5) 
43 (91.5) 
 
0.73, 
0.394# 
Cerebrovascular accident^  
(n (%)) 
Yes 
No 
 
 
 
3 (   6.0) 
47 (94.0) 
 
 
0 (   0.0) 
47 (100.0) 
 
 
0.243@ 
Type of glaucoma (n (%)) 
POAG 
NTG 
 
 
24 (48.0) 
26 (52.0) 
 
 
36 (76.6) 
11 (23.4) 
 
 
8.40, 
0.006@ 
Responder (n (%)) 
Good 
Poor 
 
 
33 (66.0) 
17 (34.0) 
 
23 (48.9) 
24 (51.1) 
 
2.89, 
0.089# 
Baseline IOP (mmHg)    
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Mean 
Range 
 
21.7 SD 6.8 
12-46 
23.7 SD 4.1 
14-32 
0.092* 
Central Corneal Thickness 
(µm) 
Mean  
Range 
 
 
517 SD 33 
431-565 
 
501 SD 35 
438-563 
 
0.027* 
Vertical CDR 
Mean  
Range 
 
 
0.78 SD 0.05 
0.7-0.9 
 
0.82 SD 0.06 
0.7-0.9 
 
0.007* 
Mean defect on HFA testing 
(dB) 
Mean 
Range 
 
-9.14 SD 7.21 
-34.28 - -2.08 
 
 
-14.03 SD 9.73 
-33.33 - -0.44 
 
0.006* 
Pattern Standard Deviation 
(PSD) in HFA testing  
Mean 
Range 
 
 
 
5.37 SD 2.81 
1.13 -13.73 
 
 
6.74 SD 3.02 
1.96- 12.78 
 
 
0.024* 
 P<0.05 is considered statistically significant based on Pearson chi-square test#, Fischer-exact 
test@ and student t-test* 
**Incomplete 12 months treatment referred to patients who failed to complete 12 months 
treatment with topical Timolol XE 0.5%. 
^ Systemic disease such as hypertension, diabetes mellitus, cardiovascular diseases, 
cerebrovascular disease and hyperlipidemia were diagnosed based on medical record and 
information from general practitioner as stated in chapter 2. Cardiovascular disease such as 
angina pectoris, myocardial infarction was included. 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, IOP: intraocular 
pressure, VCDR:  vertical cup disc ratio, HFA: Humphrey visual field analysis. 
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4.3.1.3 Predictors affecting the long term efficacy of monotherapy treatment with 
topical timolol XE 0.5% 
Sex, race, type of glaucoma, systemic co-morbidities and responsiveness to topical timolol 
were included as the categorical predictors. Age, baseline IOP, CCT, VCDR and parameters 
for visual field were included as the numerical predictors. There was no significant 
association of factors affecting long term efficacy of topical Timolol XE 0.5% in univariate 
logistic regression analysis. In spite of the absence of significant factor, baseline IOP, MD, 
PSD, CCT, type of glaucoma and responsiveness to topical Timolol were selected for 
stepwise logistic regression model.  POAG patients have 3.7 fold (95% CI 1.4, 9.5) risk of 
poor long term efficacy of topical Timolol XE 0.5% (table 4.2).   
 
Table 4.2: Factors affecting long term efficacy of topical Timolol XE 0.5% treatment by 
stepwise logistic regression model 
Variables OR(c) OR(r) SE 95% CI (LCI, UCI) p-value 
Type of 
glaucoma 
POAG 
NTG 
 
 
3.34 
-- 
 
 
3.68 
-- 
 
 
0.48 
-- 
 
 
1.43, 9.46 
-- 
 
 
0.007 
 
Responder 
Good 
Poor 
 
0.43 
-- 
 
0.45 
-- 
 
0.47 
-- 
 
0.18, 1.12 
-- 
 
0.087 
- 
 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma. 
OR: odd ratio, OR(c): crude odd ratio, OR(r): logistic odd ratio, CI: confidence interval, LCI: 
lower confidence interval, UCI: upper confidence interval 
Multicollinearity and interaction terms were checked and not found. The goodness of fit of 
the backward model was checked using the Hosmer-Lemenshow test; p=0.808. This result 
gives no evidence of lack of fit of the model. 
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4.3.1.4 ADRB2 and genotype value based on Fisher model 
Based on Fisher model, -20T/C was found to express additive genotype value in term of 
respond to topical Timolol XE 0.5% (table 4.3).  
Table 4.3: Fisher model on genotype value of ADRB2  
SNPs Additive effect 
       N=97 
Dominant effect  
         N=97 
Both 
   N=97 
f p-value 
 
f p-value f p-value 
46A/G 
 
0.09 0.767 0.52 0.473 0.36 0.695 
79C/G 
 
0.22 0.642 0.02 0.887 0.31 0.732 
-47T/C 
 
1.34 0.250 0.62 0.433 1.12 0.331 
-20T/C 
 
3.70 0.057 0.01 0.904 1.90 0.156 
 
4.3.1.5: Association between ADRB2 and pressure lowering effect of topical Timolol XE 
0.5% monotherapy 
One-way ANOVA was conducted to examine the association between ADRB2 and pressure 
lowering effect of topical Timolol XE 0.5%. In general, ADRB2 exerted more effect on 
Malay glaucoma patients compared to Chinese on pressure lowering effect of Timolol XE 
0.5% (table 4.4). Mean baseline IOP was significantly higher in Malays with 79CC and -
47CC (table 4.4). Similarly, -47CC demonstrated significantly higher mean baseline IOP in 
Chinese glaucoma patients. There was also significant difference in mean IOP of 46A/G at 12 
months post-treatment in Malays patients (table 4.4).  79C/G and -47T/C shown significant 
association with mean IOP on analysis combining Malays and Chinese (table 4.5). Mean 
baseline IOP was significantly higher in patients with 79CC and -47CC (table 4.5).  
 
 
266 
 
Table 4.4: Association between ADRB2 and pressure lowering effect of topical Timolol 
XE 0.5% in Malays and Chinese 
Visits  Malays 
                Mean IOP (SD) 
                     Chinese 
              Mean IOP (95% CI) 
                        46A/G                     46A/G 
 AA (n) AG (n) GG (n) p-value AA (n) AG (n) GG (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
25.2(5.8) 
(25) 
18.0(4.7) 
(25) 
17.0(3.1) 
(21) 
16.9(3.0) 
(15) 
14.9(2.9) 
(11) 
21.8(5.6) 
(37) 
16.9(5.2) 
(37) 
15.6(3.6) 
(32) 
15.5(2.4) 
(24) 
14.5(3.2) 
(19) 
22.8(5.9) 
(4) 
18.5(2.4) 
(4) 
18.0(8.0) 
(4) 
12.0 (--) 
(1) 
22.0 (--) 
(1) 
0.080^ 
 
0.618 
 
0.307 
 
0.113 
 
0.010 
21.2(5.7) 
(13) 
17.3(5.0) 
(13) 
16.6(4.6) 
(12) 
15.3(4.4) 
(9) 
14.3(3.7) 
(7) 
22.2(5.5) 
(18) 
16.6(3.6) 
(18) 
16.6(3.4) 
(16) 
15.8(4.8) 
(14) 
14.8(3.7) 
(12) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.601 
 
0.658 
 
0.989 
 
0.821 
 
0.795 
                       79C/G                         79C/G 
 CC (n) CG (n) GG (n) p-value CC (n) CG (n) GG (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
24.0(5.7) 
(53) 
18.0(5.0) 
(53) 
16.9(3.9) 
(45) 
16.4(2.7) 
(30) 
15.1(3.3) 
(21) 
19.7(4.2) 
(10) 
15.5(3.5) 
(10) 
13.8(2.2) 
(9) 
14.4(2.2) 
(7) 
15.3(4.8) 
(7) 
18.7(9.1) 
(3) 
13.0(1.7) 
(3) 
15.0(4.6) 
(3) 
15.3(3.1) 
(3) 
13.3(3.1) 
(3) 
0.037 
 
0.088^ 
 
0.070^ 
 
0.224 
 
0.713 
22.3(5.3) 
(28) 
17.2(4.2) 
(28) 
16.8(4.0) 
(25) 
15.8(4.8) 
(20) 
14.7(3.9) 
(16) 
17.3(6.1) 
(3) 
14.0(3.5) 
(3) 
15.0(1.7) 
(3) 
14.3(2.1) 
(3) 
14.0(1.0) 
(3) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
0.143 
 
0.216 
 
0.464 
 
0.613 
 
0.771 
                          -20T/C                            -20T/C 
 TT (n) CT (n) CC (n) p-value TT (n) CT (n) CC (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.4(4.8) 
(7) 
19.6(8.0) 
(7) 
16.7(3.7) 
(6) 
15.0(3.5) 
(4) 
15.0(6.1) 
(3) 
21.9(5.0) 
(21) 
17.1(4.2) 
(21) 
16.2(4.0) 
(18) 
15.6(2.2) 
(11) 
15.4(4.7) 
(8) 
23.9(6.4) 
(38) 
17.2(4.6) 
(38) 
16.3(3.9) 
(33) 
16.3(2.9) 
(25) 
14.8(2.8) 
(20) 
0.429 
 
0.470 
 
0.963 
 
0.591 
 
0.932 
23.3(9.2) 
(4) 
15.5(4.1) 
(4) 
15.3(3.8) 
(4) 
14.3(4.3) 
(4) 
13.0(4.8) 
(4) 
20.5(4.9) 
(12) 
16.9(4.2) 
(13) 
16.6(4.6) 
(9) 
15.6(3.8) 
(7) 
14.4(3.6) 
(7) 
22.4(5.0) 
(15) 
17.3(3.8) 
(15) 
16.9(3.6) 
(15) 
16.1(5.2) 
(12) 
15.5(3.2) 
(8) 
0.583 
 
0.771 
 
0.753 
 
0.798 
 
0.547 
                           -47T/C                              -47T/C 
 TT (n) CT (n) CC (n) p-value TT (n) CT (n) CC (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
12.0(--) 
(1) 
12.0(--) 
(1) 
11.0(--) 
(1) 
12.0(--) 
(1) 
10.0(--) 
(1) 
20.3(4.6) 
(8) 
15.9(3.7) 
(8) 
13.9(2.4) 
(7) 
15.0(2.0) 
(5) 
16.4(5.3) 
(5) 
23.7(5.8) 
(57) 
17.7(5.0) 
(57) 
16.7(3.8) 
(49) 
16.2(2.8) 
(34) 
14.9(3.1) 
(25) 
0.043 
 
0.329 
 
0.065^ 
 
0.227 
 
0.256 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
14.0(2.8) 
(2) 
12.0(0.0) 
(2) 
14.5(2.1) 
(2) 
14.0(2.8) 
(2) 
13.5(0.7) 
(2) 
22.3(5.2) 
(29) 
17.2(4.2) 
(29) 
16.7(3.9) 
(26) 
15.8(4.7) 
(21) 
14.7(3.8) 
(17) 
0.036 
 
0.090^ 
 
0.439 
 
0.611 
 
0.667 
267 
 
n: number of patients, Visit 1: IOP at 1 month, Visit 2: IOP at 3 months, Visit 3: IOP at 6 
months, Visit 4: IOP at 12 months 
P<0.05 and ^p<0.10 based on One-way ANOVA 
 
 
Table 4.5: Association between ADRB2 and pressure lowering effect of topical Timolol 
XE 0.5% monotherapy in glaucoma patients 
Visits                           Mean IOP (95%CI) 
 
p-value 
                                   46A/G 
AA 
(n) 
AG 
(n) 
GG 
(n) 
Baseline 
 
1 month 
 
3 months 
 
6months 
 
12 
months 
 
23.8 (21.8, 25.8) 
(38) 
17.8 (16.2, 19.3) 
(38)  
16.8 (15.5, 18.1) 
(33) 
16.3 (14.8, 17.8) 
(24) 
14.7 (13.1, 16.2) 
(18) 
21.9 (20.4, 23.4) 
(55)  
16.8 (15.5, 18.1) 
(55) 
15.9 (14.9, 17.0) 
(48) 
15.6 (14.5, 16.8) 
(38)  
14.6 (13.4, 15.8) 
(31) 
22.8(13.4, 32.1) 
(4) 
18.5 (14.7, 22.3) 
(4) 
18.0 (15.2, 30.8) 
(4)  
12.0 (--) 
(1)  
22.0 (--) 
(1) 
0.309 
 
0.537 
 
0.410 
 
0.418 
 
0.012* 
 
                                     79C/G  
 CC 
(n) 
CG 
(n) 
GG 
(n) 
 
Baseline 
  
23.4 (22.2, 24.6) 
(81) 
19.2 (16.4, 21.9) 
(13) 
18.7(13.9, 21.2) 
(3) 
0.020* 
1 month 
 
17.7 (16.7, 18.8) 
(81) 
15.2 (13.1, 17.2) 
(13) 
 
13.0 (8.7, 17.3) 
(3) 
0.048* 
3 months 
 
16.8 (15.9, 17.8) 
(70) 
14.1 (12.8, 15.4) 
(12) 
15.0 (13.6, 26.4) 
(3) 
0.055 
6months 
 
16.1 (15.1, 17.2) 
(50) 
14.4 (12.9, 15.9) 
(10) 
15.3 (7.7, 22.9) 
(3) 
0.344 
12 
months 
 
14.9 (13.8, 16.1) 
(37) 
14.9 (12.1, 17.8) 
(10) 
13.3 (9.7, 20.9) 
(3) 
0.762 
                                       -20T/C  
 TT 
(n) 
TC 
(n) 
CC 
(n) 
 
Baseline 
 
22.7 (18.5, 27.0) 
(11) 
21.4 (19.6, 23.1) 
(33) 
23.5(21.8, 25.2) 
(53) 
0.259 
1 month 
 
18.1 (13.5, 22.7) 
(11) 
17.1 (15.5, 18.6) 
(33) 
17.2 (16.0, 18.4) 
(53) 
0.813 
3 months 
 
16.1 (13.5, 18.7) 
(10) 
16.3 (14.7, 17.9) 
(27) 
16.5 (15.4, 17.6) 
(48) 
0.953 
6months 14.6 (11.6, 17.7) 15.6 (14.2, 17.0) 16.2 (14.8, 22.9) 0.470 
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 (8) (18) (37) 
12 
months 
 
13.9 (9.3, 18.5) 
(7) 
14.9 (12.7, 17.2) 
(15) 
15.0 (13.9, 16.1) 
(28) 
0.746 
                                     -47T/C  
 TT 
(n) 
TC 
(n) 
CC 
(n) 
 
Baseline 
 
12.0  
(1) 
19.0 (15.5, 22.5) 
(10) 
23.3 (22.1, 24.5) 
(89) 
0.013* 
1 month 12.0 
(1) 
15.1 (12.5, 17.7) 
(10) 
17.6 (16.6, 18.6) 
(86) 
0.152 
3 months 
 
11.0  
(1) 
14.0 (12.3, 15.7) 
(9) 
16.8 (15.9, 17.6) 
(78) 
0.044* 
6months 
 
12.0 
(1) 
14.7 (12.8, 16.6) 
(7) 
16.0 (15.1, 17.0) 
(55) 
0.348 
12 
months 
 
10.0 
(1) 
15.6 (11.3, 19.8) 
(7) 
14.8 (13.8, 15.9) 
(42) 
0.345 
*P<0.05 is considered statistically significant based on One-way ANOVA  
 
4.3.1.5: Responsiveness to topical Timolol XE 0.5% monotherapy and ADRB2  
The cut off point for definition of good responder to timolol was predetermined as more than 
a 20% reduction at the last IOP measurement from the baseline. Mean IOP reduction of 
topical Timolol XE 0.5% is 5.5 SD 5.0 mmHg, based on the different between the baseline 
IOP and summation of IOP divided by the number of visits.  The mean percentage of 
reduction was 23 SD 18%. Based on stratified meta-analysis, there was no significant 
association of ADRB2 and response to monotherapy treatment of topical Timolol XE 0.5% 
(table 4.6).  
 
Age at presentation, sex, type of glaucoma, CCT and baseline IOP were included as possible 
predictors for respond to topical timolol in univariate logistic regression analysis. Baseline 
IOP was found to be significant predictors for responds to topical timolol (table 4.7). 
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Table 4.6: Stratified Mantel-Haenszel meta-analysis on ADRB2 and responsiveness to 
topical Timolol XE 0.5% monotherapy 
          Malays       Chinese Stratified Meta-analysis 
  
SNPs   Allele frequency   Allele frequency OR 
(95%CI) 
SE P-
meta 
P-het 
 Good 
responder 
N=39  
Poor 
responder 
N=27 
Good 
responder 
N=17 
Poor 
responder 
N=14 
    
46A/G 
A 
G 
 
 
0.705 
0.295 
 
0.593 
0.407 
 
0.676 
0.324 
 
0.780 
0.250 
 
0.79 
(0.43, 
1.45) 
 
0.31 
 
0.446 
 
0.205 
79C/G 
C 
G 
 
 
0.897 
0.103 
 
0.852 
0.148 
 
0.971 
0.029 
 
0.929 
0.071 
 
0.60 
(0.23, 
1.58) 
 
0.49 
 
0.303 
 
0.705 
491C/T 
C 
G 
 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
1.000 
0 
 
-- 
 
-- 
 
-- 
 
-- 
-20T/C 
T 
C 
 
 
0.243 
0.757 
 
 
0.296 
0.704 
 
 
0.324 
0.676 
 
 
0.321 
0.679 
 
 
0.84 
(0.45, 
1.58) 
 
0.32 
 
0.595 
 
0.681 
-47T/C 
T 
C 
 
 
0.051 
0.949 
 
 
0.111 
0.889 
 
 
0.000 
1.000 
 
 
0.071 
0.929 
 
 
3.07 
(0.88, 
10.73) 
 
0.64 
 
0.079 
 
0.312 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
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Table 4.7: Univariate logistic regression on the predictors for responsiveness to topical 
Timolol XE 0.5% monotherapy 
Predictors OR SE 95% CI for OR p-value 
 
46A/G 
AA 
AG 
GG 
 
-- 
0.19 
0.18
 
 
-- 
1.45 
1.39 
 
-- 
0.01, 3.34 
0.01, 2.70 
 
-- 
0.258 
0.213 
 
79C/G 
CC 
CG 
GG 
 
 
-- 
0.60 
0.11 
 
-- 
1.67 
2.11 
 
-- 
0.02, 15.83 
0.00, 6.69 
 
-- 
0.260 
0.289 
-20T/C 
CC 
CT 
TT 
 
 
-- 
0.69 
1.08 
 
-- 
0.89 
0.53 
 
-- 
0.12, 3.98 
0.38, 3.04 
 
-- 
0.678 
0.885 
Sex 
Male 
Female 
 
0.71 
-- 
 
 
0.51 
-- 
 
0.27, 1.92 
-- 
 
0.502 
-- 
Age 
 
1.00 0.03 0.94, 1.05 0.856 
Type of 
glaucoma 
POAG 
NTG 
 
 
 
3.66 
-- 
 
 
 
0.83 
-- 
 
 
 
0.72, 18.68 
--- 
 
 
 
0.118 
-- 
 
Baseline IOP  
 
0.81 0.09 0.68, 0.96 0.014 
CCT 
 
0.98 0.01 0.96, 1.01 0.248 
OR: odd ratio, CI: confidence interval, POAG: primary open angle glaucoma, NTG: normal 
tension glaucoma, IOP: intraocular pressure, CCT: central corneal thickness 
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.576. 
This result gives no evidence of lack of fit of the model. 
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4.3.2: Pressure lowering effect of topical latanoprost 0.005% and PTGFR  
4.3.2.1: Demographic data 
Details of demographic characteristics are available in table 2.11 of chapter 2. A total of 87 
glaucoma (64 POAG and 22 NTG) patients were recruited; 39 of them were treated with 
topical latanoprost 0.005% monotherapy and 47 of them required adjunctive therapy. At the 
end of 12 months follow up only 65 (74.7%) patients were still part of study treatment 
protocol. As was the case with the entire cohort of subjects, more than half received 
adjunctive treatment of latanoprost, with the majority being POAG sufferers. 
Glaucoma patients who completed a full 12 months treatment were younger with less severe 
glaucoma based on vertical cup disc ratio (VCDR) and visual field parameter. Thicker CCT 
and lower baseline IOP are also found to associate with failure to complete 12 months 
treatment (table 4.8).  
 
Table 4.8: Univariate analysis on the potential clinical predictors that affect the ability 
to complete 12 months treatment of topical latanoprost 0.005% 
Characteristic 
 
Completed 12 months 
treatment 
N=65 
Incomplete 12months 
treatment** 
N=21 
p-value 
Age at presentation 
(Mean (SD)) 
66.7 SD 8.8 
 
68.1 SD 10.5 0.532# 
Ethnicity (n (%)) 
Malay 
Chinese 
 
 
44(67.7) 
21(32.3) 
 
14(66.7) 
7(33.3) 
 
0.01, 
0.931* 
Gender (n (%)) 
Male 
Female 
 
 
44 (67.7) 
21 (32.3) 
 
16 (76.2) 
5 (23.8) 
 
0.54, 
0.467* 
Mean baseline IOP 
(mmHg) 
22.0 SD 3.6 
 
23.7 SD 5.5 0.103# 
VCDR (Mean (SD)) 0.79 SD 0.08 
 
0.80 SD 0.08 0.583# 
Humphrey visual field 
(Mean SD) 
MD 
 
 
-10.91 SD 8.22 
 
 
-11.99 SD 9.21 
 
 
0.624# 
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PSD 6.42 SD 3.14 
 
6.80 SD 3.37 0.648# 
CCT (Mean SD in µm) 512 SD 37 
 
502 SD 46 0.309# 
Type of glaucoma (n 
(%)) 
POAG 
NTG 
 
 
 
46 (67.7) 
19 (27.9) 
 
 
 
18 (81.8) 
3 (13.7) 
 
 
 
0.393@ 
Treatment modalities 
(n (%)) 
Monotherapy 
Adjunctive 
 
 
32 (49.2) 
33 (50.8) 
 
 
7 (33.3) 
14 (66.7) 
 
 
 
1.62, 
0.203* 
Hypertension^ 
Yes 
No 
 
44 (67.7) 
21 (32.3) 
 
11 (52.4) 
10 (47.6) 
 
1.61, 
0.204* 
 
Diabetes mellitus^ 
Yes 
No 
 
29 (44.6) 
36 (55.4) 
 
5 (23.8) 
16 (76.2) 
 
2.87, 
0.090* 
 
Cardiovascular diseases^ 
Yes 
No 
 
10 (15.4) 
55 (84.6) 
 
1 (  4.8) 
20 (95.2) 
 
0.281@ 
 
 
Hyperlipidemia^ 
Yes 
No 
 
29 (44.6) 
36 (55.4) 
 
9 (42.9) 
12 (57.1) 
 
0.20, 
0.888* 
 
 
 P<0.05 is considered statistical significant based on Pearson chi-square test*, Fischer exact 
test@ and student t-test#. 
**Incomplete treatment referred to patients who failed to complete 12 months treatment with 
topical Latanoprost 0.005%. 
^ Systemic disease such as hypertension, diabetes mellitus, cardiovascular diseases and 
hyperlipidemia were diagnosed based on medical record and information from general 
practitioner as stated in chapter 2. Cardiovascular disease such as angina pectoris, myocardial 
infarction was included. 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, IOP: intraocular 
pressure, CCT: central corneal thickness, VCDR: vertical cup disc ratio, HFA: Humphrey 
visual field analysis. 
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4.3.2.2 Predictors affecting the long term efficacy of topical Latanoprost 0.005% 
Sex, race, systemic co-morbidities and responder were included as the categorical predictors. 
Age, baseline IOP, CCT, VCDR and parameters for visual field were included as the 
numerical predictors. There was no significant association of factors affecting long term 
efficacy of topical latanoprost 0.005% in simple logistic regression model. In spite of the 
absence of significant factor based on simple logistic regression, baseline IOP, MD, PSD, 
CCT and responder were selected for stepwise logistic regression model. It is no surprise that 
good responsiveness to topical latanoprost and higher baseline IOP were identified as 
significant predictor for long term efficacy of topical latanoprost 0.005% (table 4.9).   
 
Table 4.9: Stepwise logistic regression on factors affecting the ability of glaucoma 
patients to complete treatment protocol  
Variables OR (c) OR (r) 95% CI (LCI, UCI)(a) 
 
SE p-value 
HFA MD 0.95 0.96 0.87, 1.06 0.05 0.447 
 
HFA PSD 
 
0.89 0.92 0.77, 1.12 0.09 0.376 
Baseline IOP 0.82 0.83 0.71, 0.98 0.08 0.024 
 
Responder* 
Good 
Poor 
 
6.91 
- 
 
4.55 
- 
 
 
1.22, 16.98 
- 
 
0.67 
- 
 
0.024 
- 
 
*Good responder is based on ≥25% IOP reduction from baseline; Poor responder is based on 
<25% IOP reduction from baseline 
(a): Backward LR multiple logistic regression model was applied; OR: odd ratio, OR(c): crude 
odd ratio, OR(r): logistic odd ratio, CI: confidence interval, LCI: lower confidence interval, 
UCI: upper confidence interval  
Multicollinearity and interaction terms were checked and not found. 
The goodness of fit of the backward model was checked using the Hosmer-Lemenshow test; 
p=0.835. This result gives no evidence of lack of fit of the model. 
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4.3.2.3 SNPs of PTGFR and genotype value based on Fisher model 
The overall mean IOP reduction for each SNP was selected as phenotype value. Based on 
Fisher‟s model, rs4650581 was found to exert a significant dominant effect (p=0.007) and 
combination of additive and dominant effect (p=0.014).  On the other hand, rs2146490, 
rs34012237, rs33966768, rs3766335 and rs7543738 were significant as dominant effect but 
borderline significant on combination of both effects.  The SNP rs35978825 was borderline 
significant as dominant effect (p=0.054) and also on combination of effect (p=0.075). There 
was no significant quantitative trait locus (QTL) as addictive effect (table 4.10). Additive 
genotype value is commonly used in analysis of complex disease such as glaucoma. Thus, 
rs4650581, rs2146490, rs33966768, rs3766335, rs7543738 and rs35978825 were selected for 
subsequent analysis. 
 
Table 4.10: Quantitative trait locus on IOP reduction in PTGFR based on Fisher model 
SNPs 
N=90 
Addictive effect Dominant effect Both 
 
f p-value f p-value F p-value 
rs3766331 1.37 0.245 0.02 0.898 1.32 0.273 
rs3766355 0.15 0.703 0.72 0.398 0.40 0.673 
rs3766353 1.25 0.267 2.08 0.153 1.15 0.320 
rs35978825 1.25 0.267 3.81 0.054 2.66 0.075 
rs1830673 0.04 0.840 0.06 0.803 0.07 0.933 
rs3766351 0.27 0.602 0.05 0.817 0.25 0.776 
rs1555541 0.10 0.748 0.01 0.938 0.05 0.949 
rs10489785 1.75 0.189 1.43 0.235 0.92 0.401 
rs12094298 1.67 0.200 3.46 0.066 1.73 0.183 
rs34077564 0.01 0.903 0.90 0.346 0.46 0.633 
rs35123627 1.62 0.206 3.25 0.075 1.63 0.201 
rs2146489 0.08 0.779 0.04 0.834 0.04 0.956 
rs2057424 0.08 0.779 0.12 0.734 0.13 0.875 
rs15101588 0.99 0.322 0.01 0.913 0.52 0.599 
rs34528585 1.74 0.190 3.22 0.076 1.61 0.205 
rs12044011 0.71 0.401 0.08 0.772 0.38 0.687 
rs1322930 0.19 0.664 0.08 0.779 0.10 0.909 
rs34852041 0.42 0.517 1.02 0.316 0.59 0.557 
rs33994937 0.40 0.531 1.74 0.191 1.32 0.273 
rs6424776 0.44 0.511 0.01 0.933 0.22 0.805 
rs72673925 1.60 0.209 3.33 0.072 1.69 0.191 
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rs28832602 1.57 0.214 3.79 0.055 1.98 0.145 
rs34572897 1.73 0.192 1.66 0.201 0.97 0.383 
rs1590314 0.40 0.528 0.01 0.908 0.20 0.816 
rs12058120 0.24 0.622 1.14 0.288 0.57 0.567 
rs12725125 0.24 0.622 1.14 0.288 0.57 0.567 
rs4261075 0.00 0.987 0.03 0.870 0.01 0.986 
rs34012602 1.68 0.198 2.37 0.127 1.21 0.302 
rs67351117 3.13 0.080 1.49 0.226 1.58 0.213 
rs672561 1.73 0.192 1.67 0.199 0.99 0.377 
rs12401416 0.00 0.996 0.69 0.410 0.35 0.709 
rs6424778 0.00 0.992 0.68 0.398 0.14 0.712 
rs577333 1.04 0.311 0.19 0.667 0.52 0.597 
rs520171 2.19 0.142 1.43 0.235 1.14 0.326 
rs551253 0.03 0.858 0.04 0.836 0.11 0.899 
rs552328 2.64 0.108 1.19 0.279 1.50 0.230 
rs11162504 0.21 0.651 1.25 0.266 0.73 0.484 
rs11162505 0.06 0.814 0.18 0.674 0.11 0.897 
rs554173 0.95 0.333 0.88 0.352 0.54 0.585 
rs554185 0.66 0.417 0.22 0.637 0.82 0.445 
rs556817 1.14 0.289 0.10 0.747 0.68 0.510 
rs473027 0.49 0.488 0.13 0.720 0.26 0.770 
rs668005 0.76 0.387 0.35 0.553 0.43 0.650 
rs2146490 1.59 0.211 4.92 0.029 2.59 0.081 
rs530871 0.27 0.606 0.31 0.580 0.23 0.798 
rs538275 0.00 0.970 0.01 0.911 0.01 0.994 
rs589958 0.10 0.749 0.11 0.742 0.15 0.864 
rs3766338 0.07 0.792 0.35 0.558 0.18 0.836 
rs590309 0.00 0.982 0.28 0.601 0.15 0.863 
rs622346 0.07 0.796 0.00 0.961 0.06 0.939 
rs13374108 0.34 0.560 0.09 0.767 0.26 0.773 
rs34012237 1.60 0.210 5.38 0.023 2.84 0.064 
rs33966768 1.61 0.208 4.20 0.043 2.15 0.122 
rs501078 0.23 0.634 0.60 0.442 0.34 0.714 
rs3766335 1.61 0.208 5.48 0.022 2.86 0.062 
rs7543738 1.33 0.252 4.56 0.036 2.70 0.073 
rs686262 0.22 0.639 0.14 0.705 0.20 0.816 
rs4650581 1.52 0.220 7.58 0.007 4.49 0.014 
rs3766332 2.88 0.093 0.09 0.765 2.30 0.106 
rs3753380 1.07 0.303 0.10 0.753 0.54 0.582 
rs12093097 0.04 0.840 0.00 0.949 0.02 0.976 
rs1073610 0.63 0.429 3.72 0.057 1.87 0.160 
rs1073611 0.69 0.409 3.30 0.073 1.65 0.198 
P< 0.05 is considered statistically significant based on Fisher model 
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4.3.2.4 PTGFR and long term pressure lowering effect of topical latanoprost 0.005%  
At the end of 12 months follow up, 65 patients were still on topical latanoprost. One way 
ANOVA was conducted on the mean IOP (SD) on each follow up visit according to genotype 
of selected SNPs. The selection of SNPs of PTGFR was based on genotype value derived 
from Fisher model (table 4.10). There was no significant difference in mean IOP at each visit 
among Malay patients with open angle glaucoma (table 4.11). In general, those with 
homozygous wild presented with higher mean baseline IOP but with relatively good IOP 
reduction on subsequent visits.  
 
Due to relatively small number of glaucoma patients from Chinese descent were recruited in 
this study, majority of the SNPs were devoid of homozygous minor alleles. Chinese 
glaucoma patients with rs2146490GG were found to have significantly higher mean IOP 
compared to those with rs2146490GC at 12 months (table 4.11). There was no significant 
difference between mean IOP at each follow up visit and genotype frequency of selected 
SNPs found in PTGFR (table 4.12). 
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Table 4.11: Association between mean IOP at each follow up visits and genotype of 
selected SNPs of PTGFR in Malays and Chinese 
Visits  Malays 
                          N=58 
                  Mean IOP (SD) (mmHg) 
                     Chinese 
                       N=28 
              Mean IOP (SD) (mmHg) 
                        rs4650581                        rs4650581        
 TT (n) TA (n) AA (n) p-value TT (n) TA (n) AA (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.1(4.6) 
(48) 
15.4(2.8) 
(48) 
15.5(4.8) 
(44) 
14.9(3.1) 
(40) 
14.5(2.5) 
(34) 
23.1(3.4) 
(8) 
15.6(1.3) 
(8) 
14.0(2.7) 
(8) 
13.9(1.8) 
(8) 
15.3(3.5) 
(8) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.0) 
(2) 
16.0(0.0) 
(2) 
13.5(3.5) 
(2) 
0.422 
 
0.974 
 
0.669 
 
0.555 
 
0.667 
22.7(3.5) 
(25) 
16.1(4.0) 
(25) 
15.4(4.1) 
(24) 
16.0(3.1) 
(21) 
15.4(2.7) 
(18) 
24.3(4.7) 
(3) 
16.3(2.1) 
(3) 
13.0(3.0) 
(3) 
13.0(3.0) 
(3) 
13.3(3.5) 
(3) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.458 
 
0.916 
 
0.339 
 
0.137 
 
0.247 
 rs34012237 rs34012237 
 TT (n) TC (n) CC (n) p-value TT (n) TC (n) CC (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.1(4.5) 
(49) 
15.3(2.8) 
(49) 
15.2(4.8) 
(45) 
14.9(3.1) 
(42) 
14.4(2.5) 
(36) 
23.3(3.7) 
(7) 
15.5(0.7) 
(7) 
15.6(2.6) 
(7) 
13.8(1.7) 
(6) 
16.5(3.0) 
(6) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.0) 
(2) 
16.0(0.0) 
(2) 
13.5(3.5) 
(2) 
0.406 
 
0.749 
 
0.962 
 
0.606 
 
0.159 
22.8(3.5) 
(26) 
16.1(3.9) 
(26) 
15.4(4.0) 
(25) 
16.0(3.0) 
(22) 
15.5(2.6) 
(19) 
23.5(6.4) 
(2) 
16.0(2.8) 
(2) 
11.5(2.1) 
(2) 
11.5(2.1) 
(2) 
11.5(2.1) 
(2) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.797 
 
0.968 
 
0.190 
 
0.056 
 
0.053 
 rs3766335 rs3766335 
 GG (n) GA (n) AA (n) p-value GG (n) GA (n) AA (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.1(4.5) 
(49) 
15.3(2.8) 
(49) 
15.2(4.8) 
(45) 
14.9(3.1) 
(44) 
14.4(2.5) 
(36) 
23.3(3.7) 
(7) 
16.1(1.5) 
(7) 
15.6(2.6) 
(7) 
13.9(1.7) 
(7) 
16.5(3.0) 
(6) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.7) 
(2) 
16.0(0.0) 
(2) 
13.5(3.5) 
(2) 
0.406 
 
0.749 
 
0.962 
 
0.606 
 
0.159 
22.7(3.5) 
(27) 
16.0(3.9) 
(27) 
15.2(4.1) 
(26) 
15.7(3.2) 
(23) 
15.2(2.8) 
(20) 
28.0(0.0) 
(1) 
18.0(0.0) 
(1) 
13.0(0.0) 
(1) 
13.0(0.0) 
(1) 
13.0(0.0) 
(1) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
0.145 
 
0.622 
 
0.598 
 
0.420 
 
0.456 
 rs2146490 rs2146490 
 GG (n) GA (n) AA (n) p-value GG (n) GA (n) AA (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
22.3(4.5) 
(50) 
15.5(2.8) 
(55) 
15.0(4.8) 
(46) 
14.8(3.1) 
22.3(3.8) 
(6) 
14.8(1.6) 
(6) 
14.8(2.3) 
(6) 
14.0(1.9) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.0) 
(2) 
16.0(0.0) 
0.498 
 
0.845 
 
0.945 
 
0.676 
22.9(3.5) 
(24) 
16.3(4.0) 
(24) 
15.7(4.1) 
(23) 
15.9(3.1) 
22.5(4.4) 
(4) 
15.3(2.2) 
(4) 
12.0(1.8) 
(4) 
14.0(3.4) 
-- 
 
-- 
 
-- 
 
-- 
0.833 
 
0.636 
 
0.092 
 
0.286 
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Visit 4 
 
(42) 
14.5(2.4) 
(36) 
(6) 
15.6(3.8) 
(6) 
(2) 
13.5(3.5) 
(2) 
 
0.435 
(20) 
15.7(2.4) 
(17) 
(4) 
12.5(3.3) 
(4) 
 
-- 
 
0.035 
 rs33966768 rs33966768 
 TT (n) TC (n) CC (n) p-value TT (n) TC (n) CC (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.3(4.5) 
(48) 
15.4(2.8) 
(48) 
15.4(4.9) 
(44) 
14.9(3.1) 
(41) 
14.4(2.5) 
(35) 
22.4(4.3) 
(8) 
15.6(2.0) 
(8) 
15.8(2.7) 
(8) 
13.6(1.7) 
(7) 
16.1(2.9) 
(7) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.0) 
(2) 
16.0(0.0) 
(2) 
13.5(3.5) 
(2) 
0.498 
 
0.974 
 
0.971 
 
0.438 
 
0.233 
22.8(3.5) 
(26) 
16.1(3.9) 
(26) 
15.4(4.0) 
(25) 
16.0(3.0) 
(22) 
15.5(2.6) 
(19) 
23.5(6.4) 
(2) 
16.0(2.8) 
(2) 
11.5(2.1) 
(2) 
11.5(2.1) 
(2) 
11.5(2.1) 
(2) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.797 
 
0.968 
 
0.190 
 
0.056 
 
0.053 
 rs7543738 rs7543738 
 CC (n) CG (n) GG (n) p-value CC (n) CC (n) GG (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.1(4.5) 
(51) 
15.4(2.8) 
(51) 
15.3(4.7) 
(47) 
15.0(3.0) 
(44) 
14.6(2.6) 
(38) 
23.0(3.5) 
(6) 
15.8(1.3) 
(6) 
15.6(2.8) 
(6) 
14.2(2.0) 
(5) 
15.4(4.0) 
(5) 
18.0(--) 
(1) 
15.0(--) 
(1) 
16.0(--) 
(1) 
16.0(--) 
(1) 
16.0(--) 
(1) 
0.582 
 
0.917 
 
0.968 
 
0.828 
 
0.676 
22.7(3.5) 
(27) 
16.0(3.9) 
(27) 
15.2(4.1) 
(26) 
15.7(3.2) 
(23) 
15.2(2.8) 
(20) 
28.0(0.0) 
(1) 
18.0(0.0) 
(1) 
13.0(0.0) 
(1) 
13.0(0.0) 
(1) 
13.0(0.0) 
(1) 
-- 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.145 
 
0.622 
 
0.598 
 
0.420 
 
0.456 
 rs67351117 rs67351117 
 CC (n) CT (n) TT (n) p-value CC (n) CT (n) TT (n) p-value 
Baseline 
 
Visit 1 
 
Visit 2 
 
Visit 3 
 
Visit 4 
 
22.2(4.6) 
(48) 
15.3(2.8) 
(48) 
15.2(4.9) 
(44) 
14.8(3.1) 
(41) 
14.6(2.8) 
(36) 
22.9(3.7) 
(8) 
16.5(1.1) 
(8) 
15.8(2.6) 
(8) 
14.6(2.1) 
(7) 
15.2(1.5) 
(6) 
18.5(0.7) 
(2) 
15.5(0.7) 
(2) 
16.0(0.0) 
(2) 
16.0(0.0) 
(2) 
13.5(3.5) 
(2) 
0.459 
 
0.467 
 
0.931 
 
0.826 
 
0.745 
23.3(3.5) 
(25) 
16.3(3.9) 
(25) 
15.6(4.0) 
(24) 
16.0(3.1) 
(21) 
15.3(2.7) 
(18) 
19.5(0.7) 
(2) 
13.0(1.4) 
(2) 
10.5(0.7) 
(2) 
12.0(2.8) 
(2) 
12.5(3.5) 
(2) 
18.0(0.0) 
(1) 
17.0(0.0) 
(1) 
13.0(0.0) 
(1) 
15.0(0.0) 
(1) 
17.0(0.0) 
(1) 
0.131 
 
0.499 
 
0.201 
 
0.251 
 
0.338 
Visit 1: 1 month, Visit 2: 3 months, Visit 3: 6 months and Visit 4: 12 months post treatment 
with topical latanoprost 0.005% 
P<0.05 is considered statistically significant based on One –way ANOVA 
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Table 4.12: Association between mean IOP at each follow up visit and genotype 
frequency of selected SNPs of PTGFR   
Visits Mean IOP (95%CI) 
 
p-value 
 rs4650581  
TT 
(n) 
TA 
(n) 
AA 
(n) 
Baseline 
 
1 month 
 
3 months 
 
6months 
 
12 
months 
 
22.3(21.3, 23.3) 
(73) 
15.6(14.9, 16.4) 
(76) 
15.7(14.6, 16.8) 
(71) 
15.4(14.6, 16.1) 
(63) 
14.9(14.2, 15.6) 
(54) 
24.5(21.0, 25.9) 
(11) 
15.8(14.9, 16.7) 
(12) 
14.0(12.3, 15.7) 
(12) 
13.8(12.5, 15.0) 
(12) 
14.5(12.3, 16.7) 
(12) 
18.5(12.2, 24.9) 
(2) 
15.5(9.2, 21.9) 
(2) 
16.0(16.0, 16.0) 
(2) 
16.0(16.0,16.0) 
(2) 
13.5 (-18.3, 45.3) 
(2) 
0.289 
 
0.989 
 
0.457 
 
0.218 
 
0.708 
   
 rs34012237  
 TT 
(n) 
TC 
(n) 
CC 
(n) 
 
Baseline 
  
22.6(21.6, 23.6) 
(78) 
24.4(20.8, 28.0) 
(10) 
18.5(12.2, 24.9) 
(2) 
0.197 
1 month 
 
15.7(15.0, 16.4) 
(78) 
16.1(15.0, 17.2) 
(10) 
15.5(9.2, 21.9) 
(2) 
0.924 
3 months 
 
15.6(14.5, 16.6) 
(73) 
14.9(12.8, 17.0) 
(10) 
16.(16.0, 16.0) 
(2) 
0.899 
6months 
 
15.3(14.6, 16.1) 
(66) 
13.4(12.0, 15.0) 
(9) 
16.0(16.0, 16.0) 
(2) 
0.194 
12 
months 
 
14.8(14.2, 15.5) 
(57) 
14.9(12.2, 17.6) 
(9) 
13.5(-18.3, 25.3) 
(2) 
0.793 
   
 rs3766335  
 GG 
(n) 
GA 
(n) 
AA 
(n) 
 
Baseline 
 
22.5(21.6, 23.5) 
(79) 
25.0(21.2, 28.8) 
(9) 
18.5(12.2, 24.9) 
(2) 
0.119 
1 month 
 
15.7(15.0, 16.4) 
(79) 
16.3(15.3, 17.4) 
(9) 
15.5(9.2, 21.9) 
(2) 
0.830 
3 months 
 
15.5(14.4, 16.6) 
(74) 
15.4(13.6, 17.3) 
(9) 
16.0(16.0, 16.0) 
(2) 
0.986 
6months 
 
15.2(14.5, 16.0) 
(67) 
13.9(12.6, 15.2) 
(8) 
16.0(16.0, 16.0) 
(2) 
0.440 
12 
months 
14.8(14.1, 15.5) 
(58) 
15.5(12.9, 18.1) 
(8) 
13.5(-18.3, 25.3) 
(2) 
0.615 
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 rs2146490  
 GG 
(n) 
GA 
(n) 
AA 
(n) 
 
Baseline 
 
22.7(21.7, 23.7) 
(77) 
23.5(20.1, 26.8) 
(11) 
18.5(12.2, 24.9) 
(2) 
0.357 
1 month 15.8(15.1, 16.6) 
(77) 
15.1(14.0, 16.2) 
(11) 
15.5(9.2, 21.9) 
(2) 
0.745 
3 months 
 
15.7(14.6, 16.8) 
(72) 
14.0(12.3, 15.7) 
(11) 
16.0(16.0, 16.0) 
(2) 
0.493 
6months 
 
15.3(14.5, 16.0) 
(64) 
14.1(12.6, 15.6) 
(11) 
16.0(16.0, 16.0) 
(2) 
0.448 
12 
months 
 
15.0(11.8, 16.8) 
(55) 
14.3(11.8, 16.8) 
(11) 
13.59-18.3, 25.3) 
(2) 
0.595 
   
 rs33966768  
 TT 
(n) 
TC 
(n) 
CC 
(n) 
 
Baseline 
 
22.7(21.7, 23.7) 
(77) 
23.6(20.0, 27.3) 
(11) 
18.5(12.2, 24.9) 
(2) 
0.328 
1 month 
 
15.8(15.0, 16.5) 
(77) 
15.7(14.5, 17.0) 
(11) 
15.5(9.2, 21.9) 
(2) 
0.993 
3 months 
 
15.6(14.5, 16.7) 
(72) 
14.6(12.7, 16.6) 
(11) 
16.0(16.0, 16.0) 
(2) 
0.790 
6months 
 
15.4(14.6, 16.1) 
(65) 
13.3(12.0, 14.7) 
(10) 
16.0(16.0, 16.0) 
(2) 
0.114 
12 
months 
 
14.9(14.2,15.6) 
(56) 
14.8(12.4, 17.2) 
(10) 
13.5(-18.3, 25.3) 
(2) 
0.792 
   
 rs7543738  
 CC 
(n) 
CG 
(n) 
GG 
(n) 
 
Baseline 
 
22.5(21.6, 23.5) 
(81) 
25.0(20.8, 29.2) 
(8) 
18.0(--) 
(1) 
0.189 
1 month 15.7(15.0, 16.4) 
(81) 
16.1(15.0, 17.3) 
(8) 
15.0(--) 
(1) 
0.911 
3 months 
 
15.5(14.4, 16.5) 
(76) 
15.5(13.3, 17.7) 
(8) 
16.0(--) 
(1) 
0.993 
6months 
 
15.2(14.5, 16.0) 
(69) 
14.1(12.5, 15.8) 
(7) 
16.0(--) 
(1) 
0.647 
12 
months 
 
14.8(14.1, 15.5) 
(60) 
14.6(11.2, 17.9) 
(7) 
16.0(--) 
(1) 
0.888 
   
 rs67351117  
 CC 
(n) 
CT 
(n) 
TT 
(n) 
 
Baseline 
 
22.9(21.9, 24.0) 
(77) 
22.2(19.6, 24.8) 
(10) 
18.3(16.9, 19.8) 
(3) 
0.203 
1 month 15.7(15.0, 16.5) 15.8(14.5, 17.1) 16.0(13.5, 18.5) 0.987 
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(77) (10) (3) 
3 months 
 
15.6(14.5, 16.7) 
(72) 
14.7(12.4, 17.0) 
(10) 
15.0(10.7, 19.3) 
(3) 
0.817 
6months 
 
15.3(14.5, 16.0) 
(65) 
14.0(12.2, 15.8) 
(9) 
15.7(14.2, 17.1) 
(3) 
0.483 
12 
months 
 
14.9(14.1, 15.6) 
(57) 
14.5(12.7, 16.3) 
(8) 
14.7(6.7, 22.7) 
(3) 
0.939 
P<0.05 based on one-way ANOVA 
 
4.3.2.5 PTGFR polymorphisms and responsiveness to topical latanoprost 0.005%  
A good respond to latanoprost is defined as 25 % or more difference between baseline IOP 
and the final measurement. The minor allele frequency of rs686262 (rs686262G) 
demonstrated significant association to good respond to topical latanoprost (table 4.13). Test 
of heterogeneity was significant in a number of SNPs (rs3766353, rs12093097, rs1073610 
and rs1073611) suggesting responds to topical timolol is relatively affected by racial 
difference (table 4.13). Baseline IOP remains the strongest predictor that determines the 
respond to topical latanoprost in glaucoma patients in this present study (table 4.14 and 4.16). 
rs686262, rs37666332, rs501078, rs33994937 and rs15101588 were included in analysis of 
Malays. rs686262 and rs3766332 were included in analysis of Chinese glaucoma patients 
(table 4.15). For stepwise linear regression, only rs686262 was included (table 4.16). Age at 
the initial presentation, sex, type of glaucoma, central cornea thickness, baseline IOP and 
mean deviation of HFA were also included as predictors. rs686262GG predisposes to poor 
responds to topical latanoprost (OR 6.3[95%CI 1.3, 31.0]) (table 4.16). Baseline IOP remains 
as a strong predictor for responsiveness to topical latanoprost. 
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Table 4.13: Stratified Mantel-Haenszel analysis on PTGFR and responsiveness to 
topical latanoprost 0.005%. 
            Malays 
            N=58 
      Chinese 
        N=28 
             Stratified meta-analysis 
 
Allele frequency Allele frequency OR  
(95%CI) 
SE P-meta P-Het 
SNPs Good 
N=35 
Poor 
N=23 
Good 
N=20 
Poor 
N=8 
    
rs3766331 
A 
G 
 
0.829 
0.171 
 
0.783 
0.217 
 
0.850 
0.150 
 
0.938 
0.063 
 
0.86 
(0.37, 
2.02) 
 
0.44 
 
0.707 
 
0.485 
rs3766353 
G 
T 
 
0.757 
0.243 
 
0.848 
0.152 
 
0.725 
0.275 
 
0.438 
0.563 
 
0.90 
(0.44, 
1.84) 
 
0.37 
 
0.778 
 
0.021 
rs3766355 
C 
A 
 
0.529 
0.471 
 
0.630 
0.370 
 
0.475 
0.525 
 
0.438 
0.563 
 
1.28 
(0.68, 
2.42) 
 
0.32 
 
0.440 
 
0.421 
rs35978825 
C 
T 
 
0.886 
0.114 
 
0.891 
0.109 
 
0.925 
0.075 
 
1.000 
0 
 
1.38 
(0.45, 
4.26) 
 
0.58 
 
0.577 
 
0.290 
rs1830673 
A 
G 
 
0.471 
0.529 
 
0.457 
0.543 
 
0.300 
0.700 
 
0.313 
0.688 
 
0.97 
(0.51, 
1.85) 
 
0.33 
 
0.929 
 
0.873 
rs3766351 
T 
C 
 
0.842 
0.158 
 
0.847 
0.152 
 
0.875 
0.125 
 
1.000 
0 
 
1.44 
(0.55, 
3.80) 
 
0.50 
 
0.461 
 
0.164 
rs1555541 
T 
C 
 
0.316 
0.684 
 
0.333 
0.667 
 
0.275 
0.725 
 
0.375 
0.625 
 
1.27 
(0.65, 
2.47) 
 
0.34 
 
0.479 
 
0.680 
rs10489785 
A 
T 
 
0.900 
0.100 
 
0.891 
0.109 
 
0.925 
0.075 
 
1.000 
0 
 
1.23 
(0.39, 
3.85) 
 
0.58 
 
0.726 
 
0.259 
rs12094298 
C 
A 
 
0.929 
0.071 
 
0.935 
0.065 
 
0.950 
0.050 
 
1.000 
0 
 
1.44 
(0.35, 
5.94) 
 
0.72 
 
0.612 
 
0.401 
rs34077564 
A 
G 
 
0.855 
0.145 
 
0.813 
0.188 
 
0.875 
0.125 
 
1.000 
0 
 
1.32 
(0.50, 
3.51) 
 
0.50 
 
0.574 
 
0.145 
rs35123627 
C 
T 
 
0.900 
0.100 
 
0.913 
0.089 
 
0.925 
0.075 
 
0.938 
0.063 
 
1.18 
(0.38, 
3.64) 
 
0.58 
 
0.776 
 
0.976 
rs2146489 
A 
G 
 
0.414 
0.586 
 
0.457 
0.543 
 
0.250 
0.750 
 
0.313 
0.688 
 
1.23 
(0.64, 
2.35) 
 
0.33 
 
0.531 
 
0.855 
rs2057424         
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A 
G 
0.743 
0.257 
0.674 
0.326 
0.650 
0.350 
0.500 
0.500 
0.65 
(0.33, 
1.28) 
0.34 0.212 0.697 
rs15101588 
G 
A 
 
0.500 
0.500 
 
0.587 
0.413 
 
0.300 
0.700 
 
0.563 
0.438 
 
1.75 
(0.93, 
3.30) 
 
0.32 
 
0.084 
 
0.298 
rs34528585 
T 
A 
 
0.914 
0.086 
 
0.891 
0.109 
 
0.925 
0.075 
 
0.875 
0.125 
 
0.70 
(0.25, 
2.00) 
 
0.53 
 
0.509 
 
0.879 
rs12044011 
T 
A 
 
0.529 
0.471 
 
0.565 
0.436 
 
0.550 
0.450 
 
0.375 
0.625 
 
0.91 
(0.48, 
1.69) 
 
0.32 
 
0.754 
 
0.228 
rs1322930 
G 
A 
 
0.974 
0.026 
 
0.979 
0.021 
 
0.925 
0.075 
 
1.000 
0 
 
2.79 
(0.30, 
25.62) 
 
1.13 
 
0.366 
 
0.359 
rs34852041 
C 
T 
 
0.871 
0.129 
 
0.935 
0.065 
 
0.975 
0.025 
 
1.000 
0 
 
2.30 
(0.59, 
8.87) 
 
0.69 
 
0.228 
 
0.661 
rs33994937 
T 
C 
 
0.871 
0.129 
 
0.957 
0.043 
 
0.950 
0.050 
 
1.000 
0 
 
3.79 
(0.79, 
18.13) 
 
0.80 
 
0.095 
 
0.611 
rs6424776 
T 
C 
 
0.543 
0.457 
 
0.587 
0.413 
 
0.550 
0.450 
 
0.438 
0.563 
 
0.99 
(0.53, 
1.86) 
 
0.32 
 
0.984 
 
0.372 
rs72673925 
T 
G 
 
0.871 
0.129 
 
0.913 
0.087 
 
0.900 
0.100 
 
1.000 
0 
 
2.09 
(0.64, 
6.83) 
 
0.61 
 
0.224 
 
0.302 
rs28832602 
C 
T 
 
0.857 
0.143 
 
0.891 
0.109 
 
0.900 
0.100 
 
1.000 
0 
 
1.81 
(0.61, 
5.41) 
 
0.56 
 
0.289 
 
0.273 
rs34572897 
A 
G 
 
0.908 
0.092 
 
0.854 
0.146 
 
0.925 
0.075 
 
1.000 
0 
 
1.00 
(0.34, 
2.97) 
 
0.55 
 
0.995 
 
0.216 
rs1590314 
T 
C 
 
0.371 
0.629 
 
0.413 
0.587 
 
0.400 
0.600 
 
0.313 
0.688 
1.02 
(0.53, 
1.94) 
 
0.33 
 
0.959 
 
0.449 
rs12058120 
C 
G 
 
0.857 
0.143 
 
0.847 
0.153 
 
0.925 
0.075 
 
0.875 
0.125 
 
0.83 
(0.33, 
2.08) 
 
0.47 
 
0.694 
 
0.654 
rs12725125 
G 
A 
 
0.857 
0.143 
 
0.847 
0.156 
 
0.925 
0.075 
 
0.875 
0.125 
 
0.83 
(0.33, 
2.08) 
 
0.47 
 
0.694 
 
0.654 
rs4261075 
A 
G 
 
0.429 
0.571 
 
0.413 
0.587 
 
0.400 
0.600 
 
0.438 
0.563 
 
1.00 
(0.53, 
1.89) 
 
0.32 
 
0.999 
 
0.759 
rs34012602 
G 
 
0.886 
 
0.870 
 
0.975 
 
1.000 
 
0.95  
 
0.56 
 
0.927 
 
0.499 
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T 
 
0.114 0.130 0.025 0 (0.31 
2.87) 
rs67351117 
C 
T 
 
0.900 
0.100 
 
0.891 
0.109 
 
0.950 
0.050 
 
0.875 
0.125 
 
0.73 
(0.26 
2.06) 
 
0.53 
 
0.553 
 
0.451 
rs672561 
T 
C 
 
0.900 
0.100 
 
0.891 
0.109 
 
0.950 
0.050 
 
1.000 
0 
 
1.12 
(0.35, 
3.59) 
 
0.59 
 
0.847 
 
0.355 
rs12401416 
G 
A 
 
0.557 
0.443 
 
0.522 
0.478 
 
0.525 
0.475 
 
0.438 
0.563 
 
0.82 
(0.44, 
1.53) 
 
0.32 
 
0.526 
 
0.768 
rs6424778 
C 
T 
 
0.971 
0.029 
 
0.957 
0.043 
 
0.900 
0.100 
 
0.875 
0.125 
 
0.72 
(0.19, 
2.72) 
 
0.68 
 
0.623 
 
0.893 
rs577333 
T 
C 
 
0.357 
0.643 
 
0.413 
0.587 
 
0.250 
0.750 
 
0.375 
0.625 
 
1.39 
(0.73, 
2.67) 
 
0.33 
 
0.319 
 
0.636 
rs520171 
A 
C 
 
0.671 
0.329 
 
0.739 
0.261 
 
0.825 
0.175 
 
0.750 
0.250 
 
1.14 
(0.56, 
2.32) 
 
0.36 
 
0.714 
 
0.343 
rs551253 
G 
C 
 
0.857 
0.143 
 
0.761 
0.239 
 
0.725 
0.275 
 
0.875 
0.125 
 
0.86 
(0.39, 
1.87) 
 
0.40 
 
0.700 
 
0.086 
rs552328 
A 
G 
 
0.657 
0.343 
 
0.674 
0.326 
 
0.475 
0.525 
 
0.625 
0.375 
 
1.27 
(0.66, 
2.45) 
 
0.33 
 
0.470 
 
0.461 
rs11162504 
A 
G 
 
0.800 
0.200 
 
0.848 
0.152 
 
0.775 
0.225 
 
0.813 
0.188 
 
1.35 
(0.59, 
3.07) 
 
0.42 
 
0.476 
 
0.910 
rs11162505 
A 
G 
 
0.971 
0.029 
 
0.957 
0.043 
 
0.875 
0.125 
 
0.875 
0.125 
 
0.83 
(0.23, 
3.06) 
 
0.67 
 
0.779 
 
0.748 
rs554173 
T 
C 
 
0.843 
0.157 
 
0.826 
0.174 
 
0.800 
0.200 
 
0.688 
0.313 
 
1.28 
(0.59, 
2.81) 
 
0.40 
 
0.471 
 
0.570 
rs554185 
A 
G 
 
0.700 
0.300 
 
0.717 
0.283 
 
0.550 
0.450 
 
0.625 
0.375 
 
1.17 
(0.50, 
2.30) 
 
0.34 
 
0.647 
 
0.759 
rs556817 
A 
G 
 
0.857 
0.143 
 
0.913 
0.087 
 
0.875 
0.125 
 
0.750 
0.250 
 
1.03 
(0.41, 
2.56) 
 
0.47 
 
0.954 
 
0.142 
rs473027 
A 
G 
 
0.600 
0.400 
 
0.674 
0.326 
 
0.450 
0.550 
 
0.500 
0.500 
 
1.33 
(0.70, 
2.54) 
 
0.33 
 
0.391 
 
0.867 
rs668005 
C 
 
0.714 
 
0.673 
 
0.475 
 
0.750 
 
0.87 
 
0.32 
 
0.670 
 
0.834 
285 
 
T 0.286 0.326 0.525 0.250 (0.47, 
1.63) 
rs2146490 
G 
A 
 
0.914 
0.086 
 
0.913 
0.087 
 
0.900 
0.100 
 
1.000 
0 
 
1.50 
(0.44, 
5.12) 
 
0.63 
 
0.516 
 
0.212 
rs530871 
G 
A 
 
0.671 
0.329 
 
0.673 
0.327 
 
0.500 
0.500 
 
0.375 
0.625 
 
0.86 
(0.45, 
1.65) 
 
0.33 
 
0.650 
 
0.473 
rs538275 
G 
A 
 
0.686 
0.314 
 
0.652 
0.348 
 
0.450 
0.550 
 
0.438 
0.563 
 
0.89 
(0.46, 
1.71) 
 
0.33 
 
0.720 
 
0.888 
rs589958 
G 
A 
 
0.671 
0.329 
 
0.652 
0.348 
 
0.500 
0.500 
 
0.375 
0.625 
 
0.81 
(0.42, 
1.54) 
 
0.33 
 
0.514 
 
0.558 
rs3766338 
T 
C 
 
0.857 
0.143 
 
0.826 
0.174 
 
0.450 
0.550 
 
0.313 
0.688 
 
0.68 
(0.31, 
1.49) 
 
0.40 
 
0.336 
 
0.663 
rs590309 
T 
C 
 
0.700 
0.300 
 
 
0.652 
0.348 
 
0.450 
0.550 
 
0.313 
0.688 
 
0.72 
(0.37, 
1.39) 
 
0.34 
 
0.328 
 
0.620 
rs622346 
G 
C 
 
0.757 
0.243 
 
0.717 
0.283 
 
0.675 
0.325 
 
0.500 
0.500 
 
0.68 
(0.35, 
1.33) 
 
0.34 
 
0.256 
 
0.466 
rs13374108 
T 
A 
 
0.929 
0.071 
 
0.935 
0.065 
 
0.800 
0.200 
 
0.938 
0.063 
 
1.77 
(0.54, 
5.79) 
 
0.60 
 
0.342 
 
0.349 
rs34012237 
T 
C 
 
0.914 
0.086 
 
0.891 
0.109 
 
0.950 
0.050 
 
1.000 
0 
 
0.98 
(0.30, 
3.19) 
 
0.61 
 
0.968 
 
0.320 
rs33966768 
T 
C 
 
0.914 
0.086 
 
0.870 
0.130 
 
0.950 
0.050 
 
1.000 
0 
 
0.80 
(0.26, 
2.47) 
 
0.58 
 
0.695 
 
0.274 
rs501078 
C 
T 
 
0.457 
0.543 
 
0.326 
0.674 
 
0.400 
0.600 
 
0.250 
0.750 
 
0.55 
(0.29, 
1.08) 
 
0.34 
 
0.081 
 
0.857 
rs3766335 
G 
A 
 
0.914 
0.086 
 
0.891 
0.109 
 
0.975 
0.025 
 
1.000 
0 
 
0.87 
(0.26, 
2.94) 
 
0.62 
 
0.825 
 
0.477 
rs7543738 
C 
G 
 
0.943 
0.057 
 
0.913 
0.087 
 
0.975 
0.025 
 
1.000 
0 
 
0.76 
(0.19, 
3.02) 
 
0.70 
 
0.698 
 
0.441 
rs686262 
A 
G 
 
0.543 
0.457 
 
0.348 
0.652 
 
0.475 
0.525 
 
0.250 
0.750 
 
0.43 
(0.22, 
0.82) 
 
0.34 
 
0.011 
 
0.796 
rs4650581 
T 
 
0.886 
 
0.913 
 
0.925 
 
1.000 
 
1.76 
 
0.62 
 
0.363 
 
0.344 
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A 0.114 0.087 0.075 0 (0.52, 
5.91) 
rs3766332 
A 
T 
 
0.757 
0.243 
 
0.848 
0.152 
 
0.600 
0.400 
 
0.813 
0.187 
 
2.10 
(0.95, 
4.66) 
 
0.41 
 
0.067 
 
0.581 
rs3753380 
T 
C 
 
0.371 
0.629 
 
0.413 
0.587 
 
0.275 
0.725 
 
0.125 
0.875 
 
0.94 
(0.48, 
1.84) 
 
0.34 
 
0.848 
 
0.202 
rs12093097 
C 
T 
 
0.700 
0.300 
 
0.826 
0.174 
 
0.900 
0.100 
 
0.625 
0.375 
 
1.05 
(0.51, 
2.16) 
 
0.37 
 
0.892 
 
0.004 
rs1073610 
G 
A 
 
0.686 
0.214 
 
0.783 
0.217 
 
0.900 
0.100 
 
0.625 
0.375 
 
0.94 
(0.47, 
1.90) 
 
0.36 
 
0.886 
 
0.008 
rs1073611 
G 
A 
 
0.700 
0.300 
 
0.783 
0.217 
 
0.900 
0.100 
 
0.625 
0.375 
 
0.90 
(0.44, 
1.81) 
 
0.36 
 
0.758 
 
0.010 
OR: odd ratio, CI: confidence interval, SE: standard error  
Phet: P-value for heterogeneity between both studies (P<0.05 is considered significant 
heterogeneity based on the Breslow-Day test) 
P-meta: P-value for the meta-analysis between Malays and Chinese where the association 
between alleles and glaucoma status was measured.  
  
Table 4.14: Predictors affecting response to topical latanoprost 0.005% in Malay 
glaucoma patients 
Predictors OR SE 95% CI for OR p-value 
 
rs686262 
AA 
AG 
GG 
 
-- 
0.76 
4.03E9
 
 
-- 
1.56 
25730.22 
 
-- 
0.04, 16.06 
0.00 
 
-- 
0.858 
0.099 
rs3766332 
AA 
AT 
TT 
 
-- 
2.03 
3.56 
 
-- 
0.97 
47723.36 
 
-- 
0.30, 13.66 
0.00 
 
-- 
0.468 
1.000 
rs3399437 
TT 
TC 
CC 
 
-- 
0.21 
0.00 
 
-- 
1.29 
40192.97 
 
-- 
0.02, 2.60 
0.00 
 
-- 
0.222 
0.999 
rs501078 
CC 
CT 
TT 
 
-- 
0.48 
0.00 
 
-- 
1.66 
25730.22 
 
-- 
0.02, 12.48 
0.00 
 
-- 
0.662 
0.999 
rs15101588 
GG 
GA 
 
-- 
0.37 
 
-- 
1.17 
 
-- 
0.04, 3.71 
 
-- 
0.399 
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AA 0.24 1.48 0.01, 4.41 0.3440 
Sex 
Male 
Female 
 
0.97 
-- 
 
1.40 
-- 
 
0.11, 8.25 
-- 
 
0.974 
-- 
Age (at 
presentation) 
 
0.99 
 
0.05 
 
0.91, 1.00 
 
0.989 
Glaucoma type 
POAG 
NTG 
 
0.95 
-- 
 
1.27 
-- 
 
0.08, 11.45 
-- 
 
0.968 
-- 
Baseline IOP 0.72 0.15 0.54, 0.96 0.024 
Central corneal 
thickness 
 
1.02 
 
0.01 
 
0.99, 1.04 
 
0.280 
Mean deviation 
HFA 
 
1.01 
 
0.07 
 
0.88, 1.15 
 
0.923 
P<0.05 based on univariate logistic regression. OR: odd ratio, CI: confidence interval, 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension, IOP: intraocular pressure. The goodness of fit of this model was checked using 
the Hosmer-Lemenshow test; p=0.738. This result gives no evidence of lack of fit of the 
model. 
 
Table 4.15: Factor affecting response to topical latanoprost 0.005% in Chinese 
glaucoma patients 
Predictors OR SE 95% CI for OR p-value 
 
rs686262 
AA 
AG 
GG 
 
-- 
9.16E6 
3.03E4 
 
-- 
24854.65 
50218.26 
 
-- 
0.00 
0.00 
 
-- 
0.999 
1.000 
rs3766332 
AA 
AT 
TT 
 
-- 
0.00 
0.00 
 
-- 
11.18 
24.97 
 
-- 
0.00, 1008.68 
0.00,2.45E18 
 
-- 
0.180 
0.792 
Sex 
Male 
Female 
 
 
1.31 
-- 
 
2.19 
-- 
 
0.02, 96.20 
-- 
 
0.903 
-- 
Age (at 
presentation) 
 
 
0.84 
 
0.19 
 
0.58, 1.20 
 
0.334 
Type of 
glaucoma 
POAG 
NTG 
 
 
 
5.10E10 
-- 
 
 
 
16989.57 
-- 
 
 
 
0.00, 0.00 
-- 
 
 
0.999 
-- 
Baseline IOP  
 
0.10 1.75 0.00, 3.16 0.102 
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Central corneal 
thickness 
 
0.91 0.09 0.76, 1.09 0.304 
Mean deviation 
HFA 
2.59 0.82 0.52, 12.93 0.246 
P<0.05 based on univariate logistic regression. OR: odd ratio, CI: confidence interval, 
POAG: primary open angle glaucoma, NTG: normal tension glaucoma, OHT: ocular 
hypertension, IOP: intraocular pressure. The goodness of fit of this model was checked using 
the Hosmer-Lemenshow test; p=0.990. This result gives no evidence of lack of fit of the 
model. 
 
Table 4.16: Stepwise logistic regression on factor affecting response to topical 
latanoprost 0.005% in both Malay and Chinese glaucoma patients 
Predictors 
 
ORc ORr SE p-value 95%CI 
rs686262 
AA 
AG 
GG 
 
-- 
1.49 
6.19 
 
-- 
1.34 
6.31 
 
-- 
0.79 
0.81 
 
-- 
0.712 
0.023 
 
-- 
0.28, 6.36 
1.28, 31.02 
Baseline 
IOP 
 
0.76 
 
0.78 
 
0.77 
 
0.001 
 
0.67, 0.90 
CCT 1.01 1.01 0.01 0.102 1.00, 1.03 
P<0.05 based on stepwise logistic regression. OR: odd ratio, CI: confidence interval, IOP: 
intraocular pressure.  
The goodness of fit of this model was checked using the Hosmer-Lemenshow test; p=0.193. 
This result gives no evidence of lack of fit of the model. 
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4.4 Discussion 
4.4.1 Pressure lowering effect of timolol and ADRB2  
ADRB2 has been extensively studied in many diseases. The potential effect of ADRB2 and 
drugs response has also been studied particularly bronchodilators (Munakata et al, 2006; 
Weir et al, 1998; Tsai et al, 2006). 46A/G and 76C/G have been implicated to be responsible 
for agonist induced receptor desensitization or downregulation, with 46A enhanced down-
regulation and 76C reduced down-regulation in beta agonist drugs (Green et al, 1994; Moore 
et al, 2000). However, the association between ADRB2 and drug response is inconclusive. It 
is believed to be due to ethnic variation in allele frequency of ADRB2 (Xie et al, 2000; Lee et 
al, 2004; Brodde, 2008). 
 
Topical Timolol XE 0.5% provides reasonable pressure lowering effect in this study. 
However, only 50 glaucoma patients (51.5%) are still treated with topical timolol 
monotherapy at the end of the study protocol. 76CC and -47TT are significantly associated 
with higher mean baseline IOP. Glaucoma patients with 76CC demonstrated higher mean 
IOP at 1 and 3 months post-treatment. 76C/G was found to associate with higher IOP and 
younger age at presentation in Japanese glaucoma patients (Inagaki et al, 2006).  
 
Genetic variation of 76C/G was found to be reasonably convincing in reduction of 
bronchodilator response in the asthmatic patients (Munakata et al, 2006; Weir et al, 1998; 
Tsai et al, 2006). The impact of 76C/G in hypertension and cardiovascular diseases is not as 
convincing as in agonist response in asthmatic patients. Similarly 76C/G has not been 
identified as potential pharmacodynamic candidate gene in glaucoma management. Instead 
76C/G was found to be associated with higher likelihood to achieve ≥20% reduction from 
baseline with topical beta blockers (McCarty et al, 2008). There was significant association 
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between glaucoma patients carrying the 76C and achieving clinical significant IOP reduction. 
In fact, those with 76C have 2-fold (95%CI 1.00, 4.02) more likely to achieve clinical 
significant IOP reduction in this population based study involving Caucasians (McCarty et al, 
2008).  
 
McCarty et al (2008) conducted a population based study but the phenotype data were 
obtained retrospectively that may lead to various biases especially on the accuracy of 
obtaining IOP measurement. In addition the specific topical beta blockers were not 
mentioned. It is perhaps possible, although unlikely, that those who were 76GG or 76CG 
were treated with topical betoptic, a cardioselective beta blocker that is known to be less 
potent compared to timolol in reducing the pressure. Moreover, the definition of clinical 
significant IOP reduction at fixed or absolute figure (20% reduction) may not clinically 
represent the effectiveness of the drug. Thus, we used the IOP reduction over the time period 
in this study as a more clinically relevant endpoint. Prospective study on the pressure 
lowering effect of timolol as monotherapy allows observation of long term effect of timolol.  
 
Ethnic variation of allele frequency may also play an important role in explaining the 
difference between our study and McCarty et al (2008). For example, 76C is considered as 
wild type or common variation in Asian population (Xie et al, 2000; Lee et al, 2004) but an 
alternative variation in Caucasian population (Tomaszewski et al, 2002; McCarty et al, 2008). 
On contrary, there was no association between pressure lowering effect of timolol on healthy 
volunteers at 8 hours post instillation and ADRB2 in Caucasians residing in Europe 
(Fuchsjager-Mayrl et al, 2005). Pressure lowering effect of timolol in healthy volunteers may 
not be the same as that seen in glaucoma patients with higher baseline IOP (Katz et al, 1976; 
Boger et al, 1978). IOP reduction at 8 hours post instillation may not be ideal or reflective of 
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the actual effect of timolol due to up and down regulation of the ADRB2 receptors over a 
longer period of time. The role of ADRB2 as pharmacodynamic gene in glaucoma 
management remains elusive. There are various other factors that may affect the pressure 
lowering effect of timolol including pharmacokinetic gene such as CYP2D6. 
 
4.4.2 Pressure lowering effect and PTGFR 
 
Topical latanoprost is one of the first prostaglandin analogs introduced to the glaucoma 
pharmaceutical market. It has been proven effective in various populations and almost all 
type of glaucoma (Zhang et al, 2001). The variation of response has also been reported 
(Scherer, 2002; Cheong et al, 2008). Latanoprost provided better pressure lowering effect in 
Asians and Mexican as compared to other population (Hedmann and Larsson, 2002). 
 
To date, latanoprost and bimatoprost have been found to only activate in cell and tissue that 
express functional FP receptors (Woodwards et al, 2007; Liang et al, 2003). It is postulated 
that genetic variation of PTGFR may influence the pressure lowering effect of latanoprost. It 
was found that in homozygous mutant FP knock-out mice, latanoprost do not lower the 
pressure (Crowston et al, 2004). However, minimal pressure lowering effect was observed in 
heterozygous knock-out mice (Crowston et al, 2004).  The minimal IOP reduction in 
heterozygous knock-out mice is probably due to reduction of transcription of FP mRNA. 
Larger pressure lowering effect was observed in homozygous wild mice (Crowston et al, 
2004).  
 
 Sakurai et al (2007) found that PTGFR variation was associated with short term response to 
latanoprost in normal healthy Japanese volunteers. SNP at the promoter region, rs373380 and 
rs3766355 at introns 1 of PTGFR was found to be associated with lower percentage of 
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pressure reduction (Sakurai et al, 2007). It was then postulated that these SNPs may be 
responsible in downregulation of PTGFR expression. In the present study, these two SNPs 
were also identified in Malaysian population. However, there was no significant association 
of these SNPs with pressure lowering effect of latanoprost. Based on our pilot study 
screening the PTGFR in Malaysian population, rs3766332 was identified as novel SNP in 
Malaysian population (Hoh et al, 2007).  Upon completion of this study, we found that the 
minor allele frequency rs376632 may predisposes to good respond to topical latanoprost but 
without statistically significant association (p=0.067). However, the presence of the minor 
allele of rs686262G in the homozygous state of rs686262GG was found to predispose to poor 
respond to latanoprost up to 6.3fold (95% CI 1.3, 31.0) in the present study.  
 
Based on the Fisher‟s model for single QTL, seven SNPs in the introns 3 were identified to 
have potential dominant effect; rs4650581, rs34012237, rs3766335, rs2146490, rs33966768, 
rs6543738 and rs675351117. Interestingly, these SNPs were positioned quite closed to each 
other. The different between the present study and Sakurai et al (2007) could be due to the 
ethnic difference that resulted in different allele frequency. McCarty et al (2011) attempted to 
replicate the study by Sakurai et al (2007) as part of the Marshfield Clinic Personalized 
Medicine Research Project but failed to find significant association of rs373380 and 
rs3766355 to responsiveness to topical prostaglandin analogs. 
 
In addition, the difference in phenotypic characteristics may potentially affect the findings. 
The present study was conducted on glaucoma patients that may result in higher reduction of 
IOP. Greater reduction of IOP has been observed in POAG patients treated with latanoprost 
as compared to NTG patients, which is probably explicable on the basis of higher baseline 
IOP. The pressure reduction in normal healthy volunteers may differ from diseased patients 
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(Camras et al, 1992, Alm and Villumsen, 1991). Moreover, the present study conducted a 
longer duration of observation as compared to the earlier study. The possibility of short term 
escape or long term drift may be addressed. As latanoprost acts on receptor, similar up and 
down regulation of the receptor may occur as it has been reported with long term treatment 
with topical beta blocker (Boger, 1983). However, adherence is an important issue associated 
with long term treatment.  
 
Earlier study by Sakurai et al (2007) defined the phenotype based on specific cut off point of 
IOP reduction without considering the time effect. In this present study, the data was also 
analysed using cut off point. Higher cut off point was adopted in this present study (25% 
reduction) compared to previous studies (Sakurai et al., 2007; McCarty et al., 2011). Perhaps, 
lower cut off point will give different outcome. 
 
PTGFR is potentially an important determinant of variability of response to latanoprost in 
Malaysian population. However, how the identified SNPs caused change in the PTGFR 
product structure and function is not known, especially most of the SNPs were found in the 
intronic region. The variant in PTGFR has been reported in human ciliary body with at least 
six different isoforms (Liang et al, 2008). There is also the possibility of interaction of 
multiple genes involved in pathway of mechanism of action of topical latanoprost.  
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Chapter 5 
 
Similar to essential hypertension, glaucoma is a chronic disease. According to the mechanical 
theory, glaucoma results in glaucomatous optic neuropathy due to direct injury caused by 
increased intraocular pressure. The vascular theory explains the possibility of reduced blood 
supply to the optic nerve head due to impaired autoregulation, microvascular insult, and 
atherosclerosis; similar mechanisms have been postulated for systemic hypertension 
(Flammer et al., 1999; Flammer et al., 2007). Both essential hypertension and glaucoma are 
complex diseases, and both genetic and environmental factors (such as corticosteroid 
consumption and trauma) are responsible for the disease onset (Langman et al., 2005). 
Complex disease is often associated with multiple other factors and display genetic 
predisposition but without specific pattern of inheritance. However, the relationship between 
essential hypertension and glaucoma is still inconclusive. The current mainstay of treatment 
for essential hypertension is similar to that of glaucoma: pressure reduction to minimise 
target organ damage. Retardation of further nerve fibre layer damage is the main aim of 
glaucoma therapy. Although it is well established that intraocular pressure (IOP) is the only 
modifiable risk factor, pressure reduction does not confer a protective effect against further 
nerve fibre damage in certain patients. 
 
Topical pressure-lowering drugs are an effective, non-invasive treatment for glaucoma. 
Similar to other systemic drugs, variations have been reported in the response to topical 
pressure-lowering drugs between different populations and within the same population 
(Otaleju and Ajayi, 1999; Higginbotham et al., 2002; Netland et al., 2001; Piltz et al., 2000; 
Scherer, 2000). Variations in the response to topical ophthalmic drugs were first observed in 
1971 with the topical mydriatic drugs topical epinephrine 4% and homatropine 4% (Emiru, 
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1971). At similar drug concentrations, a longer duration of treatment was required to achieve 
mydriasis in Africans than in Caucasians (Emiru, 1971; Salminen et al., 1985). Ethnic 
influence is an intriguing issue in drug response variation. Higher amount of pigment, 
particularly in the iris, has also been implicated in drug response variation in certain 
populations (Otaleju and Ajayi, 1999; Higginbotham et al., 2002; Netland et al., 2001; Piltz et 
al., 2000). Genetic variation is believed to be responsible for both individual and population 
variations.  
 
5.1 Topical timolol and ADRB2 
5.1.1 Pressure lowering effect of topical Timolol XE 0.5% 
5.1.1.1 Mean IOP reduction  
Gellan gum, a special ingredient in timolol gel-forming solution (GFS), is a purified anionic 
heteropolysaccharide that turns into gel once it comes in contact with divalent cations in the 
precorneal tear film (Shedden, 1994). Ocular bioavailability of timolol GFS was nearly 4-fold 
higher than that of the aqueous solution in albino and pigmented rabbits (Rozier et al., 1989). 
Prolongation of ocular bioavailability reduces the instillation frequency to once daily without 
reducing efficacy. Theoretically, it also reduces systemic absorption and minimises the 
systemic side effects of non-selective topical beta-blockers (Dickstein and Aarsland, 2001; 
Uusitalo et al., 2001). 
 
Timolol GFS was found to provide almost similar pressure reduction as the aqueous solution 
in healthy volunteers and glaucoma patients, with slightly better pressure-lowering effect in 
glaucoma patients (Roselund, 1996; Shedden et al., 2001). Timolol GFS was found to 
produce 1–2 mmHg more hypotensive effect than the aqueous solution (Laurence et al., 
1993). The greater ocular hypotensive effect of the GFS was best observed between 4–8 
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hours post-instillation compared to aqueous solution (Laurence et al., 1993). However, 
timolol in aqueous solution showed better pressure-lowering effect than the GFS at 24 hours 
post-instillation (Laurence et al., 1993). This study reported short-term observations on the 
effectiveness of timolol GFS. 
 
A 3-month multicentre control trial conducted on 223 Caucasian patients showed no 
significant difference between the pressure-lowering effects of the GFS and aqueous solution 
(Roselund, 1996). Superiority of the timolol GFS was also not observed in a longer study 
(Shedden et al., 2001). However, most studies were conducted on Caucasians. Patients with 
pigmented irises required a higher concentration of timolol in the aqueous solution to achieve 
the same effect as patients with less iris pigmentation (Otaleju and Ajayi, 1999; Ong et al., 
2005; Katz and Berger, 1979). The amount of melanin is believed to be responsible for the 
variation in topical timolol responses. Reversible binding of the active ingredient in timolol to 
melanin is believed to reduce the effectiveness of timolol (Menon et al., 1989; Katz and 
Berger, 1979). This interaction is also believed to act as a slow release depot to provide 
longer pressure-lowering effects. Because GFS prolongs ocular bioavailability, perhaps it 
also improves the effectiveness of timolol in pigmented iris individuals, particularly Asian 
patients. 
 
However, limited literature is available on the effectiveness of timolol GFS in Asian patients. 
In a retrospective review involving 76 Asian glaucoma patients treated with timolol GFS 
monotherapy, the mean IOP reduction was 5.7 (standard deviation [SD] 5.3) mmHg with a 
mean percentage of reduction was 23.1% over 12 months of treatment (Ong et al., 2005). 
This study revealed that the morning dosing of timolol GFS produced a significantly better 
pressure-lowering effect than the night dosing; the morning dosing provided twice the 
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percentage of IOP reduction compared to the night dosing (Ong et al., 2005). Based on this 
finding, morning dosing was used in the current prospective study. 
  
The mean IOP reduction of timolol GFS (5.4 [SD 5.1] mmHg) in our study was almost 
similar to that of the retrospective study conducted by Ong et al. (2005). However, our 
calculation was based on the difference between baseline IOP and summation of IOP 
measurements over the follow-up period, whereas the study conducted by Ong et al. (2005) 
was based on the difference between IOP at 12 months of treatment and baseline IOP. 
Schenker et al. (2000) conducted a similar long-term study over a 12-month period to 
compare Timolol XE and timolol maleate GFS. The mean IOP reduction from baseline in 
their study ranged from 4.1 mmHg to 5.3 mmHg in glaucoma patients treated with Timolol 
XE 0.5% (Schenker et al., 2000).  
 
The mean IOP reduction from baseline in our study ranged from 6.1 mmHg to 6.8 mmHg, 
which is higher than the studies conducted by Schenker et al. (2000) and Shedden et al. 
(2001a) on mixed populations comprising a majority of Caucasians. The mean IOP reduction 
in a multicentre, double-masked, 6-month trial on Timoptic XE
®
 0.5% in a mixed population 
comprising a majority of Caucasians ranged between 6.0 and 6.4 mmHg at peak (11 am) and 
5.6 and 5.9mmHg at trough (9am)(Shedden et al., 2001a). An equal distribution of glaucoma 
patients with pigmented iris and lightly pigmented iris were recruited. In our study, IOP was 
taken between 9am to 12noon, majority were taken between 10 and 11am. IOP was obtained 
only once without considering the fluctuation of pressure. If the baseline IOP is taken at 
trough and subsequent IOP is taken at peak or vice versa, the mean IOP reduction from 
baseline will differ. There is a possibility of skewness towards pressure taken at peak rather 
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than trough, giving better pressure reduction compared to previous studies (Schenker et al, 
2000; Shedden et al, 2001a). 
 
The lack of timolol efficacy in individuals with pigmented iris, as in the Malaysian 
population, was thought to be due to the affinity of timolol for melanin (Salazar-Bookaman et 
al., 1994; Menon et al., 1989). Based on the observations in pigmented rabbits, the duration 
of action of timolol GFS was longer than that of the aqueous solution at similar concentration 
(Ohno et al., 2001). There was no evidence of increased beta-receptor occupancy rate in the 
timolol GFS group compared to the aqueous solution group (Ohno et al., 2005). Thus, it is 
unlikely that the binding affinity of timolol GFS for the beta receptor is responsible for the 
better pressure-lowering effect in our study. Longer retention of timolol GFS in the ocular 
cul-de-sac may counter the timolol-melanin binding effect and thereby improve the efficacy 
of timolol as a net effect in our study. Reversible binding of the drug to melanin in 
individuals with highly pigmented irises is believed to be responsible for the greater pressure-
lowering effect of timolol. Topical timolol in aqueous solution was reported to elicit up to a 
30% pressure reduction from baseline in Caucasians. However, 31 patients in our study 
demonstrated a good response to topical timolol GFS with up to 30% and more pressure 
reduction from baseline. Perhaps, melanin is not entirely responsible for the variation in 
timolol responses. 
 
Oral-ophthalmic drugs interaction has been reported in patients treated with oral quinidine 
and cimetidine with topical beta blocker (Edeki et al, 1995; Ishii et al, 2000). Glaucoma is 
more prevalent among elderly. Thus systemic co-morbidities such as hypertension are not 
uncommon among glaucoma patients. Salim and Shields (2010) found that 73% of glaucoma 
patients were also hypertensive in a retrospective record review study. In our present study, 
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more than half of our glaucoma patients were also hypertensive. Inadvertently, systemic 
medications may affect the effectiveness of topical Timolol XE 0.5%. In our setting, the main 
first line systemic antihypertensive medication is calcium channel blocker such as 
Amlodipine. In most developing countries, due to cost effectiveness, systemic beta blockers 
are the main first line antihypertensive medication. Our study was conducted in a teaching 
hospital, where many clinical trials have been conducted and more expensive drugs were 
available.  
 
There was no evidence of the effect oral calcium channel blockers on pressure lowering 
effect of timolol when given concomitantly in healthy Japanese volunteers (Yatsuka et al., 
1998). However, topical calcium channel blockers such as diltiazem and verapamil have 
potential effect as pressure lowering drug in animals and human (Shayegan et al., 2009; 
Siegner at al., 2000). Systemic beta blockers such as metoprolol are believed to reduce the 
efficacy of topical timolol and increase the risk of bradycardia (Schuman JS., 2000). Based 
on the available data of General Practice Research Network database in Australia, 20% of 
glaucoma patients were co-prescribed with systemic beta-blockers (Goldberg and Adena, 
2007). Systemic beta blockers were co-prescribed in 18.2% (10 patients) of our recruited 
glaucoma patients. However, there was no significant effect of systemic beta blockers on 
pressure lowering effect of topical Timolol XE 0.5%. Higher mean IOP reduction was 
observed in those who were on oral beta blockers (6.5 [3.7] mmHg) compared to oral calcium 
channel blockers (4.3 [3.8] mmHg).  
 
5.1.1.2 Long term efficacy of topical Timolol XE 0.5% 
Some patients had demonstrated a lack of IOP reduction after good IOP control during the 
treatment period. This phenomenon is known as „long-term drift‟, and was first coined by 
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Boger et al. (1978), who observed that timolol lost its effectiveness in some patients who had 
previously demonstrated good reduction in pressure over a long period. Long-term drift is 
believed to be due to the down-regulation of beta-adrenergic receptors in the eye (Boger et 
al., 1978). The pattern of mean IOP in our study did not reveal any evidence of long-term 
drift. In fact, the mean IOP reduction from baseline was greatest at the final follow-up 
measurement. However, based on the individual mean IOP reduction patterns, there was 
evidence of long-term drift and short-term escape in some patients. The disappearance of 
these effects in the final 12-month IOP patterns could be due to the fact that patients were 
dropped from the study when they failed to reach target pressure. Due to this selectivity, only 
those who demonstrated a good response to timolol GFS were analysed at the end of the 
study.  
 
Target pressure was individualised according to the severity and type of glaucoma in our 
study. Individualisation of target pressure represented the actual clinical setting. At the same 
time, it was a source of bias due to lack of standardisation in this study. In general, based on 
the mean deviation (MD) of the Humphrey visual field analysis (HFA), a majority of the 
recruited patients were in the severe stage (mean MD of -11.51dB [8.82]). Thus, a more 
stringent reduction in target pressure (30–50% reduction from baseline IOP) was adopted 
resulting in additional drug being added to the topical Timolol XE monotherapy treatment. A 
majority of our „drop outs‟ from follow-up were not due to the lack of effectiveness of 
Timolol XE but more due to not reaching the target pressure. 
 
At the end of the 12-month treatment, only 51.5% completed the entire monotherapy 
treatment. Schenker et al. (2000) found that only 71% achieved a clinically relevant response, 
predetermined as >5 mmHg IOP reduction from baseline or at least 21 mmHg IOP reduction. 
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Based on our findings, Asians patients treated with timolol GFS exhibited a better pressure-
lowering effect but failed to sustain its effectiveness through the long duration of treatment. 
A 7-year prospective study on glaucoma patients treated with topical timolol aqueous 
solution, betaxolol, and carteolol in the United Kingdom found that less than half the patients 
were able to sustain the monotherapy treatment for 5 years (Watson et al., 2001). At 12 
months, 82.3% patients were still on monotherapy treatment. The main reason for withdrawal 
was inadequate pressure-lowering effect regardless of target pressure (Watson et al., 2001). 
Similarly, in our current study, failure to achieve target pressure was the main reason. The 
more stringent individualised target pressure adopted in our study was perhaps responsible 
for the lower proportion of our patients completing the 12-month monotherapy treatment. 
Due to selectivity based on target pressure, the lowest mean IOP (14.8 [SD 3.5] mmHg) with 
the highest percentage of reduction from baseline (27.8 [SD 18.7] %) was recorded at the 12-
month follow-up. 
 
Lower target pressure was advocated for patients with more advanced glaucoma. Thus, those 
with more advanced vertical cup to disc ratio (CDR) and visual field defects were found to be 
less likely to complete the 12-month monotherapy treatment with Timolol XE in our study. 
Aggressive treatment and lower target pressure were advocated for advanced glaucoma to 
halt further nerve fibre damage. A higher mean baseline IOP was also found to be a predictor 
for failure to complete the 12-month monotherapy treatment. As expected, based on the mean 
IOP reduction in our study, a higher IOP may need more than a single therapy to achieve 
target pressure. Adherence and persistence were also related to the pressure-lowering effect 
of timolol in our population. However, we did not calculate the adherence or persistence in 
this study. Weighing the medication bottles, teaching proper instillation, and the counselling 
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conducted in our clinic were believed to be able to ascertain the adherence of our recruited 
patients.  
 
A higher baseline IOP is theoretically associated with a higher IOP reduction once treatment 
is advocated (Rulo et al., 1996). Factors that affect the baseline IOP are theoretically useful in 
predicting subsequent IOP control during the follow-up period. Collaborative Initial 
Glaucoma Treatment Study (CIGTS), a prospective, multicentre cohort study conducted on 
607 newly diagnosed patients with open angle glaucoma found that age, pseudoexfoliative 
glaucoma (type of open angle glaucoma), women, and the presence of positive relative 
afferent pupillary defects were significantly associated with baseline IOP (Musch et al., 
2008). Multivariate analysis was also conducted to identify predictors that affect the baseline 
IOP of the recruited patients in our study. Age, sex, race, type of glaucoma, central corneal 
thickness (CCT), and systemic co-morbidities, including hyperlipidemia, were included as 
possible predictors in our model.  
 
Normal tension glaucoma (NTG) was identified to be associated with significantly lower 
baseline IOP than primary open angle glaucoma (POAG). The baseline IOP for NTG was 8 -
fold lower than that of POAG (95% confidence interval [CI]: -10.1, -6.7). The pressure-
lowering effect of Timolol XE on NTG was found to be significantly lower than that on 
POAG based on repeated measure (RM) analysis of variance (ANOVA) analysis of the 12-
month follow-up measurements. Patients with NTG experienced a mean IOP reduction of 2.0 
mmHg from baseline (95% CI: 2.3, 3.7 mmHg) at 1 month compared to 7.0 mmHg (95% CI: 
5.4, 8.5 mmHg) in POAG patients. The highest mean IOP reduction of 3.5 mmHg (95% CI: 
2.6, 4.4 mmHg) or 21% reduction from baseline in NTG patients was seen at the 12-month 
follow-up. Our IOP reduction percentage was much lower than that advocated by the 
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Collaborative Normal Tension Glaucoma Study Group (1998). The group recommended a 
30% IOP reduction to prevent further visual field loss. A meta-analysis conducted on 15 
publications on common topical pressure-lowering drugs prescribed for NTG patients found 
that topical timolol aqueous solution provided mean peak and trough IOP reductions of 2.4 
mmHg (95% CI: 2.0, 2.8 mmHg) and 3.0 mmHg (95% CI: 1.7, 4.3 mmHg), respectively, 
from the baseline (Cheng et al., 2009). Even though we did not include the peak or trough 
IOP, the mean IOP reduction by timolol GFS in our study was almost similar to the mean 
peak in a previous study conducted by Cheng et al (2009). Thus, baseline IOP is a good 
predictor for determining the subsequent IOP reduction during the follow-up period.  
 
Based on univariate analysis, glaucoma patients without hyperlipidemia showed significant 
higher mean baseline IOP than those with hyperlipidemia in our study. However, RM 
ANOVA revealed no significant differences between glaucoma patients with and without 
hyperlipidemia. Glaucoma patients with hyperlipidemia demonstrated more stable pressure 
reduction than those without hyperlipidemia. All our hyperlipidemia patients were treated 
with statins, the mainstay of treatment for hypercholesterolemia. Statins are known to 
increase cerebral circulation in patients with cerebrovascular disease (Vaughan and Delanty, 
1999). Statins also inhibit rho kinase activity, which increases the aqueous outflow and 
lowers IOP (Rao et al., 2001). NTG patients treated with simvastatin for hyperlipidemia have 
a 60% reduction of risk for further visual field progression (Leung et al., 2010). Leung et al. 
(2010) also reported that patients on simvastatin exhibited slightly lower IOP that was not 
statistically significant. Confocal scanning laser polarimetry in glaucoma suspects has shown 
that statins retard the progression of structural damage to the optic nerve (de Castro et al., 
2007).  
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5.1.1.3 Side effects of topical Timolol XE 0.5% 
Two patients without any known risks of respiratory disease developed symptoms suggestive 
of respiratory impairment, and Timolol XE was discontinued. Prolonged ocular 
bioavailability reduces systemic absorption and partially protects against systemic side effects 
(Dickstein and Aarsland, 1996). The plasma concentration of timolol GFS was found to be 
lower than that of the aqueous solution; however, neither form of medication exceeded 1 
ng/mL (Shedden et al., 2001b). The 1 ng/mL plasma concentration of timolol was found to be 
more likely to induce systemic side effects. In addition, our strict selection criteria excluding 
those with respiratory and cardiovascular co-morbidities further reduced the potential 
systemic side effects. 
 
Diggory et al. (1994) found that timolol caused respiratory function impairment even in 
patients without any history of reversible airways disease. In fact, the affected patients were 
asymptomatic. His findings were later challenged for the absence of a control group, and the 
much lower values of the respiratory functions FEV1 and FVC suggest the possibility that 
patients with undiagnosed respiratory disease were recruited in his study. Betaxolol and 
timolol in aqueous solution were included in this early report on respiratory impairment in 
elderly glaucoma patients. Timolol GFS was not available at that time. Stewart et al. (2001) 
found no significant difference in FEV1, FVC, and FEV1/FVC in elderly glaucoma patients 
treated with timolol GFS and aqueous solution. The effects of timolol GFS on heart rate and 
blood pressure did not differ significantly from those of the aqueous solution (Stewart et al., 
1999).  
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5.1.2 ADRB2 and susceptibility to glaucoma 
ADRB2 gene (ADRB2) has been implicated in various diseases and responsiveness to various 
beta-blocker agonists (Kotanko et al., 1997). The main purpose of the present study was to 
evaluate the effect of ADRB2 polymorphism on the responsiveness to timolol GFS. The 
potential role of ADRB2 as the susceptibility gene for glaucoma needs to be assessed. Beta 2 
adrenoreceptors (ADRB2s) have been implicated in the regulation of aqueous humour 
formation and outflow (Trope and Clark, 1982; Nathanson, 1981; Erickson-Lamy and 
Nathanson, 1992). ADRB2s are also present in the blood vasculature of the ciliary process 
(Wax and Molinoff, 1987). ADRB2s were expressed at moderate-to-high levels in transected 
optic nerves in humans and were not expressed in areas with dead astrocytes (Mantyh et al., 
1995). There is a strong possibility that the ADRB2, which governs the functionality of 
ADRB2, is responsible for the pathogenesis and susceptibility to glaucoma via IOP 
regulation, disruption of perfusion to the optic nerve and ciliary process, or direct effect on 
nerve fibre damage. 
 
Five important single nucleotide polymorphisms (SNPs) of ADRB2; 46A/G, 79C/G, 491C/T, 
-20T/C and -47T/C, were examined in the present study because of their functional 
importance in the alteration of receptor function and receptor expression at the translational 
level (Scott et al., 1999; Green et al., 1994; Liggett, 1997). Reports on the potential role of 
ADRB2 as a susceptibility gene in glaucoma are limited. Three SNPs, 46A/G, 79C/G, and 
491C/T, were studied in POAG and primary congenital glaucoma in a Turkish population 
(Güngör et al., 2003). However, no association was found between ADRB2 and susceptibility 
to glaucoma (Güngör et al, 2003). Similarly, ADRB2 is not a susceptibility gene for POAG in 
Caucasians and African Americans, as revealed by individual SNP (46A/G and 79C/G) and 
haplotypes analyses (McLaren et al., 2007). Another study by Inagaki et al. (2006) found no 
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association between ADRB2 polymorphisms (46G/A and 79C/G) and POAG in a Japanese 
population. Despite this negative association, Inagaki et al. (2006) found that POAG 
diagnosis was made at a younger age in patients with 46AG and 46GG. 79CG and 79GG 
were associated with higher IOP compared to 79CC. ADRB2 exerts an influence on POAG in 
Japanese patients through the endophenotype of glaucoma. 
 
In our study, we found no significant difference in the allele and genotype frequencies of 
ADRB2 between glaucoma patients and control subjects. However, based on more robust 
statistical analysis; stratified meta-analysis shown that 79C/G and -20T/C is a potential 
susceptibility locus for POAG in the Malaysian population. Our finding contradicts the 
previous studies conducted in various other populations (Güngör et al., 2003; McLaren et al., 
2007; Inagaki et al., 2006).  The frequency of the 79C/G genotype in the Malaysian 
population was almost similar to the reported frequency in Chinese and Japanese populations 
(Xie et al., 1999; Inagaki et al., 2006). The frequencies of the common ADRB2 SNPs 
markedly vary with the population (Xie et al., 1999). Xie et al. (1999) found that the 
frequency of 79GG was lower in healthy Chinese volunteers than in Caucasians and African 
Americans.  
 
The Malaysian population involved in the present case-control study is an admixture of 
individuals of Malay and Chinese descent. The difference in ADRB2 SNP frequencies 
between different populations is the main cause of the inconsistent findings in case-control 
association studies on systemic diseases, such as essential hypertension (Kotanko et al., 1997; 
Kato et al., 2001; Xie et al., 2000). There is a possibility that the outcome of our case-control 
association study was influenced by population genetic variation rather than direct 
association with the disease.  
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Genomic control analysis addressed the cryptic relatedness and population heterogeneity 
between affected individuals and selected normal control subjects by calculating the inflation 
factor, λ (Devlin and Roeder, 1999). Inflation factor is best derived from at least 30 unrelated 
markers. Thus, it is not feasible to obtain the inflation factor for ADRB2 in the present study 
due to limited SNPs and several SNPs were reported to be in linkage disequilibrium (Dewar 
et al, 1998; Drysdale et al, 2000). Stratified meta-analysis on 5 codons of ADRB2 in the 
present study found no significant heterogeneity between the Malays and Chinese.  
 
SNPs at the UTR of ADRB2 were also examined in our study. A significant difference was 
observed in the -20T/C and -47T/C genotype frequencies between glaucoma patients and 
control subjects. Unfortunately, -47T/C and 46A/G violated the Hardy-Weinberg Equilibrium 
(HWE) and were excluded from haplotypes analysis.  The violation of HWE persists even 
after the analysis was conducted according to sub-population; Malays and Chinese. There 
was also no significant difference between Malays and Chinese based on Breslow-Day test of 
heterogeneity in stratified Mantel-Haenszel meta-analysis. It therefore appears unlikely that 
population stratification is responsible for the departure from HWE.  
 
The most common cause of departure from HWE is genotyping error (Hosking et al, 2004). 
The single tube multiplex PCR method adopted in our study is inexpensive, fast, and a 
relatively reliable technique. However, contamination may affect its accuracy (Zilfalil et al., 
2006). We repeated the test more than once for samples with non-satisfactory, unreliable, or 
suspected contaminated gel electrophoresis results. To further ascertain the results, 
sequencing was also performed for a majority of samples. The relatively small sample size 
may also have contributed to the departure from HWE. ADRB2 screening was conducted on 
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197 samples in the present study. Although we reached the targeted sample size with 80% 
power, it was still considered relatively small. There could be other biological effects, which 
are not known yet. For example the SNPs could be associated with other conditions that are 
not tested in this present study.  
 
Other possible reason is the presence of copy number variations (CNVs). CNVs are structural 
variations resulted from errors during mitosis and meiosis, causing duplications and deletions 
of large genomic segment that differ from reference sequence. CNVs are found in 12% to 
15% of human genome and 56% of CNVs are found within known gene (Redon et al., 2006; 
Iafrate et al., 2004). There is the possibility that SNPs may fall in the CNV region. Lee et al. 
(2008) conducted Bayesian analysis to study the potential effect of CNV on the behaviour of 
SNPs. They concluded that violation of HWE could be due to the SNP falls in the CNV 
region (Lee et al., 2008). Xu et al. (2011) reported common and rare CNVs in 3 main ethnic 
groups in Singapore; Chinese, Malays and Indians. There is ethnic difference in distribution 
of CNVs in these 3 main ethnic groups. 
 
Vine and Curtis (2009) contributed marked departure from HWE in genome wide association 
involving 463842 markers from 1504 British subjects to gene harbouring embryonic survival.  
However, our study was unable to rule out these possibilities. In addition, meta-analysis study 
conducted on 72 primary gene –disease studies found that only 46 studies reported HWE 
violation (Minelli et al., 2007). It is suggested no benefit to exclude the findings from these 
studies unless there is valid ground for rejection (Minelli et al., 2007; Trikalinos et al., 2006). 
Moreover, it was found that excluding the SNP that violate HWE does not alter the common 
odd ratios of other SNPs in case-control association studies (Trikalinos et al., 2006). Any 
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finding including statistically significant association derived from 46A/G and -47T/C in the 
present study were excluded or ignored.   
 
The frequency of non-synonymous SNP at position 491 (491C/T) is rather low in the Asian 
population. There was no variation from the homozygous for the common allele of 491C/T in 
our population.  Heterozygous form of 491C/T was considered a minor allele in our study 
population. The homozygous 491TT (Ile164) exhibited extensive signalling defects in an in 
vitro study (Green et al., 1993). Güngör et al. (2003) reported only the presence of 
homozygous for the common allele and heterozygous form of 491C/T in both glaucoma 
patients and control subjects. The 491CT (Thr164Ile) variant is very rare, occurring in 2–4% 
of all populations (Small et al., 2003). Ligget et al (1998) found that heterozygous form 
491C/T was associated with significant poor survival and increased the needs of heart 
transplant in patients with congestive heart failure. Perhaps due to rather small sample size 
and selection bias, the heterozygous form of 491C/T was not found in the current study.  
 
It is also known that SNPs in the 5′-leader cistron and the coding region are linked and form 
specific haplotypes. Haplotypes allow genotype combinations to produce cumulative effects 
on the phenotype. Strong linkage disequilibrium in ADRB2 was observed between 79G and -
47T resulted in subjects homozygous for the most common allele for -47T, almost all are also 
homozygous for 46G/A (Small et al, 2003). The most common haplotypes was -
47T46G79G491C (Arg19Gly16Glu27Thr164). Haplotypes frequency varies with the 
population. Linkage disequilibrium reduces the need to study all the functional SNPs of 
ADRB2, because the SNP variations can be predicted with some certainty from the linkage 
disequilibrium. In the present study, haplotypes analysis was only conducted on -20T/C and 
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79C/G. 46G/A and -47T/C were excluded due to violation of HWE. Non-polymorphic 
Thr164Ile was also excluded.  
 
ADBR2 screening of peripheral blood leukocytes from the Malaysian glaucoma patients and 
control subjects suggested that -20T was associated with a 1.7-fold difference (95% CI: 1.1, 
2.7) in the susceptibility to glaucoma. 79G confers potential protective effects against 
susceptibility to glaucoma. These two SNPs were in 84% linkage disequilibrium. 79C/G is 
resistant to agonist-promoted down-regulation (Liggett, 1997). A higher concentration of 
isoprenaline was needed to down-regulate the 79GG to achieve similar results as the 79CC in 
human airway smooth muscle (HASM) cells (Green et al., 1995). Locally applied 
isoprenaline produced a larger increase in forearm blood flow and vein dilatation in subjects 
with 79GG (Dishy et al., 2001). Aqueous humour formation is believed to be regulated by the 
adrenergic system, particularly ADRB2. The production of aqueous humour is related to 
activation of adenyl cyclase and synthesis of cAMP from ATP. Ciliary process ADRB2 is 
stimulated by circulating agonists, such as catecholamine, epinephrine, and norepinephrine, 
during aqueous humour production, and the presence of antagonist drugs, such as timolol, 
reduces aqueous humour production (Nathanson, 1980).  
 
Assuming that the functional alteration induced by genetic variants of ADRB2 in blood 
leukocytes are similar to those in ciliary processes, the lower resistance of 79CC to agonist-
promoted down-regulation presumably results in the maintenance of the aqueous humour 
production rate. Subsequently, if the outflow remains constant, production and outflow are in 
equilibrium and IOP is maintained within normal range. Presumably, there is also no change 
in blood flow in the ciliary processes, as ADRB2 also governs vessel activity. The end result 
is an absence of IOP elevation and a reduction in the risk of glaucoma. Perhaps, this 
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assumption helps to explain the protective effect of 79G in our POAG patients. 79G reduced 
the risk of POAG by 0.3-fold (95% CI: 0.1, 0.7; p = 0.005) but not the risk of NTG.  
 
To the best of our knowledge, no studies have been conducted on the promoter region of 
ADRB2 in glaucoma patients to date. The promoter region, including the beta upstream 
peptide (BUP), is believed to act as a translational inhibition system. SNPs in the promoter 
region have shown the potential to alter ADRB2 expression (Scott et al., 1999).The functional 
role of -20T/C has not been well studied compared to -47T/C. The functionality of the SNPs 
in the promoter region is studied using luciferase reaction. Luciferase is used to report the 
transcriptional activity in certain cells that are transfected with a genetic construct containing 
luciferase gene under the control of the promoter of certain gene. Luciferase activity was 
significantly reduced in COS-7 cells transfected with  -20C and -47C (Scott et al., 1999). -47 
is located within a small open reading frame (spanning -102 to -42) that encodes a 19-amino 
acid polypeptide, which is thought to modulate the translation of ADRB2 mRNA (Parola and 
Kobilka, 1994). -47C changes the amino acid from cysteine to arginine and causes down-
regulation of receptor expression in 
125
Iodine radioligand-binding experiments and luciferase 
assays (McGraw et al., 1998). In contrast, -47T/C and -367T/C were found to have no effects 
on ADRB2 expression either as single polymorphisms or as haplotypes in human peripheral 
blood mononuclear cells derived from asthmatic patients (Lipworth et al., 2002). The effect 
of isoprenaline on cAMP regulation was also unaffected. The allele and genotype frequencies 
of -47T/C were significantly different between glaucoma patients and control subjects in our 
study. Allele frequency of -47C was higher in glaucoma patients, suggesting that alteration of 
ADRB2 expression may play a role in susceptibility to glaucoma. However, the role of -
47T/C in susceptibility to glaucoma needs to be interpreted with caution in the presence of 
HWE violation. 
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Despite the evidence indicating a role for -20T/C in receptor expression in vitro, -20T/C does 
not alter known transcription factor-binding sites and is deemed functionless as an individual 
variant (Lipworth et al., 2002; Panebra et al., 2007). Moreover, there is no evidence for the 
involvement of -20T/C in the susceptibility to hypertension and risk of myocardial infarction 
in 2 large studies involving European-derived populations (Herrmann et al., 2002). Despite 
these negative associations, -20T/C demonstrated a strong association with glaucoma 
susceptibility in our study.  -20T also increased the risk of NTG 2.0fold (95%CI 1.1, 3.7) in 
this present study. Variation in genotype frequency between races may contribute to this 
observation. Due to little emphasis on the promoter region of ADRB2, comparison with other 
populations was not possible.  
 
Strong linkage disequilibrium was not only observed between SNPs in the promoter and 
coding regions but also within the promoter region. Johnatty and co-workers (2002) studied -
468C/G, -367T/C, -47T/C and -20T/C, 4 important SNPs in the promoter region, and 
identified 2 haplotypes GCCT and CTCT that cause a 3-fold reduction in luciferase activity 
compared to the reference haplotypes (CTTT). They concluded that polymorphisms in the 
promoter region interact to alter ADRB2 expression. The degree and direction of alteration 
was haplotypes-dependent with significant impact attributable to the -47C variant (Johnatty et 
al., 2002; Panebra et al., 2010). Haplotypes analysis with -47T/C was not possible in our 
study due to the departure from HWE. Nevertheless, we found that ADRB2 is a potential 
susceptibility gene for glaucoma in our population. The next question was does ADRB2 alter 
the response to timolol in our glaucoma patients? 
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5.1.3 ADRB2 and pressure lowering effect of topical Timolol XE 0.5% 
The role of ADRB2 in the pharmacological response to agonist drugs for various conditions, 
particularly asthma, has been extensively studied (Tan et al., 1997; Martinez et al., 1997; 
Israel et al., 2000). Despite several replication studies in various populations on beta-agonists 
in asthmatic patients, there is no conclusive evidence on the influence of ADRB2. Similarly, 
studies on systemic beta-antagonists used for essential hypertension treatment failed to 
produce concrete evidence on the influence of ADRB2 (Kotanko et al., 1997; Kato et al., 
2001; Tomaszewski et al., 2002). 
 
The phenotypic end points in our study are presented in mean IOP over 12 months of 
treatment and also using predetermined cut-off point of responsiveness to topical Timolol 
XE. A predetermined cut-off point for drug responsiveness has been adopted in many 
genotype-phenotype association studies. A good response to topical Timolol XE was defined 
at a predetermined level of 20% from baseline. This level was selected based on the mean 
percentage of IOP reduction in our study (23 [SD 18] %). Adjusting to different 
predetermined levels will result in different outcomes. For example, if the reduction is 
lowered to 15%, more patients would have been categorised as good responders. Moreover, 
this value is rather artificial and is particularly related to IOP. IOP fluctuation occurs over 24 
hours and seasonally (David et al., 1992). The significance of IOP fluctuation in the 
progression of glaucoma remains inconclusive. 
 
Glaucoma patients with 79CC demonstrated significantly higher mean baseline IOP 
compared to those with 79GG and 79CG. Our finding contradicts the previous finding in 
Japanese patients with POAG (Inagaki et al, 2006). Japanese patients with POAG 
demonstrated higher baseline IOP in 79GG and 79CG. Population variation could be 
315 
 
responsible for this observation. In fact, 79CC exerted strong effect on mean baseline IOP in 
Malays but not in Chinese in the present study. In the present study, more robust stratified 
Mantel-Haenszel meta-analysis on the allele frequency was conducted compared to Pearson 
chi square test on genotype frequency conducted in previous study. The previous study, may 
creates biased by combining the genotypic variant (79GG and 79CG) as one group and 
assumed 79CC as a reference (Inagaki et al, 2006).  
 
Glaucoma patients with 79CC showed significant higher mean IOP at 1 month and 3 months 
post-treatment compared to 79GG and 79CG. The genotypic effect diminished after 3 months 
of treatment. This could be due to the diminishing number of patients on monotherapy 
treatment with topical timolol GFS and diluting the genotypic effect. Quite substantial 
number of patients failed to achieve target pressure and „dropped out‟ from the study 
protocol. 79C/G may play a role in determining the pressure lowering effect of topical 
timolol in Malaysian glaucoma patients.  
 
Glaucoma patients with -47TT also demonstrated significant higher mean baseline IOP 
compared to -47CC and -47TC. However, there was no significant difference of mean IOP on 
subsequent follow-up. There was also significant association between 46A/G and mean IOP 
at 12 months post-treatment in our glaucoma patients when 46GG was included. However, 
only 1 patient with 46GG completed the 12-month monotherapy treatment, and excluding 
this patient resulted in no significant association. Depleted sample size due to incomplete 
monotherapy treatment reduced the power of the study. In addition, the role 46G/A and -
47T/C in pressure lowering effect of topical timolol in this present study needs to be 
interpreted with caution in the presence of HWE violation. 
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Fuchsjager-Mayrl et al. (2005) conducted a study on 89 healthy volunteers with genotypes 
that expressed the 3 main haplotypes of ADRB2 coding region non-synonymous SNPs: 
46A76C, 46G76G, and 46G76C. Topical timolol was prescribed and IOP was measured at 
8.00 AM, 12.00 noon, and 6.00 PM. IOP reduction patterns and RM ANOVA was used for 
genotype-phenotype analysis (Fuchsjager-Maryl et al., 2005). There was no significant 
association between these haplotypes and the short term IOP reduction patterns. In spite of 
recruiting healthy non-smoker Caucasian volunteers, the IOP at 4 hours post-instillation was 
found to exhibit a 40% reduction from baseline, which is almost twice the reduction in our 
population. This provides additional evidence that timolol may produce a better pressure-
lowering effect in less pigmented individuals. ADRB2 does not play a role in determining 
short term pressure lowering effect of topical timolol in Caucasians.  
 
Contradictory finding was observed in The Marshfield Clinic Personalized Medicine 
Research Project (PMRP) on 210 patients treated with topical beta-blockers for 3 months 
found that 79C/G was associated with the responder rate in topical beta-blocker treatment 
(McCarty et al., 2008). McCarty et al. (2008) also studied SNPs in MYOC, OPTN, ADRB1, 
and CYP2D6. Only two SNPs of ADRB2, 46A/G and 79C/G, were studied. The promoter 
region of ADRB2 was not included, and haplotypes analysis was not conducted. A 
predetermined cut-off point of 20% and higher from baseline was adopted in this study. 
Patients with 79C were 2.0 times (95% CI: 1.0, 4.0) more likely to achieve 20% or more IOP 
reduction from baseline (McCarty et al., 2008). The selected cut-off point for clinically 
meaningful IOP reduction was similar to that in our study. We believe that the ethnic 
variation in our population is may be partly responsible for the contradictory results. 
However, the topical beta-blockers prescribed to the patients treated in Marshfield Clinic 
were not specific (McCarty et al., 2008). Most likely both non-selective and selective beta-
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blockers were included. The possibility of topical timolol GFS use was not mentioned. Thus, 
if betaxolol had been included the overall percentage of IOP reduction would have definitely 
been different. The pressure-lowering effect of betaxolol is significantly lower than that of 
timolol or carteolol (Watson et al., 2001). Furthermore, a 3-month follow-up period was too 
short for short-term escape or long-term drift to have taken occurred. Inevitably, a higher 
proportion of patients achieved 20% or more IOP reduction from baseline. Despite certain 
drawbacks of this study, ADRB2 is a candidate pharmacodynamic gene in determining the 
response to topical beta-blockers in Caucasian populations (McCarty et al., 2008).  
 
The difference in phenotypic observation may be responsible to the contradictory finding 
between Fushjager-Maryl et al (2005) and McCarty et al (2008) in Caucasian population. 
Similarly, our study showed contradictory observation in difference phenotypic clinical 
observation. There was no significant association between ADRB2 and responsiveness to 
topical timolol GFS based on predetermined cut off point of 20% reduction of pressure from 
baseline.  
 
ADRB2 is a potential pharmacodynamic gene in Malaysian glaucoma patients. Timolol is a 
non-selective beta-blocker, and the drug target receptor also involves ADRB1 and interacts 
with other receptors, particularly the serotonin receptor (5-HT1A). The molecular structure of 
the serotonin receptor (5-HT1A) is almost similar to that of ADRB; both are GPCRs. Due to 
structural similarity, timolol has some affinity for the 5-HT1A receptor in ciliary processes 
(Inoue-Matshuhisa et al., 2003). To further understand the variation in responsiveness to 
timolol, other target receptor genes, such as ADRB1 and 5-HT1A, should be screened. Timolol 
is partially metabolised by cytochrome P450 (CYP2D6). Yuan et al (2010) conducted a study 
123 glaucoma patients treated with topical timolol aqueous solution to look into association 
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of responsiveness to timolol and heart rate. CYP2D6 rs16947 was found to increase the 
susceptibility to timolol-induced bradycardia. In addition, oral cimetidine given together with 
topical timolol causes further reduction of heart rate and improved pressure lowering effect of 
timolol (Ishii et al, 2000). Drug-metabolising enzymes, such as cytochrome P450 (CYP2D6), 
and other downstream pathways, such as adenylyl cyclase, and ion channels may also interact 
and result in individual and population variations in response to topical timolol.  
 
5.2 Topical latanoprost and PTGFR 
5.2.1 Pressure lowering effect of topical latanoprost 0.005% 
Latanoprost was reported to be a more effective glaucoma treatment than timolol in Asian 
and Mexican populations, based on 8 clinical trials conducted in the USA, UK, Scandinavia, 
Mexico, China, Philippines, Korea and Japan (Hedmann and Larsson, 2002). In those studies, 
diurnal intraocular pressure (IOP) was measured in the morning, at noon, and in the afternoon 
of the baseline visit and again at 3 and 6 months after initiation of treatment. The mean 
diurnal IOP reduction was reported to be 7.9 (SEM 0.3) mm Hg (32%) in patients treated 
once daily with latanoprost and 6.4 (0.3) mm Hg (26%) in patients treated with timolol twice 
daily. This difference was statistically significant and demonstrated superior IOP reduction 
by topical latanoprost once daily. This study also noted that the largest difference in mean 
diurnal IOP between the 2 treatments was observed in Asians and Mexicans. It was 
postulated that differences in iris pigmentation in these subjects might underlie this 
difference. In contrast, another study revealed no significant differences between topical beta-
blockers and prostaglandin analogues in IOP reduction in African American and Caucasian 
patients with ocular hypertension (OHT) (Mansberger et al., 2007).  
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The mean IOP reduction from baseline and mean percentage IOP reduction by latanoprost in 
our study were 7.1 (4.2) mm Hg and 27% (19%), respectively. This was a slightly smaller 
reduction than the previous reports on Asian populations (Hedmann and Larsson, 2002; 
Thomas et al., 2005; Aquino et al., 1999). However, our patients were treated for up to 12 
months whereas the previous studies treated for 3–6 months (Hedmann and Larsson, 2002; 
Thomas et al., 2005; Aquino et al., 1999). It is believed that the greatest effect of latanoprost 
is seen within 6 weeks of treatment initiation, during which time changes in the ciliary 
muscle extracellular matrix has almost completed and leads to improvement in uveoscleral 
outflow (Lindsey et al., 1997; Weinreb et al., 1997). A study conducted in India reported 
mean IOP reductions from baseline of 9.4 (1.9) mm Hg at 6 weeks post-treatment with 
latanoprost and 8.9 (1.7) mm Hg at 12 weeks post-treatment (Thomas et al., 2005). Moreover, 
in the earlier studies, long-term follow-up at 2 years showed that IOP reduction was stable 
without drift or tachyphylaxis in the European populations of the earlier studies (Hedmann et 
al., 2002; Alm et al., 1997).  
 
Our calculation of mean IOP reduction was based on the difference between the sum of the 
IOPs at each visit during the follow-up period and the IOPs at baseline. Thus, a slight 
increase in IOP from one visit to another would result in lower estimates of IOP reduction. In 
a previous study, the reduction in IOP was calculated as the difference between IOP at 
baseline and at the final follow-up visit (Cheong et al, 2008). Unlike the studies conducted by 
Hedmann and Larsson (2002) and Aquino et al. (1999), our study did not assess diurnal 
fluctuations in IOP. IOP was measured once between 8:00 AM and 12 noon, and patients were 
asked to instil the medication at 8:00 PM. Evening dosing of latanoprost is known to be more 
effective than morning dosing (Alm et al., 1995). In a previous study (Larsson et al., 2002), 
IOP was assessed over 24 hours in OHT patients treated with topical latanoprost in the 
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evening and topical timolol GFS (gel-forming solution) in the morning. Latanoprost was 
shown to provide better IOP reduction; however, there was a slight spike in IOP between 
8:00 PM and midnight in patients treated with topical latanoprost (Larsson et al., 2002). Thus, 
we speculate that the time of IOP measurement in our study (8:00 AM) may be indirectly 
responsible for the smaller pressure-lowering effect of latanoprost compared with earlier 
studies.  
 
In the present study, latanoprost was prescribed as either monotherapy or adjunctive therapy 
to topical Timolol XE 0.5%, with slightly more patients treated with adjunctive therapy. 
While we were recruiting for this study, latanoprost was gaining in popularity as first line 
medication but the cost of treatment was a major drawback. However, latanoprost is currently 
available as a standard therapy in our practice and most of the patients receive it at no cost, in 
particular those in lower socioeconomic groups. Because they have different mechanisms of 
action, it has been reported that the pressure-lowering effects of latanoprost plus timolol are 
additive (Bron et al., 2001; Alm et al., 1995; Rulo et al., 1994; Toris et al., 1993). In contrast, 
we found that latanoprost was more effective as a monotherapy (mean IOP reduction 7.2 
(3.2) mm Hg) than as adjunctive treatment to Timolol XE 0.5% (7.0 (4.8) mm Hg), but this 
difference was not statistically significant. In a study conducted in Italian glaucoma patients, 
IOP reduction achieved from switching timolol monotherapy to latanoprost monotherapy was 
similar to when switching to adjunctive therapy of  latanoprost and timolol (Bucci et al., 
1999). In another study, adjunctive therapy of latanoprost and timolol was compared with 
monotherapy of either latanoprost or timolol in aqueous solution (Higginbotham et al., 2002). 
The mean IOP reduction of the adjunctive therapy was comparable to latanoprost 
monotherapy but significantly superior to timolol monotherapy (Higginbotham et al., 2002).  
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Timolol gel forming solution (GFS) provides slightly better IOP reduction than aqueous 
solution due to the increased ocular bioavailability of the GFS formulation (Rozier et al., 
1989; Roselund, 1996). Theoretically, the additive pressure-lowering effect of latanoprost to 
timolol GFS should be more pronounced than with timolol in aqueous solution. However, 
there have been no studies to date comparing efficacy between these formulations as additive 
therapy to latanoprost. Clinically, timolol GFS has a slightly better pressure-lowering effect 
compared with timolol in aqueous solution, but the difference is not significant (Roselund, 
1996; Shedden et al., 2001a). Thus, it can be postulated that the additive effect of timolol 
GFS will not be as pronounced as expected. Reversible binding of timolol to ocular melanin 
might reduce its efficacy and render the additive effect of timolol plus latanoprost less 
pronounced (Menon et al., 1989; Ong et al., 2005). 
  
A retrospective review of topical latanoprost as monotherapy in Malay patients showed that 
the mean IOP reduction from baseline was 7.8 (5.3) mm Hg (Cheong et al., 2008). This 
reduction is higher than the mean IOP reduction for both latanoprost monotherapy and 
adjunctive therapy in the present study. Comparatively, the baseline IOP in our study was 
much lower than previous studies involving Asian patients (Cheong et al., 2008; Aquino et 
al., 1999; Mishima et al., 1996; Hedmann and Larsson, 2002). A higher baseline IOP has 
been observed to cause higher IOP reduction once treatment is advocated (Rulo et al., 1996). 
This may explain the reason of lower IOP reduction in the present study. 
 
We found that topical latanoprost treatment resulted in a mean reduction of IOP from 
baseline of 26.7% (19.3%), ranging from 28.9% (13.4%) at 1 month to 31.9% (13.0%) at 6 
months post-treatment. Although this percentage reduction was lower than in other 
latanoprost studies, it was superior to the effects of topical timolol XE based on indirect 
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comparison to our patients treated with topical timolol GFS (Project B). Furthermore, 65 
(75.6%) of our recruited patients completed 12 months treatment. Although our study had a 
lower mean IOP reduction than the study conducted by Cheong et al. (2008) in Malay 
patients treated with topical latanoprost monotherapy, our percentage of good responders 
(≥25% IOP reduction) was virtually the same. Cheong et al. (2008) set a predetermined cut-
off point for response of ≥20% IOP reduction from baseline. The retrospective nature of that 
study is a drawback and the conclusions may be affected by other confounding factors 
(Cheong et al., 2008).  
 
 Statistical analyses of the present study showed that the baseline IOP had a significant effect 
on the patient responsiveness to latanoprost. In other studies with topical latanoprost, patients 
with higher baseline IOP experienced greater IOP reductions post-treatment (Hedmann and 
Larsson, 2002; Alm et al., 1995; Denis et al., 2010). Baseline IOP was found to moderately 
correlate with the pressure-lowering effect of latanoprost in a retrospective study involving 
186 cases (Bayer et al., 2005). OHT patients with high baseline IOP were found to have 
better pressure reduction than those with lower baseline IOP (Mansberger et al., 2007). 
Paradoxically, lower baseline IOP was found to reduce the risk of failure in completing 12 
months of treatment in our study (0.8-fold; 95% CI [0.7–1.0]). It is perhaps not surprising 
that the most significant IOP reductions are observed in patients with higher baseline IOP, 
but the individualised target pressure reductions set for these patients may not be achieved. 
These patients are also more likely to require additional treatment or changes in medication.  
 
In the present study, adjunctive therapy was advocated to patients diagnosed with more 
advanced disease based on Humphrey visual field analysis. The target IOP was set at lower 
levels for patients with advanced disease in an attempt to retard further optic nerve damage. 
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Inevitably, most of these patients are transitioned from monotherapy to adjunctive therapy 
during the follow up period. We also found that patients with advanced glaucomatous 
damage had thinner central corneal thicknesses (CCT). CCT correlated with the severity of 
primary open-angle glaucoma (POAG), based on the Advanced Glaucoma Intervention Study 
score, the mean deviation of visual field, and the vertical and horizontal cup-to-disc ratios at 
the initial examination by glaucoma specialists (Herndon et al., 2004). The Ocular 
Hypertension Treatment Study found that thinner CCT was also a significant predictor for 
progression of OHT to POAG when race was included in the analysis (Gordon et al., 2002). 
Another study evaluated the impact of race on the response to beta-blockers and PG 
analogues and found that baseline IOP and CCT affected the responsiveness to treatment in 
African American and Caucasians (Mansberger et al., 2007).  
 
Furthermore, thicker CCT is associated with greater ocular rigidity, which reduces the 
sensitivity of detection of IOP differences following treatment (Brandt et al., 2004). 
However, thin CCT was also associated with underestimation of IOP by Goldmann 
applanation tonometry (Ehlers and Hansen, 1975). Ethnic differences also influence CCT; 
Asians tend to have thinner CCT compared to Caucasians (Aghaian et al., 2004; Shimmyo et 
al., 2003). In the present study, CCT was evaluated by non-contact specular microscopy. 
Non-contact specular microscopy provides acceptable CCT measurement and comparable 
with ultrasonic pachymetry but tends to give thinner measurement (Kawana et al., 2004; 
Mόdis et al., 2001). Thus, there is possibility of overestimation of CCT measurement that 
may leads to underestimation of IOP. However, there was no significant association between 
CCT and baseline IOP in the present study. It is not the aim of our study to evaluate the 
accuracy of non-contact specular microscopy. Nevertheless, caution must be taken in 
interpretation of CCT in this present study. 
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In the present study, patients diagnosed with normal-tension glaucoma (NTG) recorded less 
IOP fluctuation than patients with POAG. Topical latanoprost as monotherapy or adjunctive 
therapy provides good pressure-lowering effects with stable pressure reduction for 12 
months. In our population, topical latanoprost is a better choice of first line treatment than 
timolol. However, compared with other Asians population the pressure-lowering effect of 
latanoprost was slightly lower in our study (Aquino et al., 2007; Cheong et al., 2008; Thomas 
et al., 2005). These findings suggest there may be ethnic variation in the response to 
latanoprost treatment. 
 
5.2.2 Side effects of topical latanoprost 0.005% 
The side effects of latanoprost have also been postulated to be affected by ethnicity. This 
affect may lie in the unusual relationship between various topical pressure-lowering drugs 
and melanin. Latanoprost increases pigmentation of the iris, lashes, and periocular area, but 
this is not observed with timolol, which has a higher affinity for melanin (Watson and 
Stjernschantz, 1996). In our patients, hypertrichosis was the most common side effect and 
was detected as early as 3 months post-treatment. At the end of 12 months, all patients 
remaining on latanoprost had developed hypertrichosis. The incidence of hypertrichosis has 
previously been found to increase with the duration of treatment (Chiba et al., 2004). 
Hypertrichosis is regarded as a cosmetic side effect that was well accepted in this study, 
especially among the women. Thus, none of the patients raised concerns or expressed the 
desire to discontinue treatment.  
 
Latanoprost-induced iridial pigmentation (LIID) is a major concern among Caucasians, 
especially LIID causing brown patches on blue, gray, or green eyes (Watson and 
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Stjernschantz, 1996; Alm et al., 1995). The mechanism for this intriguing side effect has been 
widely studied. It is thought that the majority of the pathology occurs at the anterior stroma of 
the iris and results from increased melanin production by melanocyte, rather than melanocyte 
proliferation (Cracknell et al., 2003; Arranz-Marquez et al., 2004). In our study, we observed 
LIID in 5 patients (5.6%) at 12 months post-treatment. When latanoprost first became the 
treatment of choice for glaucoma, individuals with homogenous dark brown irises, especially 
Africans and Asians, were thought not to be affected by LIID. However, as the popularity of 
latanoprost escalated, LIID was also detected in Asians (Chou et al., 2005; Chiba et al., 
2004). Detection of LIID in dark brown irises is more difficult than in lighter coloured irises. 
Chou et al. (2005) used the Boys-Smith pigment gradation lens, which gives a more objective 
assessment, for semi-quantitative measurement of iris pigment in a study in the Japanese 
population. In our study, detection of LIID was based on the anterior segment photographs 
and slit lamp evaluations. The serial photographs gave a reasonably objective assessment of 
LIID but were insufficiently accurate. Thus, there is strong possibility that LIID was 
underdetected in our study, which may be partly responsible for the lower incidence of LIID 
compared to studies conducted in other Asians population (Chou et al., 2005; Chiba et al., 
2004).  
 
Although conjunctival hyperaemia is not a permanent side effect of latanoprost, it is the most 
concerning ocular side effect. We reported only a 3.4% incidence of conjunctival hyperaemia 
and none of the patients wished to terminate their involvement in this study. Based on the 
classification system suggested by Stewart et al. (2002), the patients‟ conjunctival 
hyperaemia was mild and had disappeared by 3 months post-treatment. Latanoprost is 
believed to cause less conjunctival hyperaemia than other prostanoid analogues due to its 
selectivity for the PTGFR (Honrubia et al., 2009; Feldman., 2003). Naturally occurring PGs 
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have the highest affinity for their respective receptors but they are also relatively non-
selective (Sharif et al., 2003). Latanoprost is more selective for PTGFR than are circulating 
PGF2α or other PG analogue drugs such as bimatoprost and travoprost (Sharif et al., 2003). 
For example, bimatoprost acid exhibits relatively high affinity for FP, EP1 and EP3 (Cantor et 
al., 2007). Bimatoprost acid is the product of hydrolytic conversion of bimatoprost and can be 
detected in the aqueous humour (Cantor et al., 2007). However, it has been suggested that the 
cause of conjunctival hyperaemia resulting from latanoprost treatment may be due to the high 
concentration of the preservative benzalkonium chloride (200 mg/ml) in those preparations, 
which is almost double the concentration in preparations of timolol (Alm et al., 1995). 
Although the presence of conjunctival hyperaemia is not thought to influence the efficacy of 
topical latanoprost (Stewart et al., 2003), a recent study has found a significant correlation 
between IOP and the severity of conjunctival hyperaemia (Kobayashi and Kobayashi, 2011). 
 
Despite the effectiveness of latanoprost for glaucoma therapy in a number of populations, 
there are reports of unresponsiveness to treatment and tachyphylaxis. In addition, some but 
not all patients develop conjunctival hyperaemia. The possible causes of such variation in the 
clinical pharmacology of latanoprost should be identified and addressed, not only to ensure 
patients receive maximally effective treatment to halt further insult to the damaged optic 
nerve, but also to minimise side effects and promote compliance to medication in the long-
term management of glaucoma. This subject raises the key question: are there interactions 
between the genetic make-up of glaucoma patients and their responsiveness to treatment with 
PG analogues? 
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5.2.3 PTGFR and susceptibility to glaucoma 
A phase 1 genome-wide association study (GWAS) of European and Asians patients with 
bipolar disorder identified PTGFR as a candidate gene (Chen et al., 2011). The PTGFR is 
abundant in the brain and optic nerve and PGF2α has been shown to exacerbate hypoxic 
neuronal injury in neuron-enriched primary cultures (Li et al., 2008), suggesting a possible 
role for PTGFR as a susceptibility gene for glaucoma. PTGFR has been shown to influence 
the contractility of myometrium during labour (Hay et al., 2010, Sugimoto et al., 1997). 
Ciliary muscle is a smooth muscle with similar structural properties to myometrium; thus, the 
regulation of PTGFR in ciliary muscle relaxation may be analogous to that in myometrium. 
Relaxation of ciliary muscle has been proposed to facilitate aqueous outflow through an 
unconventional pathway. Preliminary data from studies of gene therapy for glaucoma have 
found that the prostaglandin pathway is a potential therapeutic target for gene therapy for 
sustained lowering of IOP (Barraza et al., 2010). 
 
In the present study, the entire PTGFR gene, including the promoter region, was directly 
sequenced to identify polymorphisms. A total of 63 SNPs were identified, including a novel 
SNP rs3766332 that was reported by Hoh et al (2007) and 2 regions of microsatellite 
instability (MSI). The majority of the SNPs were found in the introns and 1 SNP, rs3766331, 
was found in exon 4. Four SNPs were found at the 5‟UTR. There is accumulating evidence of 
heterogeneity in various genes among Asian population (Cornes et al., 2012; Tan et al., 
2010). Our study included 2 major racial groups and the analysis was stratified according to 
Malays and Chinese. We found a significant difference between Malays and Chinese in the 
allele frequencies of 12 SNPs and an additional 9 SNPs had a near-significant difference 
(p < 0.1), suggesting a potential population stratification. However, genomic control analysis 
showed no inflation of λgc, suggesting that the finding in the present study is unlikely to be 
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due to population stratification. Ideally, the genomic control analysis should be conducted on 
30 unlinked markers, whereas we examined only 16 markers because of the close proximity 
of the identified SNPs and the presence of linkage disequilibrium between the SNPs.  
 
Based on the Cochran-Mantel-Haenszel test for stratified samples, we identified 4 intronic 
SNPs (rs11162505, rs554185, rs551253 and rs556817) as potentially associated with 
glaucoma in Malays. Interestingly, none of the 63 identified SNPs showed significantly 
different frequencies between glaucoma patients and control subjects in Chinese residents of 
Malaysia. The inability to detect significant associations between PTGFR SNPs and 
susceptibility to glaucoma in this population may be due to the small patient sample size. 
Tests for heterogeneity were significant in rs11162505. Genotype frequency rs11162505 
shown significant difference between glaucoma and controls (p=1.72E-4) in Malays but not 
among the Chinese. The minor allele of rs11162505 (rs11162505G) exerts a strong and 
significant effect as a protective SNP against glaucoma (OR 0.3; 95% CI 0.1, 0.5). The minor 
allele of rs554185 also confers protection against glaucoma in Malaysian population (OR 0.7; 
95%CI 0.4, 1.0). The position of rs11162505 and rs554185 is just 49bp apart and in strong 
linkage disequilibrium (LD).  Allele frequency of haplotypes GG of rs11162505 and 
rs554185 shown significant difference between glaucoma patients and controls (p=4.0x10
-4
). 
Another haplotypes GA of these two SNPs also showed significant association with 
glaucoma (p=3.0x10
-4
).  In addition, the minor allele of another intronic polymorphism 
rs551253 was also found to confer protective effect against glaucoma. However, rs551253 
violated HWE and excluded from further analysis.  
 
On univariate analysis, the minor allele of rs11162505G in the heterozygous state 
(rs11162505GC) confers strong protective effect against glaucoma in Malays but not in 
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Chinese, which provide further support the significant difference in heterogeneity test. 
Interestingly, rs554185AG was found to increase the susceptibility to glaucoma in Malays 
but reduces the risk of glaucoma in Chinese. Stepwise logistic regression combining Malays 
and Chinese demonstrated rs11162505GC provides strong protective effect against glaucoma 
but the effect of rs554185AG was no longer significant. On the other hand, rs556817AG was 
also found to reduce the risk of glaucoma and rs3766338TC increases the risk of glaucoma 
4.2 folds (95% CI 1.2, 14.0). Based on the findings of our study, PTGFR is a potential 
protective gene against glaucoma. 
 
Further analysis was conducted according to the type of glaucoma: POAG and NTG. The 
minor allele of rs11162505, rs686262 and rs551253 was found to confer significant 
protective effect against POAG. The minor allele of two SNPs; rs12093097 and rs1073610 
found in the promoter region, increase the risk of POAG. However, on the stepwise logistic 
regression, only rs11162505AG was found to confer significant protective effect against 
POAG. The minor allele of rs556817 and rs6424776 showed significant effect in reducing the 
risk of NTG. On contrary, the minor allele of rs7543738 increases the risk of NTG 3.8folds 
(95% CI 1.2, 12.1). In general, rs11162505 and rs556817 seems to confer protective effect 
against POAG and NTG respectively. 
 
In the present study, the majority of SNPs were found in PTGFR introns. In general, intronic 
SNPs are noncoding polymorphisms that do not affect protein expression. However, the rapid 
progress of genetic research, especially following the Human Genome Project, has resulted in 
the identification of numerous susceptibility alleles for varying diseases. With respect to 
ocular diseases, an intronic SNP and common variant in the complement factor H gene 
(CFH) were found to increase susceptibility to age-related macular degeneration by 7.4-fold 
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(95% CI 2.9–19) (Klein et al., 2005). The patients in that study were recruited from the Age-
Related Eye Disease Study (AREDS Research Group, 2001). The association of SNP 
rs11162505 in PTGFR in the present study does not reach the significance (set at 10
-7
) of a 
genome wide association study (GWAS); nonetheless, this allele was demonstrated to have a 
significant protective effect against glaucoma. Replication study in other populations is 
necessary to ascertain the role of PTGFR in glaucoma. 
 
SNP markers of CDKN2B-AS1 gene (located at chromosome 9p21) were found to associate 
with the risk of glaucoma in European derived population (Ramdas et al., 2011). The minor 
allele of a locus of CDKN2B-AS1 gene was found to confer protective effect against this 
large sample of glaucoma patients of European derived population. Replication study 
conducted in Japanese population found similar GWAS significant of CDKN2B-AS1 gene 
(Nakano et al., 2012). However, marker of CDKN2B-AS1 gene was found to significantly 
increase susceptibility to glaucoma. Nakano et al (2012) contributed this different was due to 
smaller sample size and the inclusion of NTG.  
 
Dinucleotide microsatellite instability (MSI) identified in this study was shown to not 
associate with susceptibility to glaucoma. However, it is possible than an interaction between 
the regions of MSI and SNPs may be responsible for susceptibility to glaucoma or 
responsiveness to medication. A large-scale multi-centre study conducted on colorectal 
cancer patients found 3 SNPs that were associated with the methylation status of the MLH1. 
These SNPs caused loss of MLH1 protein and induced MSI leading to microsatellite unstable 
(MSI-H) colorectal cancer (Mrkonjc et al., 2010). The role of MSI in pathogenesis of 
colorectal cancer is well established but the role in complex disease such as glaucoma is not 
known. Intronic MSI was found to associate with susceptibility with a number of 
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neurodegenerative diseases such as Friedreich ataxia, asparagines synthetase gene causing 
acute lymphoblastic leukaemia and NOS3 gene in hypertension (Bidichandani et al., 1998; 
Akagi et al., 2006; Jemaa et al., 2009). Thus, the possibility remains that the MSI and SNPs 
found in the present study could cause amino acid changes or other alterations of PTGFR 
function.  
 
There are reports of alternative splice variants of PTGFR in various tissues, including ocular 
tissue (Hay et al., 2010; Vielhauer et al., 2004; Liang et al., 2008). Two alternatively spliced 
isoforms of the FP receptor, designated FPA and FPB, have been cloned from human corpus 
luteum, placenta, uterus, heart, and ocular tissue (Pierce et al., 1997; Vielhauer et al., 2004). 
The isoforms have almost identical structures except at the carboxyl terminus and have 
indistinguishable radioligand binding activity. However, they differ in their signalling 
capacity, specifically in their functional coupling to phosphatidylinositol hydrolysis. Liang et 
al. (2008) reported the presence of 6 alternatively spliced mRNAs in human ciliary body, 
resulting from the insertion of 5 additional exons between exons 2 and 3 of wild-type 
PTGFR. Of note, almost two-thirds of the SNPs identified in the present study are located in 
Intron 3 (between exons 3 and 4, exon 3 is also part of the identified spliced variant), 
including rs11162505, rs554185 and rs556817. Thus, it is possible that these SNPs are 
located within the additional exons in the PTGFR splice variants isolated from human ciliary 
body.  
 
The role of PTGFR in the pathogenesis of glaucoma has not previously been studied. Loss of 
Heterozygosity of PTGFR has been shown to increase susceptibility to breast cancer (Soosey-
Alaoui et al., 2001). Because PTGFR is abundant in the brain (Yanai et al., 2005), changes in 
PTGFR function could be associated with chemical or structural changes that may be 
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responsible for glaucoma. PTGFR is also expressed at the retina and optic nerve where it is 
postulated to provide a neuroprotective effect (Ocklind et al., 1996; Nakanishi et al., 2006). It 
was found that PTGFR is not only activated and desensitised by PGF2α but also by F2 
isoprostanes (Kunapuli et al., 1997). F2 isoprostanes, especially 12-iso-PGF2α, activate 
PTGFR in a specific and saturable manner (Kunapuli et al., 1997). 12-iso-PGF2α is produced 
in large amounts as a result of free radical cyclization (O‟Connor et al., 1984), which usually 
occurs under conditions of oxidative stress, as has been postulated to contribute to glaucoma 
and heart failure. It is thus possible that genetic variation in the PTGFR gene may influence 
the affinity of 12-iso-PGF2α for PTGFR. 
 
COX is the rate-limiting enzyme in the biosynthesis of prostaglandins. Two isoforms, COX-1 
and COX-2, have been identified and characterised (Vane et al., 1998). COX-1 is expressed 
in most tissues and is known as a housekeeping enzyme, while COX-2 is expressed in 
specific tissues under normal physiological conditions but its transcription is upregulated by 
factors such as pro-inflammatory cytokines (Beiche et al., 1996; Yamagata et al., 1993). Lack 
of COX-2 expression in non-pigmented epithelium of the ciliary body at various stages of 
POAG suggested the potential role of COX-2 in POAG (Maihöfner et al., 2001). 
Glucocorticoid inhibit expression of COX-2, suggesting a role for COX-2 in juvenile 
glaucoma and the possibility of an interaction with the trabecular meshwork inducible 
glucocorticoid response gene (TIGR) also known as Myocilin (MYOC) (Maihöfner at al., 
2001). PTGFR is localized close to COX-2 and TIGR in ciliary epithelium and ciliary body. 
PTGFR, COX-2 and MYOC are located in close proximity on chromosome 1q at 13.1, 25 and 
24.3 respectively (Michels-Rautenstrauss et al., 1998; Tay et al., 1994; Betz et al., 1999). 
Since glaucoma is a complex disease, perhaps the genetic variations of these genes may 
actually increase the susceptibility to glaucoma.  
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5.2.4 PTGFR and pressure lowering effect of topical latanoprost 0.005% 
Latanoprost failed to reduce IOP in homozygous PTGFR knockout mice (FPKO) over a short 
duration (Crowston et al., 2002). This indicates that PTGFR is important in determining the 
functionality of prostaglandin analogues. Surprisingly, bimatoprost and unoprostone have no 
IOP-lowering effect in FPKO mice (Ota et al., 2005; Crowston et al., 2005), suggesting that 
these analogues stimulate the PTGFR either directly or indirectly through unknown 
mechanisms and that most PG analogues act in a PTGFR-dependent manner. Recent work on 
prostanoid gene therapy found that injection of cats with lentiviral vectors encoding codon-
optimised COX-2 and codon-optimised FP receptor (FPR) produced sustained reductions in 
IOP of up to 35% (Barraza et al., 2010). The PTGFR gene is thus important in determining 
the pressure-lowering effect of latanoprost and is a potential pharmacodynamic gene. 
 
We selected certain SNPs in PTGFR based on the Fisher model of mapping quantitative trait 
loci. As glaucoma is a complex disease, ideally SNPs with significant additive genotype 
values should be selected. However, no SNP showed significant additive genotype value, and 
instead, SNPs with significant dominant and combination genotype values were selected. 
These were rs4650581, rs34012237, rs3766335, rs2146490, rs3966768, rs7543738 and 
rs6735117. One-way ANOVA was used to analyse the mean IOP at each visit of the patients 
with the selected SNP genotype. Due to the possibility of an effect of race on IOP, the 
analysis was further divided for Malays and Chinese. There was no significant difference in 
the mean IOP at each visit for patients with any of the selected SNPs, except for rs2146490 in 
Chinese glaucoma patients. Patients with rs2146490GG had significantly higher mean IOP 
measurements at 12 months post-treatment compared to patients with rs2146490GA.  
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Sakurai et al. (2007) conducted a short-term study on the pressure-lowering effect of 
latanoprost on healthy Japanese volunteers. There was significant association between the 
presence of rs3753380 and rs3766355 and percentage latanoprost-induced IOP reduction 
from baseline at 7 days post-treatment. Patients were defined as low responders to latanoprost 
(less than 10% reduction in IOP), medium responders (between 10% and 25% reduction) and 
good responders (more than 25% reduction). However, studying the responsiveness to 
latanoprost in healthy volunteers is not a fair representation of the phenotype because healthy 
volunteers have normal baseline IOP. Moreover, the percentage latanoprost-induced IOP 
reduction is dependent on the baseline IOP (Herndon et al, 2004; Bayer et al., 2005; 
Mansberger et al., 2007), with patients with higher baseline IOP achieving higher percentage 
of IOP reduction (Alm et al., 1997).  
 
The SNPs identified by Sakurai et al. (2007) at the promoter region (rs3753380) and intronic 
region (rs376355) were also identified in our study. However, our study showed that these 2 
SNPs are not susceptibility genes for glaucoma, nor are they potential candidates as 
pharmacodynamic genes. Differences in the study populations may explain the difference in 
genotype-phenotype association of the PTGFR. McCarty et al. (2011) suggested that a 
discrepancy in the minor allele of rs3766335 in Europeans and Japanese is responsible for the 
lack of replication between the studies. These authors genotyped a population based at the 
Marshfield Clinic Personalized Medicine Research Project for the PTGFR polymorphisms 
rs3753380 and rs376355 in an attempt to replicate the study conducted in the Japanese 
population. However, the population included glaucoma patients seen at the Marshfield clinic 
whereas the Japanese study was conducted on healthy volunteers. McCarty et al. (2011) 
observed no association between the presence of SNPs rs375580 and rs376355 in PTGFR 
and the patient response to PG analogues at 90 days post–treatment.  
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In the present study, the responsiveness to latanoprost was defined as good or poor based on a 
predetermined cut-off point of 25% reduction in IOP from baseline. This cut-off point was 
selected based on the mean IOP reduction of latanoprost in our study and was higher than in 
previous studies conducted in Japanese (Sakurai et al., 2007) and European (McCarty et al., 
2011) populations. A stratified Cochran Mantel-Haenszel analysis of 63 SNPs was conducted 
on the good (≥25% reduction from baseline) and poor (<25% reduction from baseline) 
responders. There was a significant association between SNP rs686262 and the 
responsiveness to latanoprost. The major allele of rs686262 (rs686262A) provides a 
protective effect against poor responder or reduces risk of poor responder to topical 
latanoprost 0.005% (0.4 folds (95% CI 0.2, 0.8). The final model of stepwise logistic 
regression showed that rs686262GG was associated with increased risk of poor 
responsiveness to latanoprost 6.3-fold (95% CI 1.3–31.0). We identified a novel SNP 
rs3766332 earlier during screening of PTGFR exons, the minor allele of rs3766332 shown 
borderline significant as predictor for responsiveness to treatment (Hoh et al., 2007). This is 
perhaps due to rather small sample size in the present study. 
 
Based on the findings from the present study, we consider PTGFR to be a potential 
pharmacodynamic gene. However, future studies aimed at replicating our findings should 
focus on topical latanoprost as monotherapy rather than combining the adjunctive and 
monotherapy. The postulated mechanism of action of latanoprost is complex and not well 
established. MMP has also been identified as a potential pharmacodynamic gene. To improve 
our understanding of the pharmacogenetics of latanoprost, genes that may be involved in the 
postulated mechanism of action of latanoprost, such as COX-2 and MMP, should be screened. 
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More robust genetic screening techniques, such as microarray techniques, might provide 
better detection of potential pharmacodynamic and pharmacokinetic genes. 
 
5.3 Limitation and recommendation 
The major limitation in this present study was relatively small number of total recruits. This 
is mainly due to high number of drop-out. Most of the „drop-out‟ was those who even failed 
to turn up during the first visit, 1 month post treatment. The number of actual recruits was 
more than the total recruits reported in this study.  
 
Lack of randomisation, is also a potential source of bias. For example, newly diagnosed 
glaucoma patients with suspicious of respiratory impairment or history of chronic smoking 
were automatically assigned to Project P. Moreover, those with more advanced disease or 
higher IOP were more likely to be assigned to Project P. This is based on the reported 
effectiveness of topical latanoprost 0.005% in Asians (Hedmann and Larsson., 2002). This 
may be responsible for quite a large number of patients were treated with topical latanoprost 
as adjunctive therapy in Project P.  
 
Setting individualised target pressure emulates the actual clinical setting. At the same time, 
individualised target pressure was the main reason for patients been „dropped-out‟ from the 
study protocol. Even if topical timolol or latanoprost provide good pressure lowering but may 
not reach the targeted pressure. Pressure lowering effect of the drugs may not be accurately 
reflective in this study. In the future, perhaps a randomised control trial study should be 
adopted with a definitive target pressure.  
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5.4 Conclusion: Pharmacogenetics in glaucoma management 
The present study provides additional evidence of the potential role of pharmacogenetics in 
glaucoma management. Timolol XE 0.5% monotherapy provided good pressure reduction 
and higher levels of reduction than reported in previous studies. The mean baseline IOP of 
genotype -47CC of ADRB2 was significantly higher than of genotypes -47GG and -47CG. 
However, there was no association of ADRB2 with responsiveness to topical Timolol XE. In 
addition, 79G and -20C of ADRB2 were found to be potential susceptibility markers for 
glaucoma.  
 
The pressure-lowering effects of topical latanoprost 0.005% was better than that of topical 
Timolol XE based on indirect observation, but was lower than the mean IOP reduction 
observed in other studies conducted in Asian glaucoma patients. We identified one SNP in 
the flanking region of exon 4, rs686262, was found to associate with responsiveness to 
topical latanoprost. There was significant association between the genotype frequency of 
rs11162505 and glaucoma in Malays. The minor allele of rs11162505, rs554185 and 
rs551253 appeared to confer a strong protective effect against glaucoma.  
 
Perhaps, in the future, a simple fast genetic screening is useful in helping ophthalmologist to 
choose appropriate treatment for glaucoma patients. ADRB2 and PTGFR are the potential 
markers to be included in the future genetic screening tool. The pharmacokinetic genes such 
as CYP2D6 and other potential genes that play a role in the mechanism of action of the drugs 
such as MMP should also be included as the potential markers.  
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PATIENT INFORMATION SHEET AND CONSENT FORM 
Pharmacogenetics of glaucoma; a study of the role of beta2-ar and prostanoid (FP) 
receptor gene polymorphisms in pressure lowering effect of topical timolol and 
latanoprost 
 
PROJECT B: Topical timolol 
Introduction 
 
You are invited to take part voluntarily in a research study involving topical Timolol. Timolol 
is one of the commonly used anti-glaucoma drugs. Before agreeing to participate in this 
research study, it is important that you read and understand this form.  It describes the 
purpose, procedures, benefits, risks, discomforts, and precautions of the study.  It also 
describes your right to withdraw from the study at anytime.  If you agree to participate, you 
will receive a copy of this form to keep for your records. 
Purpose of the Study 
 
The purpose of this study is to determine whether the variation of the genetic make-up of 
patients, who are on timolol therapy, affects the intraocular pressure lowering effect of 
timolol. 
 
All the information obtained in this study will be kept CONFIDENTIAL.  It is possible that 
information collected during this study will be analyzed by the sponsor in the future for other 
possible uses or other medical or scientific purposes other than those currently proposed. 
 
Requirements to participate 
 
The doctor in charge of this study or a member of the study staff has discussed with you the 
requirements for participation in this study.  It is important that you are completely truthful 
with the doctor and staff about you health history.  You should not participate in this study if 
you do not meet all the requirements. 
Some of the requirements to be in this study are – 
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 Adults aged above 40 years. 
 Had been diagnosed to have primary open angle glaucoma, normal tension 
glaucoma or ocular hypertension. 
 Prescription of topical timolol upon confirmation of diagnosis 
You cannot participate in this study if you are - 
 
 Unwilling to be started on topical timolol XE 0.5%  
 Allergic to topical timolol 
 Known to suffer from:-  
Chronic obstructive airway disease, bronchial asthma, pulmonary disease, 
psychiatric illness, liver and renal disease. 
 
You need to agree to use the drug as instructed by the doctor and staff of the research project 
and to return any unused drug and containers at the end of the study or as otherwise 
instructed by the doctor. 
Procedure of the study 
 
Visit 1 
If you are diagnosed to have primary open angle glaucoma, normal tension glaucoma or 
ocular hypertension during your visit to the Eye Clinic and agree to participate in this study, 
you will receive treatment with topical timolol.  You will undergo several baseline ocular 
examinations to check your intraocular pressure, optic nerve head assessment and a visual 
field test. Three ml of blood will be taken for genetic analysis. Any remaining blood after the 
genetic analysis will be discarded. You will then be prescribed with topical timolol XE 0.5% 
on morning. You must follow the instructions given by the doctor involved in this study with 
regards to the dosage and follow-up plan.  
 
You will then be given an appointment for your second visit. 
Visit 2 
During your second visit (one month after your first visit), a repeat eye examination on your 
intraocular pressure, optic nerve head and visual field test will be carried out. Should you 
choose to withdraw from the study, you will still be followed up for your disease. You‟ll be 
asked regarding any side effects of timolol.  If all goes well, you would then be continued on 
topical timolol XE.  
 
You will then be given an appointment for your third visit. 
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Visit 3 
During your third visit (2 months after your second visit), a repeat eye examination on your 
intraocular pressure, optic nerve head and visual field test will be carried out. You‟ll be asked 
again regarding any side effects of timolol.   
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. On the 
other hand, if topical timolol XE is effective in controlling your disease, you will be 
continued on topical timolol XE and given another appointment for your fourth visit. 
 
Visit 4 
During your forth visit (3 months after your third visit), a repeat eye examination on your 
intraocular pressure, optic nerve head and visual field test will be carried out. You‟ll be asked 
again regarding any side effects of timolol 
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. On the 
other hand, if topical timolol XE is effective in controlling your disease, then you will be 
continued on topical timolol XE and given another appointment for your fifth visit. (The 
appointment 3 months from this visit will not be included in the study but for continuation of 
your treatment. You need to continue your follow-up accordingly.) 
Visit 5 
During your fifth visit (6 months from your fourth visit), you‟ll be on topical timolol XE for 
12 months. As usual, a repeat eye examination on your intraocular pressure, optic nerve head 
and visual field test will be carried out.  
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. This is 
the last visit for this study. If all goes well, you will be continued on topical timolol XE and 
you will continue your follow-up and treatment in the Eye Clinic. 
Risks 
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There may be some risks if you participate in this study, which relate to the usage of standard 
glaucoma medication. You may encounter some ocular or systemic side effects. Examples of 
side effects include burning sensation or ocular discomfort or pain, breathlessness and 
palpitations. Some of the side effects are transient and mild. However, if the side effects are 
hazardous to health, topical timolol will be stopped immediately. In addition to the risk 
named above, the study procedures may have other unknown risks. There may be unknown 
risks of possible harmful interaction with other medication you may be taking. These risks 
would be present if you used the mediation outside of this research project. 
 
You should follow carefully the doctor‟s directions for taking this study drug to avoid 
undesirable incidence. 
Other Treatments 
 
You do not have to take part in this study to be treated for your illness or condition.  Other 
treatments and therapies for your condition are available, including your current therapy, 
including the medication used in this research project. The doctor who is involved in this 
study can discuss these treatments and therapies with you. 
Participation in the Study 
 
Your participation in this study is entirely voluntary.  You may refuse to take part in the study 
or you may stop your participation in the study at anytime, without a penalty or loss of 
benefits to which you are otherwise entitled. 
 
The doctor who is involved in this study may stop your participation even without your 
consent. 
 
If you stop being part of this study, the doctor or the staff member will talk to you about any 
medical issues regarding the discontinuation of your participation. 
Treatment and Compensation for Injury 
 
If you follow the directions of the study doctor and staff and you are physically injured due to 
any substance or procedure properly given under the plan for this study, the sponsor will pay 
the medical expenses for the treatment of that injury which are not covered by your medical 
insurance, by a government program, or by any other third party. 
389 
 
Possible Benefits 
 
The drug and the study procedures will be provided at no cost to you.  You may receive 
information about your health from any physical examination and laboratory tests to be done 
in this study. 
 
You will be paid RM 50 to reimburse you for transportation, parking, meal, or other expenses 
related to your participation in this study.  If you withdraw from the study early, you will be 
paid for these expenses for the portion of the study that you did complete. 
 
Information obtained from this study will benefit the sponsor of the study (Ministry of 
Science, Technology and Information of Malaysia) and may benefit patients in the future. 
 
Investigator Payment 
 
The sponsor (Ministry of Science, Technology and Information of Malaysia) is paying the 
study doctor and/or her institution for their work in this study. 
Questions 
 
If you have any question about this study or your rights, please contact  
 Dr. Liza Sharmini Ahmad Tajudin  0976664563/0199179227 
 
If you have any questions about your rights as a participant in a research study, please contact 
the Ethical Review Board of the University Hospital. 
 
Confidentialty 
 
Your medical information will be kept confidential by the doctor and staff involved in this 
study and will not be made publicly available unless disclosure is required by the law. 
 
Data obtained from this study that does not identify you individually will be given to the 
sponsor and/or its representatives and may be published. Your original medical records may 
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be reviewed by the sponsor and/or its representatives, the Ethical Review Board (ERB) for 
this study, and regulatory authorities for the purpose of verifying clinical trial procedures 
and/or data.  Your medical information may be held and processed on a computer. 
 
By signing this consent form, you authorize the record review, information storage and data 
transfer described above. 
Signatures 
 
To be entered into the study, you or a legal representative must sign and date the signature 
page (see Attachment 1) 
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Attachment 1: Consent Form 
                                       
Information and consent form 
Attachment 1 
Consent form 
 
To take part in this study, you or your legal guardian must sign this page. 
Thereby signing this form, I certified that: 
 I have read and understand all the information provided in this 
information consent form. 
 I have been given enough time to consider it 
 All my questions had been answered satisfactorily 
 I voluntarily agree to take part in this study, and will obey all the 
procedures and willing to give all the information required to the 
investigators when needed. 
 I can terminate my participation at any time without any reason 
 I have received a copy of the information and consent form for my own 
safe keeping. 
 
 
Patient‟s signature 
Patient‟s name:        Registration number 
IC number:      
 
 
Signature of legal guardian                 Date: (DD/MM/YY) 
Name : 
IC number:      
 
Name of the investigator 
 
Signature of the investigator       Date: (DD/MM/YY) 
_____________________________________________                  
Signature of the witness       Date: (DD/MM/YY) 
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Name : 
IC number:                                                            
PATIENT INFORMATION SHEET AND CONSENT FORM 
Pharmacogenetics of glaucoma; a study of the role of beta2-ar and prostanoid (FP) 
receptor gene polymorphisms in pressure lowering effect of topical timolol and 
latanoprost 
 
PROJECT P: Topical Latanoprost 
Introduction 
 
You are invited to take part voluntarily in a research study of the drug topical Latanoprost. 
Latanoprost is one of the medicines used for treating disease called glaucoma and you will 
receive this medication as your glaucoma treatment. Before agreeing to participate in this 
research study, it is important that you read and understand the information written on this 
form.  It describes the purpose, procedures, benefits, risks, discomforts, and precautions of 
the study.  It also explains about your right to withdraw yourself from this study at any stage 
of the study.  If you agree to participate, you will receive a copy of this information sheet for 
your reference. 
Purpose of the Study 
The purpose of this study is to determine whether the variation of the genetic make-up 
(polymorphisms) of prostanoid receptor in glaucoma patient treated with topical latanoprost 
therapy is associated with the effectiveness pressure lowering effect of the drug. 
All the information obtained in this study will be kept CONFIDENTIAL.  It is possible that 
information collected during this study will be analyzed by the sponsor in the future for other 
possible uses or other medical or scientific purposes other than those currently proposed.  
Requirements to participate 
The doctor involved in this study or a member of the staff must discuss with you the 
requirements for participation in this study.  It is important that you are completely truthful 
with the doctor and staff about you health history.  You should not participate in this study if 
you do not meet all the requirements. 
The requirements to be recruited in this study are: 
 Adults aged above 40 years. 
 Had been diagnosed to have primary open angle glaucoma, normal tension 
glaucoma or ocular hypertension. 
 Previously treated with topical timolol but the pressure is not well control or 
evidence of progression of glaucoma 
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You cannot participate in this study if you are - 
 
 Unwilling to be started on topical latanoprost 0.005%  
 Allergic to topical latanoprost 
 History of previous trabeculectomy surgery 
You need to agree to use the drug as instructed by the doctor and staff of the research project 
and to return any unused drug and containers at the end of the study or as otherwise 
instructed by the doctor. 
Procedure of the study 
Visit 1 
If you are diagnosed to have primary open angle glaucoma, normal tension glaucoma or 
ocular hypertension during your visit to the Eye Clinic and agree to participate in this study, 
you will receive treatment with topical latanoprost.  You will undergo several baseline ocular 
examinations to check your intraocular pressure, optic nerve head assessment and visual field 
test. Photograph of your optic nerve and anterior part of the eye will also be taken. Three ml 
of blood will be taken for genetic analysis. Any remaining blood after the genetic analysis 
will be discarded. You will then be prescribed with topical latanoprost 0.005% on nocte. You 
must follow the instructions given by the doctor involved in this study with regards to the 
dosage and follow-up plan.  
You will then be given an appointment for your second visit. 
Visit 2 
During your second visit (one month after your first visit), a repeat eye examination on your 
intraocular pressure, optic nerve head and visual field test will be carried out. Should you 
choose to withdraw from the study, you will still be followed up for your disease. You‟ll be 
asked regarding any side effects of timolol.  However, if your intraocular pressure fails to 
reduce to the target level, you will be advised to either to add or switching to another drug. 
Once this happen, you will be excluded from the study. If all goes well, you would then be 
continued on topical latanoprost.  
 
You will then be given an appointment for your third visit. 
Visit 3 
During your third visit (2 months after your second visit), a repeat eye examination on your 
intraocular pressure, optic nerve head, visual field test and anterior segment photograph will 
be carried out. You‟ll be asked again regarding any side effects of topical latanoprost.   
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. On the 
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other hand, if topical latanoprost is effective in controlling your disease, you will be 
continued on the treatment and given another appointment for your fourth visit. 
 
Visit 4 
During your forth visit (3 months after your third visit), a repeat eye examination on your 
intraocular pressure, optic nerve head, visual field test and anterior segment photograph will 
be carried out. You‟ll be asked again regarding any side effects of latanoprost 
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. On the 
other hand, if topical latanoprost is effective in controlling your disease, then you will be 
continued on the treatment and given another appointment for your fifth visit. (The 
appointment 3 months from this visit will not be included in the study but for continuation of 
your treatment. You need to continue your follow-up accordingly.) 
Visit 5 
During your fifth visit (6 months from your fourth visit), you‟ll be on topical latanoprost for 
12 months. As usual, a repeat eye examination on your intraocular pressure, optic nerve head, 
visual field test and anterior segment photography will be carried out.  
During this time, if  
 your intraocular pressure is uncontrolled 
 there is sign of progression of the disease 
 the side effects is intolerable 
 
Your treatment maybe changed or you may be given additional medications or an operation 
maybe planned. If this happens, you will be automatically excluded from the study. This is 
the last visit for this study. If all goes well, you will be continued on topical latanoprost and 
you will continue your follow-up and treatment in the Eye Clinic. 
Risks 
There may be some risks if you participate in this study, which relate to the usage of standard 
glaucoma medication. You may encounter some ocular or systemic side effects. Examples of 
side effects include burning sensation or ocular discomfort or pain, breathlessness and 
palpitations. Some of the side effects are transient and mild. However, if the side effects are 
hazardous to health, topical latanoprost will be stopped immediately. In addition to the risk 
named above, the study procedures may have other unknown risks. There may be unknown 
risks of possible harmful interaction with other medication you may be taking. These risks 
would be present if you used the mediation outside of this research project. 
Other Treatments 
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You do not have to take part in this study to be treated for your illness or condition.  Other 
treatments and therapies for your condition are available, including your current therapy 
and/or the treatment being studied in this research project. The doctor who is involved in this 
study can discuss these treatments and therapies with you. 
Participation in the Study 
 
Your participation in this study is entirely voluntary.  You may refuse to take part in the study 
or you may stop your participation in the study at anytime, without a penalty or loss of 
benefits to which you are otherwise entitled. 
The doctor who is involved in this study may stop your participation even without your 
consent. 
If you stop from being part of this study, the doctor or the staff member will talk to you about 
any medical issues regarding the discontinuation of your participation. 
Treatment and Compensation for Injury 
If you follow the directions of the study doctor and staff and you are physically injured due to 
any substance or procedure properly given under the plan for this study, the sponsor will pay 
the medical expenses for the treatment of that injury which are not covered by your medical 
insurance, by a government program, or by any other third party. 
Possible Benefits 
 
The drug and the study procedures will be provided at no cost to you.  You may receive 
information about your health from any physical examination and laboratory tests to be done 
in this study. 
You will be paid RM 50 to reimburse you for transportation, parking, meal, or others expense 
related to your participation in this study.  If you withdraw from the study early, you will be 
paid for these expenses for the portion of the study that you did complete. 
Information obtained from this study will benefit the sponsor of the study (Ministry of 
Science, Technology and Information of Malaysia) and may benefit patients in the future. 
Questions 
 
If you have any question about this study or your rights, please contact  
 Dr. Liza Sharmini Ahmad Tajudin  0976664563/0199179227 
 
If you have any questions about your rights as a participant in a research study, please contact 
The Ethical Review Board of the University Hospital. 
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Confidentiality 
 
Your medical information will be kept confidential by the doctor and staff involved in this 
study and will not be made publicly available unless disclosure is required by the law. 
 
Data obtained from this study that does not identify you individually will be given to the 
sponsor and/or its representatives and may be published. Your original medical records may 
be reviewed by the sponsor and/or its representatives, the ERB for this study, and regulatory 
authorities for the purpose of verifying clinical trial procedures and/or data.  Your medical 
information may be held and processed on a computer. 
 
By signing this consent form, you authorize the record review, information storage and data 
transfer described above. 
Signatures 
 
To be entered into the study, you or a legal representative must sign and date the signature 
page (see Attachment 1) 
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Attachment 1: Consent Form 
                                       
Information and consent form  
Attachment 1 
Consent form 
 
To take part in this study, you or your legal guardian must sign this page. 
Thereby signing this form, I certified that: 
 I have read and understand all the information provided in this 
information consent form. 
 I have been given enough time to consider it 
 All my questions had been answered satisfactorily 
 I voluntarily agree to take part in this study, and will obey all the 
procedures and willing to give all the information required to the 
investigators when needed. 
 I can terminate my participation at any time without any reason 
 I have received a copy of the information and consent form for my own 
safe keeping. 
 
 
Patient‟s signature 
Patient‟s name:        Registration number 
IC number:      
 
 
Signature of legal guardian                 Date: (DD/MM/YY) 
Name : 
IC number:        
 
Name of the investigator 
 
Signature of the investigator       Date: (DD/MM/YY) 
_____________________________________________                  
Signature of the witness       Date: (DD/MM/YY) 
Name : 
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IC number:                                                            
 
 
CLINICAL RECORD FORM: PROJECT B 
 
                                                                                            Index no:  
A. Demographic data 
 
Name:                                                            Address: 
RN:                           
Age:              year (at diagnosis) 
 
Sex:               Male 
                      Female                                     Contact no: 
 
Race:             Malay 
                      Chinese                                    Date of first presentation: 
                       Indian 
                   
                      Other specify __________ 
 
  Interracial marriage within 3 generation (If yes, do not enrol) 
 
B Inclusion / Exclusion criteria 
 
1. Laterally              Bilateral 
                                Unilateral              OD 
                                                              OS 
N Y 
399 
 
2. Confirmation of diagnosis (Baseline) 
 * Gonioscopic findings            Open        Date: ___________ 
                                                           Closed (If closed, do not enrol) 
  
* CDR (cup to disc ratio)           OD            OS           
                                                                                               Date: ____________                                                                                                                             
                                                                                    (Date of qualifying optic disc                     
                 If not seen, give reason      ______       ______    examination) 
 
      Glaucomatous features                                          
      
     (If no, do not enrol unless for OHT) 
 
 * Visual field (VF)                     OD            OS         Date: ____________ 
                       PSD                                                                (reliable VF within 3 months 
                       MD                                                                  of diagnosis) 
                                                                                               FP 
                                                                                               FN 
                                                                            FL 
 
                              
 
                 Glaucomatous changes                                         
     (If no, do not enrol unless for OHT) 
 
 * IOP(mmHg)                            OD             OS 
 
N Y N Y 
N Y N Y 
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 * CCT 
 
3. Diagnosis:                                      POAG 
                                                           OHT 
                                                           NTG 
 
4. Systemic diseases 
  DM   Drugs: __________ 
   
                        HPT   Drugs: __________ 
   
                        CVA   Drugs: __________ 
   
                        Hyperlipidemia Drugs: __________ 
   
                        IHD / MI  Drugs: __________ 
Respiratory problem: Asthma 
    
                                    COPD 
    
                                    PTB 
    
                                    Lung Cancer 
    
                                    Smoker                               (If yes, do not enrol) 
4. Any history of allergy to beta blocker 
Y N 
N 
N 
Y 
N Y 
N Y 
N Y 
Y 
Y 
Y 
Y 
N 
N 
Y 
N 
N Y 
N 
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    (If yes, do not enrol) 
 
C. OUTCOME I (effectiveness) 
 
Schedule 
visit 
Date IOP CDR VF Comment 
Visit 1 
(1 month) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 2 
(3 months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 3 
(6 months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 
(12 
months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:_______________ 
Adequate IOP control 
If no, state additional 
drug_________________ 
Surgical intervention 
If yes, state the 
procedure:____________ 
 
    PSD 
MD 
 
Y N 
N 
Y 
Y 
N 
N 
N 
N 
Y N 
Y 
Y 
N Y 
N 
Y N 
Y 
N Y 
Y N 
Y 
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C. OUTCOME II (genotype) 
 
 Genotype 
 
Allele Homozygous  
Wild type 
Homozygous 
Mutant 
Heterozygous 
16  
 
  
27  
 
  
164  
 
  
-20  
 
  
-47  
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CLINICAL RECORD FORM: PROJECT P 
 
                                                                                            Index no:  
A. Demographic data 
 
Name:                                                            Address: 
RN:                           
Age:              year (at diagnosis) 
 
Sex:               Male 
                      Female                                     Contact no: 
 
Race:             Malay 
                      Chinese                                    Date of first presentation: 
                       Indian 
                       
                      Other specify __________ 
 
  Interracial marriage within 3 generations (If yes, do not enrol) 
 
B Inclusion / Exclusion criteria 
 
1. Laterally              Bilateral 
                                Unilateral              OD 
                                                              OS 
Y N 
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2. Confirmation of diagnosis (Baseline) 
 * Gonioscopic findings            Open        Date: ___________ 
                                                           Closed (If closed, do not enrol) 
  
* CDR (cup to disc ratio)           OD            OS           
                                                                                               Date: ____________                                                                                                                             
                                                                                    (Date of qualifying optic disc                     
                 If not seen, give reason      ______       ______    examination) 
 
      Glaucomatous features                                         (If no, do not enrol) 
 
 * Visual field (VF)                     OD            OS         Date: ____________ 
                       PSD                                                                (reliable VF within 3 months 
                       MD                                                                  of diagnosis) 
                                                                                               FP 
                                                                                               FN 
                                                                                               FL 
                  
                 Glaucomatous changes                                         
     (If no, do not enrol unless OHT) 
  
 
*CCT 
 
 * IOP                                          OD             OS 
 
            
N Y N Y 
N Y N Y 
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  * Diagnosis                            POAG 
                                                           OHT 
                                                           NTG 
 
3. Treatment  Monotherapy 
   Adjunctive therapy 
   (Only enrol, if Timolol is the first line drug) 
   Switch therapy 
   (Only enrol, if Timolol is the only previous drug)  
 
4. Ocular problem 
 Dry eye 
 
 Inflammatory eye disease 
 (Uveitis/ sclerotic) 
 
 Ocular injury 
 
 Filtrating surgery 
      (If yes, do not enrol) 
 
5. Any history of allergy to latanoprost                           (If yes, do not enrol) 
 
 
 
 
 
N Y 
Y 
Y 
Y 
Y 
N 
N 
N 
N 
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C. OUTCOME I (effectiveness) 
Schedule 
visit 
Date IOP CDR VF Comment 
Visit 1 
(1 month) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 2 
(3 months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 3 
(6 months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:________________ 
Adequate IOP control 
If no, state additional 
drug__________________ 
Surgical intervention 
If yes, state the 
procedure:_____________ 
 
    PSD 
MD 
 
Visit 
(12 
months) 
 OD OS OD OS OD OS Progression 
If yes, state 
reason:_______________ 
Adequate IOP control 
If no, state additional 
drug_________________ 
Surgical intervention 
If yes, state the 
procedure:____________ 
 
    PSD 
MD 
 
 
Y N 
N 
Y 
Y 
N 
N 
N 
N 
Y N 
Y 
Y 
N Y 
N 
Y N 
Y 
N Y 
Y N 
Y 
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D. OUTCOME II (side effect) 
 
Schedule visit Date   Conjunctival 
hyperaemia 
Hypertricho
sis 
LIID Iritis Comments 
Visit 1 
(1 month) 
 
      
Visit 2 
(3 months) 
 
      
Visit 3 
(6 months) 
 
      
Visit 4 
(12 months) 
 
      
 
 
E. POLYMORPHISM (genotype) 
 
 
 
 
 
 
 
 
 
 
 
 
408 
 
 
 
409 
 
 
410 
 
 
 
411 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
